Rank	NCT Number	Title	Acronym	Status	Study Results	Conditions	Interventions	Outcome Measures	Sponsor/Collaborators	Gender	Age	Phases	Enrollment	Funded Bys	Study Type	Study Designs	Other IDs	Start Date	Primary Completion Date	Completion Date	First Posted	Results First Posted	Last Update Posted	Locations	Study Documents	URL
1	NCT02301962	Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer		Recruiting	No Results Available	Cancer	Drug: Panitumumab	Number of subjects with adverse event.|Progression free survival.|Overall Response Rate.|Duration of response.	Dr. Reddy's Laboratories Limited|Amgen	All	18 Years and older   (Adult, Older Adult)	Phase 4	58	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DRL-INDG02-PAN/2018	July 28, 2015	June 30, 2021	January 31, 2022	November 26, 2014		May 16, 2019	DRL Investigational Site, Vijayawada, Andhra Pradesh, India|DRL Investigational Site, Mumbai, Maharashtra, India|DRL Investigational Site, Nagpur, Maharashtra, India|DRL Investigational Site, Nashik, Maharashtra, India|DRL Investigational Site, Nashik, Maharashtra, India|DRL Investigational Site, Ludhiāna, Punjab, India|DRL Investigational Site, Jaipur, Rajasthan, India|DRL Investigational Site, Madurai, Tamilnadu, India|DRL Investigational Site, Hyderabad, Telangana, India|DRL Investigational Site, Kolkata, West Bengal, India|DRL Investigational Site, New Delhi, India|DRL Investigational Site, New Delhi, India		https://ClinicalTrials.gov/show/NCT02301962
2	NCT00768222	Coated VICRYL* Plus Suture Compared to Chinese Silk in Scheduled Breast Cancer Surgery		Completed	Has Results	Breast Cancer	Device: silk suture|Device: VICRYL* Plus suture	Mean Score on Cosmetic Outcome Visual Analog Scale (VAS)|Mean Cosmetic Outcome Score on Modified Hollander Scale|Mean Surgical Site Infection Score on Modified ASEPSIS Scale	Ethicon, Inc.|Johnson & Johnson Medical, China	All	18 Years and older   (Adult, Older Adult)	Phase 4	101	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	200-08-002	October 2008	March 2009	May 2009	October 8, 2008	August 25, 2011	August 31, 2011	Capital Medical Univ. affiliated Hospital, Beijing, China|Jilin Univ. affiliated Second Hospital, Changchun, China|Dalian Medical Univ. affiliated first Hospital, Dalian, China|First Affiliated Hospital, Sun Yat-sen Univ., Guangzhou, China|Fudan Univ. affiliated Zhongshan Hospital, Shanghai, China|Shanghai Jiao Tong Univ. affiliated Ruijin Hospital, Shanghai, China		https://ClinicalTrials.gov/show/NCT00768222
3	NCT02116582	A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer		Completed	Has Results	Metastatic Castration-Resistant Prostate Cancer	Drug: Enzalutamide	Radiographic Progression-free Survival (rPFS)|Overall Survival (OS)|Percentage of Participants With a Prostate-specific Antigen (PSA) Response|Time to PSA Progression|Number of Participants With Adverse Events (AEs)	Astellas Pharma Europe B.V.|Medivation, Inc.|Astellas Pharma Inc	Male	18 Years and older   (Adult, Older Adult)	Phase 4	215	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	9785-CL-0410|2013-002271-17	May 23, 2014	May 8, 2016	September 29, 2017	April 17, 2014	June 8, 2017	November 15, 2018	Site BE32001, Brussels, Flemish Brabant, Belgium|Site BE32004, Gent, Belgium|Site BE32007, Hasselt, Belgium|Site BE32003, Kortrijk, Belgium|Site BE32002, Liege, Belgium|Site FR33015, Angers cedex 02, France|Site FR33009, Caen Cedex 05, France|Site FR33010, Creteil cedex, France|Site FR33014, Le Mans, France|Site FR33013, Lyon Cedex 3, France|Site FR33003, Marseille CEDEX 9, France|Site FR33008, Nantes Saint Herblain Cedex, France|Site FR33002, Nimes, France|Site FR33001, Paris cedex 15, France|Site FR33011, Paris, France|Site FR33007, Rennes, France|Site FR33005, Suresnes, France|Site FR33012, Villejiuf, France|Site DE49005, Nuertingen, Baden-Wuerttemberg, Germany|Site DE49015, Bergisch Gladbach, Northwest, Germany|Site DE49017, Duisburg, NRW, Germany|Site DE49014, Berlin, Germany|Site DE49003, Berlin, Germany|Site DE49009, Bonn, Germany|Site DE49010, Dresden, Germany|Site DE49016, Duesseldorf, Germany|Site DE49004, Goettingen, Germany|Site DE49001, Hamburg, Germany|Site DE49008, Hamburg, Germany|Site DE49007, Hannover, Germany|Site DE49002, Heidelberg, Germany|Site DE49012, Munster, Germany|Site DE49006, Tubingen, Germany|Site ES34004, Santiago de Compostela, A Coruna, Spain|Site ES34009, Badalona, Spain|Site ES34011, Barcelona, Spain|Site ES34006, Barcelona, Spain|Site ES34008, Barcelona, Spain|Site ES34001, Madrid, Spain|Site ES34003, Madrid, Spain|Site ES34002, Madrid, Spain|Site ES34010, Madrid, Spain|Site GB44001, Sutton, Surrey, United Kingdom|Site GB44004, Birmingham, United Kingdom|Site GB44009, Brighton, United Kingdom|Site GB44002, Glasgow, United Kingdom|Site GB44007, London, United Kingdom|Site GB44003, Northwood, Middlesex, United Kingdom|Site GB44010, Plymouth, United Kingdom|Site GB44006, Withington, United Kingdom		https://ClinicalTrials.gov/show/NCT02116582
4	NCT01995513	Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients	PLATO	Active, not recruiting	Has Results	Prostate Cancer	Drug: Enzalutamide|Drug: Abiraterone|Drug: Placebo for Enzalutamide|Drug: Prednisone	Progression Free Survival (PFS)|Time to Prostate Specific Antigen (PSA) Progression|Prostate Specific Antigen (PSA) Response Rate|Objective Response Rate (ORR)|Rate of Pain Progression|Time to First Use of New Antineoplastic Therapy for Prostate Cancer|Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Global Score|Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Social/Family Well-Being Domain Scores|Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Emotional Well-Being Domain Scores|Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Functional Well-Being Domain Scores|Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Prostate Cancer Domain Scores|Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Physical Well-Being Domain Scores|Time to Degradation of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) Global Score	Pfizer|Astellas Pharma Inc|Medivation LLC, a wholly owned subsidiary of Pfizer Inc.	Male	18 Years and older   (Adult, Older Adult)	Phase 4	509	Industry	Interventional	Allocation: Randomized|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	MDV3100-10|2013-000722-54|C3431013|PLATO, C3431013	October 22, 2013	November 15, 2016	May 31, 2024	November 26, 2013	November 17, 2017	August 8, 2019	Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Urology of Virginia, PLLC, Virginia Beach, Virginia, United States|Regional Imaging Border, Albury, New South Wales, Australia|Terry White Chemist, Albury, New South Wales, Australia|Concord Cancer Centre, Medical Oncology Department, Concord, New South Wales, Australia|Epic Pharmacy Lismore, Lismore, New South Wales, Australia|Macquarie University Hospital Pharmacy, North Ryde, New South Wales, Australia|Macquarie University, North Ryde, New South Wales, Australia|Epic Pharmacy Port Macquarie base hospital, Port Macquarie, New South Wales, Australia|Port Macquarie Base Hospital,North Coast Cancer Institute, Port Macquarie, New South Wales, Australia|North Shore Radiology and Nuclear Medicine, St Leonards, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|Sydney Adventist Hospital, Sydney, New South Wales, Australia|Northern NSW Local Health District, Tweed Heads, New South Wales, Australia|Pharmacy Department, The Tweed Hospital, Tweed Heads, New South Wales, Australia|Queensland Diagnostic Imaging, Tweed Heads, New South Wales, Australia|Sydney Adventist Hospital, Wahroonga, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Icon Cancer Care Wesley, Auchenflower, Queensland, Australia|River City Pharmacy - APHS, Auchenflower, Queensland, Australia|Icon Cancer Care Chermside, Chermside, Queensland, Australia|Gold Coast Radiology PTY LTD, Hope Island, Queensland, Australia|Icon Cancer Care South Brisbane, South Brisbane, Queensland, Australia|Icon Cancer Care, South Brisbane, Queensland, Australia|South Coast Radiology, Tugun, Queensland, Australia|Adelaide Cancer Centre, Kurralta Park, South Australia, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia|Cancer Care SA Pty Ltd, Kurralta Park, South Australia, Australia|Tenpharm Pty Ltd trading as EPIC Pharmacy Tennyson, Kurralta Park, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Cabrini Health - Cabrini Hospital, Malvern, Victoria, Australia|Border Medical Oncology, Wodonga, Victoria, Australia|Algemeen Ziekenhuis Groeninge, Kortrijk, West-vlaanderen, Belgium|Cliniques universitaires saint-Luc, Bruxelles, Belgium|Universitaire Ziekenhuizen Leuven, Leuven, Belgium|Rigshospitalet CPC 7521, Copenhagen, Norrebro, Denmark|Arhus Universitetshospital, Arhus N, Denmark|Rigshospitalet, Copenhagen, Denmark|Frederiksberg Hospital, Frederiksberg, Denmark|Helsingin yliopistollinen keskussairaala, Meilahden sairaala, Helsinki, Finland|Oulun yliopistollinen sairaala, Oulu, Finland|Tampereen yliopistollinen Sairaala, Tampere, Finland|Institut Gustave Roussy - Service d'Urologie, Villejuif Cedex, France|Farmacia, Azienda Ospedaliera "Istituti Ospitalieri" di Cremona, Cremona, Italy|Medicina Nucleare, Azienda Ospedaliera "Istituti Ospitalieri" di Cremona, Cremona, Italy|Servizio di Radiologia, Azienda Ospedaliera "Istituti Ospitalieri" di Cremona, Cremona, Italy|U.O di Oncologia-Presidio Ospedaliero di Cremona-Istituti Ospitalieri di Cremona, Cremona, Italy|Laboratorio Farmaci Antiblastici, Meldola (FC), Italy|U.O. Oncologia Medica, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura, Meldola (FC), Italy|UO Radiologia, Meldola (FC), Italy|Farmacia Ospedaliera, A.O.U. San Luigi Gonzaga, Orbassano TO, Italy|SCDU Oncologia Medica II Pad, A.O.U. San Luigi Gonzaga, Orbassano TO, Italy|SCDU Radiodiagnostica, A.O.U. San Luigi Gonzaga, Orbassano TO, Italy|SS Medicina Nucleare, A.O.U. San Luigi Gonzaga, Orbassano TO, Italy|Farmacia, Ospedale Forlanini, Roma, Italy|Azienda Ospedaliera S. Camillo Forlanini, UOC per il governo clinico in Oncologia Medica, Roma, Italy|UOC Radiologia, Azienda Ospedaliera S. Camillo Forlanini, Roma, Italy|Fakultna nemocnica s poliklinikou F.D. Roosevelta, Banska Bystrica, Slovakia|Institut nuklearnej a molekularnej mediciny, Banska Bystrica, Slovakia|Fakultna nemocnica s poliklinikou F.D. Roosevelta, Banska Bystrica, Slovakia|Bratislavske radiodiagnosticke centrum,a.s., Bratislava, Slovakia|CUIMED, s.r.o., urologicka ambulancia, Bratislava, Slovakia|Univerzitna nemocnica martin, Martin, Slovakia|Jessenius-diagnosticke centrum, a.s., Nitra, Slovakia|Uroexam, spol. s r.o., Urologicka ambulancia, Nitra, Slovakia|IZOTOPCENTRUM, s.r.o., Nitra, Slovakia|GAMMALAB, spol.s r.o., Oddelenie nuklearnej mediciny, Trnava, Slovakia|CO Badalona-Instituto Germans Trias i Pujol, Badalona, Barcelona, Spain|ALTAHIA, Xarxa Assistencial Universitaria de Manresa, Manresa, Barcelona, Spain|Hospital Universitari Parc Tauli, Sabadell, Barcelona, Spain|Hospital Universitario Son Espases, Palma, Islas Baleares, Spain|Hospital del Mar, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Urologmottagningen, Goteborg, Sweden|Urologiska kliniken, Malmo, Sweden|Oriola, Molnlycke, Sweden|Apoteket AB Kliniska Provningar Molnlycke, Molnlycke, Sweden|Rontgenkliniken, Orebro, Sweden|Urologmottagningen, Orebro, Sweden|East and North Hertfordshire NHS Trust, Northwood, Middlesex, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom|Velindre NHS Trust, Cardiff, United Kingdom|University College Hospitals NHS Trust, London, United Kingdom|The Royal Marsden NHS Foundation Trust, London, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom|Oxford University Hospitals NHS Trust, Oxford, United Kingdom		https://ClinicalTrials.gov/show/NCT01995513
5	NCT03333655	Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy		Recruiting	No Results Available	Neoplasms	Procedure: Biopsy	Number of Gene Alterations in at-Progression Biopsy of Patricipants with Acquired Immune Escape	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	100	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	ML40108	February 16, 2018	April 20, 2020	April 20, 2020	November 7, 2017		August 14, 2019	UCSF Comp Canc Ctr, San Francisco, California, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine; Dept of Medicine/Div of Medical Oncology, Saint Louis, Missouri, United States|Herbert Irving Comprehensive Cancer Center; Herbert Irving Pavillion, New York, New York, United States|Sarah Cannon Cancer Center, Arrington, Tennessee, United States|Centre Leon Berard; Service Oncologie Medicale, Lyon, France|Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O), Toulouse, France|Seoul National University Hospital; Department of Oncology, Seoul, Korea, Republic of|Clinica Universitaria de Navarra; Servicio de oncología, Pamplona, Navarra, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Barts Hospital; Institute of Cancer, London, United Kingdom		https://ClinicalTrials.gov/show/NCT03333655
6	NCT01961544	Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer	ESKIMO	Completed	Has Results	Breast Neoplasms|Breast Cancer	Drug: Eribulin mesylate	Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Treatment-emergent Serious Adverse Event (SAE)|Disease Control Rate (DCR)	Eisai Korea Inc.|Eisai Inc.	Female	20 Years and older   (Adult, Older Adult)	Phase 4	101	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EKI-CT-1301	June 2013	July 2015	July 2015	October 11, 2013	October 7, 2016	October 7, 2016	Chungbuk National University Hospital, Cheongju, Chungcheongbuk-do, Korea, Republic of|National Cancer Center, Goyang, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of|Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of|Dong-A University Hospital, Busan, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01961544
7	NCT01977651	A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide	UPWARD	Completed	No Results Available	Metastatic Castration-resistant Prostate Cancer (mCRPC)	Drug: Enzalutamide	The proportion of evaluable subjects with at least one confirmed seizure as adjudicated by the Independent Adjudication Committee (IAC)	Astellas Pharma Global Development, Inc.|Medivation, Inc.|Astellas Pharma Inc	Male	Child, Adult, Older Adult	Phase 4	424	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	9785-CL-0403|2013-003022-92|U1111-1157-0224	September 24, 2013	February 1, 2016	January 11, 2019	November 7, 2013		February 15, 2019	Site US10005, Anchorage, Alaska, United States|Site US10024, Detroit, Michigan, United States|Site US10026, Bronx, New York, United States|Site US10001, New York, New York, United States|Site US10014, New York, New York, United States|Site US10039, Syracuse, New York, United States|Site US10016, Durham, North Carolina, United States|Site US10008, Dallas, Texas, United States|Site US10025, Seattle, Washington, United States|Site AR54001, Berazategui, Buenos Aires, Argentina|Site AR54006, Ciudad Autonoma de BuenosAires, Buenos Aires, Argentina|Site AR54002, Buenos Aires, Caba, Argentina|Site AR54003, Cordoba, Argentina|Site AR54004, Santa Fe, Argentina|Site AR54005, Tucuman, Argentina|Site AU61012, Kogarah, New South Wales, Australia|Site AU61005, Randwick, New South Wales, Australia|Site AU61011, Sydney, New South Wales, Australia|Site AU61001, Tweed Heads, New South Wales, Australia|Site AU61002, Nambour, Queensland, Australia|Site AU61007, Adelaide, South Australia, Australia|Site AU61004, Ballarat, Victoria, Australia|Site BE32004, Anderlecht, Belgium|Site BE32001, Kortrijk, Belgium|Site BE32003, Liege, Belgium|Site CA15005, Abbotsford, British Columbia, Canada|Site CA15014, Halifax, Nova Scotia, Canada|Site CA15004, Brampton, Ontario, Canada|Site CA15010, Scarborough, Ontario, Canada|Site CA15001, Quebec City, Quebec, Canada|Site CL56001, Temuco, IX Region, Chile|Site CL56004, Santiago, Chile|Site CL56002, Temuco, Chile|Site CL56003, Vina del Mar, Chile|Site CZ42004, Praha 2, Czechia|Site CZ42002, Praha 6, Czechia|Site FI35803, Helsinki, Finland|Site FI35801, Oulu, Finland|Site FI35802, Tampere, Finland|Site FR33002, Lyon Cedex 03, France|Site FR33004, Rouen Cedex, France|Site FR33005, Suresnes, France|Site DE49009, Nürtingen, Baden-Württemberg, Germany|Site DE49003, Berlin, Germany|Site DE49001, Munster, Germany|Site HU36002, Sopron, Gyor-Moson Sopron, Hungary|Site IL97202, Kfar Saba, HaMerkaz, Israel|Site IL97201, Be'er Ya'akov, Israel|Site IL97203, Beer-Sheva, Israel|Site IL97205, Haifa, Israel|Site IL97204, Jerusalem, Israel|Site IL97208, Nahariya, Israel|Site IL97206, Petah-Tiqva, Israel|Site IL97207, Ramat Gan, Israel|Site IT39005, Meldola, Emilia-Romagna, Italy|Site IT39001, Cremona, Lombardia, Italy|Site IT39002, Arezzo, Italy|Site IT39003, Roma, Italy|Site KR82006, Seongnam-Si, Gyeonggi-do, Korea, Republic of|Site KR82007, Seoul, Korea, Republic of|Site KR82003, Seoul, Korea, Republic of|Site KR82001, Seoul, Korea, Republic of|Site KR82004, Seoul, Korea, Republic of|Site NZ64001, Hamilton, New Zealand|Site SG65002, Singapore, Singapore|Site ES34007, Hospitalet de Llobregat, Barcelona, Spain|Site ES34005, Sabadell, Barcelona, Spain|Site ES34001, Pamplona, Navarra, Spain|Site ES34003, Barcelona, Spain|Site ES34004, Barcelona, Spain|Site ES34006, Madrid, Spain|Site SE46001, Goteborg, Sweden|Site SE46002, Orebro, Sweden|Site TW88601, Kaohsiung, Taiwan|Site TW88603, Taipei City, Taiwan|Site GB44002, Sutton, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT01977651
8	NCT02679755	Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer		Active, not recruiting	No Results Available	Breast Cancer	Drug: Palbociclib|Drug: Letrozole	Percentage of patients with treatment-emergent averse events (AEs) or serious adverse events (SAEs)|Objective Response|Change from Baseline in Dimension Health State EuroQol (EQ-5D) Score	Pfizer	Female	18 Years and older   (Adult, Older Adult)	Phase 4	252	Industry	Interventional	Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment	A5481037	March 9, 2016	July 25, 2019	July 25, 2019	February 10, 2016		July 16, 2019	Alexander David Guminski, North Sydney, New South Wales, Australia|Alexander Maxwell Menzies, North Sydney, New South Wales, Australia|Benjamin Carl Forster, North Sydney, New South Wales, Australia|Frances Mary Boyle, North Sydney, New South Wales, Australia|HPS Pharmacies - North Sydney, North Sydney, New South Wales, Australia|Mater Hospital Sydney, North Sydney, New South Wales, Australia|Royal North Shore Hospital - Clinical Trials Pharmacy, St Leonards, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|Pathology North-RNS, Sydney, New South Wales, Australia|Icon Cancer Care Wesley, Auchenflower, Queensland, Australia|River City Pharmacy, Auchenflower, Queensland, Australia|Icon Cancer Care Chermside, Chermside, Queensland, Australia|Haematology & Oncology Clinics of Australia Pty Ltd trading as Icon Cancer Care Corporate Office, South Brisbane, Queensland, Australia|Icon Cancer Care South Brisbane, South Brisbane, Queensland, Australia|Icon Cancer Foundation, South Brisbane, Queensland, Australia|Icon Cancer Care Southport, Southport, Queensland, Australia|Flinders Medical Centre-Pharmacy Department, Bedford Park, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Monash Health-Parmacy, Clayton, Victoria, Australia|Monash Health, Clayton, Victoria, Australia|Peter MacCallum Cancer Centre Pharmacy, Melbourne, Victoria, Australia|Sunshine Hospital Pharmacy - Clinical Trials, St Albans, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Pharmacy Department, Murdoch, Western Australia, Australia|Rajiv Gandhi Cancer Institute And Research Centre, New Delhi, Delhi, India|Dr. B.R.A Institute Rotary Cancer Hospital, All India Institue of Medical Sciences, New Delhi, Delhi, India|The Gujarat Cancer & Research Institute, Ahmedabad, Gujarat, India|Manipal Hospital, Bangalore, Karnataka, India|HealthCare Global Enterprises Ltd., Bangalore, Karnataka, India|Kasturba Hospital, Manipal Centre For Clinical Research, Manipal, Karnataka, India|Tata Memorial Centre, Tata Memorial Hospital, Mumbai, Maharashtra, India|Meditrina Institute Of Medical Sciences, Nagpur, Maharashtra, India|Shatabdi Hospital, Nashik, Maharashtra, India|Deenanath Mangeshkar Hospital and Research Center, Pune, Maharashtra, India|Sahyadri Speciality Hospital, Pune, Maharashtra, India|Apollo Speciality Hospital, Chennai, Tamilnadu, India		https://ClinicalTrials.gov/show/NCT02679755
9	NCT02918968	Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer		Active, not recruiting	No Results Available	Prostate Cancer	Drug: Enzalutamide|Drug: Flutamide|Other: Androgen deprivation therapy	Time to prostate specific antigen (PSA) progression with 1st line AAT|Time to PSA progression with 1st line AAT + 2nd line AAT|PSA response rate to 1st line AAT (50%)|PSA response rate to 1st line AAT (90%)|PSA response rate to 1st line AAT (50%) at Week 13|PSA response rate to 1st line AAT (90%) at Week 13|Time to PSA decrease by 50% from baseline with 1st line AAT|Time to discontinuation of 1st line AAT|Time to discontinuation of 2nd line AAT|Radiographic progression-free survival (rPFS)|Safety assessed by incidence of adverse events|Safety assessed by laboratory test: hematology|Safety assessed by laboratory test: biochemistry|Safety assessed by blood pressure|Safety assessed by pulse rate|Safety assessed by ECOG Performance Status	Astellas Pharma Inc|Pfizer	Male	20 Years and older   (Adult, Older Adult)	Phase 4	206	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	9785-MA-3051	November 2, 2016	March 2020	March 2020	September 29, 2016		July 11, 2019	Site JP00024, Nagoya, Aichi, Japan|Site JP00025, Nagoya, Aichi, Japan|Site JP00038, Matsuyama, Ehime, Japan|Site JP00051, Iizuka, Fukuoka, Japan|Site JP00045, Isesaki, Gunma, Japan|Site JP00005, Maebashi, Gunma, Japan|Site JP00043, Ota, Gunma, Japan|Site JP00054, Hakodate, Hokkaido, Japan|Site JP00001, Sapporo, Hokkaido, Japan|Site JP00002, Sapporo, Hokkaido, Japan|Site JP00048, Sapporo, Hokkaido, Japan|Site JP00055, Mito, Ibaraki, Japan|Site JP00019, Sagamihara, Kanagawa, Japan|Site JP00020, Yokohama, Kanagawa, Japan|Site JP00021, Yokohama, Kanagawa, Japan|Site JP00044, Yokosuka, Kanagawa, Japan|Site JP00046, Kashihara, Nara, Japan|Site JP00033, Kurashiki, Okayama, Japan|Site JP00028, Hirakata, Osaka, Japan|Site JP00030, Osakasayama, Osaka, Japan|Site JP00027, Suita, Osaka, Japan|Site JP00009, Kitaadachi-gun, Saitama, Japan|Site JP00022, Hamamatsu, Shizuoka, Japan|Site JP00049, Utsunomiya, Tochigi, Japan|Site JP00011, Bunkyo-ku, Tokyo, Japan|Site JP00017, Bunkyo-ku, Tokyo, Japan|Site JP00013, Koto-ku, Tokyo, Japan|Site JP00014, Nakano-ku, Tokyo, Japan|Site JP00016, Shinagawa-ku, Tokyo, Japan|Site JP00018, Shinjuku-ku, Tokyo, Japan|Site JP00034, Ube, Yamaguchi, Japan|Site JP00010, Chiba, Japan|Site JP00053, Chiba, Japan|Site JP00039, Fukuoka, Japan|Site JP00040, Fukuoka, Japan|Site JP00050, Fukuoka, Japan|Site JP00035, Hiroshima, Japan|Site JP00026, Kyoto, Japan|Site JP00006, Nagano, Japan|Site JP00008, Nagano, Japan|Site JP00041, Nagasaki, Japan|Site JP00029, Osaka, Japan|Site JP00031, Osaka, Japan|Site JP00032, Osaka, Japan|Site JP00042, Saga, Japan|Site JP00037, Tokushima, Japan|Site JP00052, Toyama, Japan		https://ClinicalTrials.gov/show/NCT02918968
10	NCT03220178	Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy	PRECYCLE	Recruiting	No Results Available	Breast Neoplasm	Drug: Palbociclib|Drug: Fulvestrant|Drug: Anastrozole|Drug: Letrozole|Drug: Exemestane	DQoL|Progression-free survival|Overall survival|Drug intake|Global health status	Palleos Healthcare GmbH|WSG WOMEN´S HEALTHCARE STUDY GROUP|CANKADO|Pfizer|AGO-TraFo|AGO-B|Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V.	Female	18 Years and older   (Adult, Older Adult)	Phase 4	960	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PH001-PreCycle	July 24, 2017	December 31, 2024	March 31, 2025	July 18, 2017		March 25, 2019	University Hospital Mainz, Mainz, Germany		https://ClinicalTrials.gov/show/NCT03220178
11	NCT03035032	A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients		Active, not recruiting	No Results Available	Prostate Cancer	Drug: Leuprolide	Incidence of drug-related adverse events|Percentage of participants with testosterone < 20 ng/dL|Percentage of participants with testosterone 20-50 ng/dL|Percentage of participants with testosterone > 50 ng/dL|Time to Prostate Specific Antigen (PSA) progression|Change from baseline in quality of life assessed by EORTC QLQ-PR25|Change from baseline in quality of life assessed by EQ5D-5L	Astellas Pharma Singapore Pte. Ltd.|Astellas Pharma Inc	Male	18 Years and older   (Adult, Older Adult)	Phase 4	107	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	7015-MA-3072	June 23, 2017	November 2019	November 2019	January 27, 2017		March 21, 2019	Site HK01001, Hong Kong, Hong Kong|Site HK01002, Hong Kong, Hong Kong|Site ID02001, Jakarta, DKI Jakarta, Indonesia|Site MY03002, Batu Caves, Selangor, Malaysia|Site MY03001, Kuala Lumpur, Malaysia|Site PH04001, Makati City, Metro Manila, Philippines|Site PH04003, Manila, Metro Manila, Philippines|Site PH04002, San Juan, Metro Manila, Philippines|Site SG05001, Singapore, Singapore|Site SG05002, Singapore, Singapore|Site SG05003, Singapore, Singapore|Site TW06001, Taichung, Taiwan|Site TW06002, Taichung, Taiwan|Site TW06003, Taipei, Taiwan|Site TH07001, Muang, Chiang Mai, Thailand|Site TH07004, Hat Yai, Songkhla, Thailand|Site TH07003, Bangkok, Thailand|Site VN08001, Ho Chi Minh City, Vietnam|Site VN08002, Ho Chi Minh City, Vietnam		https://ClinicalTrials.gov/show/NCT03035032
12	NCT00014638	Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer		Completed	No Results Available	Breast Cancer	Drug: letrozole		Novartis	Female	18 Years and older   (Adult, Older Adult)	Phase 4		Industry	Interventional	Primary Purpose: Treatment	CDR0000068583|NOVARTIS-CFEM345A-US10	January 2001	March 2002	March 2002	November 13, 2003		February 21, 2013	Alta Bates Comprehensive Cancer Center, Berkeley, California, United States|Long Beach Memorial Breast Center, Long Beach, California, United States|Cancer Research Network, Inc., Hollywood, Florida, United States|Oncology-Hematology Group of South Florida, Miami, Florida, United States|Pharm Research, Pinecrest, Florida, United States|Cancer Research Network Inc., Plantation, Florida, United States|Good Samaritan Medical Center, West Palm Beach, Florida, United States|Illinois Oncology, Ltd., Belleville, Illinois, United States|Joliet Oncology/Hematology Associates, Ltd., Joliet, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Southwest Oncology Association, Lafayette, Louisiana, United States|New Mexico Oncology-Hematology, Albuquerque, New Mexico, United States|Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States|Oncology Partnership Network, Cincinnati, Ohio, United States|Memphis Cancer Center, Memphis, Tennessee, United States|Dial Research Associates, Inc., Nashville, Tennessee, United States|Center for Oncology Research and Treatment, Medical City Hospital, Dallas, Texas, United States|Intermountain Hematology/Oncology Associates, Inc., Salt Lake City, Utah, United States|Cascade Cancer Center, Kirkland, Washington, United States		https://ClinicalTrials.gov/show/NCT00014638
13	NCT00237224	Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole		Completed	No Results Available	Breast Cancer	Drug: Letrozole	Identify Eg and/or Pg receptors in breast cancer patients in adjuvant treatment with tamoxifen for 4-5 years|Identify the number of patients in adjuvant treatment with tamoxifen within 4-5 years or close to end this treatment time|Determine the relation of positive Eg / Pg receptors vs negative (unknown) Eg / Pg receptors and the only selection criteria for the adjuvant treatment with tamoxifen is postmenopause status	Novartis Pharmaceuticals|Novartis	Female	45 Years to 80 Years   (Adult, Older Adult)	Phase 4	40	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CFEM345EMX01	February 2003	February 2007		October 12, 2005		November 19, 2009	Novartis Investigative Site, Guadalajara, Zacatecas, México DF, Mexico		https://ClinicalTrials.gov/show/NCT00237224
14	NCT03564938	Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).		Recruiting	No Results Available	Colorectal Neoplasms	Drug: Regorafenib (Stivarga, BAY73-4506)	Number of Adverse Events|Changes in Eastern Cooperative Oncology Group Performance Status (ECOG PS)|Abnormal laboratory changes with clinical significance|Changes in vital signs|Disease control rate (DCR) defined as proportion of patients achieving complete response (CR), partial response (PR), or SD (stable disease) per Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1|Overall response rate (ORR) defined as proportion of patients achieving CR, and PR per RECIST v.1.1|Progression free survival (PFS)|Overall survival (OS)	Bayer	All	18 Years and older   (Adult, Older Adult)	Phase 4	100	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	19214	July 30, 2018	May 20, 2021	May 20, 2021	June 21, 2018		August 6, 2019	HCG-City Cancer Centre, Vijayawada, Andhra Pradesh, India|BLK Super Speciality Hospital, New Delhi, Delhi, India|Sir Ganga Ram Hospital, New-Delhi, Delhi, India|The Gujarat Cancer & Research Institute, Ahmedabad, Gujarat, India|Manipal Hospital, Bangalore, Karnataka, India|Healthcare Global Enterprises Ltd, Bangalore, Karnataka, India|Tata Memorial Hospital, Mumbai, Maharashtra, India|Fortis Hospital, West-Mumbai, Maharashtra, India|Apollo Speciality Hospitals, Madurai, Tamil N?du, India|IPGME & R / SSKM Hospital, Kolkata, West Bengal, India|Health Point Hospital, Kolkata, West Bengal, India|Indraprastha Apollo Hospital, New Delhi, India		https://ClinicalTrials.gov/show/NCT03564938
15	NCT02034708	Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors	REMIND	Completed	Has Results	Primary Brain Tumor	Drug: Dotarem®|Drug: Gadovist®/Gadavist®	Percentage of Patients With Overall Lesion Visualization and Characterization Scored as Good or Excellent	Guerbet	All	18 Years and older   (Adult, Older Adult)	Phase 4	279	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic	DGD-44-058	June 2014	September 2015	September 2015	January 13, 2014	October 25, 2016	December 30, 2016	University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Arizona Medical Center, Tucson, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Infinity Clinical Research, LLC, Hollywood, Florida, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Quest Research Institute, Farmington Hills, Michigan, United States|Spectrum Health, Grand Rapids, Michigan, United States|Washington University, St. Louis, Missouri, United States|Winthrop University Hospital Clinical Trials Center, Mineola, New York, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|MUSC (Medical University of South Carolina), Charleston, South Carolina, United States|UVM MRI Center for Biomedical Imaging, Burlington, Vermont, United States|University of Washington Medical Center, Seattle, Washington, United States|Fundacion Abood Shaio, Bogota, Colombia|Fundacion Cardioinfantil Instituto de Cardiologia, Bogota, Colombia|Instituto Nacional de Cancerologia, Bogota, Colombia|Centro Medico Imbanaco, Cali, Colombia|Fundacion Instituto de Alta Tecnologia Medica de Antioquia IATM, Medellin, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Chungbuk National University, Cheongju-si, Chungcheongbuk-do, Korea, Republic of|Chonbuk national Univ Hosp, Jeonju-si, Jeollabuk-do, Korea, Republic of|Seoul St.Mary Hospital, Seoul, Seocho-gu, Korea, Republic of|Asan medical center, Seoul, Songpa-Gu, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of|Morales Vargas Centro de Investigación S.C., Leon, Guanajuato, Mexico|Centro Neurologico ABC, Mexico, Mexico Distrito Federal, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo Leon, Mexico|Winsett Rethman S.A. de C.V., Monterrey, Nuevo León, Mexico|Hospital CIMA, Chihuahua, Mexico|Centro Regiomontano de Investigacion S.C., Monterrey, Mexico|Clinical Research Institute S.C., Tlanepantla, Mexico		https://ClinicalTrials.gov/show/NCT02034708
16	NCT03583944	A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer		Active, not recruiting	No Results Available	Breast Neoplasms	Drug: Eribulin Mesylate	Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Number of Participants with TEAEs Related to Laboratory Parameters|Objective Tumor Response|Objective Response Rate (ORR)	Eisai Inc.	Female	18 Years and older   (Adult, Older Adult)	Phase 4	200	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	E7389-M065-401	March 28, 2018	August 2019	November 2019	July 12, 2018		March 11, 2019	Sir Ganga Ram Hospital, New Delhi, Delhi, India|HEMATO-ONCOLOGY CLINIC Vedanta Institute of Medical Sciences, Ahmedabad, Gujarat, India|HealthCare Global Enterprises Ltd, Bangalore, Karnataka, India|Srinivasam Cancer Care Multispecialty Hospitals India Pvt Ltd, Bangalore, Karnataka, India|KR Hospital Mysore Medical College, Mysore, Karnataka, India|Tata Memorial Hospital Department of Oncology, Mumbai, Maharashtra, India|HCG NCHRI Cancer Centre, Nagpur, Maharashtra, India|Lokmanya Hospital, Pune, Maharashtra, India|All India Institute of Medical Sciences, Bhubaneswar, Orissa, India|Deep Hospital, Ludhiana, Punjab, India|Sawai Man Singh Hospital, Jaipur, Rajasthan, India|MNJ Institute of Oncology and Regional Cancer Centre, Hyderabad, Telangana, India|J.K.Cancer Institute, Kanpur, Uttar Pradesh, India|King George's Medical University,(Erstwhile Chhatrapati Shahuji Maharaj Medical University), Lucknow, Uttar Pradesh, India|Ajanta Research Centre, Ajanta Hospital & IVF Centre, Lucknow, Uttar Pradesh, India|Nilratan Sircar Medical College and Hospital, Kolkata, West Bengal, India|Netaji Subhash Chandra Bose Cancer Institute, Kolkata, West Bengal, India|IPGME&R S.S.K.M Hospital, Kolkata, West Bengal, India		https://ClinicalTrials.gov/show/NCT03583944
17	NCT01719757	PROspective Non-interventional Open laBEl Trial for TARGIN in Korean Patients With Cancer Pain	PROBE	Completed	Has Results	Cancer	Drug: Oxycodone/Naloxone	Change in Numeric Rating Scales (NRS) Score|Change of Eastern Cooperative Oncology Group(ECOG) Performance Status|Change of Constipation Assessment From Baseline to Visit 2(End Visit)|Overall Satisfaction Assessment About Efficacy and Tolerability of Oxycodone/Naloxone by the Investigator and Subject	Mundipharma Korea Ltd	All	20 Years and older   (Adult, Older Adult)	Phase 4	359	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OXN11-KR-404	July 2012	October 2013	April 2014	November 1, 2012	August 19, 2016	August 19, 2016	13 sites including Yeungnam University Medical Center, Daegu, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01719757
18	NCT01511874	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer		Completed	No Results Available	Prostate Cancer	Drug: ELIGARD 22.5mg	Ratio of subjects whose blood testosterone concentration is maintained below 50ng/dl at 4 weeks after injection of ELIGARD 22.5mg|Ratio of subjects whose blood testosterone concentration is maintained below 50ng/dL until 24weeks|Ratio of subjects whose blood testosterone concentration exceed 50ng/dL until 24weeks|Change in self assessment scale grade|Ratio of subjects whose blood testosterone concentration is below 20ng/dL at 4weeks and 24weeks|Change in ECOG performance status|Change in blood prostate-specific antigen|Change in QoL_EPIC grade|Change in penile length|Change in testicular volume	HanAll BioPharma Co., Ltd.	Male	20 Years and older   (Adult, Older Adult)	Phase 4	42	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	fr-HE530-01	January 2011	May 2013	December 2013	January 19, 2012		September 23, 2015	Department of Urology,Yonsei University,College of Medicine, Gangnam Severance Hospital, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01511874
19	NCT03573960	A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer		Recruiting	No Results Available	Thyroid Neoplasms	Drug: Lenvatinib	Percentage of Participants with Grade 3 or Higher Treatment-emergent Adverse Events (TEAEs)|Number of Dose Reductions|Time to First Dose Reduction|Objective Response Rate (ORR)|Progression-free Survival (PFS)|Percentage of Participants with Greater Than or Equal to (>=) Grade 2 Other TEAEs	Eisai Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 4	50	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	E7080-M091-507	May 10, 2018	February 1, 2020	August 1, 2020	June 29, 2018		May 20, 2019	City Cancer Centre, Vijayawada, Andhra Pradesh, India|All India Institute of Medical Sciences, New Delhi, Delhi, India|Indraprastha Apollo Hospital, New Delhi, Delhi, India|Shetty's Hospital, Bangalore, Karnataka, India|Deenanath Mangeshkar Hospital, Pune, Maharashtra, India|All India Institute of Medical Sciences, Bhubaneshwar, Odisa, India|S. P. Medical College & A. G. Hospitals, Bīkaner, Rajasthan, India|BL Kapoor Hospital, New Delhi, New Delhi, India|Indrayani Hospital, Alandi, Pune, India		https://ClinicalTrials.gov/show/NCT03573960
20	NCT03511378	Assessment of the Immunogenicity of Peg-filgrastim Versus Neulasta® as an Adjunct to Chemotherapy in Patients With Breast Cancer		Recruiting	No Results Available	Breast Cancer	Drug: Lupin's Pegfilgrastim|Drug: Neulasta®	Primary Immunogenicity Endpoint: Cumulative Incidence of anti-pegfilgrastim antibodies (binding & neutralizing) at the end of cycle 4 (Day 84)|Secondary Immunogenicity endpoint: Incidence of anti-pegfilgrastim antibodies (binding & neutralizing) on Day 10, Day 21, Day 42, Day 63 and Day 84.|Secondary Immunogenicity endpoint: Cumulative Incidence of anti-peg antibodies (binding & neutralizing) at the end of cycle 4 (Day 84).|Secondary Immunogenicity Endpoint: Incidence of anti-peg antibodies (binding & neutralizing) on Day 10, Day 21, Day 42, Day 63 and Day 84.|Secondary Safety Endpoint: Incidence of AEs over time to end of study|Secondary Safety Endpoint, Respiratory rate : Number of patients with clinically meaningful changes from baseline in vital signs over the time.|Secondary Safety Endpoint, Body Temperature: Number of patients with clinically meaningful changes from baseline in vital signs over the time.|Secondary Safety Endpoint, Pulse rate: Number of patients with clinically meaningful changes from baseline in vital signs over the time.|Secondary Safety Endpoint, Blood pressure: Number of patients with clinically meaningful changes from baseline in vital signs over the time.|Secondary Safety Endpoint: Number of patients with abnormal clinically significant physical examination findings over the period.|Secondary Safety Endpoint, hematology: Number of patients with clinically meaningful abnormal clinical laboratory findings over the time.|Secondary Safety Endpoint, blood biochemistry: Number of patients with clinically meaningful abnormal clinical laboratory findings over the time.|Secondary Safety Endpoint, urinanalysis: Number of patients with clinically meaningful abnormal clinical laboratory findings over the time.	Lupin Ltd.	Female	18 Years and older   (Adult, Older Adult)	Phase 4	150	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LRP/PegGCSF/2016/004	March 6, 2018	March 6, 2019	March 6, 2019	April 27, 2018		April 30, 2018	Apple Hospital, Sūrat, Gujarat, India		https://ClinicalTrials.gov/show/NCT03511378
21	NCT00323479	Arthralgia During Anastrozole Therapy for Breast Cancer		Completed	Has Results	Early Breast Cancer	Drug: Anastrozole	Number of Participants With New Events of Arthralgia|Functional Index of Cochin at 12 Months in Patients Under Anastrozole.|Serum Collagen Degradation Type I - CTX-I at 12 Months in Patients Under Anastrozole|Kellgren and Lawrence Score at 12 Months in Patients Under Anastrozole|Synovial Membrane Thickness at 12 Months in Patients Under Anastrozole|Percentage of Participant With Therapeutic Maintenance Under Anastrozole	AstraZeneca	Female	18 Years and older   (Adult, Older Adult)	Phase 4	114	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D5392L00013|2005-00-5441-19 EUDRACT number	June 2006	January 2009	January 2009	May 9, 2006	April 6, 2012	April 6, 2012	Research Site, Bordeaux, France|Research Site, Caen, France|Research Site, Lyon, France|Research Site, Paris, France|Research Site, Poitiers, France		https://ClinicalTrials.gov/show/NCT00323479
22	NCT02660229	An Interventional Study for Patient With Cancer Pain to Evaluate the Efficacy and Safety of OxyNorm® Compared to Morphine Sulfate Through the IV Continuous Infusion.	SWITCH	Completed	Has Results	Cancer Pain	Drug: Oxycodone Hydrochloride|Drug: Morphine Sulphate	Change in the Mean Pain Score(NRS) From Baseline(Day 0) to Day 5.|Total Dose of IV(IV Infusion+Bolus Injection) Study Drug Administered During the Treatment Duration|Patient's Overall Satisfaction With Each Continuous Infusion on Day 5 After Randomization|Investigator's Overall Satisfaction With IV Infusion on 5 Days After Randomization	Mundipharma Korea Ltd	All	19 Years and older   (Adult, Older Adult)	Phase 4	66	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	OXI15-KR-401	November 2015	July 2016	July 2016	January 21, 2016	November 19, 2018	November 19, 2018	Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT02660229
23	NCT00363311	Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men		Completed	Has Results	Neoplasms, Prostate	Drug: Dutasteride|Drug: Matching placebo	Number of Participants With Prostate Cancer (PCa) Progression [Restricted Crude Rate Analysis: Number of Participants With PCa Divided by Number of Participants in the Intent-to-Treat (ITT) Population Who Had >=1 Post-baseline Biopsy or Had a Progression|Number of Participants With Therapeutic Progression|Number of Participants With Pathologic Progression|Participants With at Least One Post-baseline Biopsy With the Indicated Prostate Cancer (PCa) Diagnosis|Participants With at Least One Post-baseline Biopsy With the Indicated Prostate Cancer (PCa) Diagnosis for Their Final Biopsy|Number of Cancer-positive Cores in a 12-core Biopsy|Change From Baseline in the Number of Cancer-positive Cores in a 12-core Biopsy at Years 1.5, 3, and 0-3|Mean Percentage of Cancer-positive Cores in a 12-core Biopsy|Change From Baseline in the Percentage of Cancer-positive Cores in a 12-core Biopsy at Years 1.5, 3, and 0-3|Cumulative Length of Cancer Tumor Core|Change From Baseline in the Cumulative Length of Cancer Tumor Core at Years 1.5, 3, and 0-3|Number of Participants With the Indicated Change From Baseline in Gleason Score (GS) on Repeat Biopsy at Year 1.5|Number of Participants With the Indicated Change From Baseline in Gleason Score on Repeat Biopsy at Years 0-3|Number of Participants With the Indicated Total Gleason Score|Number of Biopsies With the Indicated Clinical Tumor Stage at Baseline|Number of Post-baseline Biopsies With the Indicated Change From Baseline in Clinical Stage|Prostate Volume (PV) LOCF|Change From Baseline in Prostate Volume at Years 1.5 and 3|Percent Change From Baseline in Prostate Volume at Years 1.5 and 3|Total Memorial Anxiety Scale Scores for Prostate Cancer (MAX-PC)|Change From Baseline in Total Memorial Anxiety Scale Scores for Prostate Cancer (MAX-PC) LOCF|Total MAX-PC Anxiety Subscale Score Related to PSA Testing|Change From Baseline in MAX-PC Anxiety Subscale Score Related to PSA Testing (LOCF)|Total MAX-PC Fear of Recurrence Subscale Score|Change From Baseline in MAX-PC Fear of Recurrence Subscale Score (LOCF)|Total Functional Assessment of Cancer Therapy Scale, Prostate Module (FACT-P) Score|Change From Baseline in Total FACT-P Score (LOCF)|Percent Change From Baseline in Total FACT-P Score (LOCF)|Change From Baseline in FACT-P Physical Well-Being Subscale Score (LOCF)|Change From Baseline in FACT-P Social Well-Being Subscale Score (LOCF)	GlaxoSmithKline	Male	50 Years to 80 Years   (Adult, Older Adult)	Phase 4	302	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	AVO105948	July 2006	March 2010	July 2010	August 15, 2006	June 14, 2011	January 18, 2017	GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Beverly Hills, California, United States|GSK Investigational Site, Laguna Hills, California, United States|GSK Investigational Site, Mission Hills, California, United States|GSK Investigational Site, Modesto, California, United States|GSK Investigational Site, San Bernardino, California, United States|GSK Investigational Site, Torrance, California, United States|GSK Investigational Site, Englewood, Colorado, United States|GSK Investigational Site, Wheat Ridge, Colorado, United States|GSK Investigational Site, New Britain, Connecticut, United States|GSK Investigational Site, Trumbull, Connecticut, United States|GSK Investigational Site, Washington, District of Columbia, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Largo, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Roswell, Georgia, United States|GSK Investigational Site, Coeur D'Alene, Idaho, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Melrose Park, Illinois, United States|GSK Investigational Site, Fort Wayne, Indiana, United States|GSK Investigational Site, Newburgh, Indiana, United States|GSK Investigational Site, Overland Park, Kansas, United States|GSK Investigational Site, Shreveport, Louisiana, United States|GSK Investigational Site, Annapolis, Maryland, United States|GSK Investigational Site, Greenbelt, Maryland, United States|GSK Investigational Site, Watertown, Massachusetts, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, St. Cloud, Minnesota, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Marlton, New Jersey, United States|GSK Investigational Site, Albuquerque, New Mexico, United States|GSK Investigational Site, Albany, New York, United States|GSK Investigational Site, Elmont, New York, United States|GSK Investigational Site, Garden City, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Orchard Park, New York, United States|GSK Investigational Site, Syracuse, New York, United States|GSK Investigational Site, Greensboro, North Carolina, United States|GSK Investigational Site, Salisbury, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Springfield, Oregon, United States|GSK Investigational Site, Bala Cynwyd, Pennsylvania, United States|GSK Investigational Site, Lancaster, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Memphis, Tennessee, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Temple, Texas, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Virginia Beach, Virginia, United States|GSK Investigational Site, Williamsburg, Virginia, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Spokane, Washington, United States|GSK Investigational Site, Surrey, British Columbia, Canada|GSK Investigational Site, Victoria, British Columbia, Canada|GSK Investigational Site, Victoria, British Columbia, Canada|GSK Investigational Site, Fredericton, New Brunswick, Canada|GSK Investigational Site, Barrie, Ontario, Canada|GSK Investigational Site, Brampton, Ontario, Canada|GSK Investigational Site, Brantford, Ontario, Canada|GSK Investigational Site, Burlington, Ontario, Canada|GSK Investigational Site, Burlington, Ontario, Canada|GSK Investigational Site, Guelph, Ontario, Canada|GSK Investigational Site, Kitchener, Ontario, Canada|GSK Investigational Site, North Bay, Ontario, Canada|GSK Investigational Site, Oakville, Ontario, Canada|GSK Investigational Site, Scarborough, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Chicoutimi, Quebec, Canada|GSK Investigational Site, Greenfield Park, Quebec, Canada|GSK Investigational Site, Laval, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Pointe-Claire, Quebec, Canada|GSK Investigational Site, Quebec City, Quebec, Canada|GSK Investigational Site, Trois Rivieres, Quebec, Canada		https://ClinicalTrials.gov/show/NCT00363311
24	NCT01176916	Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China		Completed	No Results Available	Breast Neoplasms	Drug: Aromasin (exemestane)	Time-to-event, where event is defined as the earliest occurrence any of the following: Locoregional/distant recurrence of the primary breast cancer; Appearance of 2nd primary or contralateral breast cancer; Death|The proportion of subjects experiencing the event|The incidence rate (per annum) defined as a ratio of the number of events and the total exposure times (in years) to Aromasin® therapy|The relationship between Her2 overexpression level and time-to-event|The incidence of adverse events and discontinuation of Aromasin® due to adverse event	Pfizer	Female	18 Years to 99 Years   (Adult, Older Adult)	Phase 4	564	Industry	Interventional	Masking: None (Open Label)	A5991093|NRA5990043	February 9, 2011	November 30, 2018	November 30, 2018	August 6, 2010		July 16, 2019	The First Affiliated Hospital of Bengbu Medical College/Medical Oncology Department, Bengbu, Anhui, China|The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China|The Second Hospital of Anhui Medical University, Hefei, Anhui, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China|The First hospital of LanZhou university, Lanzhou, Gansu, China|Breast Surgery of The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|SUN YAT-SEN Memorial Hospital , SUN YAT-SEN University, Guangzhou, Guangdong, China|Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China|Thyroid and breast surgery, Shenzhen City, Guangdong, China|Affiliated hospital of Guangdong medical college, ZhanJiang, Guangdong, China|Hainan General Hospital, Haikou, Hainan, China|Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Henan provincial people's hospital, Zhengzhou, Henan, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|Jingzhou Hospital Tongji Medical College Huazhong university of science and Technology, Jingzhou, Hubei, China|Breast and thyroid surgery of the Central Hospital of WuHan, WuHan, Hubei, China|Hunan Provincial People's Hospital, Changsha, Hunan, China|Xiangya Hospital Central South University /Department of Breast, Changsha, Hunan, China|The Affiliated Hospital of inner Mongolia medical university, Hu He Hao Te, Inner Mongolia, China|Changzhou No.2 People's Hospital, Changzhou, Jiangsu, China|Jiangsu Cancer Hospital/ Surgery Department, Nanjing, Jiangsu, China|Jinling Hospital, Nanjing, Jiangsu, China|Jiangsu Province Hospital/ Surgery Department, Nanjing, Jiangsu, China|Nanjing Maternity and Child Health Care Hospital/Department of Breast Surgery, Nanjing, Jiangsu, China|Suzhou Municipal Hospital, Suzhou, Jiangsu, China|The first hospital of jilin university, Changchun, Jilin, China|The Fourth Affiliated Hospital Of China Medical University, ShenYang, Liaoning, China|The First Affiliated Hospital of The Fourth Military Medical University, Xi'an, Shaanxi, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China|Linyi People's Hospital, Linyi, Shandong, China|The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China|Qingdao municipal Hospital, Qingdao, Shandong, China|Breast Surgery of The Weifang People's Hospital, Weifang, Shandong, China|Breast Surgery of YanTai Yu Huang Ding Hospital, Yan Tai, Shandong, China|Breast and thyroid surgery of Central Hospital of Zibo, Zibo, Shandong, China|West China Hospital, Sichuan University/ Oncology Department, Chengdu, Sichuan, China|Sichuan Provincial People's Hospital, Chengdu, Sichuan, China|Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China|Tianjin Cancer Hospital/Breast cancer department, Tianjin, Tianjin, China|Affiliated Cancer Hospital of Xinjiang Medical University, Urumchi, Xinjiang, China|Yunnan Cancer Hospital, Kunming, Yunnan, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|Cancer Hospital Chinese Academy of medical sciences, Beijing, China|Fifth Medical Center of the PLA General Hospital, Beijing, China|Beijing Cancer Hospital, Beijing, China|Peking University Third Hospital/Department of Oncology, Beijing, China|China-Japan Friendship Hospital, Beijing, China|Fudan University Shanghai Cancer center/Department of Breast Surgery, Shanghai, China|Yangpu District Central Hospital, Shanghai, China|Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, China		https://ClinicalTrials.gov/show/NCT01176916
25	NCT00470834	Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy		Completed	Has Results	Neoplasms, Prostate	Drug: dutasteride|Drug: placebo|Drug: bicalutamide	Time to Disease Progression|Time to Treatment Failure|Number of Participants With PSA Response|Change From Baseline in Total PSA at Months 6, 12, 18, 21, and 42|Number of Participants With Metastatic Disease	GlaxoSmithKline	Male	40 Years to 90 Years   (Adult, Older Adult)	Phase 4	127	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	AVO108943	May 2007	February 2013	February 2013	May 8, 2007	November 1, 2013	February 27, 2017	GSK Investigational Site, Homewood, Alabama, United States|GSK Investigational Site, Huntsville, Alabama, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Anaheim, California, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, San Bernardino, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Washington, District of Columbia, United States|GSK Investigational Site, Aventura, Florida, United States|GSK Investigational Site, Daytona Beach, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Galesburg, Illinois, United States|GSK Investigational Site, Evansville, Indiana, United States|GSK Investigational Site, Fort Wayne, Indiana, United States|GSK Investigational Site, Jeffersonville, Indiana, United States|GSK Investigational Site, Overland Park, Kansas, United States|GSK Investigational Site, New Orleans, Louisiana, United States|GSK Investigational Site, Shreveport, Louisiana, United States|GSK Investigational Site, Annapolis, Maryland, United States|GSK Investigational Site, Watertown, Massachusetts, United States|GSK Investigational Site, Chaska, Minnesota, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Albany, New York, United States|GSK Investigational Site, Garden City, New York, United States|GSK Investigational Site, Manhasset, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Syracuse, New York, United States|GSK Investigational Site, Concord, North Carolina, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Bala Cynwyd, Pennsylvania, United States|GSK Investigational Site, Lancaster, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Myrtle Beach, South Carolina, United States|GSK Investigational Site, Memphis, Tennessee, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Norfork, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Virginia Beach, Virginia, United States|GSK Investigational Site, Williamsburg, Virginia, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Surrey, British Columbia, Canada|GSK Investigational Site, Victoria, British Columbia, Canada|GSK Investigational Site, Barrie, Ontario, Canada|GSK Investigational Site, Burlington, Ontario, Canada|GSK Investigational Site, North Bay, Ontario, Canada|GSK Investigational Site, Oakville, Ontario, Canada|GSK Investigational Site, Scarborough, Ontario, Canada|GSK Investigational Site, Sudbury, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Greenfield Park, Quebec, Canada|GSK Investigational Site, Laval, Quebec, Canada|GSK Investigational Site, Pointe-Claire, Quebec, Canada|GSK Investigational Site, Quebec, Canada		https://ClinicalTrials.gov/show/NCT00470834
26	NCT00198263	Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck Cancer		Completed	No Results Available	Head and Neck Cancer	Combination Product: Medpulser Electroporation with Bleomycin	To characterize local tumor recurrence through 8 months post-EPT/bleomycin treatment|To measure pharmacoeconomic factors (hospital costs, extent of medical interventions, medication use) in subjects treated by EPT/bleomycin|To evaluate organ function and appearance using the Performance Status Scale (PSS) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck (EORTC QLQ - H&N 35) at 4 and 8 months following treatment|To document the performance of the MedPulser® System during EPT/bleomycin treatment|To monitor local and systemic adverse events through the Month 4 follow-up study visit	Inovio Pharmaceuticals	All	18 Years and older   (Adult, Older Adult)	Phase 4	95	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EU-HNBE-2003	January 2004	September 2008	September 2008	September 20, 2005		October 3, 2017	Inovio Biomedical Corporation, San Diego, California, United States		https://ClinicalTrials.gov/show/NCT00198263
27	NCT00688909	Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer	REAL	Completed	No Results Available	Breast Cancer	Drug: letrozole	Proportion of patients discontinuing due to grade 2 or higher arthralgia-myalgia.|Time to discontinuation due to grade 2 or higher arthralgia- myalgia.|Proportion of patients discontinuing, irrespective of cause.	Novartis Pharmaceuticals|Novartis	Female	50 Years and older   (Adult, Older Adult)	Phase 4	261	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	CFEM345DUS59	March 2008	June 2009	June 2009	June 3, 2008		February 24, 2017	Clearview Cancer Center, Huntsville, Alabama, United States|Hematology Oncology Services of Arkansas, Little Rock, Arkansas, United States|Grass Valley Hematology Oncology, Grass Valley, California, United States|Aptium Oncology - Comprehensive Cancer Care of the Desert, Palm Springs, California, United States|Bay Area Cancer Research Group, Pleaseant Hill, California, United States|Front Range Specialist, Fort Collins, Colorado, United States|Lynn Cancer Center, Boca Raton, Florida, United States|Florida Cancer Specialists, Fort Meyers, Florida, United States|Memorial Cancer Center, Hollywood, Florida, United States|Palm Beach Cancer Specialists, West Palm Beach, Florida, United States|Northeast Georgia Cancer Care, LLC, Athens, Georgia, United States|Augusta Oncology, Augusta, Georgia, United States|Oncology Specialist of North Georgia, Gainesville, Georgia, United States|The Cancer Instiute at Alexian Brothers, Elk Grove Village, Illinois, United States|Evanston Northwestern Hospital, Evanston, Illinois, United States|Edward H. Kaplan MD & Associates - North Shore Cancer Research Associates, Skokie, Illinois, United States|Cancer Care of Kansas, Wichita, Kansas, United States|Kentuckiana Cancer Institute, Louisville, Kentucky, United States|Mercy Hospital, Portland, Maine, United States|Mercey Hospital, Baltimore, Maryland, United States|Maryland Hematology Oncology Associates, PA, Baltimore, Maryland, United States|Suburban Hospital Cancer Program, Bethesda, Maryland, United States|Hematology Oncology Asssociates of Ohio & Michigan, Lambertville, Michigan, United States|Center for Cancer Care and Research, St Louis, Missouri, United States|Ballas Cancer Center, LLC DBA - St Louis, St. Louis, Missouri, United States|Southeast Nebraska Hematology & Oncology Consultants, Lincoln, Nebraska, United States|Trinitas Comprehensive Cancer Center, Elizabeth, New Jersey, United States|Hematology-Oncology Assoc of Northern New Jersey, Morristown, New Jersey, United States|Somerset Hematology & Oncology, Somerville, New Jersey, United States|Cooper University Hospital, Vorhees, New Jersey, United States|Broom Oncology, Binghamton, New York, United States|Cancer Care of W. NC, Ashville, North Carolina, United States|Marion L. Shepard Cancer Center, Washington, North Carolina, United States|Summa Health System, Akron, Ohio, United States|Mukesh Bhatt, MD, INC., Medina, Ohio, United States|Berks Hematology Oncology, West Reading, Pennsylvania, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|The West Clinic, Memphis, Tennessee, United States|Tenessee Oncology, Nashville, Tennessee, United States|Coastal Bend Cancer Center, Corpus Christi, Texas, United States|Center for Oncology Research and Treatment, Dallas, Texas, United States|Central Utah Clinic, American Fork, Utah, United States|Northern Utah Associates, Ogden, Utah, United States|Medical Oncology & Hematology Associates of Northern Virginia, Fairfax, Virginia, United States|Rockingham Memorial Hospital Regional Cancer Center, Harrisonburg, Virginia, United States|Peninsula Cancer Center, Newport News, Virginia, United States|Green Bay Oncologist, St Vincent Hospital, Green Bay, Wisconsin, United States|Oncology Alliance, Wauwatosa, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT00688909
28	NCT00242554	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases		Completed	No Results Available	Prostate Cancer	Drug: Zoledronic acid	To evaluate the tolerability and safey of zoledronic acid 4mg, IV, for the following eficacy metrics: QoL, Safety (Aes) and evaluation of pain|No secondary outcomes/objectives planned	Novartis Pharmaceuticals|Novartis	Male	18 Years to 80 Years   (Adult, Older Adult)	Phase 4	150	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CZOL446EMX01	October 2002	July 2007		October 20, 2005		February 23, 2017			https://ClinicalTrials.gov/show/NCT00242554
29	NCT00544986	A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer		Completed	No Results Available	Breast Cancer	Drug: Anastrozole	1. Tolerability(safety) 2.Efficacy (a) Time to tumor progression TTP (b) Objective Response (OR) Rate (c) Symptom Evaluation|Efficacy (a) Time to treatment failure TTF (b)Duration of Response DOR (c) Duration of Clinical Benefit	AstraZeneca	Female	18 Years and older   (Adult, Older Adult)	Phase 4		Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D5391L00001	June 2005	November 2007	November 2007	October 16, 2007		January 30, 2013			https://ClinicalTrials.gov/show/NCT00544986
30	NCT00237133	Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women	PREDICT	Completed	No Results Available	Locally Advanced Breast Cancer	Drug: Letrozole	Safety and tolerability of Letrozole	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	112	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CFEM345EBR01	March 2003	January 2009	January 21, 2009	October 12, 2005		February 24, 2017	Novartis Investigative Site, Barretos - SP, Brazil|Novartis Investigative Site, Florianopolis - SC, Brazil|Novartis Investigative Site, Fortaleza/CE, Brazil|Novartis Investigative Site, Goiania/GO, Brazil|Novartis Investigative Site, Jau -SP, Brazil|Novartis Investigative Site, Porto Alegre/RS, Brazil|Novartis Investigative Site, Ribeirao - SP, Brazil|Novartis Investigative Site, Rio de Janeiro, Brazil|Novartis Investigative Site, Santo Andre, Brazil|Novartis Investigative Site, Sao Paulo/SP, Brazil|Novartis Investigative Site, Vitoria/ES, Brazil		https://ClinicalTrials.gov/show/NCT00237133
31	NCT00237146	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy		Completed	No Results Available	Prostate Cancer	Drug: Zoledronic acid	Evaluate the effects of Zometa® (Zoledronic Acid) i.v in doses of 4mg for measure the following parameters of efficacy: Quality of Life, Incidence of Events related to the skeleton	Novartis Pharmaceuticals|Novartis	Male	18 Years and older   (Adult, Older Adult)	Phase 4	38	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CZOL446EVE01	November 2003	March 2008	March 2008	October 12, 2005		February 23, 2017	Novartis Investigative Site, Caracas, Venezuela		https://ClinicalTrials.gov/show/NCT00237146
32	NCT00219271	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer		Completed	No Results Available	Prostate Cancer	Drug: Zoledronic acid	To assess the activity of one year treatment with zoledronic acid|Three-year disease free survival|Change in bone mineral density at 12, 24 and 36 months versus baseline|Changes in bone resorption markers at 12, 24 and 36 months versus baseline|Safety and tolerability through abnormal values and AE reporting	Novartis Pharmaceuticals|University of Athens|Novartis	Male	18 Years to 80 Years   (Adult, Older Adult)	Phase 4	60	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CZOL446GGR01	September 2003	September 2009	September 2009	September 22, 2005		May 31, 2017	Novartis Investigative Site, Athens, Greece		https://ClinicalTrials.gov/show/NCT00219271
33	NCT02805153	PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy		Completed	No Results Available	Breast Cancer	Drug: PEG-rhG-CSF|Drug: rhG-CSF	the occurrence rate of grade IV neutropenia during the first chemotherapy cycle|the non-occurrence rate of grade IV neutropenia (ANC < 0.5 x 10^9/L)during the next three consecutive cycles chemotherapy(except the first chemotherapy cycle)|the duration of grade IV neutropenia (ANC < 0.5 x 10^9/L) during the next three consecutive cycles chemotherapy(except the first chemotherapy cycle)	CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 4	215	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	CSPC-PGC-IV-01	April 2013	February 2016	February 2016	June 17, 2016		June 20, 2016			https://ClinicalTrials.gov/show/NCT02805153
34	NCT00219219	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases		Completed	No Results Available	Prostate Cancer	Drug: Zoledronic acid	occurence of skeletale related events (SREs) over time (time to first SRE,skeletal morbidity rate and proportion of patients experiencing SRE)|Bone pain|Use of analgesic medication and ECOG performance status every three months|Bone specific alkaline phosphatase, serum N-telopeptide and parathyroid hormone will be evaluated after one month of treatment and then every three months	Novartis|Società Italiana di Urologia (SIU)	Male	18 Years and older   (Adult, Older Adult)	Phase 4		Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CZOL446EIT04	September 2003		October 2006	September 22, 2005		April 14, 2015	Bologna, Bologna, Italy		https://ClinicalTrials.gov/show/NCT00219219
35	NCT00391690	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer		Completed	No Results Available	Prostate Cancer	Drug: Zoledronic acid	• To assess the relationship between change in bone parameters and bone scan with respect to bone metastases|Assessment of course of bone parameters (PINP, amino-terminal propeptide of procollagen type 1) and (ICTP, Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen)|Assessment of course of Prostate-specific antigen (PSA)|Assessment of correlation of bone parameters and PSA|Assessment of optimal intervals for bone scans based on serum markers|Assessment of time to rise in bone markers PINP and ICTP|• Time to detection of bone metastases in bone scan	Novartis	Male	18 Years and older   (Adult, Older Adult)	Phase 4	99	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CZOL446GDE22	February 2006	December 2010		October 24, 2006		November 18, 2016	Novartis Investigative Site, Tuebingen, Germany		https://ClinicalTrials.gov/show/NCT00391690
36	NCT01968018	A Study of Safety and Effectiveness of Ultracet in Patients With Chronic Cancer Pain		Completed	No Results Available	Cancer	Drug: Tramadol HCI/acetaminophen	Change From Baseline in Brief Pain Inventory (BPI) Pain Severity "Pain at Its Worst" (BPI Item 3) at Day 42|Change from Baseline in Analgesic Effect as Assessed by Brief Pain Inventory (BPI) Item 5 Score|Number of Participants With Adverse Events|Number of Doses of Rescue Medication Over Time|Number of Participants With Patient Global Assessment (PGA)|Number of Participants With Investigator Global Assessment|Change From Baseline in Quality of Life (QOL) by Using Functional Assessment of Cancer Therapy General Scale (FACT-G) Total Score at Day 42	Janssen-Cilag Ltd.,Thailand	All	18 Years and older   (Adult, Older Adult)	Phase 4	35	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CR013510|TRAMAPANA4001	July 2004	April 2007	April 2007	October 23, 2013		October 23, 2013	Bangkok, Thailand		https://ClinicalTrials.gov/show/NCT01968018
37	NCT02419742	Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen		Active, not recruiting	No Results Available	Breast Cancer	Drug: Carboplatin|Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Doxorubicin|Drug: Paclitaxel|Drug: Trastuzumab	Percentage of Participants Experiencing Clinically Significant Changes in Cardiac Function As Determined by Left Ventricular Ejection Fraction (LVEF) Measurements Using Echocardiography|Percentage of Participants With Adverse Events|Disease Free Survival (DFS)|Overall Survival (OS)	Hoffmann-La Roche	Female	18 Years and older   (Adult, Older Adult)	Phase 4	109	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML28714	August 18, 2015	December 28, 2020	December 28, 2020	April 17, 2015		July 10, 2019	Yashoda Hospital, Hyderabad, Andhra Pradesh, India|Rajiv Gandhi Cancer Institute & Research Center, New Delhi, Delhi, India|Manipal Hospital; Department of Oncology, Bangalore, Karnataka, India|Jehangir Clinical Development Centre Pvt. Ltd; Cancer Research Room, Pune, Maharashtra, India|MAX Balaji Hospital, Delhi, India|Dr. GVN Cancer Institute; Medical Oncology, Trichy, India		https://ClinicalTrials.gov/show/NCT02419742
38	NCT02343081	Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System		Completed	Has Results	Brain Neoplasms, Malignant, Primary	Drug: Temozolomide	Cmax|AUC0-t|AUC0-∞|Number of Adverse Events (AEs) and Serious Adverse Events (SAEs)	Monte Verde SA|FLENI Instituto de Rehabilitación y Educación Terapéutica, BA, Argentina.|Bioanalytical Unit, Laboratorio Raffo S.A., BA, Argentina.|FLENI Multi-Specialty Research Center, BA, Argentina.	All	21 Years and older   (Adult, Older Adult)	Phase 4	24	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RFF -0208	January 2012	October 2013	October 2013	January 21, 2015	April 2, 2015	April 2, 2015	FLENI Instituto Clínico-Quirúrgico de Diagnóstico y Tratamiento, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|FLENI Instituto de Rehabilitación y Educación Terapéutica, Escobar, Buenos Aires, Argentina		https://ClinicalTrials.gov/show/NCT02343081
39	NCT02445586	Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer		Completed	No Results Available	Breast Cancer	Drug: Docetaxel|Drug: Pertuzumab|Drug: Trastuzumab	Percentage of Participants with Adverse Events (AEs)|Percentage of Participants with Congestive Heart Failure (CHF) and/or Significant Decline in Left Ventricular Ejection Fraction (LVEF)|Change from Baseline in LVEF at Year 3 as Determined by Either Echocardiogram (ECHO) or Multigated Acquisition (MUGA) Scan|Percentage of Participants with Objective Response of Complete Response (CR) or Partial Response (PR) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1|Progression-Free Survival (PFS) Using RECIST Version 1.1|Overall Survival (OS)	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	52	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML29282	August 17, 2015	September 26, 2018	September 26, 2018	May 15, 2015		July 29, 2019	Rajiv Gandhi Cancer Institute & Research Center, New Delhi, Delhi, India|Tata Memorial Hospital; Dept of Medical Oncology, Mumbai, Maharashtra, India|Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute, Mumbai, Maharashtra, India|Jehangir Clinical Development Centre Pvt. Ltd; Cancer Research Room, Pune, Maharashtra, India|Christian Medical College & Hospital; Medicine, Vellore, Tamil NADU, India|Indo-American Cancer Hospital & Research Center, Hyderabad, Telangana, India|TATA Medical Centre; Medical Oncology, Kolkata, WEST Bengal, India|M S Ramaiah Memorial Hospital, Bangalore, India|MAX Balaji Hospital, Delhi, India		https://ClinicalTrials.gov/show/NCT02445586
40	NCT00766831	An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain		Completed	Has Results	Cancer Pain	Drug: Hydromorphone	Percentage of Treatment Response in Sleep Disturbance Caused by Cancer Pain|Sleep Disturbance Questionnaire: Analgesic Administration|Sleep Disturbance Questionnaire: Frequency of Waking Up|Sleep Disturbance Questionnaire: Wake up Due to Unbearable Pain|Korean Brief Pain Inventory (K-BPI) Questionnaire Score|Participant's Pain Intensity|Number of Times the Short-Acting Opioid Analgesic Administered for Breakthrough Pain|Number of Participants With Each Grade of Eastern Cooperative Oncology Group (ECOG) Performance Status Score|Number of Participants With Clinical Global Impression-Improvement (CGI-Improvement) Score|Number of Participants in Each Category of Global Assessment of Overall Efficacy of Study Drug Assessed by Participants|Number of Participants in Each Category of Global Assessment of Overall Efficacy of Study Drug Assessed by Investigators|Percentage of Participants Who Preferred the Oral Long-Action Opioids Analgesic or Study Drug|Percentage of Participants With Different Reasons for Their Preference for Oral Long-Action Opioids Analgesic or Study Drug	Janssen Korea, Ltd., Korea	All	20 Years and older   (Adult, Older Adult)	Phase 4	190	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CR014806|HYD-KOR-4002	October 2008	June 2010	June 2010	October 6, 2008	August 26, 2013	October 23, 2013			https://ClinicalTrials.gov/show/NCT00766831
41	NCT01896479	A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer	EXAMINER	Recruiting	No Results Available	Medullary Thyroid Cancer	Drug: Cabozantinib (XL184) 140 mg|Drug: Cabozantinib (XL184) 60 mg|Drug: Placebo tablet|Drug: Placebo capsule	Progression Free Survival|Objective Response Rate	Exelixis	All	18 Years and older   (Adult, Older Adult)	Phase 4	188	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	XL184-401	December 2014	May 2020	October 2020	July 11, 2013		December 6, 2018	St. Leonards, New South Wales, Australia|Herston, Queensland, Australia|Kurralta Park, South Australia, Australia|Heidelberg, Victoria, Australia|Parkville, Victoria, Australia|Québec, Quebec, Canada|Québec, Canada|Toronto, Canada|Osijek, Croatia|Zagreb, Croatia|Zagreb, Croatia|Bordeaux, Gironde, France|Angers, Maine-et-Loire, France|Lyon, Rhône, France|Villejuif, Val-de-Marne, France|Dijon, France|Paris, France|Strasbourg Cedex, France|Budapest, Hungary|Debrecen, Hungary|Jerusalem, Israel|Petach Tikva, Israel|Safed, Israel|Catania, CT, Italy|Roma, RM, Italy|Sienna, SI, Italy|Pisa, Toscana, Italy|Milano, Italy|Padua, Italy|Torino, Italy|Goyang, Gyeonggido, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Amsterdam, Noord Holland, Netherlands|Leiden, Zuid-Holland, Netherlands|Groningen, Netherlands|Gliwice, Slaskie, Poland|Poznań, Wielkopolskie, Poland|Bucharest, Romania|Bucharest, Romania|Cluj-Napoca, Romania|Cluj-Napoca, Romania|Timisoara, Romania|Novosibirsk, Russian Federation|Obninsk, Russian Federation|St. Petersburg, Russian Federation|Yaroslavl, Russian Federation|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Lund, Skane Ian, Sweden|Uppsala, Uppsala Ian, Sweden		https://ClinicalTrials.gov/show/NCT01896479
42	NCT03988114	A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer	proMONARCH	Not yet recruiting	No Results Available	Metastatic Breast Cancer	Drug: Abemaciclib|Drug: Nonsteroidal Aromatase Inhibitor (NSAI)	Progression Free Survival (PFS)|Objective Response Rate (ORR): Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR)|Duration of Response (DoR)|Disease Control Rate (DCR): Percentage of Participants with a Best Overall Response of CR, PR, or Stable Disease (SD)|Clinical Benefit Rate (CBR): Proportion of Participants with Best Overall Response of CR, PR, or SD with Duration of SD for at Least 6 Months|Time to Response (TTR)	Eli Lilly and Company	All	18 Years and older   (Adult, Older Adult)	Phase 4	650	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17395|I3Y-MC-JPCX|2019-001781-16	September 16, 2019	March 23, 2022	March 23, 2023	June 17, 2019		August 5, 2019	Arizona Oncology Associates, P.C., Tempe, Arizona, United States|Compassionate Cancer Care Medical Group Inc, Fountain Valley, California, United States|California Cancer Associates in Research and Excellence, San Marcos, California, United States|Cancer Center of Santa Barbara with Sansum Clinic, Santa Barbara, California, United States|BayCare Medical Group, Clearwater, Florida, United States|Cancer Specialists of North Florida -St Augustine, Saint Augustine, Florida, United States|St Joseph's Hospital, Tampa, Florida, United States|Cleveland Clinic of Florida, Weston, Florida, United States|Summit Cancer Care, Savannah, Georgia, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Illinois Cancer Specialists-Niles, Niles, Illinois, United States|Community Health Network, Indianapolis, Indiana, United States|Central Maine Medical Center, Lewiston, Maine, United States|Oncology Hematology West, Omaha, Nebraska, United States|Broome Oncology LLC, Johnson City, New York, United States|Texas Oncology-Arlington South, Arlington, Texas, United States|Texas Oncology - Bedford, Bedford, Texas, United States|Texas Oncology P.A., Dallas, Texas, United States|Texas Oncology - Medical City Dallas, Dallas, Texas, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|Texas Oncology-Memorial City, Houston, Texas, United States|Renovatio Clinical, Houston, Texas, United States|Texas Oncology-McKinney, McKinney, Texas, United States|Texas Oncology- Mesquite, Mesquite, Texas, United States|Texas Oncology-Plano West, Plano, Texas, United States|University of Texas Health Science Center - San Antonio, San Antonio, Texas, United States|US Oncology, The Woodlands, Texas, United States|Texas Oncology-Deke Slayton Cancer Center, Webster, Texas, United States|Hematology Oncology Associates of Fredericksburg Inc., Fredericksburg, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Shenandoah Oncology, P.C., Winchester, Virginia, United States|Centro de Oncologia e Investigacion Buenos Aires, Berazategui, Buenos Aires, Argentina|CEMEDIC, Caba, Buenos Aires, Argentina|CENIT Centro de Neurociencias, Investigación y Tratamiento, Caba, Ciudad Autonoma Buenos Aires, Argentina|Clinica Adventista de Belgrano, Ciudad Autonoma Buenos Aires, Argentina|Sanatorio Parque, Salta, Argentina|Centro Polivalente de Asistencia e Inv. Clinica CER-San Juan, San Juan, Argentina|Universitätsklinikum Graz, Graz, Steiermark, Austria|Universitätsklinik Innsbruck, Innsbruck, Tirol, Austria|Universitätsklinikum Salzburg, Salzburg, Austria|AKH, Wien, Austria|AKH, Wien, Austria|Algemeen Ziekenhuis St Jan Brugge, Brugge, Belgium|Hopital De Jolimont, Haine-St.- Paul, Belgium|VZW REgional Ziekenhuis Jan Yperman, Ieper, Belgium|Instituto de Cancer de Londrina, Londrina, Parana, Brazil|Hospital de Caridade Ijui, Ijui, Rio Grande Do Sul, Brazil|Hospital São Lucas - PUCRS - ONCOLOGY, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Bruno Born de Lajeado, Lajeado, RS, Brazil|Fundação PIO XII, Barretos, Sao Paulo, Brazil|Hospital de Base Fac de Medicina de Sao Jose do Rio Preto, Sao Jose Rio Preto, Sao Paulo, Brazil|Faculdade de Medicina do ABC, Santo Andre, SP, Brazil|Hospital das Clinicas da FMRP, Ribeirao Preto, São Paulo, Brazil|INCA - Instituto Nacional Do Cancer, Rio de Janeiro, Brazil|Fundacao Antonio Prudente-Hosp. do Cancer AC Camargo, Sao Paulo, Brazil|Soc. Beneficente de Senhoras Hospital Sirio Libanes-Oncology, São Paulo, Brazil|Clin. Pesq.e Centro Estudos Oncologia Ginecológica e Mamária, São Paulo, Brazil|Clinica Onco Star, São Paulo, Brazil|Hämatologisch-Onkologische Praxis Augsburg, Augsburg, Bavaria, Germany|Universität Leipzig - Universitätsklinikum, Leipzig, Sachsen, Germany|St. Vincenz-Krankenhaus GmbH-Frauen- und Kinderklinik St. Louise, Paderborn, Germany|Istituto Tumori Fondazione G. Pascale IRCCS, Napoli, Naples, Italy|Fondazione Piemonte l'Oncologia-Istituto Ricerca Cura Cancro, Candiolo, Torino, Italy|Policlinico S. Orsola Malpighi - Universita di Bologna, Bologna, Italy|Azienda Ospedaliera Universitaria Ospedale San Martino di Genova, Genova, Italy|IRCCS Ospedale San Raffaele, Milano, Italy|Istituto Oncologico Veneto, Padova, Italy|Centro di Riferimento Oncologico, Udine, Italy|Puerto Rico Hematology/Oncology Group, Bayamon, Puerto Rico|Ad-Vance Medical Research, Ponce, Puerto Rico|E-DA Cancer Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|MacKay Memorial Hospital, Taipei, Taiwan|Koo Foundation Sun Yan-Sen Cancer Center, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT03988114
43	NCT01094184	A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer	BATMAN	Completed	Has Results	Breast Cancer	Drug: Bevacizumab|Drug: Paclitaxel|Drug: Docetaxel	Change From Baseline in Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B) Score at Cycle 2|Change From Baseline in FACT-B Score at Cycle 3|Change From Baseline in FACT-B Score at Cycle 4|Change From Baseline in FACT-B Score at Cycle 5|Change From Baseline in FACT-B Score at Cycle 6|Change From Baseline in FACT-B Score at Cycle 7|Change From Baseline in FACT-B Score at Cycle 8|Change From Baseline in FACT-B Score At Cycle 9|Change From Baseline in FACT-B Score at Cycle 10|Change From Baseline in FACT-B Score at Cycle 11|Change From Baseline in FACT-B Score at Cycle 12|Change From Baseline in FACT-B Score at Cycle 13|Change From Baseline in FACT-B Score at Cycle 14|Change From Baseline in FACT-B Score at Cycle 15|Change From Baseline in FACT-B Score at Cycle 16|Change From Baseline in FACT-B Score at Cycle 17|Change From Baseline in FACT-B Score at Cycle 18|Change From Baseline in FACT-B Score at Cycle 20|Change From Baseline in FACT-B Score at Cycle 21|Change From Baseline in FACT-B Score at Cycle 22|Change From Baseline in FACT-B Score at Cycle 23|Change From Baseline in FACT-B Score at Cycle 24|Change From Baseline in FACT-B Score at Cycle 25|Change From Baseline in FACT-B Score at Cycle 26|Change From Baseline in FACT-B Score at Cycle 27|Change From Baseline in FACT-B Score at Cycle 28|Change From Baseline in FACT-B Score at Cycle 29|Change From Baseline in FACT-B Score at Cycle 30|Change From Baseline in FACT-B Score at Cycle 32|Change From Baseline in FACT-B Score at Cycle 36|Change From Baseline in FACT-B Score at Cycle 37|Change From Baseline in FACT-B Score at Cycle 39|Change From Baseline in FACT-B Score at Cycle 42|Change From Baseline in FACT-B Score at Cycle 44|Change From Baseline in FACT-B Score at Cycle 46|Change From Baseline in FACT-B Score at End of Study|Change From Baseline in Euro Quality of Life (EQ-5D) - Health State Questionnaire Score at Cycle 2|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 3|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 4|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 5|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 6|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 7|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 8|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 9|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 10|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 11|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 12|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 13|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 14|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 15|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 16|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 17|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 18|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 20|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 21|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 22|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 23|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 24|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 25|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 26|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 27|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 28|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 29|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 30|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 32|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 36|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 37|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 39|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 40|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 42|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 44|Change From Baseline in EQ-5D- Health State Questionnaire Score at Cycle 46|Change From Baseline in EQ-5D- Health State Questionnaire Score at End of Study|Change From Baseline in EQ-5D - Visual Analogue Scale (VAS) Score at Cycle 2|Change From Baseline in EQ-5D-VAS Score at Cycle 3|Change From Baseline in EQ-5D-VAS Score at Cycle 4|Change From Baseline in EQ-5D-VAS Score at Cycle 5|Change From Baseline in EQ-5D-VAS Score at Cycle 6|Change From Baseline in EQ-5D-VAS Score at Cycle 7|Change From Baseline in EQ-5D-VAS Score at Cycle 8|Change From Baseline in EQ-5D-VAS Score at Cycle 9|Change From Baseline in EQ-5D-VAS Score at Cycle 10|Change From Baseline in EQ-5D-VAS Score at Cycle 11|Change From Baseline in EQ-5D-VAS Score at Cycle 12|Change From Baseline in EQ-5D-VAS Score at Cycle 13|Change From Baseline in EQ-5D-VAS Score at Cycle 14|Change From Baseline in EQ-5D-VAS Score at Cycle 15|Change From Baseline in EQ-5D-VAS Score at Cycle 16|Change From Baseline in EQ-5D-VAS Score at Cycle 17|Change From Baseline in EQ-5D-VAS Score at Cycle 18|Change From Baseline in EQ-5D-VAS Score at Cycle 20|Change From Baseline in EQ-5D-VAS Score at Cycle 21|Change From Baseline in EQ-5D-VAS Score at Cycle 22|Change From Baseline in EQ-5D-VAS Score at Cycle 23|Change From Baseline in EQ-5D-VAS Score at Cycle 24|Change From Baseline in EQ-5D-VAS Score at Cycle 25|Change From Baseline in EQ-5D-VAS Score at Cycle 26|Change From Baseline in EQ-5D-VAS Score at Cycle 27|Change From Baseline in EQ-5D-VAS Score at Cycle 28|Change From Baseline in EQ-5D-VAS Score at Cycle 29|Change From Baseline in EQ-5D-VAS Score at Cycle 30|Change From Baseline in EQ-5D-VAS Score at Cycle 32|Change From Baseline in EQ-5D-VAS Score at Cycle 36|Change From Baseline in EQ-5D-VAS Score at Cycle 37|Change From Baseline in EQ-5D-VAS Score at Cycle 39|Change From Baseline in EQ-5D-VAS Score at Cycle 40|Change From Baseline in EQ-5D-VAS Score at Cycle 42|Change From Baseline in EQ-5D-VAS Score at Cycle 44|Change From Baseline in EQ-5D-VAS Score at Cycle 46|Change From Baseline in EQ-5D-VAS Score at End of Study|Percentage of Participants Who Died Due to Any Cause|Overall Survival|Percentage of Participants With Disease Progression|Time to Disease Progression|Percentage of Participants By Karnofsky Performance Status Scale Scores	Hoffmann-La Roche	Female	18 Years and older   (Adult, Older Adult)	Phase 4	49	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML22780|2009-014279-37	March 2010	December 2015	December 2015	March 26, 2010	March 22, 2018	March 22, 2018	Bangor, United Kingdom|Cottingham, United Kingdom|Exeter, United Kingdom|Grimsby, United Kingdom|Harrogate, United Kingdom|Plymouth, United Kingdom|Portsmouth, United Kingdom|Preston, United Kingdom|Somerset, United Kingdom|Wolverhampton, United Kingdom		https://ClinicalTrials.gov/show/NCT01094184
44	NCT04031885	A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer		Not yet recruiting	No Results Available	Metastatic Breast Cancer	Drug: Abemaciclib|Drug: Fulvestrant|Drug: Standard Chemotherapy	Objective Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)|Progression Free Survival (PFS)|Time to Response (TTR)|Duration of Response (DoR)|PFS 2	Eli Lilly and Company	Female	18 Years and older   (Adult, Older Adult)	Phase 4	300	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17320|I3Y-MC-JPCU	July 31, 2019	April 15, 2021	November 15, 2021	July 24, 2019		August 12, 2019	Honor Health Research Institute, Avondale, Arizona, United States|University of Arizona Cancer Center, Phoenix, Arizona, United States|Yuma Regional Cancer Center, Yuma, Arizona, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Chan Soon- Shiong Institute for Medicine, Costa Mesa, California, United States|Compassionate Cancer Care Medical Group Inc, Fountain Valley, California, United States|St. Joseph Heritage Medical Group, Fullerton, California, United States|Scripps Clinic, La Jolla, California, United States|UCLA Medical Center, Los Angeles, California, United States|TRIO - Translational Research in Oncology-US, Inc., Los Angeles, California, United States|Comprehensive Cancer Centers of the Desert, Palm Springs, California, United States|Redlands Community Hospital, Redlands, California, United States|Torrance Memorial Medical Center, Redondo Beach, California, United States|University of California, Davis - Health Systems, Sacramento, California, United States|Banner MD Anderson Cancer Center, Greeley, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|Ocala Oncology, P.A., Ocala, Florida, United States|Millennium Oncology, Pembroke Pines, Florida, United States|Tallahassee Memorial Cancer Center, Tallahassee, Florida, United States|Cleveland Clinic of Florida, Weston, Florida, United States|Candler Medical Oncology Practice, Savannah, Georgia, United States|Tift Regional Health System Anita Stewart Oncology Center, Tifton, Georgia, United States|Kaiser Permanente Center for Health Research, Honolulu, Hawaii, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Reliant Medical Group, Inc., Worcester, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Oncology Hematology West, Omaha, Nebraska, United States|Weill Cornell Medical College, New York, New York, United States|SUNY At Stony Brook, Stony Brook, New York, United States|White Plains Hospital, White Plains, New York, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|WellSpan Health/York Cancer Center Oncology Research, York, Pennsylvania, United States|Womens and Infants, Providence, Rhode Island, United States|Baptist Cancer Center, Memphis, Tennessee, United States|Baptist Cancer Center, Memphis, Tennessee, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|Oncology Consultants Cancer Center, Houston, Texas, United States|Renovatio Clinical, Houston, Texas, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Centro Integrado de Cancer del Sur, PSC, Coto Laurel, Puerto Rico|Bella Vista Oncology Group, Mayaguez, Puerto Rico|Ponce Medical School, Ponce, Puerto Rico|Centro de Cancer de la Mujer, Ponce, Puerto Rico|Clinical Research Puerto Rico, Inc., San Juan, Puerto Rico|Fundacion de Investigacion de Diego, San Juan, Puerto Rico		https://ClinicalTrials.gov/show/NCT04031885
45	NCT00172003	Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis		Completed	No Results Available	Renal Cell Cancer|Neoplasm Metastasis	Drug: Zoledronic acid	Rate of skeletal complications|Time to first skeletal complication|Bone pain|Time to overall progression of disease|Overall survival|Bone turnover parameters	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	50	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CZOL446EDE15	September 2004	July 2009	July 2009	September 15, 2005		November 18, 2016	Novartis investigative Site, Offenbach, Germany		https://ClinicalTrials.gov/show/NCT00172003
46	NCT01471756	Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia		Completed	No Results Available	Neoplasms|Gastric Cancer	Procedure: Standard of Care Procedure as described in ARM	Efficacy of Two Devices used in EMR|Compare the Use of Two Injectates	Mayo Clinic|US Endoscopy	All	18 Years and older   (Adult, Older Adult)	Phase 4	66	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	10-008104	October 2011	July 2013	May 2014	November 16, 2011		September 8, 2014	Mayo Clinic, Jacksonville, Florida, United States		https://ClinicalTrials.gov/show/NCT01471756
47	NCT00082277	Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer	SABRE	Completed	No Results Available	Breast Cancer	Drug: Anastrozole|Drug: Risedronate Sodium	The change from baseline in lumbar spine (L1-L4) bone mineral density (BMD)|Change from baseline in total hip BMD|Change from baseline in lumbar spine (L1-L4) BMD|Change from baseline in bone formation markers|Change from baseline in bone resorption and formation markers|Change from baseline in LDL-cholesterol|Change from baseline in LDL-cholesterol, HDL-cholesterol, total cholesterol, and serum triglycerides	AstraZeneca	Female	55 Years and older   (Adult, Older Adult)	Phase 4	237	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	D5392C00050|SABRE	April 2004	October 2007	October 2007	May 6, 2004		January 26, 2011	Research Site, Palm Springs, California, United States|Research Site, Jacksonville, Florida, United States|Research Site, New Orleans, Louisiana, United States|Research Site, New York, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Houston, Texas, United States|Research Site, Burnaby, Canada|Research Site, Edmonton, Canada|Research Site, Montreal, Canada|Research Site, Quebec City, Canada|Research Site, Vancouver, Canada|Research Site, Bordeaux, France|Research Site, Caen, France|Research Site, Lyon, France|Research Site, Saint-Cloud, France|Research Site, Saint-Herblain, France|Research Site, Athens, Greece|Research Site, Iraklion, Greece|Research Site, Den Haag, Netherlands|Research Site, Goes, Netherlands|Research Site, Ijssel, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Bloemfontain, South Africa|Research Site, Cape Town, South Africa|Research Site, Tygerberg, South Africa|Research Site, Pamplona, Spain|Research Site, Pontevedra, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Belfast, United Kingdom|Research Site, Bolton, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Luton, United Kingdom		https://ClinicalTrials.gov/show/NCT00082277
48	NCT00129961	Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients		Completed	Has Results	Skin Neoplasms|Kidney Transplantation	Drug: sirolimus|Drug: cyclosporine or tacrolimus	New Biopsy-Confirmed Nonmelanoma Skin Cancer (NMSC) Lesions Per Subject Per Year|Time to First Biopsy Confirmed New NMSC Lesion.|Number of Lesion Free Subjects|Percentage of Patients With New Biopsy-confirmed NMSC: Squamous Cell Carcinoma (SCC) and Basal Cell Carcinoma (BCC)|Grade Distribution of NMSC Lesions|Number of Recurrent NMSC Lesions Per Subject-year|Subjects Reporting Incidence of Metastatic Disease Related to NMSC.|Death Due to NMSC|Number of Subjects Who Discontinue Assigned Therapy|Nankivell-Calculated Glomerular Filtration Rate (GFR)|Serum Creatinine Level|Number of Participants That Died|Graft Survival Measured by Graft Loss|Number of Subjects With Biopsy-Confirmed Acute Rejection|Spot Urine Protein:Creatinine Ratio	Wyeth is now a wholly owned subsidiary of Pfizer	All	18 Years and older   (Adult, Older Adult)	Phase 4	86	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	0468H1-407	August 2005	January 2009	January 2009	August 12, 2005	March 23, 2012	April 11, 2012	San Diego, California, United States|San Francisco, California, United States|Gainesville, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Charleston, South Carolina, United States|Nashville, Tennessee, United States|Madison, Wisconsin, United States|Camperdown, New South Wales, Australia|Wooloongabba, Queensland, Australia|Woodville, South Australia, Australia|Adelaide, Australia|Clayton, Australia|Herston, Australia|Parkville, Australia|Randwick, Australia|Westmead, Australia|Vancouver, British Columbia, Canada|Grafton, Auckland, New Zealand		https://ClinicalTrials.gov/show/NCT00129961
49	NCT02869789	An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers		Recruiting	No Results Available	Lung Cancer	Drug: Nivolumab in combination with Ipilimumab	Number of participants who experience high grade AEs (Adverse Events)|Percentage of participants who experience high grade AEs|Progression-free survival (PFS)|ORR|Duration of Response (DOR)|Functional Assessment of Cancer Therapy-Lung (FACT-L)|Overall Survival (OS)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 4	1100	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-817|2016-002621-10	September 14, 2016	June 16, 2020	November 17, 2021	August 17, 2016		July 12, 2019	Alabama Oncology, Birmingham, Alabama, United States|Local Institution, Chandler, Arizona, United States|Arizona Oncology Assoc, Pc-Hal, Phoenix, Arizona, United States|Arizona Oncol Assoc Dba (Hem Onc Physicians&Extenders) Hope, Tucson, Arizona, United States|Local Institution, Hot Springs, Arkansas, United States|University Of Arkansas For Medical Sciences, Little Rock, Arkansas, United States|CBCC Global Research, Inc., Bakersfield, California, United States|Local Institution, Berkeley, California, United States|Marin Cancer Care, Inc, Greenbrae, California, United States|Local Institution, La Jolla, California, United States|Los Angeles Hematology/Oncology Medical Group, Los Angeles, California, United States|Ucla, Los Angeles, California, United States|Torrance Health Association, Redondo Beach, California, United States|Local Institution, San Diego, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|St. Mary's Hospital Regional Cancer Center, Grand Junction, Colorado, United States|Memorial Cancer Institute, Hollywood, Florida, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|Florida Cancer Affiliates - Ocala, Ocala, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Northside Hospital, Inc, Atlanta, Georgia, United States|Local Institution, Macon, Georgia, United States|Local Institution, Boise, Idaho, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Local Institution, Skokie, Illinois, United States|Local Institution, Indianapolis, Indiana, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Kentucky One Health St. Joseph East Cancer Center, Lexington, Kentucky, United States|Maryland Oncology Hematology, P.A., Columbia, Maryland, United States|Minnesota Oncology Hematology, Pa, Edina, Minnesota, United States|Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States|St. Francis Cancer Treatment Center, Grand Island, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Cancer Care Specialists, Reno, Nevada, United States|Essex Oncology Of North Jersey P.A., Belleville, New Jersey, United States|Summit Medical Group, Florham Park, New Jersey, United States|Saint Barnabas Medical Cancer Center, Livingston, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Dumc, Durham, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Local Institution, Oklahoma City, Oklahoma, United States|Good Samaritan Hospital Corvallis, Corvallis, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Willamette Valley Cancer Center, Springfield, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Local Institution, Langhorne, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Guthrie Medical Group, Pc, Sayre, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|Tennessee Oncology, Pc, Nashville, Tennessee, United States|Texas Oncology, PA - South Austin Cancer Center, Austin, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology-Fort Worth 12th Ave, Fort Worth, Texas, United States|Texas Oncology-Longview, Longview, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|Texas Oncology Cancer Care And Research Center, Waco, Texas, United States|Virginia Cancer Specialists, Pc, Fairfax, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Valley Medical Center, Renton, Washington, United States|Medical Oncology Associates, Spokane, Washington, United States|Instituto Medico Especializado Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Hospital Italiano De Buenos Aires, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Centro Medico San Roque, Tucuman, Argentina|Local Institution, Gent, Belgium|Local Institution, Liege, Belgium|Local Institution, Sint-Niklaas, Belgium|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Newmarket, Ontario, Canada|Local Institution, Greenfield Park, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Hopital Du Sacre-Coeur De Montreal, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-Centre-du-Quebec, Trois-Rivieres, Quebec, Canada|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Fundacion Arturo Lopez Perez, Santiago, Chile|Komplexni onkologicke centrum, Novy Jicin, Czechia|Onkologicka klinika VFN a 1. LF UK, Praha 2, Czechia|Local Institution, Bordeaux, France|Local Institution, Dijon Cedex, France|Local Institution, Marseille Cedex 20, France|Local Institution, Nice, France|Local Institution, Paris, France|Local Institution, Pessac cedex, France|Local Institution, Rennes Cedex 9, France|Local Institution, Saint Herblain, France|Local Institution, Strasbourg Cedex, France|Local Institution, Toulon Cedex, France|Krankenhaus Nordwest GmbH, Frankfurt, Germany|SRH Wald-Klinikum Gera GmbH., Gera, Germany|Klinikum Kassel, Kassel, Germany|Klinik Loewenstein gGmbH, Loewenstein, Germany|Helios Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany|Sotiria General Hospital, Athens, Greece|Metropolitan Hospital, Neo Faliro, Greece|Papageorgiou General Hospital, Thessaloniki, Greece|Local Institution, Budapest, Hungary|Local Institution, Matrahaza, Hungary|Local Institution, Genova, Italy|IRST Meldola, Meldola, Italy|Local Institution, Milan, Italy|Local Institution, Napoli, Italy|Ospedale Degli Infermi, Rimini, Italy|Local Institution, Siena, Italy|Azienda Ospedaliera S. Maria, Terni, Italy|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Cuernavaca, Morelos, Mexico|Local Institution, Mazatlan, Sinaloa, Mexico|Local Institution, Monterrey, NL, Mexico|Local Institution, Queretaro, Mexico|Local Institution, Groningen, Netherlands|Local Institution, Rotterdam, Netherlands|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Oddzial Wewnetrzny, Sucha Beskidzka, Poland|Klinika Nowotworow Pluca i Klatki Piersiowej, Warszawa, Poland|Focus Lab Plus SRL, Bucuresti, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|Prof. Dr. Ion Chiricuta Institute Of Oncology Day Care Dep, Romania, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, A Coru?a, Spain|Local Institution, Barcelona, Spain|Local Institution, Jaen, Spain|Local Institution, Madrid, Spain|Local Institution, Majadahonda - Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Zaragoza, Spain|University Hospital Basel, Basel, Switzerland|University Hospital Zuerich, Zuerich, Switzerland|Local Institution, Adana, Turkey|Local Institution, Antalya, Turkey|Local Institution, Istanbul, Turkey|Local Institution, Leicester, Leicestershire, United Kingdom|Local Institution, Edinburgh, Midlothian, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Newcastle Upon Tyne, United Kingdom|Local Institution, Wirral, United Kingdom		https://ClinicalTrials.gov/show/NCT02869789
50	NCT03641560	A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy		Active, not recruiting	No Results Available	Metastatic Castration Resistant Prostate Cancer	Drug: Enzalutamide|Drug: Androgen deprivation therapy (ADT)	Safety assessed by incidence of adverse events (AEs)|Number of participants with laboratory test abnormalities and/or AEs|Number of participants with physical examination abnormalities and/or AEs|Number of participants with vital sign abnormalities and/or AEs|Efficacy assessed by prostate-specific antigen (PSA) response rate (≥ 50% reduction from baseline)	Astellas Pharma Inc	Male	18 Years and older   (Adult, Older Adult)	Phase 4	52	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	9785-CL-0413	September 19, 2018	May 2020	May 2020	August 22, 2018		July 24, 2019	Site IN00002, Ahmedabad, India|Site IN00004, Hubli, India|Site IN00008, Kolkata, India|Site IN00003, Nashik, India|Site IN00007, Nashik, India|Site IN00010, New Delhi, India|Site IN00001, Pune, India|Site IN00011, Surat, India		https://ClinicalTrials.gov/show/NCT03641560
51	NCT01301729	A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment		Completed	Has Results	Breast Cancer	Drug: Docetaxel|Drug: Paclitaxel|Drug: Trastuzumab	Progression-Free Survival (PFS)|Overall Response Rate|Duration of Response|Overall Survival|Percentage of Participants With an Adverse Event (AE)|Determination of Biomarkers Indicative for Response (Serum and Tumour Tissue Analyses)|Clinical Benefit Rate|Time to Progression	Hoffmann-La Roche	Female	18 Years and older   (Adult, Older Adult)	Phase 4	32	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML25288	March 2011	July 2014	July 2014	February 23, 2011	December 29, 2016	December 29, 2016	Beijing, China|Beijing, China|Beijing, China|Beijing, China|Chengdu, China|Guangzhou, China|Guangzhou, China|Guangzhou, China|Hangzhou, China|Hangzhou, China|Harbin, China|Nanjing, China|Shanghai, China|Shenyang, China|Wuhan, China|Wuhan, China|Zhengzhou, China		https://ClinicalTrials.gov/show/NCT01301729
52	NCT00035997	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis		Completed	No Results Available	Prostate Cancer	Drug: Zometa	Changes in bone mineral density of the lumbar spine (L2-L4) at 12 months|Changes in biochemical markers of bone turnover over 12 months|Changes in bone mineral density of the total hip at 12 months|Time to first skeletal-related event|Overall safety measured by adverse events (AEs)	Novartis Pharmaceuticals|Novartis	Male	18 Years and older   (Adult, Older Adult)	Phase 4	261	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CZOL446EUS24|US24	April 2002	January 2004	January 2004	May 8, 2002		November 23, 2009	Norwood Clinic, Birmingham, Alabama, United States|Alaska Clinical Research Center, LLC, Anchorage, Alaska, United States|Advanced Urology Medical Center, Anaheim, California, United States|Urology Associates of Central CA, Fresno, California, United States|Center for Urological Research, La Mesa, California, United States|Atlantic Urological Medical Group, Long Beach, California, United States|Advanced Urology Medical Offices, Los Angeles, California, United States|Advanced Urology Medical Office, Los Angeles, California, United States|Boulder Medical Center, Boulder, Colorado, United States|Urology Associates, P.C., Denver, Colorado, United States|Atlantic Urological Associates, Daytona Beach, Florida, United States|Southwest Florida Urologic Association, Fort Myers, Florida, United States|Diagnostic Clinic, Largo, Florida, United States|DMI Health Care Group, Inc., Largo, Florida, United States|Marvin Stein, MD, Margate, Florida, United States|Miami Cancer Institute, Miami, Florida, United States|Advanced Research Institute, New Port Richey, Florida, United States|Florida Foundation for Healthcare Research, Ocala, Florida, United States|Urology Associates of Northeast Florida, PA, Orange Park, Florida, United States|Winter Park Urology Associates, Orlando, Florida, United States|Pinellas Urology, Inc., St. Petersburg, Florida, United States|Southeastern Urological Center, Tallahassee, Florida, United States|Georgia Urology Research Institute, Atlanta, Georgia, United States|Ball Memorial Hospital, Muncie, Indiana, United States|Urological Associates PC, Davenport, Iowa, United States|Drs. Werner, Murdock and Francis PA Urology Associates, Greenbelt, Maryland, United States|Urology Associates of Middlesex County, Inc., Marlborough, Massachusetts, United States|Lakeside Urology, P.C., Saint Joseph, Michigan, United States|Millennium Medical Center, Southfield, Michigan, United States|Kansas City Urology Care, Kansas City, Missouri, United States|The Prostate Center of Greater St. Louis, St. Louis, Missouri, United States|American Academy of Urology, Las Vegas, Nevada, United States|Urological Surgical Associates, Edison, New Jersey, United States|UroResearch, LLC, Morristown, New Jersey, United States|Shaukat M. Qureshi, MD, Pennsville, New Jersey, United States|Urology Associates, Stratford, New Jersey, United States|Associates in Urology, LLC, West Orange, New Jersey, United States|AccuMed Research Associates, Garden City, New York, United States|Urological Surgeons of Long Island PC, Garden City, New York, United States|Kingston Urological Assoc., Kingston, New York, United States|Cary Urology, P.A., Cary, North Carolina, United States|Matrix Research, LLC, Greenville, North Carolina, United States|The Urology Group, Cincinnati, Ohio, United States|Southwest Urology, Parma, Ohio, United States|Roger N. Andrews, MD Inc., Arcadia, Pennsylvania, United States|Urologic Surgery, PC, Bala Cynwyd, Pennsylvania, United States|James W. Thompson, MD Ltd., Bryn Mawr, Pennsylvania, United States|Urology Institute of Pittsburgh, Monroeville, Pennsylvania, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States|Center for Urologic Care of Berks County, West Reading, Pennsylvania, United States|Grand Strand Urology, Myrtle Beach, South Carolina, United States|Urology Center of the South P.C., Germantown, Tennessee, United States|Murfreesboro Medical Clinic, Murfreesboro, Tennessee, United States|Urology Associates, PA, Nashville, Tennessee, United States|Research Across America, Carrollton, Texas, United States|CAMC Clinical Trials, Charleston, West Virginia, United States		https://ClinicalTrials.gov/show/NCT00035997
53	NCT02405858	A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy		Completed	No Results Available	Metastatic Castration-Resistant Prostate Cancer	Drug: Abiraterone Acetate|Drug: Prednisolone	Percentage of Participants Achieving Prostate-specific Antigen (PSA) Response (PSA Response Rate) by 12 Weeks of Therapy|Duration of PSA Response|Time to PSA Response|Percentage of Participants Achieving PSA Response by 24 weeks of Therapy|PSA-based Progression-free Survival (PSA-PFS)|Maximum Serum PSA Decline Evaluation|Percentage of Participants With Radiographic Objective Response Rate (RAD-ORR) in Participants with Measurable Lesions at Baseline|Radiographic Progression-free Survival (RAD-PFS)|Time to Next Treatment|Overall Survival|Brief Pain Inventory - Short Form|Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)	Janssen Pharmaceutical K.K.	Male	20 Years and older   (Adult, Older Adult)	Phase 4	51	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CR106841|ABI-C-14-JP-001-V03	April 10, 2015	December 31, 2017	December 31, 2017	April 1, 2015		December 21, 2018	Asahi, Japan|Higashi-Ibaraki, Japan|Kanazawa, Japan|Kobe, Japan|Koshigaya, Japan|Kumamoto, Japan|Narashino, Japan|Okayama, Japan|Sagamihara, Japan|Sakura, Japan|Shinjuku-Ku, Japan|Sunto, Japan|Yokohama, Japan|Yokosuka, Japan		https://ClinicalTrials.gov/show/NCT02405858
54	NCT02726009	A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer		Active, not recruiting	No Results Available	Prostate Cancer	Drug: Degarelix	Frequency of adverse events|Severity of adverse events|Clinically significant changes in laboratory values (hematology and clinical biochemistry)|Clinically significant changes in vital signs|Cumulative probability of no Prostate Specific Antigen (PSA) failure|Cumulative probability of Progression Free Survival (PFS)|Change in International Prostate Symptom Score (IPSS)|Change in physician's satisfaction score	Ferring Pharmaceuticals	Male	18 Years to 79 Years   (Adult, Older Adult)	Phase 4	228	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	000201	May 2016	June 2020	June 2020	April 1, 2016		June 26, 2019	S. P Medical College and AG of Hospitals, Bikaner, Rajasthan, India|Krishna Institute of Medical Sciences, Secunderabad, Telangana, India|Bodyline Hospitals, Ahmedabad, India|HCG Multi Specialty Hospital, Ahmedabad, India|Shalby Hospital, Ahmedabad, India|HealthCare Global Enterprises Limited, Bangalore, India|KLE's Dr. Prabhakar Kore Hospital & MRC, Belgaum, India|Apollo Speciality Hospital, Chennai, India|Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India|Muljibhai Patel Urological Hospital, Gujrat, India|CHL Hospital, Indore, India|SMS Medical College & Attached Hospital's, Jaipur, India|Tata Medical Center, Kolkata, India|King's George Medical University, Lucknow, India|Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India|Tata Memorial Hospital, Mumbai, India|Government Medical College and Super Specialty Hospital, Nagpur, India|Rml & Pgimer, New Delhi, India|Aman Hospital and Research Center, Vadodara, India		https://ClinicalTrials.gov/show/NCT02726009
55	NCT01743560	An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis	4EVERUK	Completed	Has Results	Oestrogen Receptor Positive Advanced Breast Cancer	Drug: RAD001|Drug: Exemestane	Best Overall Response of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer|Overall Response Rate of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer|Progression-free Survival (PFS) Events as Per Investigators - FAS|Progression-free Survival (PFS) by Median Time in Weeks as Per Investigators - FAS|Progression-free Survival (PFS) - % Event-free Probability Estimate - FAS|Overall Survival (OS) Events (Number of Deaths) - FAS|Overall Survival (OS) - % Event-free Probability Estimate - FAS|Change From Baseline EORTC Quality of Life Questionnaire of Cancer Patients QLQ-C30 at Each Time Point|Percentage of Patient Responses in EuroQoL 5-dimension Questionnaire - FAS|Change From Baseline in EuroQoL 5-dimension Visual Analogue Scores - FAS	Novartis Pharmaceuticals|Novartis	Female	18 Years and older   (Adult, Older Adult)	Phase 4	52	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CRAD001YGB11|2012-003689-41	January 31, 2013	August 15, 2016	August 15, 2016	December 6, 2012	April 1, 2019	July 18, 2019	Novartis Investigative Site, Epping, Essex, United Kingdom|Novartis Investigative Site, Inverness, Invernesshire, United Kingdom|Novartis Investigative Site, Ipswich, Suffolk, United Kingdom|Novartis Investigative Site, Sutton, Surrey, United Kingdom|Novartis Investigative Site, Cardiff, United Kingdom|Novartis Investigative Site, Denbighshire, United Kingdom|Novartis Investigative Site, East Kilbride, United Kingdom|Novartis Investigative Site, East Yorkshire, United Kingdom|Novartis Investigative Site, Edinburgh, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Portsmouth, United Kingdom		https://ClinicalTrials.gov/show/NCT01743560
56	NCT02441894	Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer	PEGAZUS	Completed	No Results Available	Prostate Cancer	Drug: CABAZITAXEL XRP6258|Drug: PEG-G-CSF|Drug: Prednisolone|Drug: Dexchlorpheniramine or Diphenhydramine|Drug: Ranitidine|Drug: Metoclopramide, Granisetron, or Ondansetron|Drug: Dexamethasone	Number of patients with FN (all grades) during study Cycle 1|Number of patients with FN (all grades)|Number of patients with Grade ≥3 neutropenia|Number of patients with Grade ≥3 diarrhea|Number of dose delays in the start of drug administration due to AEs|Number of dose reductions due to AEs|Percent change in relative dose intensity due to AEs|Number of patients with FN-related hospitalization|Number of patients who used IV anti-infective drugs|Changes of PSA levels from baseline|Number of patients with adverse events	Sanofi	Male	20 Years and older   (Adult, Older Adult)	Phase 4	21	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CABAZL07239|U1111-1155-8055	April 2015	February 2016	November 2016	May 12, 2015		January 24, 2017	Investigational Site Number 392004, Chuo-ku, Chiba, Japan|Investigational Site Number 392008, Kita-gun, Japan|Investigational Site Number 392007, Kobe-shi, Hyogo, Japan|Investigational Site Number 392005, Nagakute-shi, Aichi, Japan|Investigational Site Number 392006, Osaka Sayama-shi, Osaka, Japan|Investigational Site Number 392001, Shinjuku-ku, Tokyo, Japan|Investigational Site Number 392002, Yokohama-shi, Kanagawa, Japan|Investigational Site Number 392009, Yokohama-shi, Japan		https://ClinicalTrials.gov/show/NCT02441894
57	NCT02567331	A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer		Completed	No Results Available	Colorectal Cancer	Drug: Capecitabine	Incidence of adverse events|Response rate, ie, percentage of participants with complete, partial, and overall response|Pharmacoeconomic analysis: Treatment-related and AE-related spending/savings\n	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	28	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML18017	October 2004	April 2006	April 2006	October 2, 2015		November 2, 2016	Plovdiv, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria		https://ClinicalTrials.gov/show/NCT02567331
58	NCT00121836	A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer		Completed	Has Results	Breast Cancer	Drug: Capecitabine|Drug: Bevacizumab	Overall Survival|Number of Subjects With Adverse Events|Premature Withdrawal From Study Due to Adverse Events|Number of Participants With Marked Laboratory Abnormalities	Hoffmann-La Roche	Female	18 Years and older   (Adult, Older Adult)	Phase 4	109	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML18527	June 2005	December 2008	December 2008	July 21, 2005	March 4, 2011	April 27, 2011	Birmingham, Alabama, United States|Birmingham, Alabama, United States|Birmingham, Alabama, United States|Birmingham, Alabama, United States|Birmingham, Alabama, United States|Birmingham, Alabama, United States|Burbank, California, United States|Glendale, California, United States|Glendale, California, United States|Los Angeles, California, United States|San Diego, California, United States|Farmington, Connecticut, United States|Bonita Springs, Florida, United States|Boynton Beach, Florida, United States|Bradenton, Florida, United States|Cape Coral, Florida, United States|Fort Myers, Florida, United States|Fort Myers, Florida, United States|Naples, Florida, United States|Naples, Florida, United States|Port Charlotte, Florida, United States|Sarasota, Florida, United States|Sarasota, Florida, United States|Venice, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Tucker, Georgia, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Indianapolis, Indiana, United States|Waterloo, Iowa, United States|Scarborough, Maine, United States|Prince Frederick, Maryland, United States|Lansing, Michigan, United States|Kansas City, Missouri, United States|Kansas City, Missouri, United States|Kansas City, Missouri, United States|Kansas City, Missouri, United States|Kansas City, Missouri, United States|Kansas City, Missouri, United States|Lincoln, Nebraska, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Brick, New Jersey, United States|Neptune, New Jersey, United States|Red Bank, New Jersey, United States|Rochester, New York, United States|Hickory, North Carolina, United States|Canton, Ohio, United States|Oklahoma City, Oklahoma, United States|Beaufort, South Carolina, United States|Charleston, South Carolina, United States|Florence, South Carolina, United States|Hilton Head Island, South Carolina, United States|Sumter, South Carolina, United States|Abingdon, Virginia, United States|Milwaukee, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT00121836
59	NCT02075606	Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients	CALM-NET	Completed	Has Results	NeuroEndocrine Tumours	Drug: lanreotide acetate	Assessment of Clinical Symptomatic Response|Percentage of Subjects With Time Point Responses According to Response Evaluation Criteria in Solid Tumours (RECIST) Assessments at Weeks 25 and 53|Mean Change From Baseline in Number of Episodes of Diarrhoea and Flushing|Mode Symptom Severity of Episodes of Flushing|Quality of Life (QoL) Questionnaire: European Organisation for Research and Treatment of Cancer (EORTC) QoL Questionnaire (QLQ)-C30|QoL Questionnaire: EORTC QLQ-G.I.NET21|Percentage of Subjects Alive and Progression Free at One Year	Ipsen	All	18 Years and older   (Adult, Older Adult)	Phase 4	50	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	A-97-52030-270|2013-002194-22	May 2014	June 2017	June 2017	March 3, 2014	June 7, 2019	June 7, 2019	Basingstoke & North Hampshire Hospital, Basingstoke, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|University Hospital Wales, Cardiff, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|St James's University Hospital, Leeds, United Kingdom|University Hospital Aintree, Liverpool, United Kingdom|Hammersmith Hospital, London, United Kingdom|King's College Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|Maidstone Hospital, Maidstone, United Kingdom|The Christie Hospital, Manchester, United Kingdom|Norfolk & Norwich Hospital, Norwich, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom|Southampton University Hospital, Southampton, United Kingdom	"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02075606/SAP_000.pdf|"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02075606/Prot_001.pdf	https://ClinicalTrials.gov/show/NCT02075606
60	NCT00127933	XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer		Completed	Has Results	Breast Cancer	Drug: capecitabine [Xeloda]|Drug: Taxotere|Drug: Herceptin (HER2-neu positive patients only)	Percentage of Participants Assessed for Pathological Complete Response (pCR) Plus Near Complete (npCR) in Primary Breast Tumor at Time of Definitive Surgery|Percentage of Participants With Complete Pathological Response in the Primary Breast Tumor at the Time of Definitive Surgery|Percentage of Participants With Overall Clinical Response (Complete Response (CR) Plus Partial Response (PR))|Percentage of Participants With Local Recurrence|Participants With Disease-Free Survival|Participants With Overall Survival	Hoffmann-La Roche	Female	18 Years and older   (Adult, Older Adult)	Phase 4	157	Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML18530	August 2005	April 2009	July 2009	August 9, 2005	August 10, 2011	August 10, 2011	Los Angeles, California, United States|Montebello, California, United States|Palm Springs, California, United States|San Diego, California, United States|Farmington, Connecticut, United States|Melbourne, Florida, United States|Miami, Florida, United States|Tamarac, Florida, United States|Savannah, Georgia, United States|Indianapolis, Indiana, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Alexandria, Louisiana, United States|Scarborough, Maine, United States|Baltimore, Maryland, United States|Edina, Minnesota, United States|Jefferson City, Missouri, United States|Rolla, Missouri, United States|St Louis, Missouri, United States|Neptune, New Jersey, United States|Albuquerque, New Mexico, United States|Albuquerque, New Mexico, United States|Albuquerque, New Mexico, United States|Santa Fe, New Mexico, United States|New York, New York, United States|Charlotte, North Carolina, United States|Canton, Ohio, United States|Pittsburgh, Pennsylvania, United States|Pottsville, Pennsylvania, United States|Charleston, South Carolina, United States|Georgetown, South Carolina, United States|Sumter, South Carolina, United States|Memphis, Tennessee, United States|Memphis, Tennessee, United States|Dallas, Texas, United States|Dallas, Texas, United States|Burlington, Vermont, United States|Abingdon, Virginia, United States		https://ClinicalTrials.gov/show/NCT00127933
61	NCT02581423	A Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon Cancer		Completed	No Results Available	Colorectal Cancer	Drug: Capecitabine	Incidence of adverse events (AEs)|Incidence of treatment discontinuation due to AEs|Incidence of toxocity-related dose reductions	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	63	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML18601	August 2005	March 2007	March 2007	October 21, 2015		November 2, 2016	Blagoevgrad, Bulgaria|Ruse, Bulgaria|Shumen, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Veliko Tarnovo, Bulgaria		https://ClinicalTrials.gov/show/NCT02581423
62	NCT00649090	A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer		Completed	No Results Available	Breast Neoplasms	Drug: exemestane	Assess for serious adverse events|Safety Surveillance Program	Pfizer	Female	Child, Adult, Older Adult	Phase 4	1549	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	A5991077	March 2005	April 2007	April 2007	April 1, 2008		September 29, 2008	Pfizer Investigational Site, Aalst, Belgium|Pfizer Investigational Site, Antwerpen, Belgium|Pfizer Investigational Site, Arlon, Belgium|Pfizer Investigational Site, Baudour, Belgium|Pfizer Investigational Site, Bonheiden, Belgium|Pfizer Investigational Site, Bouge, Belgium|Pfizer Investigational Site, Boussu, Belgium|Pfizer Investigational Site, Braine-l'Alleud, Belgium|Pfizer Investigational Site, Brasschaat, Belgium|Pfizer Investigational Site, Brugge, Belgium|Pfizer Investigational Site, Brussels, Belgium|Pfizer Investigational Site, Brussels, Belgium|Pfizer Investigational Site, Brussels, Belgium|Pfizer Investigational Site, Brussels, Belgium|Pfizer Investigational Site, Brussels, Belgium|Pfizer Investigational Site, Brussel, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Charleroi, Belgium|Pfizer Investigational Site, Chenee, Belgium|Pfizer Investigational Site, Chimay, Belgium|Pfizer Investigational Site, Dendermonde, Belgium|Pfizer Investigational Site, Duffel, Belgium|Pfizer Investigational Site, Edegem, Belgium|Pfizer Investigational Site, Eupen, Belgium|Pfizer Investigational Site, Genk, Belgium|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Gilly (Charleroi), Belgium|Pfizer Investigational Site, Gosselies, Belgium|Pfizer Investigational Site, Halle, Belgium|Pfizer Investigational Site, Hasselt, Belgium|Pfizer Investigational Site, Herstal, Belgium|Pfizer Investigational Site, Hornu, Belgium|Pfizer Investigational Site, Huy, Belgium|Pfizer Investigational Site, Kortrijk, Belgium|Pfizer Investigational Site, La Louviere, Belgium|Pfizer Investigational Site, Leuven, Belgium|Pfizer Investigational Site, Libramont, Belgium|Pfizer Investigational Site, Liege, Belgium|Pfizer Investigational Site, Lier, Belgium|Pfizer Investigational Site, Liège, Belgium|Pfizer Investigational Site, Mechelen, Belgium|Pfizer Investigational Site, Merksem, Belgium|Pfizer Investigational Site, Mons, Belgium|Pfizer Investigational Site, Montigny-le-Tilleul, Belgium|Pfizer Investigational Site, Mouscron, Belgium|Pfizer Investigational Site, Namur, Belgium|Pfizer Investigational Site, Ottignies, Belgium|Pfizer Investigational Site, Rocourt, Belgium|Pfizer Investigational Site, Roeselare, Belgium|Pfizer Investigational Site, Seraing, Belgium|Pfizer Investigational Site, Sint-Niklaas, Belgium|Pfizer Investigational Site, Soignies, Belgium|Pfizer Investigational Site, Tongeren, Belgium|Pfizer Investigational Site, Torhout, Belgium|Pfizer Investigational Site, Tournai, Belgium|Pfizer Investigational Site, Turnhout, Belgium|Pfizer Investigational Site, Verviers, Belgium|Pfizer Investigational Site, Waregem, Belgium|Pfizer Investigational Site, Wilrijk, Belgium|Pfizer Investigational Site, Yvoir, Belgium		https://ClinicalTrials.gov/show/NCT00649090
63	NCT03971110	A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy.		Not yet recruiting	No Results Available	Advanced Prostate Cancer	Drug: Zoladex and Casodex	Resectability rate for primary tumour (the resectability will be assessed by central review using a digital rectal examination and confirmed by CT or MRI)|Radical prostatectomy rate|The mean PSA by the end of NHT|Percentage of positive surgical margin for primary tumour|Incidence of seminal vesicle invasion|Percentage of pathological downstaging|surgical-related variables at 12 weeks, potent rates in erectile function at 12 weeks after surgery|PFS|AEs/SAEs|PSA change from baseline|Involvement of bilateral pelvic lymph nodes|OS	AstraZeneca	Male	Child, Adult, Older Adult	Phase 4	104	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D8664C09827	July 31, 2019	January 10, 2022	January 10, 2022	June 3, 2019		June 3, 2019	The First Affilliated Hospital of Anhui Medical University, Hefei, Anhui, China|The Second Hospital of Hebei Medical Univeristy, Shijiazhuang, Hebei, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|Hunan Cancer Hospital, Changsha, Hunan, China|The First Hospital of China Medical University, Shenyang, Liaoning, China|The FirstAffiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China|Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China|Peking University First Hospital, Beijing, China|The Second Xiangya Hospital of Central South University, Changsha, China|West China Hospital, Sichuan University, Chengdu, China|The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China|The Third Affilliated Hospital, Sun Yat-Sen University, Guangzhou, China|Fudan University Shanghai Cancer Center, Shanghai, China|The First Affiliated Hospital of Xinjiang Medical University, Urumchi, China		https://ClinicalTrials.gov/show/NCT03971110
64	NCT01595009	An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)		Completed	Has Results	Neuroendocrine Tumors	Drug: Everolimus (RAD001)	Number and Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths (Core)|Number and Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths During the Extension Phase (E1)|Investigator-assessed Progression Free Survival (PFS) (Core)|Mean European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Score (Core)|Mean EORTC QLQ-G.I. NET21 Score (Core)|Number and Percentage of Participants With Ratings of 'no Problem, 'Some Problem' and 'Extreme Problem' in the EuroQol Five Dimensions Questionnaire (EQ-5D) (Core)|Mean EQ-5D Visual Analogue Scale (VAS) Score (Core)|Investigator-assessed Best Overall Response (Core)|Investigator-assessed Progression Free Survival (PFS) (E1)|Change in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Score at the End of Treatment From Baseline (Baseline = First Day of Treatment in the Extension) (E1)|Change in EORTC QLQ-G.I. NET21 Score at the End of Treatment From Baseline (Baseline = First Day of Treatment in the Extension) (E1)|Change in EuroQol Five Dimensions Questionnaire (EQ-5D) Score at the End of Treatment From Baseline (Baseline = First Day of Treatment in the Extension) (E1)|Investigator-assessed Best Overall Response During the Extension Phase (E1)	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	246	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CRAD001K24133	April 27, 2011	August 9, 2016	August 9, 2016	May 9, 2012	November 29, 2018	November 29, 2018	Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Chemnitz, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Homburg, Germany|Novartis Investigative Site, Kassel, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Osnabrück, Germany|Novartis Investigative Site, Weiden, Germany		https://ClinicalTrials.gov/show/NCT01595009
65	NCT00190697	A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment		Completed	No Results Available	Breast Cancer|Endometrial Cancer|Ovarian Cancer	Drug: arzoxifene	To allow continued treatment of patients who exhibited clinical benefit from arzoxifene|To collect long-term safety data on arzoxifene use in advanced cancer patients	Eli Lilly and Company	Female	Child, Adult, Older Adult	Phase 4	70	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	5234|H4Z-MC-JWXM	January 2001		April 2007	September 19, 2005		May 25, 2007	For information regarding investigative sites for this clinical trial, call 1-877- CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or contact your personal physician, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00190697
66	NCT01753297	A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.	PRIORITI	Active, not recruiting	No Results Available	Prostate Cancer	Drug: Triptorelin 11.25 mg	Biochemical Relapse-Free Survival (BRFS)|Event-Free Survival (EFS)|Overall Survival (OS)|Time to disease-specific mortality|PSA Doubling Time (PSADT)	Ipsen	Male	18 Years and older   (Adult, Older Adult)	Phase 4	226	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	A-38-52014-194	December 2012	September 2019	September 2019	December 20, 2012		July 25, 2019	Fudan University cancer hospital Site #156003, Shanghai, Shanghai, China|First Affiliated Hospital of the Fourth Military Medical University Site #156004, Xi'an, Shanxi, China|Chinese PLA General HospitalDepartment of UrologySite #156007, Beijing, China|Peiking University First Hospital Site #156011, Beijing, China|West China Hosspital, Sichuan UniversityDepartment of Urology Site #156008, Chengdu, China|The First Affiliated Hospital of the 3th Military Medical University of PLA (Southwest Hospital) Site # 156010, Chongqing, China|SUN YAT-SEN Cancer Center Department of Site #156009, Guangzhou, China|The third hospital affiliated to Sun Yat-sen University Site #156005, Guangzhou, China|The first hospital affiliated to medical school of Zhejiang university Site #156001, Hangzhou, China|SIH Altaian Territorial Oncological Dispensary Site #643006, Barnaul, Russian Federation|SBHI Sverdlovskaya Regional Clinical Hospital #1 Site #643004, Ekaterinburg, Russian Federation|FSBI "Research Institute of Urology" of Ministry of health care of Russia Site #643002, Moscow, Russian Federation|State Budgetary Healthcare Institution "Moscow Clinical Scientific-Practical Center named after A. S. Loginov of Healthcare Department of Moscow" Site #643009, Moscow, Russian Federation|FSBI Russian Oncological Scientific Center named after N.N. Blokhina of RAMS, 23 Site #643001, Moscow, Russian Federation|Federal State Budgetary Health care Institution "Central clinical hospital of Russian Academy of Science (CCH RAS), in-patient unit, urological department Site #643005, Moscow, Russian Federation|FSI Moscow Research Oncological Institute named after P.A.Gertsen Site #643003, Moscow, Russian Federation|Medical radiology research center named after A.F. Tsyba - branch of FSBI "National Medical Research Center of Radiology" of Ministry of healthcare of Russian Federation Site #643008, Obninsk, Russian Federation|Budgetary Health care Institution of Omsk region "Clinical oncological dispensary" Site #643007, Omsk, Russian Federation		https://ClinicalTrials.gov/show/NCT01753297
67	NCT01621100	Study to Evaluate Effectiveness and Tolerability of OROS Hydromorphone for Cancer Pain Treatment in Korean Patients		Completed	No Results Available	Cancer Pain	Drug: OROS hydromorphone	Number of patients with 50% or more average Pain Intensity Difference (PID) from 1st evaluation day (Day 1) to the 2nd evaluation day (Days 15±2)|Korean Brief Pain Inventory (K-BPI) scores|European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) scores|Patient's Global Assessment (PGA) scores|Investigator's Global Assessment scores	Janssen Korea, Ltd., Korea	All	20 Years and older   (Adult, Older Adult)	Phase 4	106	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CR100659|HYD-KOR-4003|42801PAI4012	December 2011	September 2012	September 2012	June 18, 2012		September 6, 2013	Cheonan City, Korea, Republic of|Cheonan, Korea, Republic of|Cheongju, Korea, Republic of|Daejeon, Korea, Republic of|Hwasun Gun, Korea, Republic of|Jeonju-Si, Korea, Republic of|Jinju-Si, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01621100
68	NCT00172016	A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates		Completed	No Results Available	Prostate Cancer With at Least One Bone Lesion in Patients Receiving Hormonal Therapy and Treatment With Bisphosphonates is Indicated	Drug: Zoledronic acid		Novartis Pharmaceuticals|Novartis	Male	18 Years and older   (Adult, Older Adult)	Phase 4	43	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CZOL446EHU01	January 2004	April 2005		September 15, 2005		April 30, 2012			https://ClinicalTrials.gov/show/NCT00172016
69	NCT01588990	A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer	ASCENT	Completed	Has Results	Colorectal Neoplasms	Drug: Oxaliplatin|Drug: Capecitabine|Drug: Bevacizumab|Drug: Leucovorin|Drug: 5-Fluouracil|Drug: Irinotecan	Association Between Neutrophil to Lymphocyte Ratio (NLR) [NLR ≤5 Versus NLR >5] and Progression-Free Survival (PFS) as Assessed by Hazard Ratio|PFS Until First Disease Progression as Assessed by the Investigator Based on Routine Clinical Practice: Phase A|PFS Until Second Disease Progression as Assessed by the Investigator Based on Routine Clinical Practice: Phase B|Time to Failure of Strategy (TFS): Overall|Duration of Disease Control (DDC) as Assessed by the Investigator Based on Routine Clinical Practice: Overall|Overall Survival (OS) From the Start of Treatment to Study Completion: Overall|Survival Beyond First Disease Progression: Overall|OS: Phase B|Percentage of Participants With Confirmed Complete or Partial Response as Assessed by the Investigator Based on Routine Clinical Practice: Phase A|Percentage of Participants With Confirmed Complete or Partial Response as Assessed by the Investigator Based on Routine Clinical Practice: Phase B|Percentage of Participants With Confirmed Complete or Partial Response as Assessed by the Investigator Based on Routine Clinical Practice: Overall|Percentage of Participants Who Underwent Liver Resection: Overall|Association Between NLR (NLR ≤5 Versus NLR >5) and OS as Assessed by Hazard Ratio|Association Between NLR Normalization (First NLR Post-Baseline ≤5 Versus NLR >5) and PFS as Assessed by Hazard Ratio|Association Between Longitudinal NLR (Longitudinal NLR ≤5 Versus NLR >5) and PFS as Assessed by Hazard Ratio|Association Between Longitudinal NLR (Longitudinal NLR ≤5 Versus NLR >5) and OS as Assessed by Hazard Ratio|European Quality of Life 5-Dimension (EuroQol-5D) Utility Score: Phase A|EuroQol-5D Utility Score: Phase B|Assessment of Quality of Life - Eight Dimensions (AQoL-8D) Global Utility Score: Phase A|AQoL-8D Global Utility Score: Phase B|Functional Assessment of Cancer Therapy-Colorectal (FACT-C) Score: Phase A|FACT-C Score: Phase B	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	128	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML25753	June 26, 2012	September 15, 2016	September 30, 2016	May 1, 2012	January 21, 2019	January 21, 2019	Canberra Hospital, Garran, Australian Capital Territory, Australia|Macarthur Cancer Therapy Centre, Campbelltown, New South Wales, Australia|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|St Vincent'S Hospital; Clinical Oncology, Darlinghurst, New South Wales, Australia|Mid North Coast Cancer Institute, Port Macquarie, New South Wales, Australia|Royal North Shore Hospital; Department of Medical Oncology, St Leonards, New South Wales, Australia|Sydney Adventist Hospital; Clinical Trial Unit, Sydney, New South Wales, Australia|Royal Brisbane Hospital, Brisbane, Queensland, Australia|Rockhampton Hospital, Rockhampton, Queensland, Australia|The Townsville Hospital; Townsville Cancer Centre, Townsville, Queensland, Australia|Lyell McEwin Hospital; Oncology Clinical Trials, Chemotherapy Day Unit, Elizabeth Vale, South Australia, Australia|Calvary North Adelaide; North Adeliade Oncology Centre, North Adelaide, South Australia, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Austin Hospital; Medical Oncology, Heidelberg, Victoria, Australia|Sunshine Hospital; Oncology Research, St Albans, Victoria, Australia|St John of God Murdoch Hospital; Oncology West, Murdoch, Western Australia, Australia|St John of God Hospital; Bendat Cancer Centre, Subiaco, Western Australia, Australia		https://ClinicalTrials.gov/show/NCT01588990
70	NCT00502671	A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.		Completed	Has Results	Colorectal Cancer	Drug: capecitabine [Xeloda]	Percentage of Participants With an Adverse Event (AE), Serious AE, or Death Due to an AE|Percentage of Participants With Early Withdrawal or Discontinuation Due to an AE	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	228	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML20592	July 2007	March 2012	March 2012	July 18, 2007	September 3, 2015	September 3, 2015	Arkhangelsk, Russian Federation|Astrakhan, Russian Federation|Barnaul, Russian Federation|Belgorod, Russian Federation|Chelyabinsk, Russian Federation|Ekaterinburg, Russian Federation|Irkutsk, Russian Federation|Izhevsk, Russian Federation|Kaluga, Russian Federation|Kazan, Russian Federation|Kazan, Russian Federation|Kirov, Russian Federation|Kostroma, Russian Federation|Krasnodar, Russian Federation|Kursk, Russian Federation|Lipetsk, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Novgorod Veliky, Russian Federation|Obninsk, Russian Federation|Orenburg, Russian Federation|Perm, Russian Federation|Rostov-na-donu, Russian Federation|Ryazan, Russian Federation|Salekhard, Russian Federation|Samara, Russian Federation|Smolensk, Russian Federation|Soshi, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|Stavropol, Russian Federation|Surgut, Russian Federation|Tollyatti, Russian Federation|Tomsk, Russian Federation|Tomsk, Russian Federation|Tumen, Russian Federation|Tver, Russian Federation|UFA, Russian Federation|UFA, Russian Federation|Volgograd, Russian Federation|Yuzhno-Sakhalinsk, Russian Federation		https://ClinicalTrials.gov/show/NCT00502671
71	NCT00771199	An Efficacy and Safety Study of Low-dose Transdermal Therapeutic System (TTS)-Fentanyl D-Trans in Taiwan Participants With Cancer Pain		Completed	No Results Available	Cancer, Pain	Drug: Transdermal Therapeutic System (TTS)-Fentanyl	Percentage of Participants Dropped From Study due to Adverse Events|Brief Pain Inventory (BPI) Score (Question 6)|BPI Score (Question 9) - Quality of Life (QOL)|Average Daily Dose and Final Dose of Transdermal Therapeutic System (TTS)-fentanyl|Investigator's Global Assessment Scale Score|Percentage of Participants With Treatment Satisfaction	Janssen-Cilag Ltd.	All	18 Years and older   (Adult, Older Adult)	Phase 4	14	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CR014602|FENPAI4054	October 2008	November 2008	November 2008	October 13, 2008		September 17, 2014			https://ClinicalTrials.gov/show/NCT00771199
72	NCT02074137	Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer		Completed	No Results Available	Prostate Cancer Metastatic	Drug: CABAZITAXEL XRP6258|Drug: Prednisone|Drug: Prednisolone	Number of patients with Related Serious Adverse Events|Evaluation of use of cabazitaxel in terms of treatment duration, number of cycles, dose modifications|Radiological overall response (if radiological tumor assessment done) using Recist criteria|Number of patients with at least 50% decrease in PSA	Sanofi	Male	18 Years and older   (Adult, Older Adult)	Phase 4	10	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CABAZL06499|U1111-1131-3161	July 2014	March 2016	March 2016	February 28, 2014		June 2, 2016	Investigational Site Number 356005, Kollkata, India|Investigational Site Number 356003, New Delhi, India|Investigational Site Number 356002, Trivandrum, India		https://ClinicalTrials.gov/show/NCT02074137
73	NCT01695772	A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer		Completed	Has Results	Colorectal Cancer	Drug: 5-FU based doublet chemotherapy|Drug: bevacizumab	Percentage of Participants Achieving Complete Resection (R0 Resection)|Percentage of Participants Achieving Incomplete Tumor Resection (R1 Resection)|Percentage of Participants Achieving Objective Response|Number of Participants With Disease Progression or Relapse or Death|Progression Free Survival (PFS)|Percent Probability (PP) of Being Alive and Progression Free at Months 3, 6, 9, 12, 15, and 18|Number of Participants With Disease Relapse or Death|Disease Free Survival (DFS)|Percent Probability Of Being Alive and Disease Free at Months 3, 6, 9, and 12	Hoffmann-La Roche	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	50	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML28419	October 16, 2012	April 4, 2015	May 12, 2016	September 28, 2012	July 28, 2016	June 9, 2017	Beijing Cancer Hospital, Beijing, China|Sun Yet-sen University Cancer Center, Guangzhou, China|The Second Affiliated Hospital of Zhejiang University College, Hangzhou, China|The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China|Zhongshan Hospital Fudan University, Shanghai, China|Liaoning cancer Hospital & Institute, Shenyang, China|Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology, Wuhan, China		https://ClinicalTrials.gov/show/NCT01695772
74	NCT00434317	Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases		Completed	No Results Available	Neoplasm Metastasis	Drug: Zoledronic acid	Measurement of pain assessed by a Visual Analogue Scale (VAS)|Quality of Life assessment at baseline and last visit	Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	80	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CZOL446EHU03	August 2005	April 2008		February 13, 2007		February 23, 2017	Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szekesfehervar, Hungary		https://ClinicalTrials.gov/show/NCT00434317
75	NCT02582970	A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum		Completed	Has Results	Colorectal Cancer	Drug: 5-Fluorouracil|Drug: Bevacizumab|Drug: Irinotecan|Drug: Oxaliplatin	Percentage of Participants With Adverse Events|Percentage of Participants Who Died|Duration of Survival|Percentage of Participants With Disease Progression or Death|Progression-Free Survival Time|Number of Participants With Best Overall Response|Mean Direct Medical Cost for Cancer Related Medical Care Utilization	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	40	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML18436	May 2005	October 2007	April 2008	October 21, 2015	March 9, 2017	March 9, 2017	Chai Yi, Taiwan|Kaohsiung, Taiwan|Kaohsiung, Taiwan|Taichung, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Tainan, Taiwan|Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT02582970
76	NCT00280098	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer		Completed	No Results Available	Prostatic Neoplasms	Drug: docetaxel	PSA decline|pain response|side effects occurrence	Sanofi	Male	18 Years and older   (Adult, Older Adult)	Phase 4	30	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	XRP6976J_4001	January 2006	October 2007		January 20, 2006		December 7, 2009	Sanofi-Aventis, Prague, Czech Republic		https://ClinicalTrials.gov/show/NCT00280098
77	NCT00770588	Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)	INFORM	Completed	Has Results	Non-small Cell Lung Cancer (NSCLC)	Drug: Gefitinib|Drug: Placebo	Progression Free Survival (PFS)|Overall Survival (OS)|Objective Tumour Response (ORR)|Disease Control Rate (DCR)|Symptom Improvement|Adverse Event	AstraZeneca	All	18 Years and older   (Adult, Older Adult)	Phase 4	296	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	D7913L00071	September 2008	January 2011	February 2011	October 10, 2008	August 20, 2012	February 8, 2016	Research Site, Beijing, Beijing, China|Research Site, Fuzhou, Fujian, China|Research Site, Guangzhou, Guangdong, China|Research Site, Nanning, Guangxi, China|Research Site, Zhengzhou, Henan, China|Research Site, Wuhan, Hubei, China|Research Site, Nanjing, Jiangsu, China|Research Site, Changchun, Jilin, China|Research Site, Shengyang, Liaoning, China|Research Site, Shanghai, Shanghai, China|Research Site, Xi'an, Shanxi, China|Research Site, Chengdu, Sichuan, China|Research Site, Tianjin, Tianjin, China|Research Site, Hangzhou, Zhejiang, China		https://ClinicalTrials.gov/show/NCT00770588
78	NCT00646945	Study of the Efficacy of Kalinox® 170 Bar in Adult Oncology		Completed	No Results Available	Cancer|Pain	Drug: 50% Oxygen/50% Nitrous oxide premix (Kalinox 170 bar)|Drug: 50% Oxygen/50% Nitrogen premix	pain measurement with visual analogue scale|feasibility of the kalinox 170 bar in invasives gestures in oncology|surveillance of the appearance of secondary effects	Air Liquide Santé International	All	18 Years and older   (Adult, Older Adult)	Phase 4	286	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic	2006-003226-29	September 2007	October 2008	October 2008	March 31, 2008		January 12, 2009	Centre Alexis Vautrin, Vandoeuvre les nancy, France		https://ClinicalTrials.gov/show/NCT00646945
79	NCT02658734	A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane		Active, not recruiting	No Results Available	HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer	Drug: Trastuzumab emtansine	Severity of Adverse Events|Percentage of Participants With Adverse Events|Percentage of Participants With Serious Adverse Events (SAEs)|Severity of SAEs as per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03|Percentage of Participants With Non-Serious Adverse Events of Special Interest|Laboratory Results Abnormalities|Percentage of Participants With Adverse Events Leading to Discontinuation of Study Medication|Percentage of Participants With Adverse Events Leading to Modification of Study Medication|Percentage of Participants With Adverse Events Leading to Interruption of Study Medication|Exposure to Study Medication, as Measured by the Area Under the Concentration-Time Curve (AUC)|Percentage of Participants With Drug-Induced Liver Injury Meeting Hy's Law Criteria|Percentage of Participants With Congestive Heart Failure|Left Ventricular Ejection Fraction (LVEF) Decrease as Measured by Echocardiogram|Overall Response Rate (ORR)|Progression-Free Survival (PFS)|Overall Survival (OS)	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	71	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	ML29662|2008-005713-22	November 1, 2016	December 2, 2020	December 2, 2020	January 20, 2016		June 4, 2019	Indraprastha Apollo Hospitals, New Delhi, Delhi, India|Rajiv Gandhi Cancer Inst.&Research Center; Medical Oncology, New Delhi, Delhi, India|Max Super Speciality Hospital; Medical Oncology, North WEST Delhi, Delhi, India|Apollo Hospitals International Limited, Gandhinagar, Gujarat, India|Manipal Hospital; Department of Oncology, Bangalore, Karnataka, India|Tata Memorial Hospital; Dept of Medical Oncology, Mumbai, Maharashtra, India|Jehangir Hospital, Pune, Maharashtra, India|Christian Medical College & Hospital; Medicine, Vellore, Tamil NADU, India|Healthcare Global Enterprises Limited, Bangalore, India|Artemis Health Institute, Gurgaon, India|Fortis Memorial Research Institute; Department of Medical Oncology & Haematology, Gurgaon, India|Sir Gangaram Hospital; Medical Oncology, New Delhi, India|Max Super Speciality Hospital, New Delhi, India		https://ClinicalTrials.gov/show/NCT02658734
80	NCT01649635	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer	PROSPECTA	Completed	No Results Available	Prostate Cancer	Drug: CABAZITAXEL (XRP6258)|Drug: Prednisone|Drug: Ciprofloxacin|Drug: G-CSF (Granulocyte colony-stimulating factor)	Proportion of patients with some episode of neutropenia classified as grade ≥ 3|Proportion of patients with episode of neutropenia grade ≥3|Rate of febrile neutropenia|Rate of diarrhea grade ≥3|PSA response rate|Circulating Tumor Cells Count (CTC) rate|Changes from baseline in score derived from the Functional assessment of cancer therapy-prostate (FACT-P) and the Trial Outcome Index (TOI)|Number of patients with adverse events	Sanofi	Male	18 Years and older   (Adult, Older Adult)	Phase 4	45	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CABAZ_L_06003|U1111-1123-9025	July 2012	January 2014	June 2016	July 25, 2012		July 6, 2016	Investigational Site Number 007, Centro, Brazil|Investigational Site Number 004, Curitiba, Brazil|Investigational Site Number 006, Lajeado, Brazil|Investigational Site Number 005, Porto Alegre, Brazil|Investigational Site Number 001, Santo Andre, Brazil|Investigational Site Number 002, São Paulo, Brazil		https://ClinicalTrials.gov/show/NCT01649635
81	NCT02553707	A Study to Assess the Short Term Efficacy of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Pain Due to Breast Cancer		Completed	No Results Available	Pain; Bone Neoplasms; Neoplasm Metastasis	Drug: Ibandronate	Percentage of participants with >=25% reduction in mean pain|Percentage of participants with =<35% increase in mean analgesic consumption|Change from Baseline in average pain score|Analgesic consumption|Pain response|Time to pain response	Hoffmann-La Roche	Female	18 Years and older   (Adult, Older Adult)	Phase 4	182	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML20268	July 2006	December 2008	December 2008	September 17, 2015		September 17, 2015	Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Gyor, Hungary|Gyula, Hungary|Kecskemet, Hungary|Nyíregyháza, Hungary|Szeged, Hungary|Szekesfehervar, Hungary|Szombathely, Hungary|Veszprem, Hungary|Zalaegerszeg, Hungary		https://ClinicalTrials.gov/show/NCT02553707
82	NCT02805205	PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia		Completed	No Results Available	Breast Cancer	Drug: PEG-rhG-CSF	the occurrence rate of the adverse events that are related to treatment during four consecutive cycles chemotherapy|the severity of the adverse events that are related to treatment during four consecutive cycles chemotherapy|the occurrence rate of III/ IV neutropenia during the whole chemotherapy process	CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 4	484	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	CSPC-PGC-IV-02	April 2013	February 2016	February 2016	June 17, 2016		June 20, 2016			https://ClinicalTrials.gov/show/NCT02805205
83	NCT02805166	PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy		Completed	No Results Available	Malignant Solid Tumors	Drug: PEG-rhG-CSF	The occurrence rate of adverse event during at least three consecutive cycles chemotherapy|The severity of adverse event during at least three consecutive cycles chemotherapy|the non-occurrence rate of grade IV neutropenia (ANC <0.5 x 10^9/L)during at least three consecutive cycles chemotherapy|the duration of grade IV neutropenia(ANC <0.5 x 10^9/L) during at least three consecutive cycles chemotherapy	CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.	All	18 Years and older   (Adult, Older Adult)	Phase 4	420	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	CSPC-PGC-IV-01/CSPC-PGC-IV-02	April 2013	February 2016	February 2016	June 17, 2016		June 17, 2016			https://ClinicalTrials.gov/show/NCT02805166
84	NCT00128297	Pamidronate Administration in Breast Cancer Patients With Bone Metastases		Completed	No Results Available	Breast Cancer|Neoplasm Metastasis	Drug: Pamidronate	Pamidronate efficacy to prevent first skeletal event: time until the appearance of the first skeletal event|Number of skeletal events per treatment arm|Quality of life: Short Form (SF)-36 questionnaire|Overall survival (OS)	Spanish Breast Cancer Research Group|Novartis	Female	18 Years and older   (Adult, Older Adult)	Phase 4	152	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	GEICAM 2000-01	October 18, 2000	June 4, 2004	June 4, 2004	August 9, 2005		July 31, 2019	Spanish Breast Cancer Research Group (GEICAM), San Sebastián de los Reyes, Madrid, Spain		https://ClinicalTrials.gov/show/NCT00128297
85	NCT00263055	MASCOT : Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV		Completed	No Results Available	Colonic Neoplasms	Drug: oxaliplatin	Occurrence of dose-limiting toxicity|Occurrence of one or more adverse event in a patient|Overall distribution of intensity of adverse events|Occurrence of particular adverse events and their intensities|Percent of patients completing study treatment|Percent of patients with grade 1, 2 and 3 neuropathy|Percent of intended dose delivered for 5-FU/LV and Oxaliplatin|Delays in scheduled dosing|Dose intensity, as expressed as the amount of 5-FU/LV and Oxaliplatin administered divided by the duration of treatment|•Survival Analysis •Laboratory assay and vital signs ECOG and KPS|Long term toxicity	Sanofi	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4		Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	R_9262	August 2004	June 2005		December 7, 2005		September 15, 2009	Sanofi-Aventis, Beijing, China|Sanofi-Aventis, Hong Kong, Hong Kong|Sanofi-aventis, Seoul, Korea, Republic of|Sanofi-Aventis, Taipei, Taiwan|Sanofi-Aventis, Bangkok, Thailand		https://ClinicalTrials.gov/show/NCT00263055
86	NCT00172029	Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid		Completed	No Results Available	Breast Cancer With Metastatic Bone Disease	Drug: Zoledronic acid	Percentage of patients showing complete response in bone pain palliation without having any analgesic treatment	Novartis	Female	18 Years and older   (Adult, Older Adult)	Phase 4	116	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CZOL446ETR01	April 2003	September 2005		September 15, 2005		March 29, 2010	Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey|Novartis Investigative Site, Bursa, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kayseri, Turkey|Novartis Investigative Site, Trabzon, Turkey		https://ClinicalTrials.gov/show/NCT00172029
87	NCT03301857	Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004		Active, not recruiting	No Results Available	Giant Cell Tumor of Bone	Drug: Denosumab (Cohort A)	Rate of adverse events of interest in subjects with GCTB treated with denosumab|Rate of treatment-emergent adverse events for subjects who are receiving denosumab.|Rate of serious adverse events for all subjects.|Rate of disease progression or recurrence of GCTB for all subjects.|Rate of GCTB interventions for all subjects.	Amgen	All	Child, Adult, Older Adult	Phase 4	85	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	20140114|2017-001758-32	November 13, 2017	July 19, 2023	July 19, 2023	October 4, 2017		December 10, 2018	Research Site, Santa Monica, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, New York, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Lyon CEDEX 08, France|Research Site, Villejuif, France|Research Site, Bologna, Italy|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Palma de Mallorca, Baleares, Spain|Research Site, Lund, Sweden|Research Site, Birmingham, United Kingdom		https://ClinicalTrials.gov/show/NCT03301857
88	NCT00128778	Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients		Completed	No Results Available	Breast Neoplasms	Drug: Pegylated liposomal doxorubicin	Time to progression (TTP)	Spanish Breast Cancer Research Group|Schering-Plough	Female	18 Years to 90 Years   (Adult, Older Adult)	Phase 4	288	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GEICAM 2001-01	October 28, 2002	June 1, 2007	July 7, 2010	August 10, 2005		February 21, 2019	Spanish Breast Cancer Research Group (GEICAM), San Sebastián de los Reyes, Madrid, Spain		https://ClinicalTrials.gov/show/NCT00128778
89	NCT01231659	Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer		Completed	No Results Available	Postmenopausal Women|Locally Advanced Metastatic Breast Cancer|Metastatic Breast Cancer	Drug: Everolimus + Letrozole	Overall Response Rate (ORR)|Progression Free Survival (PFS)|Overall Survival (OS)|Disease Control Rate (DCR)|Characterize the safety profile	Novartis Pharmaceuticals|Novartis	Female	18 Years and older   (Adult, Older Adult)	Phase 4	72	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CRAD001JIL05	August 9, 2011	April 30, 2017	April 30, 2017	November 1, 2010		May 14, 2018	Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Kfar Saba, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Rehovot, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Tel Aviv, Israel		https://ClinicalTrials.gov/show/NCT01231659
90	NCT00577031	OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.		Completed	Has Results	Colorectal Cancer	Drug: bevacizumab [Avastin]|Drug: Oxaliplatin|Drug: Xeloda	Progression-Free Survival (PFS): Percentage of Participants With Progressive Disease or Death|PFS: Time to Event|Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) Among Participants in the ITT Population Who Had at Least 1 Post-Baseline Assessment|Percentage of Participants With a CR or PR Among Participants in the ITT Population|Time to CR or PR Overall Response - Time to Event|Percentage of Participants With a Best Overall Response of CR or PR During First Line Treatment|Duration of Overall Response Among Participants Whose Best Response Was CR or PR During First Line Treatment - Time to Event|Percentage of Participants With a Stable Response During First Line Treatment|Duration of Stable Response|Percentage of Participants With Treatment Failure|Time to Treatment Failure|Overall Survival: Percentage of Participants That Died Due to Any Cause|Overall Survival: Time to Event|Percentage of Participants Undergoing Surgical Intervention With Residual Disease Status Post-surgery|Percentage of Participants With Best Overall Response of CR or PR by Kirsten Rat Sarcoma Viral Oncogene Homolog (K-Ras)/V-Raf Murine Sarcoma Viral Oncogene Homolog B (B-Raf) Mutation Status|European Quality of Life 5 Dimension (EQ-5D) Raw-Index Score	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	205	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML21380	February 2008	August 2011	August 2011	December 19, 2007	August 18, 2015	August 18, 2015	Bologna, Italy|Brescia, Italy|Cagliari, Italy|Cagliari, Italy|Caserta, Italy|Catanzaro, Italy|Cefalu, Italy|Fano, Italy|Firenze, Italy|Frattaminore, Italy|Grosseto, Italy|Ivrea, Italy|Latisana, Italy|Lecce, Italy|Legnago, Italy|Legnano, Italy|Macerata, Italy|Napoli, Italy|Negrar, Italy|Orbassano, Italy|Padova, Italy|Palermo, Italy|Palermo, Italy|Pavia, Italy|Reggio Calabria, Italy|Reggio Emilia, Italy|Rionero in Vulture, Italy|Roma, Italy|Roma, Italy|Roma, Italy|Roma, Italy|Salerno, Italy|San Giovanni Rotondo, Italy|Sondrio, Italy|Taormina, Italy|Torino, Italy|Torino, Italy|Verbania, Italy		https://ClinicalTrials.gov/show/NCT00577031
91	NCT00756509	Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib		Active, not recruiting	No Results Available	Gastrointestinal Stromal Tumors	Drug: Nilotinib	To evaluate the efficacy of Nilotinib in patients with unresectable or metastatic gastrointestinal stromal tumors. Efficacy is defined as the proportion of patients showing stable disease (SD), partial response (PR) or complete response (CR) during the|objective tumor response rate based on RECIST criteria (complete response (CR) and partial response PR)|time to overall response (PR or CR)|duration of response|progression free survival (PFS) during the first 6 months using RECIST criteria|overall survival (OS)|safety and tolerability|population pharmacokinetics of Nilotinib	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	34	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CAMN107DDE06|2008-000358-11	August 29, 2008	December 31, 2019	June 30, 2022	September 22, 2008		May 10, 2019	Novartis Investigative Site, HUS, Finland|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Bad Saarow, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Hospitalet de LLobregat, Cataluña, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain		https://ClinicalTrials.gov/show/NCT00756509
92	NCT00793871	Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor	GIST	Completed	Has Results	Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors	Drug: Sunitinib Malate (SU011248)	Progression-free Survival (PFS)|Overall Survival (OS)|Objective Response Rate (ORR)|Time to Tumor Progression (TTP)|Number of Participants With Abnormal Clinical Laboratory Measurements|Number of Participants With Significant Changes From Baseline in Physical Examination.|Number of Participants With Significant Vital Signs Changes From Baseline|Eastern Cooperative Oncology Group (ECOG) Performance Status	Pfizer	All	18 Years and older   (Adult, Older Adult)	Phase 4	60	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	A6181177	November 2008	April 2014	October 2014	November 19, 2008	May 1, 2015	November 20, 2015	Nanjing Bayi Hospital, Nanjing, Jiangsu, China|Beijing Cancer Hospital, Beijing, China|307 Hospital of PLA, Beijing, China|Cancer Institute & Hospital Chinese Academy of Medical Sciences and PUMC, Bejing, China		https://ClinicalTrials.gov/show/NCT00793871
93	NCT03831633	Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients		Recruiting	No Results Available	Oncology	Drug: Akynzeo|Drug: Standard of Care	Anti-emetic response	VIFORFRANCE	All	18 Years and older   (Adult, Older Adult)	Phase 4	426	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	PRAKYFRA-01	September 19, 2018	July 31, 2019	July 31, 2019	February 6, 2019		February 6, 2019	CHU Avicenne, Paris, France		https://ClinicalTrials.gov/show/NCT03831633
94	NCT01525550	A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors		Completed	Has Results	Well-differentiated Pancreatic Neuroendocrine Tumor	Drug: sunitinib	Progression-Free Survival (PFS): Investigator Assessment|Progression-Free Survival (PFS): Independent Radiological Review (IRR) Assessment|Time to Tumor Progression (TTP): Investigator Assessment|Overall Survival (OS)|Percentage of Participants With Objective Response (OR): Investigator Assessment|Duration of Response (DOR): Investigator Assessment|Time to Tumor Response (TTR): Investigator Assessment|Percentage of Participants With Objective Response (OR): Independent Radiological Review (IRR) Assessment|Duration of Response (DOR): Independent Radiological Review (IRR) Assessment|Time to Tumor Response (TTR): Independent Radiological Review (IRR) Assessment|Percentage of Participants With Chromogranin A (CgA) Response|Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)|Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21)|Plasma Concentration of Soluble Protein Biomarker (sKIT)|Minimum Observed Plasma Concentration (Ctrough) of Sunitinib and Its Metabolite SU012662|Dose-Corrected Trough Plasma Concentration of Sunitinib and Its Metabolite SU012662|Area Under the Curve (AUC24) of Sunitinib and Its Metabolite SU012662|Oral Clearance (CL/F) of Sunitinib and Its Metabolite SU012662|Half Maximal Effective Concentration (EC50) of Sunitinib|Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Adverse Events (AEs) According to Severity|Number of Participants With Clinically Significant Laboratory Abnormalities|Number of Participants With Change From Baseline in Vital Signs Abnormalities|Number of Participants With Increase From Baseline in Corrected QT Interval (QTc)|Number of Participants With Change From Baseline in Physical Examinations Findings|Number of Participants With Change From Baseline in Body Weight|Number of Participants With Eastern Co-operative Oncology Group Performance Status (ECOG-PS)	Pfizer	All	18 Years and older   (Adult, Older Adult)	Phase 4	106	Industry	Interventional	Masking: None (Open Label)|Primary Purpose: Other	A6181202|2011-004363-74	June 6, 2012	March 19, 2016	July 26, 2018	February 3, 2012	May 19, 2017	July 30, 2019	Univeristy of California, Orange, California, United States|Columbia University Medical Center, New York, New York, United States|Barwon Health - University Hospital Geelong, Geelong, Victoria, Australia|Cliniques Universitaires Saint-Luc, Gastroenterologie, Bruxelles, Brussels Gewest, Belgium|China-Japan Friendship Hospital, Beijing, Beijing, China|307 Hospital of PLA, Beijing, Beijing, China|Beijing Cancer Hospital, Beijing, Beijing, China|Nanjing Bayi Hospital, Nanjing, Jiangsu, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Fudan University Shanghai Cancer Center, Shanghai, China|Zhongshan Hospital Fudan University, Shanghai, China|Masarykuv onkologicky ustav, Brno, Czechia|Fakultni poliklinika, Praha 2, Czechia|Vseobecna Fakultni Nemocnice v Praze, Praha 2, Czechia|Hôpital Beaujon, Clichy Cedex, France|Semmelweis Egyetem/II. Sz. Belgyogyaszati Klinika, Budapest, Hungary|Tata Memorial Hospital, Mumbai, Maharashtra, India|IEO Istituto Europeo di Oncologia, IRCCS, Milano, Italy|Kyushu University Hospital, Fukuoka-shi, Fukuoka, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Oslo Universitetssykehus HF, Rikshospitalet, Oslo, Norway|Centrul de Oncologie Sf. Nectarie, Craiova, Dolj, Romania|Institutul Clinic Fundeni, Centrul de Gastroenterologie si Hepatologie, Bucuresti, Romania|Narodny Onkologicky ustav, Bratislava, Slovakia|Wits Clinical Research, Johannesburg, Gauteng, South Africa|Hospital Universitario Madrid Sanchinarro - Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain		https://ClinicalTrials.gov/show/NCT01525550
95	NCT01298193	Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients		Completed	No Results Available	Breast Cancer	Drug: Aprepitant	To determine the incidence of complete response, defined as no vomiting and no use of rescue treatment within the first cycle of Docetaxel-Cyclophosphamide for the treatment of early-stage breast cancer patients|To evaluate in cycle 2 the efficacy of aprepitant (days 1, 2 and 3) as secondary prevention in patients without complete response in cycle 1|To evaluate the toxicity of study drug (cycle 2) in those patients.	Spanish Breast Cancer Research Group|Merck Sharp & Dohme Corp.	Female	18 Years and older   (Adult, Older Adult)	Phase 4	212	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GEICAM/2009-02|2010-022689-29	May 2011	March 2013	April 2014	February 17, 2011		May 19, 2015	Badalona, Barcelona, Spain|Alcalá de Henares, Madrid, Spain|Alcorcón, Madrid, Spain|A Coruña, Spain|A Coruña, Spain|Barcelona, Spain|Barcelona, Spain|Jaén, Spain|Lleida, Spain|Lugo, Spain|Madrid, Spain|Valencia, Spain|Zaragoza, Spain		https://ClinicalTrials.gov/show/NCT01298193
96	NCT00171977	Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)		Completed	No Results Available	Gastrointestinal Stromal Tumors	Drug: Imatinib Mesylate	To evaluate the relapse-free survival (RFS) in patients receiving postoperative adjuvant therapy|To evaluate overall survival, relapse free|Safety	Novartis Pharmaceuticals|Novartis	All	20 Years to 74 Years   (Adult, Older Adult)	Phase 4	64	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CSTI571BJP07	July 2004	April 2009		September 15, 2005		August 7, 2012	Novartis Investigative Site, Tokyo, Japan		https://ClinicalTrials.gov/show/NCT00171977
97	NCT02502864	Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide		Completed	Has Results	Breast Cancer|Breast Cancer Female	Drug: Standard of Care: Docetaxel|Drug: Standard of Care: Cyclophosphamide|Other: Function Assessment of Cancer Therapy (FACT) Surveys	Rate of Achieving Targeted Area Under the Curve (AUC)|Incidence of Grade 3 and 4 Neutropenia and Febrile Neutropenia|Association Between Scores - Chemotherapy Risk Assessment Scale for High-Age Patients|Association Between Scores - Instrumental Activities of Daily Living|Association Between Scores - Cumulative Illness Rating Scale for Geriatrics	H. Lee Moffitt Cancer Center and Research Institute|Saladax Biomedical, Inc.	Female	65 Years and older   (Older Adult)	Phase 4	9	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-18118	February 9, 2016	September 29, 2017	January 31, 2019	July 20, 2015	October 18, 2018	June 6, 2019	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02502864/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02502864
98	NCT03264794	the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)		Not yet recruiting	No Results Available	Non-small Cell Lung Cancer	Drug: Gefitinib Tab （CTTQ），First medication；Gefitinib Tab （CTTQ），From the 8th day of trial|Drug: Gefitinib tablets (Yi Ruisha），First medication|Drug: Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial.	Gefitinib plasma concentration|Tmax time|AUC0-t|t 1/2|F	Jiangsu Famous Medical Technology Co., Ltd.	All	18 Years and older   (Adult, Older Adult)	Phase 4	100	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTTQ-20161017	August 2017	December 2021	June 2022	August 29, 2017		August 29, 2017			https://ClinicalTrials.gov/show/NCT03264794
99	NCT02447328	A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer		Active, not recruiting	Has Results	Locally Advanced or|Metastatic Breast Cancer	Drug: Fulvestrant	Safety(Percentage of Participants With Adverse Events and/or Adverse Drug Reactions)	AstraZeneca	Female	Child, Adult, Older Adult	Phase 4	83	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	D6998L00004	May 29, 2015	May 6, 2016	December 31, 2019	May 18, 2015	March 22, 2018	May 13, 2019	Research Site, Busan, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT02447328
100	NCT02622880	Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer Patients		Completed	No Results Available	Head and Neck Neoplasms	Dietary Supplement: immunomodulatory supplement|Dietary Supplement: IMPACT	Number of postoperative infections|Change from baseline Retinol-binding protein|Length of post-operative hospital stay|Mortality|change from baseline C-reactive protein|change from baseline albumin|change from baseline transferrin|change from baseline prealbumin|change from baseline Bioelectrical impedance analysis|change from baseline leukocytes|change from baseline Fibrinogen	Instituto de Investigación Hospital Universitario La Paz|Vegenat, S.A.	All	18 Years and older   (Adult, Older Adult)	Phase 4	68	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	VEGENAT	February 2013	December 2013	June 2014	December 7, 2015		December 7, 2015	Hospital Universitairo La Paz, Madrid, Spain		https://ClinicalTrials.gov/show/NCT02622880
101	NCT01060137	Fentanyl Matrix in Lung Cancer Pain		Completed	No Results Available	Lung Cancer|Pain	Drug: fentanyl matrix	Patient's satisfaction with pain treatment as measured by 5-point verbal scale|Difference in pain intensity measured by Numeric Rating Scale before and after treatment of the study drug measured|Detailed reasons for patient's satisfaction with the pain treatment|Patient's and investigator's satisfaction measured by 5-point verbal scale with the study drug|Dose of fentanyl matrix	Janssen Korea, Ltd., Korea	All	18 Years and older   (Adult, Older Adult)	Phase 4	268	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CR012259	May 2006	May 2007	May 2007	February 2, 2010		February 5, 2010			https://ClinicalTrials.gov/show/NCT01060137
102	NCT01317615	RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation		Completed	Has Results	Carcinoma, Large Cell|Neuroendocrine Tumors	Drug: RAD001|Drug: Paclitaxel|Drug: Carboplatin	Percentage of Participants Progression-free|Percentage of Participants With Overall Response Rate (ORR)|Percentage of Participants With Disease Control Rate (DCR)|Progression Free Survival (PFS)|Overall Survival (OS)	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	49	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CRAD001KDE37|EudraCT 2010-022273-34|2010-022273-34	April 2011	March 2015	March 2015	March 17, 2011	March 30, 2016	March 30, 2016	Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bremen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Gauting, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Hemer, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Ulm, Germany		https://ClinicalTrials.gov/show/NCT01317615
103	NCT02248571	Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab	IMPROVE	Completed	No Results Available	Breast Cancer Recurrent|HER2/Neu-negative Carcinoma of Breast|Hormone Receptor Positive Malignant Neoplasm of Breast	Drug: Bevacizumab|Drug: Capecitabine|Drug: Everolimus|Drug: Exemestane|Other: Patient questionaires	Patients' preference|Reasons for patients' preference|Patient reported treatment satisfaction|Quality of life|Progression free survival rate|Objective response rates and disease control rates based on tumor assessment (RECIST 1.1)|Safety and tolerability as measured by number of treatment-emergent adverse events (AEs) and clinical laboratory abnormalities|Physicians' treatment preference|Progression free survival for first and second treatment phase|Overall survival	iOMEDICO AG|Arbeitsgemeinschaft fur Internistische Onkologie|Novartis Pharmaceuticals	Female	18 Years and older   (Adult, Older Adult)	Phase 4	85	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other	iOM-12293	August 2014	August 31, 2017	September 30, 2017	September 25, 2014		November 13, 2017	iOMEDICO AG, Freiburg, Baden-Wuerttemberg, Germany		https://ClinicalTrials.gov/show/NCT02248571
104	NCT00727961	A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)		Completed	Has Results	Ovarian Neoplasms	Drug: Pegylated Liposomal Doxorubicin hydrochloride	Number of Participants With Complete Response|Number of Participants With Partial Response|Number of Participants With Stabilization|Number of Participants With Progression|Mean Time to Positive (Partial) Treatment Response Achievement|Median Time to Progression|Mean Survival Time During the Study	Merck Sharp & Dohme Corp.	Female	18 Years and older   (Adult, Older Adult)	Phase 4	58	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P04072	November 9, 2004	January 10, 2008	January 10, 2008	August 5, 2008	July 16, 2009	June 8, 2017			https://ClinicalTrials.gov/show/NCT00727961
105	NCT00882089	Use of the Contura™ Catheter in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer Patients		Completed	No Results Available	Breast Cancer	Device: Contura catheter	Maximum skin dose is less than or equal to 100% of the prescribed radiation dose and air/fluid pocket next to the balloon is less than or equal to 3.0% of the planning target volume for plan evaluation|Number of cases where the balloon catheter has to be explanted when the balloon-to-skin spacing is only 3-6 mm.	Cancer Center of Irvine|SenoRx, Inc.	Female	18 Years and older   (Adult, Older Adult)	Phase 4	13	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1098987	October 2007	December 2009	December 2009	April 16, 2009		January 25, 2018	Cancer Center of Irvine, Irvine, California, United States		https://ClinicalTrials.gov/show/NCT00882089
106	NCT00237159	Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis		Completed	No Results Available	Prostate Cancer Patients With Bone Metastasis	Drug: Zoledronic acid	Rate of skeletal complications|Time to first skeletal complication|Bone pain|Patients´ satisfaction with treatment|Bone turnover parameters	Novartis Pharmaceuticals|Novartis	Male	18 Years and older   (Adult, Older Adult)	Phase 4	284	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CZOL446EDE07	October 2002	December 2005		October 12, 2005		March 23, 2011			https://ClinicalTrials.gov/show/NCT00237159
107	NCT00138060	Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants		Completed	No Results Available	Metastatic Colorectal Cancer	Drug: irinotecan|Drug: 5 fluorouracil	tumor response rate|toxicity|pharmacokinetics	Institut de Recherche Clinique sur les Cancers et le Sang|Pfizer	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 4	71	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COLOGEN	June 2005	November 2008	December 2008	August 30, 2005		July 20, 2010	Department of Oncology, CHU, Grenoble, France|Department of Oncology, IPC, Grenoble, France|Department of Gastroenterology, CHLS, Pierre Benite, France|Department of Oncology - CHLS, Pierre Benite, France|Department of Oncology, ICL, Saint-Priest-en-Jarez, France|Institut Claudius Regaud, Toulouse, France		https://ClinicalTrials.gov/show/NCT00138060
108	NCT01043068	The Effect of Cancer Pain Management Protocol on Hospitalized Cancer Patients: A Pilot Study		Completed	No Results Available	Cancers, Pain	Drug: Cancer pain management	Reduction in pain scores	National Cancer Center, Korea|Janssen Korea, Ltd., Korea	All	18 Years and older   (Adult, Older Adult)	Phase 4	25	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	CAPAM-1	January 2010	December 2010	December 2010	January 6, 2010		April 27, 2012	National Cancer Center, Goyang, Gyeonggi-do, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01043068
109	NCT01196078	A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer		Completed	Has Results	Non-Small Cell Lung Cancer	Drug: erlotinib [Tarceva]|Drug: vinorelbine	Percentage of Participants Achieving a Best Overall Response of Complete Response (CR) or Partial Response (PR)|Percentage of Participants Achieving Disease Control|Duration of Response Among Participants Who Achieved Either a CR or PR|Percentage of Participants With Disease Progression|Time to Disease Progression|Overall Survival: Percentage of Participants With an Progressive Disease or Death|Overall Survival: Time to Event|Quality of Life as Measured by the Functional Assessment of Cancer Therapy (FACT) Questionnaire|Changes in Quality of Life as Measured by the FACT Questionnaire|Percentage of Participants With Changes in Quality of Life as Measured by FACT Questionnaire Scores by Category of Change|Changes in Quality of Life as Assessed by FACT-L (Lung Symptoms) Questionnaire|Percentage of Participants With Changes in FACT-L (Lung Symptoms) by Category of Change	Hoffmann-La Roche	All	70 Years and older   (Older Adult)	Phase 4	114	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML20322	February 2007	December 2010	December 2010	September 8, 2010	July 27, 2015	July 27, 2015	Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT01196078
110	NCT01020786	A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients		Completed	Has Results	Non Small Cell Lung Cancer	Drug: Pemetrexed|Drug: Carboplatin	Progression Free Survival (PFS) During the Induction and Maintenance Therapy Periods|Overall Survival (OS) During the Induction and Maintenance Therapy Periods|Percentage of Participants Who Achieve a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) During the Induction and Maintenance Therapy Periods|Percentage of Participants Who Achieved a Complete Response (CR) or Partial Response (PR) During the Induction and Maintenance Therapy Periods|Progression Free Survival (PFS) During the Maintenance Therapy Period|Overall Survival (OS) During the Maintenance Therapy Period|Percentage of Participants Who Achieved a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) During the Maintenance Therapy Period|Percentage of Participants Who Observe a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) During the Induction Therapy Period|Percentage of Participants Who Achieve a Complete Response (CR) or a Partial Response (PR) During the Induction Therapy Period	Eli Lilly and Company	All	20 Years and older   (Adult, Older Adult)	Phase 4	109	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	12628|H3E-JE-JMII	November 2009	March 2011	June 2012	November 26, 2009	March 16, 2012	August 27, 2013	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aichi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ehime, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hokkaido, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kumamoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miyagi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Niigata, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Okayama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shizuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tochigi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yamaguchi, Japan		https://ClinicalTrials.gov/show/NCT01020786
111	NCT00949910	An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)		Completed	Has Results	Non-Small Cell Lung Cancer	Drug: Erlotinib	Percentage of Participants With Objective Response According to Response Evaluation Criteria in Solid Tumors (RECIST)|Percentage of Participants With Disease Control According to RECIST|Percentage of Participants by Best Overall Response According to RECIST|Percentage of Participants With Death or Disease Progression According to RECIST|Progression-Free Survival (PFS) According to RECIST|Percentage of Participants Who Died|Overall Survival (OS)	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	6586	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MO18109|2004-000564-28|INC-9042	November 2004	April 2009	April 2009	July 31, 2009	October 4, 2016	October 5, 2016	Tirana, Albania|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Córdoba, Argentina|La Plata, Argentina|Salta, Argentina|Santa Fe, Argentina|Adelaide, Australia|Camperdown, Australia|Chermside, Australia|Frankston, Australia|Fremantle, Australia|Geelong, Australia|Kurralta Park, Australia|Malvern, Australia|Melbourne, Australia|Melbourne, Australia|Perth, Australia|St. Leonards, Australia|Sydney, Australia|Sydney, Australia|Tugun, Australia|Waratah, Australia|Wodonga, Australia|Wollongong, Australia|Bludesch, Austria|Grimmenstein, Austria|Innsbruck, Austria|Klagenfurt, Austria|Kufstein, Austria|Leoben, Austria|Linz, Austria|Linz, Austria|Natters, Austria|Oberpullendorf, Austria|Salzburg, Austria|Wels, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Zams, Austria|Aalst, Belgium|Antwerpen, Belgium|Antwerpen, Belgium|Antwerpen, Belgium|Arlon, Belgium|Baudour, Belgium|Blankenberge, Belgium|Borgerhout, Belgium|Boussu, Belgium|Brasschaat, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Charleroi, Belgium|Edegem, Belgium|Genk, Belgium|Gent, Belgium|Gilly, Belgium|Godinne, Belgium|Gosselies, Belgium|Haine-saint-paul, Belgium|Hasselt, Belgium|Kortrijk, Belgium|Libramont, Belgium|Liege, Belgium|Mons, Belgium|Namur, Belgium|Oostende, Belgium|Ottignies, Belgium|Oudenaarde, Belgium|Roeselare, Belgium|Sint-niklaas, Belgium|Tielt, Belgium|Tournai, Belgium|Turnhout, Belgium|Wilrijk, Belgium|Banja Luka, Bosnia and Herzegovina|Sarajevo, Bosnia and Herzegovina|Belo Horizonte, Brazil|Belo Horizonte, Brazil|Belo Horizonte, Brazil|Belo Horizonte, Brazil|Brasilia, Brazil|Brasilia, Brazil|Campinas, Brazil|Campinas, Brazil|Caxias do Sul, Brazil|Curitiba, Brazil|Curitiba, Brazil|Curitiba, Brazil|Fortaleza, Brazil|Fortaleza, Brazil|Fortaleza, Brazil|Ijui, Brazil|Jaú, Brazil|Joao Pessoa, Brazil|Porto Alegre, Brazil|Porto Alegre, Brazil|Porto Alegre, Brazil|Porto Alegre, Brazil|Recife, Brazil|Ribeirao Preto, Brazil|Rio de Janeiro, Brazil|Rio de Janeiro, Brazil|Rio de Janeiro, Brazil|Rio de Janeiro, Brazil|Salvador, Brazil|Salvador, Brazil|Salvador, Brazil|Santos, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sorocaba, Brazil|Plovdiv, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Santiago, Chile|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Chengdu, China|Guangzhou, China|Guangzhou, China|Hangzhou, China|Harbin, China|Nanjing, China|Shanghai, China|Shanghai, China|Shanghai, China|Tianjin, China|Wuhan, China|Bogota, Colombia|Cali, Colombia|Zagreb, Croatia|Brno, Czech Republic|Hradec Kralove, Czech Republic|Olomouc, Czech Republic|Plzen, Czech Republic|Praha, Czech Republic|Guayaquil, Ecuador|Quito, Ecuador|Cairo, Egypt|Giza, Egypt|Giza, Egypt|Tallin, Estonia|Tartu, Estonia|Haemeenlinna, Finland|Helsinki, Finland|Helsinki, Finland|Joensuu, Finland|Kuopio, Finland|Oulu, Finland|Pori, Finland|Tampere, Finland|Turku, Finland|Vaasa, Finland|Amberg, Germany|Augsburg, Germany|Aurich, Germany|Bad Berka, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Bonn, Germany|Celle, Germany|Dortmund, Germany|Dresden, Germany|Essen, Germany|Flensburg, Germany|Frankfurt Am Main, Germany|Frankfurt, Germany|Freiburg, Germany|Gauting, Germany|Gerlingen, Germany|Giessen, Germany|Grosshansdorf, Germany|Halle (saale), Germany|Hamburg, Germany|Hamburg, Germany|Heidelberg, Germany|Herne, Germany|Homburg/Saar, Germany|Kassel, Germany|Koblenz, Germany|Köln, Germany|Köln, Germany|Leipzig, Germany|Leverkusen, Germany|Lostau, Germany|Löwenstein, Germany|Lübeck, Germany|Mainz, Germany|Mannheim, Germany|Minden, Germany|Muenchen, Germany|Mönchengladbach, Germany|München, Germany|München, Germany|Neuruppin, Germany|Nürnberg, Germany|Oldenburg, Germany|Osnabrück, Germany|Rostock, Germany|Saarbruecken, Germany|Trier, Germany|Ulm, Germany|Wangen, Germany|Wiesbaden, Germany|Wuerselen, Germany|Wuppertal, Germany|Athens, Greece|Athens, Greece|Athens, Greece|Haidari, Greece|Heraklion, Greece|Neo Faliro, Greece|Thessaloniki, Greece|Thessaloniki, Greece|Thessaloniki, Greece|Guatemala City, Guatemala|Hong Kong, Hong Kong|Hong Kong, Hong Kong|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Deszk, Hungary|Kecskemet, Hungary|Mátraháza, Hungary|Nyíregyháza, Hungary|Pecs, Hungary|Torokbalint, Hungary|Bangalore, India|New Delhi, India|New Delhi, India|Pune, India|Vellore, India|Jakarta, Indonesia|Cork, Ireland|Dublin, Ireland|Dublin, Ireland|Dublin, Ireland|Dublin, Ireland|Galway, Ireland|Ashkelon, Israel|Beer Sheva, Israel|Haifa, Israel|Haifa, Israel|Holon, Israel|Jerusalem, Israel|Jerusalem, Israel|Kfar Saba, Israel|Nahariya, Israel|Petach Tikva, Israel|Ramat-gan, Israel|Rehovot, Israel|Safed, Israel|Tel Aviv, Israel|Zerifin, Israel|Ancona, Italy|Avellino, Italy|Aviano, Italy|Bari, Italy|Benevento, Italy|Bergamo, Italy|Bollate, Italy|Bologna, Italy|Bologna, Italy|Brescia, Italy|Candiolo, Italy|Catania, Italy|Catanzaro, Italy|Cosenza, Italy|Cuneo, Italy|Fabriano, Italy|Feltre - Bl, Italy|Firenze, Italy|Genova, Italy|La Spezia, Italy|Lido di Camaiore, Italy|Livorno, Italy|Meldola, Italy|Messina, Italy|Milano, Italy|Milano, Italy|Milano, Italy|Mirano, Italy|Modena, Italy|Napoli, Italy|Napoli, Italy|Nuoro, Italy|Orbassano, Italy|Palermo, Italy|Palermo, Italy|Parma, Italy|Pavia, Italy|Perugia, Italy|Pescara, Italy|Pisa, Italy|Rionero in Vulture, Italy|Roma, Italy|Roma, Italy|Roma, Italy|Roma, Italy|Roma, Italy|Roma, Italy|Salerno, Italy|Salerno, Italy|San Giovanni Rotondo, Italy|Sassari, Italy|Siena, Italy|Sondrio, Italy|Taormina, Italy|Torino, Italy|Trento, Italy|Udine, Italy|Bundang City, Korea, Republic of|Busan, Korea, Republic of|Cheonan, Korea, Republic of|Daegu, Korea, Republic of|Daegu, Korea, Republic of|Daegu, Korea, Republic of|Daejeon, Korea, Republic of|Gwangju, Korea, Republic of|Iksan, Korea, Republic of|Incheon, Korea, Republic of|Kyunggi-do, Korea, Republic of|Pusan, Korea, Republic of|Pusan, Korea, Republic of|Pusan, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Suwon, Korea, Republic of|Riga, Latvia|Riga, Latvia|Kaunas, Lithuania|Vilnius, Lithuania|Kuala Lumpur, Malaysia|Acapulco, Mexico|Chihuahua, Mexico|Chihuahua, Mexico|Guadalajara, Mexico|Guadalajara, Mexico|Juarez, Mexico|Leon, Mexico|Leon, Mexico|Matamoros, Mexico|Merida, Mexico|Merida, Mexico|Mexicali, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Monterrey, Mexico|Monterrey, Mexico|Monterrey, Mexico|Monterrey, Mexico|Obregon, Mexico|Obregon, Mexico|Puebla, Mexico|San Luis Potosi, Mexico|Tampico, Mexico|Tijuana, Mexico|Toluca, Mexico|Torreon, Mexico|Zapopan, Mexico|'s Hertogenbosch, Netherlands|Alkmaar, Netherlands|Amersfoort, Netherlands|Amstelveen, Netherlands|Amsterdam, Netherlands|Amsterdam, Netherlands|Amsterdam, Netherlands|Amsterdam, Netherlands|Amsterdam, Netherlands|Arnhem, Netherlands|Assen, Netherlands|Beverwijk, Netherlands|Boxmeer, Netherlands|Breda, Netherlands|Capelle Ad Yssel, Netherlands|Den Haag, Netherlands|Drachten, Netherlands|Eindhoven, Netherlands|Enschede, Netherlands|Groningen, Netherlands|Groningen, Netherlands|Haarlem, Netherlands|Harderwijk, Netherlands|Heerlen, Netherlands|Helmond, Netherlands|Hengelo, Netherlands|Hoofddorp, Netherlands|Leiden, Netherlands|Leiderdorp, Netherlands|Maastricht, Netherlands|Nieuwegein, Netherlands|Nijmegen, Netherlands|Roermond, Netherlands|Rotterdam, Netherlands|Sliedrecht, Netherlands|Veldhoven, Netherlands|Venlo, Netherlands|Vlaardingen, Netherlands|Vlissingen, Netherlands|Zaandam, Netherlands|Zwolle, Netherlands|Christchurch, New Zealand|Hamilton, New Zealand|Palmerston North, New Zealand|Wellington, New Zealand|Panama City, Panama|Callao, Peru|Lima, Peru|Lima, Peru|Lima, Peru|Gdansk, Poland|Lublin, Poland|Olsztyn, Poland|Poznan, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Zabrze, Poland|Lisboa, Portugal|Porto, Portugal|Setubal, Portugal|São Martinho do Bispo, Portugal|Vila Nova de Gaia, Portugal|Alba Iulia, Romania|Baia Mare, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Cluj Napoca, Romania|Oradea, Romania|Sibiu, Romania|Suceava, Romania|Timisoara, Romania|Barnaul, Russian Federation|Kazan, Russian Federation|Kazan, Russian Federation|Krasnodar, Russian Federation|Krasnodar, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Obninsk, Russian Federation|Samara, Russian Federation|Smolensk, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|Stavropol, Russian Federation|Tumen, Russian Federation|Ufa, Russian Federation|Volgograd, Russian Federation|Riyadh, Saudi Arabia|Belgrade, Serbia|Novi Sad, Serbia|Banska Bystrica, Slovakia|Bratislava, Slovakia|Kosice, Slovakia|Nitra, Slovakia|Poprad, Slovakia|Ljubljana, Slovenia|Falun, Sweden|Goeteborg, Sweden|Göteborg, Sweden|Linkoeping, Sweden|Lund, Sweden|Malmoe, Sweden|Stockholm, Sweden|Uppsala, Sweden|Aarau, Switzerland|Aarau, Switzerland|Baden, Switzerland|Chur, Switzerland|Locarno, Switzerland|Luzern, Switzerland|Zürich, Switzerland|Changhua, Taiwan|Kaohsiung, Taiwan|Kaohsiung, Taiwan|Kaohsiung, Taiwan|Taichung, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Bangkok, Thailand|Ankara, Turkey|Ankara, Turkey|Ankara, Turkey|Ankara, Turkey|Istanbul, Turkey|Istanbul, Turkey|Istanbul, Turkey|Izmir, Turkey|Izmir, Turkey|Shhiye, Ankara, Turkey|Montevideo, Uruguay|Caracas, Venezuela|Caracas, Venezuela		https://ClinicalTrials.gov/show/NCT00949910
112	NCT01287754	A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations		Completed	Has Results	Non-Small Cell Lung Cancer	Drug: erlotinib [Tarceva]	Progression-Free Survival (PFS) Among Erlotinib-Treated Participants With the EGFR Mutation|Number of Erlotinib-Treated Participants With the EGFR Mutation With an Objective Response Per RECIST v1.1|Overall Survival (OS) Among Erlotinib-Treated and Untreated Participants|Percentage of Participants Alive at 6 and 12 Months|Percentage of Participants With EGFR Mutation at Screening	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	24	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML25575	October 2011	November 2013	November 2013	February 1, 2011	June 2, 2015	June 2, 2015	Helsinki, Finland|Kuopio, Finland|Oulu, Finland|Pori, Finland|Turku, Finland		https://ClinicalTrials.gov/show/NCT01287754
113	NCT02476968	To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer	ORZORA	Active, not recruiting	No Results Available	BRCA or HRR+ Mutated Ovarian Cancer Patients	Drug: Olaparib	Time from study enrolment to disease progression (assessed according to RECIST 1.1 guidelines) or death.|Time to death and Time to second progression event or death if this occurs before second progression event.|Time to first and second treatment commencement or death and time to olaparib discontinuation or death.|Functional Assessment of Cancer Therapy-Ovarian (FACT-O), Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue, and ORZORA QoL Additional Items Questionnaire|Safety summary tables, Functional Living Index-Emesis (FLIE) Questionnaire, and concomitant medication use.	AstraZeneca	Female	18 Years to 130 Years   (Adult, Older Adult)	Phase 4	178	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	D0816C00012	September 28, 2015	November 22, 2019	November 22, 2019	June 22, 2015		June 24, 2019	Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Novy Jicin, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 5, Czechia|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Kecskemét, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Bari, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Perugia, Italy|Research Site, Bialystok, Poland|Research Site, Gdansk, Poland|Research Site, Kielce, Poland|Research Site, Poznan, Poland|Research Site, Poznań, Poland|Research Site, Warszawa, Poland|Research Site, Badalona, Spain|Research Site, Barcelona, Spain|Research Site, Burgos, Spain|Research Site, L'Hospitalet de Llobregat, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, San Cristobal de La Laguna, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Zaragoza, Spain|Research Site, Belfast, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle upon Tyne, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Swansea, United Kingdom|Research Site, Taunton, United Kingdom|Research Site, Westcliff on Sea, United Kingdom|Research Site, Wirral, United Kingdom		https://ClinicalTrials.gov/show/NCT02476968
114	NCT00122720	The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery		Completed	No Results Available	Colorectal Cancer	Drug: Darbepoetin Alfa	The functional capacity measured by postoperative fatigue, work capacity, balance, and quality of life|Muscular strength|Weight|Body composition|Blood transfusion|Postoperative complications	Herning Hospital|Amgen	All	18 Years and older   (Adult, Older Adult)	Phase 4	200	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment	2612-2277	June 2003		January 2006	July 22, 2005		July 7, 2006	Surgical Department, Middelfart Hospital, Middelfart, Fyn, Denmark|Surgical Department, Odense University Hospital, Odense, Fyn, Denmark|Surgical Department, Svendborg Hospital, Svendborg, Fyn, Denmark|Surgical Department, Herning Hospital, Herning, Ringkobing, Denmark|Surgical Department, Aarhus University Hospital, Aarhus, Denmark		https://ClinicalTrials.gov/show/NCT00122720
115	NCT00380718	Chemotherapy for Patients With Non-Small Cell Lung Cancer		Completed	Has Results	Non-small Cell Lung Cancer	Drug: pemetrexed	Proportion of Participants With a Complete or Partial Response (Objective Response Rate [ORR])|Proportion of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), and Stable Disease (SD) (Disease Control Rate [DCR])|Overall Survival|Progression-Free Survival (PFS)|Duration of Response|Time to Treatment Failure|Time to Tumor Progression	Eli Lilly and Company	All	18 Years and older   (Adult, Older Adult)	Phase 4	33	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	10720|H3E-MC-JMIC	November 2006	September 2008	November 2009	September 26, 2006	October 6, 2009	November 16, 2010	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT00380718
116	NCT01313780	A Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone Compared to OxyContin in Korean Cancer Patients	TOP	Completed	Has Results	Cancer	Drug: Oxycodone/Naloxone|Drug: Oxycodone(single compound)	Change of Pain Intensity From Baseline(visit1) to 4weeks.(visit3)|Change in Bowel Habits.	Mundipharma Korea Ltd	All	20 Years and older   (Adult, Older Adult)	Phase 4	128	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OXN10-KR-002	May 2011	October 2013	June 2014	March 14, 2011	October 27, 2016	December 22, 2017	AMC, Seoul, Pungnap-dong, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01313780
117	NCT01161563	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration		Completed	Has Results	Prostate Cancer	Drug: Triptorelin pamoate|Drug: Leuprolide acetate	Patient Bother From Injection Site Burning and/or Stinging|Discomfort From Injection	Watson Pharmaceuticals	Male	18 Years and older   (Adult, Older Adult)	Phase 4	118	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)	TRE1001	July 2010	April 2011	April 2011	July 13, 2010	September 6, 2013	September 6, 2013	Watson Investigational Site, Homewood, Alabama, United States|Watson Investigational Site, Daytona Beach, Florida, United States|Watson Investigational Site, Orange City, Florida, United States|Watson Investigational Site, Coeur D'Alene, Idaho, United States|Watson Investigational Site, Carmel, Indiana, United States|Watson Investigational Site, Jeffersonville, Indiana, United States|Watson Investigational Site, Shreveport, Louisiana, United States|Watson Investigational Site, Las Vegas, Nevada, United States|Watson Investigational Site, Mt Laurel, New Jersey, United States|Watson Investigational Site, Voorhees, New Jersey, United States|Watson Investigational Site, Albany, New York, United States|Watson Investigational Site, Syracuse, New York, United States|Watson Investigational Site, Lancaster, Pennsylvania, United States|Watson Investigational Site, Myrtle Beach, South Carolina, United States|Watson Investigational Site, Dallas, Texas, United States|Watson Investigational Site, Norfolk, Virginia, United States		https://ClinicalTrials.gov/show/NCT01161563
118	NCT00241111	Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis		Completed	No Results Available	Prostate Cancer With Bone Metastasis	Drug: zoledronic acid	to assess the effectiveness of Zol in prevention of SREs in stratified groups (hormonal treatment)|to assess the effectiveness of Zol in improving pain and QoL in prostate cancer patients with bone metastases|to assess the safety of ZOL treatment|to assess resources consumption|to assess BM	Novartis Pharmaceuticals|Novartis	Male	18 Years and older   (Adult, Older Adult)	Phase 4	148	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CZOL446EFR04	September 2003	January 2006		October 18, 2005		March 6, 2017			https://ClinicalTrials.gov/show/NCT00241111
119	NCT03202381	Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix	BLADE	Recruiting	No Results Available	Prostate Cancer	Drug: Degarelix	Changes in fat body mass|changes in bone mineral density|changes in lean body mass|changes in fasting serum lipids|changes in bone turn-over markers|changes in insulin sensitivity|changes in serum follicle stimulating hormone (FSH) levels	Azienda Ospedaliera Spedali Civili di Brescia|Ferring Pharmaceuticals	Male	18 Years and older   (Adult, Older Adult)	Phase 4	35	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	NP2540-BLADE	June 26, 2017	March 2019	March 2020	June 28, 2017		June 28, 2017	Clinical Department of Urology, university Hospital Spedali Civili di Brescia, Brescia, Italy		https://ClinicalTrials.gov/show/NCT03202381
120	NCT00883675	Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer		Completed	Has Results	Non-small Cell Lung Cancer	Drug: Docetaxel-Carboplatin	Febrile Neutropenia	Michael Mann|Sanofi|Maestro Clinical, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 4	133	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MC#08-002|IIT 12230	May 2009	September 2012	December 2012	April 20, 2009	December 18, 2013	December 18, 2013	Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Beijing Chaoyang Hospital, Beijing, China|Beijing Tumor Hospital, Beijing, China|Beijing Youyi Hospital, Beijing, China|China-Japan Friendship Hospital, Beijing, China|Xuanwu Hospital, Beijing, China|First Affiliated Hospital, Guangzhou Medical College, Guangzhou, China|Sun Yat-sen Cancer Center, Guangzhou, China|Shanghai Chest Hopsital, Pulmonary Medicine, Shanghai, China|Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai, China|Shanghai Pulmonary Hospital, Shanghai, China|Tianjin Cancer Center, Tianjin, China		https://ClinicalTrials.gov/show/NCT00883675
121	NCT03423082	Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer.		Recruiting	No Results Available	Cervical Cancer|Uterine Cancer	Drug: 18F fluciclovine|Device: 18F fluciclovine PET	Lesion metabolic avidity|Optimal imaging window|Fluciclovine PET time-activity curve correlation with histopathologic tumor grading|Textural tumor heterogeneity	Nghi Nguyen|Blue Earth Diagnostics|University of Pittsburgh	Female	18 Years and older   (Adult, Older Adult)	Phase 4	10	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	PRO17120310	December 11, 2018	December 1, 2019	December 30, 2019	February 6, 2018		December 14, 2018	UPMC Presbyterian - MR Research Center, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03423082
122	NCT00372476	Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer	INV181	Completed	No Results Available	Breast Cancer	Drug: Imatinib and Vinorelbine	Maximum tolerated dose (MTD)	Novartis Pharmaceuticals|Novartis	Female	18 Years and older   (Adult, Older Adult)	Phase 4	33	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CSTI571BDE28|2005-001537-15	June 2006	July 2012	July 2012	September 7, 2006		February 7, 2017	Novartis Investigative Site, Kiel, Germany		https://ClinicalTrials.gov/show/NCT00372476
123	NCT00590213	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX	COMART	Completed	No Results Available	Prostate Cancer	Drug: Casodex 150mg|Procedure: Radiotherapy|Procedure: Haematology	To examine the value of prophylactic versus therapeutic breast radiotherapy in Casodex monotherapy induced gynaecomastia and/or breast pain|To examine the tolerability of radiotherapy to male breast|To examine the tolerability of Casodex 150mg in localized and locally advanced prostate cancer patients|To examine the efficacy of Casodex 150mg in prostate cancer patients	AstraZeneca	Male	18 Years and older   (Adult, Older Adult)	Phase 4	125	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	7054TR/01	June 2003			January 10, 2008		January 25, 2008	Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Diyarbak?r, Turkey|Research Site, Edirne, Turkey|Research Site, Eskisehir, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Manisa, Turkey|Research Site, Samsun, Turkey		https://ClinicalTrials.gov/show/NCT00590213
124	NCT00451906	A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.		Completed	Has Results	Non-Squamous Non-Small Cell Lung Cancer	Drug: Platinum-based chemotherapy|Drug: Bevacizumab [Avastin]	Number of Participants With Adverse Events of Special Interest|Number of Participants With Serious Adverse Events Related to Bevacizumab|Duration of Overall Survival|Time to Disease Progression|Number of Participants With Central Nervous System Bleeding	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	2252	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MO19390	August 2006	June 2009	June 2009	March 26, 2007	April 25, 2016	May 24, 2016	Buenos Aires, Argentina|Chaco-resistencia, Argentina|Cordoba, Argentina|Córdoba, Argentina|Tucuman, Argentina|St. Leonards, New South Wales, Australia|Waratah, New South Wales, Australia|Auchenflower, Queensland, Australia|Chermside, Queensland, Australia|Tugun, Queensland, Australia|Box Hill, Victoria, Australia|Geelong, Victoria, Australia|Malvern, Victoria, Australia|Wodonga, Victoria, Australia|Perth, Western Australia, Australia|Sydney, New South Wales, Australia|Bludesch, Austria|Bregenz, Austria|Feldkirch, Austria|Graz, Austria|Innsbruck, Austria|Knittelfeld, Austria|Kufstein, Austria|Linz, Austria|Linz, Austria|Natters, Austria|Salzburg, Austria|St Veit An Der Glan, Austria|Vöcklabruck, Austria|Wels, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Zams, Austria|Banja Luka, Bosnia and Herzegovina|Sarajevo, Bosnia and Herzegovina|Salvador, Bahia, BA, Brazil|Fortaleza, CE, Brazil|Vitoria, ES, Brazil|Goiania, GO, Brazil|Belo Horizonte, MG, Brazil|Belo Horizonte, MG, Brazil|Recife, PE, Brazil|Rio De Janeiro, RJ, Brazil|Rio de Janeiro, RJ, Brazil|Rio de Janeiro, RJ, Brazil|Ijui, RS, Brazil|Porto Alegre, RS, Brazil|Porto Alegre, RS, Brazil|Porto Alegre, RS, Brazil|Porto Alegre, RS, Brazil|Campinas, SP, Brazil|Campinas, SP, Brazil|Jau, SP, Brazil|Ribeirao Preto, SP, Brazil|Santos, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Vancouver, British Columbia, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Beijing, China|Beijing, China|Beijing, China|Guangzhou, China|Guangzhou, China|Hangzhou, China|Shanghai, China|Shanghai, China|Bogota, Colombia|Cali, Colombia|Manizales, Colombia|Brno, Czech Republic|Plzen, Czech Republic|Praha, Czech Republic|Herlev, Denmark|Hillerod, Denmark|Naestved, Denmark|Århus, Denmark|Guayaquil, Ecuador|Quito, Ecuador|Cairo, Egypt|Cairo, Egypt|Tallinn, Estonia|Tartu, Estonia|Helsinki, Finland|Paimio, Finland|Pori, Finland|Tampere, Finland|Aix En Provence, France|Avignon, France|Besancon, France|Beziers, France|Bordeaux, France|Brest, France|Caen, France|Chalon Sur Saone, France|Clermont-ferrand, France|GAP, France|Grenoble, France|Le Chesnay, France|Lille, France|Lille, France|Lille, France|Lyon, France|Marseille, France|Marseille, France|Marseille, France|Meaux, France|Nancy, France|Neuilly Sur Seine, France|Paris, France|Paris, France|Perpignan, France|Reims, France|St Julien En Genevois, France|Strasbourg, France|Strasbourg, France|Toulon, France|Toulon, France|Toulouse, France|Toulouse, France|Valenciennes, France|Vandoeuvre Les Nancy, France|Augsburg, Germany|Bad Berka, Germany|Bayreuth, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Bielefeld, Germany|Bonn, Germany|Coswig, Germany|Donaustauf, Germany|Düsseldorf, Germany|Ebensfeld, Germany|Erlangen, Germany|Essen, Germany|Frankfurt, Germany|Freiburg, Germany|Gauting, Germany|Gerlingen, Germany|Grosshansdorf, Germany|Göttingen, Germany|Halle (Saale), Germany|Hamburg, Germany|Hamburg, Germany|Hannover, Germany|Hannover, Germany|Karlsruhe, Germany|Kiel, Germany|Köln, Germany|Leer, Germany|Leipzig, Germany|Leverkusen, Germany|Löwenstein, Germany|Magdeburg, Germany|Mainz, Germany|Minden, Germany|Muenchen, Germany|Neuruppin, Germany|Nürnberg, Germany|Oldenburg, Germany|Rostock, Germany|Treuenbrietzen, Germany|Ulm, Germany|Villingen-Schwenningen, Germany|Wiesbaden, Germany|Wolfsburg, Germany|Wuerselen, Germany|Hong Kong, Hong Kong|Hong Kong, Hong Kong|Shatin, Hong Kong|Budapest, Hungary|Mátraháza, Hungary|Pecs, Hungary|Szombathely, Hungary|Torokbalint, Hungary|Reykjavik, Iceland|Beer Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Jerusalem, Israel|Kfar-Saba, Israel|Ramat Gan, Israel|Tel Aviv, Israel|Zerifin, Israel|Avezzano, Abruzzo, Italy|Pescara, Abruzzo, Italy|Potenza, Basilicata, Italy|Rionero in Vulture, Basilicata, Italy|Catanzaro, Calabria, Italy|Avellino, Campania, Italy|Napoli, Campania, Italy|Bologna, Emilia-Romagna, Italy|Carpi, Emilia-Romagna, Italy|Modena, Emilia-Romagna, Italy|Rimini, Emilia-Romagna, Italy|Aviano, Friuli-Venezia Giulia, Italy|Udine, Friuli-Venezia Giulia, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Sora, Lazio, Italy|Viterbo, Lazio, Italy|Genova, Liguria, Italy|Genova, Liguria, Italy|La Spezia, Liguria, Italy|Bergamo, Lombardia, Italy|Cremona, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Pavia, Lombardia, Italy|S Fermo Della Battaglia, Lombardia, Italy|Sondrio, Lombardia, Italy|Ancona, Marche, Italy|Novara, Piemonte, Italy|Bari, Puglia, Italy|Brindisi, Puglia, Italy|San Giovanni Rotondo, Puglia, Italy|Cagliari, Sardegna, Italy|Sassari, Sardegna, Italy|Catania, Sicilia, Italy|Catania, Sicilia, Italy|Palermo, Sicilia, Italy|Taormina, Sicilia, Italy|Arezzo, Toscana, Italy|Lido Di Camaiore, Toscana, Italy|Pisa, Toscana, Italy|Camposampiero, Veneto, Italy|Feltre - Bl, Veneto, Italy|Negrar, Veneto, Italy|Bologna, Umbria, Italy|Forli, Emilia-Romagna, Italy|Riga, Latvia|Riga, Latvia|Beirut, Lebanon|Kaunas, Lithuania|Klaipeda, Lithuania|Vilnius, Lithuania|Chihuahua, Mexico|Leon, Mexico|Mexico City, Mexico|Mexico City, Mexico|Arnhem, Netherlands|Breda, Netherlands|Den Haag, Netherlands|Eindhoven, Netherlands|Groningen, Netherlands|Haarlem, Netherlands|Helmond, Netherlands|Hoofddorp, Netherlands|Nieuwegein, Netherlands|Schiedam, Netherlands|Tiel, Netherlands|Zwolle, Netherlands|Bialystok, Poland|Krakow, Poland|Lublin, Poland|Poznan, Poland|Warszawa, Poland|Warszawa, Poland|Zabrze, Poland|Braga, Portugal|Coimbra, Portugal|Lisboa, Portugal|Lisboa, Portugal|Lisboa, Portugal|Porto, Portugal|Porto, Portugal|Santa Maria Da Feira, Portugal|Setubal, Portugal|Vila Nova De Gaia, Portugal|Bucharest, Romania|Cluj Napoca, Romania|Timisoara, Romania|Balashikha, Russian Federation|Engels, Russian Federation|Irkutsk, Russian Federation|Kislino, Kursk Region, Russian Federation|Krasnodar, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Samara, Russian Federation|Smolensk, Russian Federation|Stavropol, Russian Federation|Tumen, Russian Federation|Tver, Russian Federation|Ulyanovsk, Russian Federation|Belgrade, Serbia|Bratislava, Slovakia|Kosice, Slovakia|Nitra, Slovakia|Poprad, Slovakia|Golnik, Slovenia|Ljubljana, Slovenia|Elche, Alicante, Spain|Manresa, Barcelona, Spain|Mataro, Barcelona, Spain|Sabadell, Barcelona, Spain|Terrassa, Barcelona, Spain|Santander, Cantabria, Spain|Palma De Mallorca, Islas Baleares, Spain|Alcorcon, Madrid, Spain|Pamplona, Navarra, Spain|La Laguna, Tenerife, Spain|Barakaldo, Vizcaya, Spain|Alicante, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Girona, Spain|Huesca, Spain|La Coruña, Spain|Lugo, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Murcia, Spain|Salamanca, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Zaragoza, Spain|Gothenburg, Sweden|Lund, Sweden|Malmoe, Sweden|Oerebro, Sweden|Stokholm, Solna, Sweden|Umea, Sweden|Uppsala, Sweden|Aarau, Switzerland|Baden, Switzerland|Genolier, Switzerland|Locarno, Switzerland|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Ankara, Turkey|Gaziantep, Turkey|Istanbul, Turkey|Istanbul, Turkey|Izmir, Turkey|Sıhhiye, ANKARA, Turkey|Aberdeen, United Kingdom|Belfast, United Kingdom|Birmingham, United Kingdom|Cambridge, United Kingdom|Cardiff, United Kingdom|Manchester, United Kingdom|Nottingham, United Kingdom|Suffolk, United Kingdom|Barcelona, Venezuela|Barquisimeto, Venezuela|Porlamar, Venezuela		https://ClinicalTrials.gov/show/NCT00451906
125	NCT01017549	Post Market Study Using the Xoft Axxent System		Completed	Has Results	Breast Cancer	Radiation: Electronic brachytherapy (Axxent System)	Number of Participants With Delivery of 34 Gy in 10 Fractions|Serious Adverse Device Related Events Reported During the Course of the Study Through 6 Month Follow-up.	Xoft, Inc.	Female	50 Years and older   (Adult, Older Adult)	Phase 4	44	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1-04	March 2007	August 2013	August 2013	November 20, 2009	April 11, 2011	June 17, 2016	Mills Peninsula Hospital, San Mateo, California, United States|Wellstar-Kennestone Cancer Center, Marietta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Little Company of Mary Hospital, Evergreen Park, Illinois, United States|Holy Cross Medical Center, Silver Spring, Maryland, United States|Beth Israel Medical Center, New York, New York, United States|Dickstein Cancer Center- White Plains Hospital, White Plains, New York, United States|Oklahoma University Health Science Center, Oklahoma City, Oklahoma, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Swedish Cancer Institute, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT01017549
126	NCT02584933	Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study		Recruiting	No Results Available	ALK Positive Malignancies	Drug: ceritinib	Number of Participants with Adverse Events as a Measure of Safety and Tolerability	Novartis Pharmaceuticals|Novartis	All	12 Years and older   (Child, Adult, Older Adult)	Phase 4	252	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CLDK378A2X01B	December 11, 2015	December 14, 2020	December 31, 2021	October 23, 2015		August 2, 2019	Highlands Oncology Group, Fayetteville, Arkansas, United States|Loma Linda University, Loma Linda, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Essex Oncology of North Jersey PA, Belleville, New Jersey, United States|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Auckland, Australia|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Natal, RN, Brazil|Novartis Investigative Site, Barretos, Sao Paulo, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Changchun, Jilin, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Guangzhou, China|Novartis Investigative Site, Monteria, Colombia|Novartis Investigative Site, Brno, Czech Republic, Czechia|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Saint-Herblain Cédex, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Regensburg, Bavaria, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Perugia, PG, Italy|Novartis Investigative Site, Bologna, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Kashiwa, Chiba, Japan|Novartis Investigative Site, Fukuoka-city, Fukuoka, Japan|Novartis Investigative Site, Akashi, Hyogo, Japan|Novartis Investigative Site, Koto ku, Tokyo, Japan|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, La Coruna, Galicia, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan, Taiwan		https://ClinicalTrials.gov/show/NCT02584933
127	NCT01230710	A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression		Completed	Has Results	Non-Small Cell Lung Cancer	Drug: Erlotinib	Percentage of Participants With Progression-free Survival at Week 52|Progression-free Survival (PFS)|Overall Survival|Percentage of Participants With a Complete Response (CR) or a Partial Response (PR)|Percentage of Participants With Disease Control	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	51	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML25478	March 2011	September 2013	September 2013	October 29, 2010	March 30, 2015	March 30, 2015	Bangalore, India|Chennai, India|Delhi, India|Hyderabad, India|Jaipur, India|Kolkata, India|Nasik, India		https://ClinicalTrials.gov/show/NCT01230710
128	NCT00805701	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation		Completed	No Results Available	Prostate Cancer	Drug: avodart|Drug: Placebo	the effect of dutasteride on dysuria, voiding and LUTS	Bay State Clinical Trials, Inc.|GlaxoSmithKline	Male	35 Years to 90 Years   (Adult, Older Adult)	Phase 4	40	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	047838	January 2009	April 2014	April 2014	December 10, 2008		May 14, 2014	Bay State Clinical Trials, Inc., Watertown, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT00805701
129	NCT02237157	A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer		Active, not recruiting	No Results Available	Pancreatic Cancer	Drug: Gemcitabine, local delivery	Determine the maximum tolerated dose of gemcitabine to be delivered locally to the pancreas|CA19-9 tumor reduction	RenovoRx	All	18 Years and older   (Adult, Older Adult)	Phase 4	20	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	RR1	March 2015	September 2016	December 2021	September 11, 2014		August 29, 2018	El Camino Hospital, Oncology, Mountain View, California, United States|Florida Hospital, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT02237157
130	NCT02238847	Pre-operative Biliary SEMS RCT During Neoadjuvant Therapy		Completed	No Results Available	Pancreatic Cancer	Device: WallFlex™ Biliary RX Fully Covered/Uncovered Stent System	Successful pre-operative biliary drainage defined as absence of reinterventions for the management of biliary obstructive symptoms.|Occurrence and severity of adverse events|Occurrence and severity of surgical complications|Occurrence and severity of peri-surgical complications|Stent Placement Success|Improvement of biliary obstructive symptoms as relative to baseline|Improvement of Laboratory Liver Function Tests (LFTs) as relative to baseline|Number of biliary re-interventions|Ability to complete neoadjuvant therapy as intended without stent related interruptions of neoadjuvant therapy|Stent migration rate|Assessment by surgeon of interference, if any, of SEMS on time to surgery and/or success of pancreaticoduodenectomy|For patients transitioning to palliative management: Successful biliary drainage defined as absence of reinterventions for the management of biliary obstructive symptoms from stent placement to 1 year after stent placement|Type of biliary re-interventions|Reason of biliary re-interventions|Timing of biliary re-interventions	Boston Scientific Corporation	All	18 Years and older   (Adult, Older Adult)	Phase 4	120	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	90905950|E7034	March 24, 2015	February 21, 2018	April 10, 2018	September 12, 2014		April 25, 2018	Indiana University Medical Center, Indianapolis, Indiana, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Virginia Mason Medical Center, Seattle, Washington, United States|The Medical College of Wisconsin, Milwaukee, Wisconsin, United States|CUB Hopital Erasme, Brussels, Belgium|Centre Hospitalier de l'Université de Montréal-Saint-Luc Hospital, Montreal, Quebec, Canada|Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy|Tokyo University Hospital, Tokyo, Japan|Asan Medical Center, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT02238847
131	NCT02475057	Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists		Completed	No Results Available	Prostatic Neoplasms|Cardiovascular Diseases	Drug: Degarelix (LHRH antagonist)|Drug: LHRH agonist|Device: EndoPAT2000	Change in Reactive Hyperemia Index from baseline to twelve months|Change in High sensitivity troponin (hsTn) value|Change in C-reactive protein value|Change in D-dimer value|Change in N-terminal pro-brain natriuretic peptide (NT-proBNP) value	Rabin Medical Center|Ferring Pharmaceuticals	Male	18 Years to 90 Years   (Adult, Older Adult)	Phase 4	80	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	0102-15-RMC	August 2015	July 2018	June 2019	June 18, 2015		June 12, 2019	Rambam Health Care Campus, Haifa, Israel|Rabin Medical Center - Beilinson Hospital, Petah Tikva, Israel		https://ClinicalTrials.gov/show/NCT02475057
132	NCT00029224	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions		Completed	No Results Available	Breast Cancer|Multiple Myeloma|Prostate Cancer	Drug: zoledronic acid	Pain score assessed by change from baseline|Quality of life|Time in infusion chair|Safety assessed by adverse events (AEs)	Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	500	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CZOL446EUS16	October 2001	November 2002	November 2002	January 10, 2002		February 1, 2012	Stockton Hematology Oncology Medical Group, Stockton, California, United States|Osceola Cancer Center, Kissimmee, Florida, United States|Nevada Cancer Center, Las Vegas, Nevada, United States|Hematology-Oncology Associates PC, Albuquerque, New Mexico, United States|New Mexico Oncology Hematology Consultants, Albuquerque, New Mexico, United States|Hematology Oncology Associates, PC, Medforo, Oregon, United States|Virginia Physicians, Inc, Richmond, Virginia, United States		https://ClinicalTrials.gov/show/NCT00029224
133	NCT03853551	Osimertinib Study in Indian Patients		Recruiting	No Results Available	Non Small Cell Lung Cancer (NSCLC)	Drug: Osimertinib	To assess the safety of osimertinib	AstraZeneca	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 4	60	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D5161C00005	April 15, 2019	June 30, 2020	June 30, 2020	February 25, 2019		August 15, 2019	Research Site, Mumbai, Maharashtra, India|Research Site, Mumbai, Maharashtra, India|Research Site, Delhi, New Delhi, India|Research Site, Delhi, New Delhi, India|Research Site, Delhi, New Delhi, India|Research Site, Hyderabad, West Bengal, India|Research Site, Hyderabad, West Bengal, India|Research Site, Kolkata, West Bengal, India		https://ClinicalTrials.gov/show/NCT03853551
134	NCT00537771	Liver Safety Under Upfront Arimidex vs Tamoxifen	HEART	Completed	Has Results	Breast Cancer	Drug: Anastrozole|Drug: Tamoxifen	Incidence of Fatty Liver Disease|Incidence of Abnormal Liver Function|Time to Treatment Failure	AstraZeneca	Female	Child, Adult, Older Adult	Phase 4	384	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	D5392L00023	September 2007	December 2011	December 2011	October 1, 2007	January 25, 2013	January 25, 2013	Research Site, Fuzhou, Fujian, China|Research Site, Guangzhou, Guangdong, China|Research Site, Nanning, Guangxi, China|Research Site, Wuchang, Hubei, China|Research Site, Wuhan, Hubei, China|Research Site, Nanjing, Jiangsu, China|Research Site, Changchun, Jilin, China|Research Site, Dalian, Liaoning, China|Research Site, Jinan, Shandong, China|Research Site, Shanghai, Shanghai, China|Research Site, Taiyuan, Shanxi, China|Research Site, Xian, Shanxi, China|Research Site, Chengdu, Sichuan, China|Research Site, Kunming, Yunnan, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Tianjin, China		https://ClinicalTrials.gov/show/NCT00537771
135	NCT03550482	Oncoxin® and Quality of Life in Cancer Patients		Completed	No Results Available	Gastric Cancer Stage II|Non-small Cell Lung Cancer Stage II|Non-small Cell Lung Cancer Stage III|Gastric Cancer Stage III	Dietary Supplement: ONCOXIN®	Quality of life improvement|Emotional Quality of life|Toxicity produced by Chemotherapy|Physical Quality of Life|Nutritional level	Catalysis SL	All	50 Years to 70 Years   (Adult, Older Adult)	Phase 4	133	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	OOS-CANCER-5	November 1, 2017	March 15, 2019	May 15, 2019	June 8, 2018		June 5, 2019	Kazakh Research Institute of Oncology and Radiology, Almaty, Kazakhstan|State Municipal Enterprise on the Right of Economic Management "Almaty Oncology Center" of Almaty Healthcare Administration, Almaty, Kazakhstan|State-funded Institution of Khanty-Mansiysk Regional Clinical Hospital, Ugra, Tyumen Region, Russian Federation|Medical Center "EVIMED" LLC, Chelyabinsk, Russian Federation|State-funded Healthcare Institution Oncologic Clinical Dispensary No.1, Moscow, Russian Federation|The Loginov Moscow Clinical Scientific Center, www.mknc.ru, Moscow, Russian Federation|Medical University "Reaviz", Samara, Russian Federation|Non-government Healthcare Institution " Hospital of JSC Russian Railways Hospital at the Station Smolensk, Smolensk, Russian Federation|State-funded Institution "Surgut Regional Hospital", Surgut, Russian Federation		https://ClinicalTrials.gov/show/NCT03550482
136	NCT00375765	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer		Completed	No Results Available	Benign Prostatic Hyperplasia|Prostate Cancer	Drug: Dutasteride	Relative change in PSA(Prostate-specific antigen)expression per cell at 3 months|Relative change in PCA3 (a prostate cancer-specific gene) expression per cell at 3 months Relative change in prostate volume at 3 months	GlaxoSmithKline	Male	50 Years and older   (Adult, Older Adult)	Phase 4	40	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	104274	April 2005	July 2007	July 2007	September 13, 2006		January 19, 2017	GSK Investigational Site, Nijmegen, Netherlands|GSK Investigational Site, Nijmegen, Netherlands		https://ClinicalTrials.gov/show/NCT00375765
137	NCT00063609	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy		Completed	No Results Available	Prostate Cancer	Drug: zoledronic acid	Percent change in bone mineral density of the lumbar spine (L2-L4) at one year.|Percent changes in bone mineral density of the total hip|biochemical markers of bone turnover at one year	Novartis Pharmaceuticals|Novartis	Male	18 Years and older   (Adult, Older Adult)	Phase 4	200	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention	CZOL446GUS45|ZENITH	April 2003		April 2005	July 3, 2003		September 13, 2017	Millennium Therapeutics & Research, Birmingham, Alabama, United States|Medical Affiliated Research Center, Huntsville, Alabama, United States|Alaska Clinical Research Center, Anchorage, Alaska, United States|Advanced Clinical Therapeutics, Tucson, Arizona, United States|Donald Gleason, MD, Tucson, Arizona, United States|Arkansas Urology, Little Rock, Arkansas, United States|Advanced Urology Med. Center, Anaheim, California, United States|Atlantic Urological Medical Group, Long Beach, California, United States|San Diego Uro. Research, San Diego, California, United States|Western Clinical Research, Torrance, California, United States|Connecticut Surgical Group, Hartford, Connecticut, United States|Grove Hill Urology, New Britain, Connecticut, United States|Atlantic Urological Associates, Daytona Beach, Florida, United States|University of Miami School of Medicine, Dept. of Urology, Miami, Florida, United States|Advanced Research Institute, Inc., New Port Richey, Florida, United States|Urosearch, Ocala, Florida, United States|Southeastern Urological Center, PA, Tallahassee, Florida, United States|Medisphere Medical Research Center, LLC, Evansville, Indiana, United States|The Iowa Clinic, PC, Iowa Urology Research, Des Moines, Iowa, United States|Summitt Clinical Research, Owings Mills, Maryland, United States|Millennium Medical Center, Southfield, Michigan, United States|Quality Clinical Research LLC, Springfield, Nebraska, United States|Associated Urologic Specialist, PA, Marlton, New Jersey, United States|Morristown Memorial Hospital, Morristown, New Jersey, United States|Associates In Urology, LLC, West Orange, New Jersey, United States|AccuMed Research Associates, Garden City, New York, United States|Urological Surgeons of L.I., Garden City, New York, United States|Staten Island Urological Research, PC, Staten Island, New York, United States|The Urology Group, Cincinnati, Ohio, United States|Urological Associates, Inc., Columbus, Ohio, United States|Mount Vernon Urological Associates, Mount Vernon, Ohio, United States|Oregon Urology Specialists, Eugene, Oregon, United States|The Urology Clinic, Portland, Oregon, United States|Urologic Associates of Allentown, Allentown, Pennsylvania, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States|Triangle Urological Group, Pittsburgh, Pennsylvania, United States|Urologic Surgeons of New England, P.C., Providence, Rhode Island, United States|University Urological Research Institute, Providence, Rhode Island, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Integrity Clinical Research, LLC, Germantown, Tennessee, United States|Urology San Antonio Research, San Antonio, Texas, United States|Salt Lake Research, Salt Lake City, Utah, United States|Seattle Urological Associates, Seattle, Washington, United States|Rockwood Clinic, Spokane, Washington, United States		https://ClinicalTrials.gov/show/NCT00063609
138	NCT01552291	The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies	Glutaminprojec	Completed	No Results Available	Malnourishment|Gastrointestinal Tumors	Dietary Supplement: Glutamine|Drug: Placebo	Morbidity|Postoperative cell damage|Inflammatory response|Nutritional status|Perioperative immunocompetence	University Hospital Inselspital, Berne|Fresenius Kabi	All	Child, Adult, Older Adult	Phase 4	42	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care	170/11	May 2012	February 10, 2018	February 12, 2018	March 13, 2012		February 13, 2018	Department of visceral surgery and transplant surgery, Berne University Hospital, Berne, Switzerland		https://ClinicalTrials.gov/show/NCT01552291
139	NCT01496313	To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer		Active, not recruiting	Has Results	Thyroid Cancer	Drug: 300mg vandetanib|Drug: 150mg vandetanib	Overall Response Rate (ORR) for Vandetanib 150 and 300mg With Responses Determined by the Investigator|Best Objective Response|Duration of Objective Response (RECIST 1.1) by Treatment Arm|Time to Objective Response (RECIST 1.1) by Treatment Arm|Percentage Change From Baseline in Target Lesion Size (RECIST 1.1) by Treatment Arm|Plasma Concentration of Vandetanib in the Bloodstream (Cmax) for Patients by Treatment Arm.	Genzyme, a Sanofi Company|Sanofi	All	18 Years and older   (Adult, Older Adult)	Phase 4	81	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	D4200C00097|2011-004701-24|LPS14809	June 2012	April 2014	December 2019	December 21, 2011	November 27, 2015	November 14, 2016	Research Site, Houston, Texas, United States|Research Site, Olomouc, Czech Republic|Research Site, Praha 5, Czech Republic|Research Site, Bangalore Karnataka, India|Research Site, Vellore, India|Research Site, Beer Sheva, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Petach Tikva, Israel|Research Site, Catania, Italy|Research Site, Milano, Italy|Research Site, Palermo, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Siena, Italy|Research Site, Torino, Italy|Research Site, Groningen, Netherlands|Research Site, Leiden, Netherlands|Research Site, Gliwice, Poland|Research Site, Warszawa, Poland|Research Site, Zgierz, Poland|Research Site, Saint Petersburg, Russian Federation|Research Site, Cardiff, United Kingdom|Research Site, Greater London, United Kingdom|Research Site, London, United Kingdom|Research Site, Tyne & Wear, United Kingdom		https://ClinicalTrials.gov/show/NCT01496313
140	NCT01720550	PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care		Completed	No Results Available	Cancer-related Fatigue	Drug: Astragalus Polysaccharides 500 mg|Drug: Astragalus Polysaccharides 250 mg	Fatigue Improvement Response Rate|The fatigue improvement response rate among patients within and between cycles (by BFI-T)|The fatigue improvement by multiple BFI-T score percentage change levels among patients between two study arms|The mean of patients' fatigue score change from baseline within and between cycles (by BFI-T)|Symptoms and Quality of Life Assessments: SS11 from EORTC QLQ-C30 (including the evaluation of the quality of sleep, appetite, pain, fatigue, nausea, vomiting and global quality of life)|Karnofsky performance score|The correlation between Weight change and the related blood c-reactive protein level|Physical Examination|Labolatory Safety Examination|Incidence of Adverse Events as a Measure of Safety and Tolerability|Vital signs|Immune Biomarkers	PhytoHealth Corporation	All	20 Years and older   (Adult, Older Adult)	Phase 4	323	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	PH-CP012 (II)	November 2012	June 2017	June 2017	November 2, 2012		September 10, 2018	Changhua Christian Hospital, Changhua, Taiwan|Chang Gung Memorial Hospital, Kaohsiung Branch, Kaohsiung City, Taiwan|Chang Gung Memorial Hospital, Lakeview Branch, Keelung City, Taiwan|China Medical University Hospital, Taichung, Taiwan|Chi Mei Hospital, Loiuying Campus, Tainan, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Taipei Medical University -Shung Ho Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan		https://ClinicalTrials.gov/show/NCT01720550
141	NCT03899155	Pan Tumor Nivolumab Rollover Study		Not yet recruiting	No Results Available	Cancer	Drug: Nivolumab	Number of Participants with Adverse Events (AEs)|Number of Participants With AEs Related to Treatment|Number of Participants With AEs Leading to Discontinuation|Number of Participants With Serious AEs (SAEs) and Death|Number of Participants With Select AEs	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 4	1200	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-8TT|2018-004362-34	June 28, 2019	October 24, 2022	June 30, 2025	April 2, 2019		July 2, 2019	Local Institution, San Francisco, California, United States|Local Institution, Orlando, Florida, United States|Local Institution, Tampa, Florida, United States|Local Institution, Louisville, Kentucky, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Saint Louis, Missouri, United States|Local Institution, Lebanon, New Hampshire, United States|Local Institution, Albuquerque, New Mexico, United States|Local Institution, New York, New York, United States|Local Institution, New York, New York, United States|Local Institution, Durham, North Carolina, United States|Local Institution, Allentown, Pennsylvania, United States|Local Institution, Bethlehem, Pennsylvania, United States|Local Institution, Philadelphia, Pennsylvania, United States|Local Institution, Greenville, South Carolina, United States|Local Institution, Nashville, Tennessee, United States|Local Institution, Salt Lake City, Utah, United States|Local Institution, Charlottesville, Virginia, United States|Local Institution, Charlottesville, Virginia, United States|Local Institution, Madison, Wisconsin, United States|Local Institution, Buenos Aires, Argentina|Local Institution, Caba, Argentina|Local Institution, Coffs Harbour, New South Wales, Australia|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Sydney, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Malvern, Victoria, Australia|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, VinadelMar, Valparaiso, Chile|Local Institution, Santaigo, Chile|Local Institution, Santiago, Chile|Local Institution, Odense C, Denmark|Local Institution, Helsinki, Finland|Local Institution, Bordeaux, France|Local Institution, Grenoble, France|Local Institution, Lille, France|Local Institution, Montpellier, France|Local Institution, Paris, France|Local Institution, TOULOUSE Cedex 9, France|Local Institution, Villejuif, France|Local Institution, Gera, Germany|Local Institution, Goettingen, Germany|Local Institution, Goettingen, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kiel, Germany|Local Institution, Kiel, Germany|Local Institution, Koeln, Germany|Local Institution, Mainz, Germany|Local Institution, Tubingen, Germany|Local Institution, Athens, Greece|Local Institution, Neo Faliro, Greece|Local Institution, Ramat-gan, Israel|Local Institution, Bari, BA, Italy|Local Institution, Bergamo, Italy|Local Institution, Genova, Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Morelia, Michioacan, Mexico|Local Institution, Oslo, Norway|Local Institution, Gdansk, Poland|Local Institution, Lodz, Poland|Local Institution, Warszawa, Poland|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, San Sabastian Gipuzkoa, Spain|Local Institution, Valencia, Spain|Local Institution, Goteborg, Sweden|Local Institution, Malmoe, Sweden|Local Institution, Umea, Sweden		https://ClinicalTrials.gov/show/NCT03899155
142	NCT01401075	RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients		Completed	No Results Available	Gastric Cancer	Drug: mistletoe extract|Drug: doxifluridine	Quality of Life|Immunomodulation|Safety and tolerability	Abnoba Gmbh	All	19 Years to 70 Years   (Adult, Older Adult)	Phase 4	32	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	AB-AVQ20-1.0	March 2006	April 2008	April 2008	July 25, 2011		November 7, 2012	ASAN Medical Center, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01401075
143	NCT01136226	Evaluate Recovery of Testosterone for Patients Using Eligard	Eligard	Completed	Has Results	Prostate Cancer	Drug: Eligard (TM)	Serum Testosterone Recovery|Safety Assessments	Chesapeake Urology Research Associates|Sanofi-Synthelabo	Male	50 Years to 80 Years   (Adult, Older Adult)	Phase 4	42	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CURA-RT-001	October 2003	June 2009	June 2009	June 3, 2010	July 16, 2013	October 24, 2018			https://ClinicalTrials.gov/show/NCT01136226
144	NCT01060124	An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Cancer Participants With Inadequately Controlled Pain by Non-Narcotic Analgesics		Completed	Has Results	Pain; Cancer	Drug: Fentanyl D-trans	Percentage of Participants Satisfied With Pain Treatment|Difference in Pain Intensity Before and After Administration of (TTS)-Fentanyl D-trans	Janssen Korea, Ltd., Korea	All	20 Years and older   (Adult, Older Adult)	Phase 4	103	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CR012256|FEN-KOR-13	April 2007	February 2009	February 2009	February 2, 2010	April 26, 2013	April 29, 2014			https://ClinicalTrials.gov/show/NCT01060124
145	NCT00334139	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer		Completed	No Results Available	Prostate Cancer|Breast Cancer|Bone Metastasis	Drug: Zoledronic Acid	Bone turnover assessed by bone turnover parameters|Pain|Change in prostate specific antigen|Quality of Life|Correlation between pain and bone turnover|Correlation between bone complications and bone turnover	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	411	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CZOL446EDE28	May 2006	July 2009	July 2009	June 6, 2006		February 7, 2017	Novartis Investigative Site, Ulm, Germany		https://ClinicalTrials.gov/show/NCT00334139
146	NCT02001857	Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer.		Completed	No Results Available	Prostate or Bladder Cancer	Drug: 1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.	development of a radiographic lymphocele on abdominal ultrasonography|volume of radiographic lymphoceles|duration of postoperative drainage catheter|volume produced by postoperative drainage catheter (lymphorrhea)|time between operation and first flatus, first peristalsis, first passing of stool and removal of gastrostomy tube (signs of ileus recuperation).|development of a symptomatic lymphocele.|decrease in serum hemoglobin on the first postoperative day|duration of hospital stay|total cost	University Hospital, Ghent|Takeda	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 4	200	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	EC/2013/472|2013-000782-36	September 2013	February 2017	August 2017	December 5, 2013		August 25, 2017	Ghent University Hospital, Ghent, Belgium		https://ClinicalTrials.gov/show/NCT02001857
147	NCT00395863	Multihance at 3 Tesla in Brain Tumors		Completed	Has Results	Brain Tumor	Drug: Multihance|Drug: Arm 2 - Magnevist	Global Diagnostic Preference Between the Two Exams|Lesion Border Delineation|Lesion Contrast Enhancement Between the Two Exams|Lesion-to-brain Ratio (LBR) for Each Lesion - Reader 1|Lesion-to-brain Ratio (LBR) for Each Lesion - Reader 2|Lesion-to-brain Ratio (LBR) for Each Lesion - Reader 3|Contrast-to-noise Ratio (CNR) for Each Lesion - Reader 1|Contrast-to-noise Ratio (CNR) for Each Lesion - Reader 2|Contrast-to-noise Ratio (CNR) for Each Lesion - Reader 3|Percentage of Contrast Enhancement of the Lesion - Reader 1|Percentage of Contrast Enhancement of the Lesion - Reader 2|Percentage of Contrast Enhancement of the Lesion - Reader 3	Bracco Diagnostics, Inc	All	18 Years and older   (Adult, Older Adult)	Phase 4	46	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic	MH 126	November 2006	February 2008	March 2008	November 6, 2006	July 31, 2009	April 14, 2015	Bracco Diagnostics, Inc., Princeton, New Jersey, United States		https://ClinicalTrials.gov/show/NCT00395863
148	NCT03349463	Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers.		Recruiting	No Results Available	Cervical Cancer|Endometrial Cancer|Ovarian Epithelial Cancer	Drug: Fluciclovine F18	18F-Fluciclovine uptake in gynecologic neoplasms	Bital Savir-Baruch|Blue Earth Diagnostics|Loyola University	Female	18 Years and older   (Adult, Older Adult)	Phase 4	30	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	209877	November 14, 2018	December 2019	December 2019	November 21, 2017		March 21, 2019	Loyola University Medical Center, Maywood, Illinois, United States		https://ClinicalTrials.gov/show/NCT03349463
149	NCT02485691	Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent	CARD	Active, not recruiting	No Results Available	Prostate Cancer Metastatic	Drug: cabazitaxel XRP6258|Drug: enzalutamide|Drug: abiraterone acetate|Drug: prednisone	Radiographic progression-free survival defined as the time from randomization to the occurrence of radiological tumor progressions using RECIST 1.1 and progression of bone lesions using Prostate Cancer Working Group 2 (PCWG2) criteria|Radiographic progression-free survival defined as the time from randomization to the occurrence of death due to any cause|Number of patients achieving PSA decline >=50%|Progression-free survival-Time|Overall survival defined as the time interval from the date of randomization to the date of death due to any cause|Time to Prostate Specific Antigen (PSA) progression defined as the time interval between the date of randomization and the date of PSA progression using PCWG2 definition|Number of patients achieving tumor response|Duration of tumor response|Pain response using Brief Pain Inventory-Short Form (BPI-SF) for pain intensity score|Time to pain progression|Symptomatic skeletal event (SSE) rate|Assessment of Health-related Quality of Life (HRQOL) using the Functional Assessment of Cancer Therapy - Prostate (FACT-P) scale|Assessment of health status using the 5-Level EuroQol Group's 5-Dimension (EQ-5D-5L) questionnaire|Number of treatment-emergent adverse events (TEAEs)	Sanofi	Male	18 Years and older   (Adult, Older Adult)	Phase 4	234	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LPS14201|2014-004676-29|U1111-1166-5329	November 9, 2015	August 2019	August 2019	June 30, 2015		April 29, 2019	Investigational Site Number 040002, Linz, Austria|Investigational Site Number 040003, Wien, Austria|Investigational Site Number 040004, Wien, Austria|Investigational Site Number 056013, Brugge, Belgium|Investigational Site Number 056011, Brugge, Belgium|Investigational Site Number 056007, Brussels, Belgium|Investigational Site Number 056003, Bruxelles, Belgium|Investigational Site Number 056002, Bruxelles, Belgium|Investigational Site Number 056006, Charleroi, Belgium|Investigational Site Number 056001, Gent, Belgium|Investigational Site Number 056005, Leuven, Belgium|Investigational Site Number 056010, Roeselare, Belgium|Investigational Site Number 056008, Turnhout, Belgium|Investigational Site Number 203005, Brno, Czechia|Investigational Site Number 203001, Olomouc, Czechia|Investigational Site Number 203002, Plzen, Czechia|Investigational Site Number 203003, Praha 4, Czechia|Investigational Site Number 250012, Besancon, France|Investigational Site Number 250010, Clermont Ferrand, France|Investigational Site Number 250006, LYON Cedex 8, France|Investigational Site Number 250019, Lyon, France|Investigational Site Number 250004, Marseille, France|Investigational Site Number 250011, Montpellier, France|Investigational Site Number 250002, PARIS Cedex 15, France|Investigational Site Number 250013, Paris, France|Investigational Site Number 250007, Paris, France|Investigational Site Number 250014, Plerin, France|Investigational Site Number 250016, Reims, France|Investigational Site Number 250018, Saint-Mandé, France|Investigational Site Number 250009, Strasbourg, France|Investigational Site Number 250005, Suresnes, France|Investigational Site Number 250008, Tours, France|Investigational Site Number 250001, Villejuif, France|Investigational Site Number 276028, Aschaffenburg, Germany|Investigational Site Number 276027, Berlin, Germany|Investigational Site Number 276008, Berlin, Germany|Investigational Site Number 276022, Duisburg, Germany|Investigational Site Number 276013, Düsseldorf, Germany|Investigational Site Number 276016, Erlangen, Germany|Investigational Site Number 276023, Essen, Germany|Investigational Site Number 276002, Frankfurt am Main, Germany|Investigational Site Number 276007, Göttingen, Germany|Investigational Site Number 276009, Hamburg, Germany|Investigational Site Number 276001, Hamburg, Germany|Investigational Site Number 276017, Homburg/Saar, Germany|Investigational Site Number 276026, Jena, Germany|Investigational Site Number 276012, Köln, Germany|Investigational Site Number 276025, Lübeck, Germany|Investigational Site Number 276004, Magdeburg, Germany|Investigational Site Number 276019, Mainz, Germany|Investigational Site Number 276018, Mannheim, Germany|Investigational Site Number 276006, Münster, Germany|Investigational Site Number 276003, Nürtingen, Germany|Investigational Site Number 276010, Rostock, Germany|Investigational Site Number 276024, Stuttgart, Germany|Investigational Site Number 276011, Tübingen, Germany|Investigational Site Number 276020, Wuppertal, Germany|Investigational Site Number 300001, Athens, Greece|Investigational Site Number 300002, Athens, Greece|Investigational Site Number 300005, Marousi, Athens, Greece|Investigational Site Number 300004, Thessaloniki, Greece|Investigational Site Number 352001, Reykjavik, Iceland|Investigational Site Number 372001, Dublin 24, Ireland|Investigational Site Number 372003, Dublin 7, Ireland|Investigational Site Number 372004, Dublin, Ireland|Investigational Site Number 380003, Arezzo, Italy|Investigational Site Number 380004, Brescia, Italy|Investigational Site Number 380005, Candiolo, Italy|Investigational Site Number 380009, Meldola, Italy|Investigational Site Number 380007, Napoli, Italy|Investigational Site Number 380006, Napoli, Italy|Investigational Site Number 380011, Parma, Italy|Investigational Site Number 380002, Pisa, Italy|Investigational Site Number 380001, Roma, Italy|Investigational Site Number 380008, Verona, Italy|Investigational Site Number 528002, Breda, Netherlands|Investigational Site Number 528007, Enschede, Netherlands|Investigational Site Number 528003, Nijmegen, Netherlands|Investigational Site Number 528005, Rotterdam, Netherlands|Investigational Site Number 528004, Sittard-Geleen, Netherlands|Investigational Site Number 578001, Grålum, Norway|Investigational Site Number 578002, Trondheim, Norway|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724004, Madrid, Spain|Investigational Site Number 724002, Madrid, Spain|Investigational Site Number 724003, Sevilla, Spain|Investigational Site Number 826001, Sutton, United Kingdom		https://ClinicalTrials.gov/show/NCT02485691
150	NCT01328054	A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval		Completed	Has Results	Cancer	Drug: lapatinib|Drug: placebo matching lapatinib	Treatment Difference in Duration of Cardiac Ventricular Depolarization and Repolarization Interval (QT) in Fridericia-corrected QT Interval (QTcF) Values Between Placebo and Lapatinib 2000mg|Change From Baseline in the Holter ECG Parameters of QT Interval, Corrected QT Interval (QTc), Bazett Corrected QTc Interval (QTcB), Individual-corrected QT Interval (QTcI), RR Interval, PR Interval, and QRS Duration at Indicated Time Points|Number of Participants With 12-lead Holter ECG Findings at the Indicated Time Points|Number of Participants With the Worst-case Post-Baseline 12-lead Holter ECG Findings With Significant ST, T Wave, and U Wave Abnormalities|Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)|Mean Albumin, and Hemoglobin at the Indicated Time Points|Mean Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) at the Indicated Time Points|Mean Direct Bilirubin, Total Bilirubin, and Creatinine at the Indicated Time Points|Mean Calcium, Chloride, Carbon Dioxide (CO2), Potassium, Sodium, Magnesium and Urea at the Indicated Time Points|Mean Total Neutrophils (ANC [Absolute Neutrophil Count]), Platelets and Leukocyte Count at the Indicated Time Points|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points|Change From Baseline in Heart Rate at the Indicated Time Points|Number of Participants With 12-lead ECG Findings at Indicated Time Points|Mean Area Under the Plasma Drug Concentration-time Curve (AUC) From Time Zero (Pre-dose) to the Last Time of Quantifiable Concentration (AUC[0-t]) and From Time Zero (Pre-dose) to 24 Hours Post Dose (AUC[0-24]) for Lapatinib|Mean Maximum Plasma Concentration (Cmax) and Observed Plasma Concentration at 24 Hours Post-dose (C24) of Lapatinib|Median Time to Cmax (Tmax) and the Time Prior to the First Quantifiable (Non-zero) Lapatinib Plasma Concentration (Tlag) Following the Last (3rd) Lapatinib Dose	GlaxoSmithKline	All	18 Years and older   (Adult, Older Adult)	Phase 4	58	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	114271	December 2011	March 2015	March 2015	April 4, 2011	June 8, 2016	June 8, 2016	GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Lebanon, New Hampshire, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT01328054
151	NCT00198276	Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer		Completed	No Results Available	Cancer	Combination Product: MedPulser Electroporation with bleomycin	Local tumor control|Pharmacoeconomic factors (e.g. hospital costs, extent of medical interventions, medication use)|MedPulser instrument and applicator performance|Adverse events	Inovio Pharmaceuticals	All	18 Years and older   (Adult, Older Adult)	Phase 4	88	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EU-CCBE-2003	February 2004	September 2008	September 2008	September 20, 2005		October 3, 2017	Inovio Biomedical Corporation, San Diego, California, United States		https://ClinicalTrials.gov/show/NCT00198276
152	NCT00099541	Non-small Cell Lung Cancer Registry		Completed	No Results Available	Non-Small-Cell Lung Cancer|Pleural Effusion, Malignant	Drug: zoledronic acid	Group 1: Time to the first occurrence of an skeletal related event (SRE) in unresectable stage IIIB/IV NSCLC patients with bone metastases|Group 2: Observational|Patients with an SRE will be evaluated for:|Time from stage IIIB/IV NSCLC diagnosis to progression to bone|Time from bone metastasis diagnosis to presentation of clinical symptoms of skeletal complications|The effect of serum NTX levels on the development of skeletal events (SREs), and|Overall survival|Group 2: Obervational	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	300	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CZOL446EUS99|US99|Z-NEXT	November 2004		November 2007	December 16, 2004		November 23, 2009	Birmingham Hematology and Oncology Associates, Birmingham, Alabama, United States|Hembree Cancer Center-St. Edward Mercy Medical Center, Fort Smith, Arkansas, United States|Pacific Cancer Medical Center Inc., Anaheim, California, United States|Bay Area Cancer Research Group, Concord, California, United States|Fresno Hem/Onc Medical Group, Fresno, California, United States|Beaver Med Group, Highland, California, United States|Redwood Regional Medical Group, Santa Rosa, California, United States|Stockton Hem. Onc., Stockton, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Front Range Cancer Specialists, Fort Collins, Colorado, United States|Greeley Medical Clinic, Greeley, Colorado, United States|Western Hematology/Oncology, Lakewood, Colorado, United States|Hematology Oncology PC, Stamford, Connecticut, United States|Christiana Care Health Services, Newark, Delaware, United States|Gainesville Hematology Oncology Associates, Gainesville, Florida, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Center for Cancer Care & Research, Lakeland, Florida, United States|Lake Heart & Cancer Center, Leesburg, Florida, United States|Melbourne Internal Medicine Assoc (MIMA) Century Research, Melbourne, Florida, United States|Pasco Pinellas Cancer Center, New Port Richey, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Mid- Florida Hematology & Oncology Centers, PA, Orange City, Florida, United States|Space Coast Medical, Titusville, Florida, United States|Vero Beach Hematology/Oncology, Vero Beach, Florida, United States|Hematology & Oncology of N.E. GA, Athens, Georgia, United States|Augusta Onc. Associates, Augusta, Georgia, United States|Suburban Hematology-Oncology, Snellville, Georgia, United States|Regional Cancer Center, Danville, Illinois, United States|The Cancer Institute at Alexian Brothers, Elk Grove Village, Illinois, United States|Lekha Babu M.D Ltd., Flossmoor, Illinois, United States|Joliet Oncology Hematology Associates, Ltd, Joliet, Illinois, United States|LaGrange Oncology Associates, LaGrange, Illinois, United States|Northwest Medical Specialists, Niles, Illinois, United States|Midwest Cancer Research Group, Skokie, Illinois, United States|Medical Consultants, PC, Muncie, Indiana, United States|Kentuckiana Cancer Center, PLLC, Louisville, Kentucky, United States|W. Kentucky Hematology's Oncology Group, PSC, Paducah, Kentucky, United States|Cabrini Center for Cancer Care, Alexandria, Louisiana, United States|Louisiana Oncology Associates, Lafayette, Louisiana, United States|Hematology and Oncology Specialists, Metairie, Louisiana, United States|Highland Clinic, APMC, Shreveport, Louisiana, United States|Sinai Hospital, Baltimore, Maryland, United States|Maryland Hematology/Oncology Associates, Baltimore, Maryland, United States|David H. Smith, MD, Chestertown, Maryland, United States|Oncology-Hematology Associates, PA, Clinton, Maryland, United States|Maryland Oncology, Columbia, Maryland, United States|St. Joseph Medical Center, Towson, Maryland, United States|Caritas Holy Family Hospital, Methuen, Massachusetts, United States|Fallon Clinic, Worcester, Massachusetts, United States|Henry Ford Medical Center, Detroit, Michigan, United States|Singh & Arora Hematology/Oncology, Flint, Michigan, United States|Hubert Humphrey Cancer Center, Robbinsdale, Minnesota, United States|Heartland Hematology/Oncology Associates Inc., Kansas City, Missouri, United States|St. Joseph Onocology, Inc., St. Joseph, Missouri, United States|University Hematology Oncology, Inc., St. Louis, Missouri, United States|St. John's Mercy Medical Center, St. Louis, Missouri, United States|Sierra Nevada Oncology Care, Carson City, Nevada, United States|Nevada Cancer Center, Las Vegas, Nevada, United States|US Oncology, Las Vegas, Nevada, United States|Center For Cancer & Hematologic Disease, Cherry Hill, New Jersey, United States|HOANNJ/Carol G. Simon Cancer Center, Morristown, New Jersey, United States|Medical Hematology/Oncology, Somerset, New Jersey, United States|Hematology-Oncology Associates of CNY, East Syracuse, New York, United States|Huntington Medical Group, Huntington Station, New York, United States|Broome Oncology, Johnson City, New York, United States|Kin Yui Lam, MD, New York, New York, United States|Alamance Regional Medical Ctr. Cancer Ctr., Burlington, North Carolina, United States|Raleigh Hematology Oncology Associates, Raleigh, North Carolina, United States|Summa Health System, Akron, Ohio, United States|OHCI, Cincinnati, Ohio, United States|Mukesh Bhatt, MD, Medina, Ohio, United States|Lawrence M. Stallings, MD, LLC, Wooster, Ohio, United States|M. Farouk Kanaa, MD, Inc., Oklahoma City, Oklahoma, United States|Cancer Treatment Center, Tulsa, Oklahoma, United States|Oncology-Hematology of Lehigh Valley PC, Bethlehem, Pennsylvania, United States|Paul V. Woolley MD PC, Johnstown, Pennsylvania, United States|Chester County Hematology/Oncology Services, West Chester, Pennsylvania, United States|South Carolina Oncology Assoc., PA, Columbia, South Carolina, United States|Palmetto Hematology Oncology, P.C, Spartanburg, South Carolina, United States|Associates in Oncology and Hematology, Chattanooga, Tennessee, United States|The Family Cancer Center, PLLC, Collierville, Tennessee, United States|McLeod Cancer & Blood Center, Johnson City, Tennessee, United States|Kingsport Hematology-Oncology, Kingsport, Tennessee, United States|Eastern Connecticut Hematology/Oncology, Memphis, Tennessee, United States|Oncology Hematology of South Florida, Memphis, Tennessee, United States|The West Clinic, Memphis, Tennessee, United States|Southwest Regional Cancer Center, Austin, Texas, United States|St. Joseph Regional Cancer Ctr., Bryan, Texas, United States|Coastal Bend Cancer Center, Corpus Christi, Texas, United States|Center for Oncology Research and Treatment, PA, Dallas, Texas, United States|Oncology Consultants P.A., Houston, Texas, United States|South Texas Oncology & Hematology, San Antonio, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Cancer Outreach, Abingdon, Virginia, United States|Lynchburg Oncology, Lynchburg, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Oncology/Hematology Association of SW VA, Roanoke, Virginia, United States|Western WA Med. Grp. Oncology, Everett, Washington, United States|Western Washington Oncology, Lacey, Washington, United States|Swedish Health Services, Seattle, Washington, United States|Oncology Alliance, S.C., Glendale, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT00099541
153	NCT01129336	Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients	MACS1295	Completed	Has Results	First or Second Line HER2-negative Breast Cancer|Metastatic Disease Without Bone Metastasis	Drug: Zoledronic acid|Drug: Standard Therapy	Number of Participants With Progression Free Survival (PFS)|Percentage of Patients With Circulating Tumor Cell Levels of at Least 5 Per 7.5 mL of Peripheral Blood by Month|Time to Progression (TTP)|Change From Baseline in Urine NTX by Month	Novartis Pharmaceuticals|Novartis	Female	18 Years and older   (Adult, Older Adult)	Phase 4	44	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CZOL446EUS147	June 2010	August 2012	August 2012	May 24, 2010	February 12, 2014	May 20, 2014	Highlands Oncology Group, Fayetteville, Arkansas, United States|Clopton Clinic, Jonesboro, Arkansas, United States|Hematology Oncology Services of Arkansas, Little Rock, Arkansas, United States|Kaiser Permanente Medical Group Kaiser Permanente - Hawaii, Anaheim, California, United States|Wilshire Oncology Medical Group, La Verne, California, United States|Loma Linda University Loma Linda Cancer Center, Loma Linda, California, United States|Hematology and Medical Oncology, Waterbury, Connecticut, United States|Florida Cancer Specialists DeptofFloridaCancerSpecialists, Fort Myers, Florida, United States|Lakeland Regional Cancer Center Dept. of Lakeland Regional, Lakeland, Florida, United States|Space Coast Medical Associates, Titusville, Florida, United States|Kootenai Medical Center Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Oncology Specialists, SC Lutheran General Cancer Instit, Park Ridge, Illinois, United States|Cancer Center of Kansas, Witchita, Kansas, United States|Park Nicollet Institute Dept. of Park Nicollet, St. Louis Park, Minnesota, United States|St. John's Mercy Medical Center St. John's Mercy Med Ctr, St. Louis, Missouri, United States|Hematology Oncology Centers of the Northern Rockies Hema Onc Ctr N. Rockies (4, Billings, Montana, United States|Southeast Nebraska Oncology Cancer Center, Lincoln, Nebraska, United States|Reno Oncology Consultants, Reno, Nevada, United States|Somerset Hematology Oncology Associates Somerset Hema Oncol Assoc (2), Somerset, New Jersey, United States|Cooper Cancer Center, Voorhees, New Jersey, United States|NYU Langone Arena Oncology, Lake Success, New York, United States|Marion L. Shepard Cancer Center, Washington, North Carolina, United States|Piedmont Hematology and Oncology Associates Piedmont Hem/Onc Assoc (2), Winston-Salem, North Carolina, United States|Hematology Oncology Center, Inc., Elyria, Ohio, United States|Milton S Hershey Medical Center Hershey Medical Center (4), Hershey, Pennsylvania, United States|Berks Hematology Oncology, West Reading, Pennsylvania, United States|Abington Hematology Oncology Associates, Inc, Willow Grove, Pennsylvania, United States|The West Clinic, Memphis, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|South Texas Oncology and Hematology, PA South Texas Oncology (2), San Antonio, Texas, United States|East Texas Medical Center Cancer Institute Tyler Hem/Onc (3), Tyler, Texas, United States|Medical Oncology & Hematology Associates of Northern VA Med. Onc&Hem Assoc. of No.VA, Reston, Virginia, United States|Northwest Medical Specialties, Tacoma, Washington, United States		https://ClinicalTrials.gov/show/NCT01129336
154	NCT00230217	Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy		Completed	No Results Available	Tumors|Hyperuricemia|Tumor Lysis Syndrome	Drug: Rasburicase (SR29142)	Positive response based on plasma uric acid levels.|safety assessment	Sanofi	All	Child, Adult, Older Adult	Phase 4	94	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	EFC5339	March 2004	July 2006	July 2006	September 30, 2005		March 30, 2009	Alta Bates Comprehensive Cancer Center, Berkley, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|University of Florida Health Science Center at Jacksonville, Jacksonville, Florida, United States|New York Medical College, Valhalla, New York, United States|University of Oklahoma HSC, Oklahoma City, Oklahoma, United States|University of Pennsylvania Health Systems, Philadelphia, Pennsylvania, United States|Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States		https://ClinicalTrials.gov/show/NCT00230217
155	NCT00764621	Health Economic Evaluation of Primovist-enhanced Liver MRI		Completed	No Results Available	Colorectal Neoplasms|Neoplasm Metastasis	Procedure: Primovist MRI|Procedure: Extracellular contrast media (ECCM) MRI|Procedure: Contrast-enhanced CT	Primary variable is the proportion of patients in each of the three treatment groups for whom further imaging is required after initial imaging to come to a therapy decision.|Proportion of patients with intra-operatively modified surgical plans based on initial imaging with either Primovist-, ECCM-MRI or CE-CT	Bayer	All	18 Years and older   (Adult, Older Adult)	Phase 4	360	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	91789|312041|2008-000583-16	October 2008	September 2010	November 2010	October 2, 2008		November 4, 2014	Graz, Austria|Wien, Austria|Wien, Austria|Karlsruhe, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|München, Bayern, Germany|Frankfurt, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Dortmund, Nordrhein-Westfalen, Germany|Dortmund, Nordrhein-Westfalen, Germany|Magdeburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Berlin, Germany|Candiolo, Torino, Italy|Ancona, Italy|Bologna, Italy|Brescia, Italy|Chieti, Italy|Napoli, Italy|Seoul,, Korea, Korea, Republic of|Gyeunggi-do, South Korea, Korea, Republic of|Hwasun, Korea, Republic of|Jeonbuk, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Amsterdam, Netherlands|Leiden, Netherlands|Utrecht, Netherlands|Santa Cruz de Tenerife, Canarias, Spain|Barcelona, Spain|Sevilla, Spain|Stockholm, Sweden|Stockholm, Sweden|Uppsala, Sweden|Basel, Basel-Stadt, Switzerland|St. Gallen, Sankt Gallen, Switzerland|Bern, Switzerland|Genève, Switzerland|Luzern, Switzerland|Bangkok, Thailand|Songkhla, Thailand		https://ClinicalTrials.gov/show/NCT00764621
156	NCT01739764	An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol		Active, not recruiting	No Results Available	Neoplasms	Drug: Vemurafenib	Percentage of Participants With Continued Access to Vemurafenib|Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	450	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GO28399|2012-003144-80	February 19, 2013	December 31, 2019	June 24, 2020	December 3, 2012		June 10, 2019	Highlands Oncology Group, Rogers, Arkansas, United States|UCLA Department of Medicine, Los Angeles, California, United States|Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States|University of Chicago Medical Center; Medicine, Section of Pulmonary, Chicago, Illinois, United States|Siouxland Regional Cancer Center d/b/a June E. Nylen Cancer Center, Sioux City, Iowa, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|The University of Kansas Cancer Center, Kansas City, Missouri, United States|New York University Medical Center PRIME, New York, New York, United States|Evelyn H. Lauder Center, New York, New York, United States|University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States|Mary Crowley Medical Research Center; Oncology, Dallas, Texas, United States|M D Anderson Physician Network, Webster, Texas, United States|University of Washington Seattle Cancer Care Alliance, Seattle, Washington, United States|Peninsula and South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia|N.N. Alexandrov National Cancer Centre of Belarus, Minsk District, Belarus|Vitebsk Regional Clinical Oncology Dispensary, Vitebsk, Belarus|Institut Jules Bordet, Brussels, Belgium|University Clinical Center of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina|University Clinic Centre Sarajevo, Sarajevo, Bosnia and Herzegovina|Hospital de Clínicas de Porto Alegre; Laboratorio de Dor e Neuromodulação, Porto Alegre, RS, Brazil|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia|Clinical Hospital Centre Zagreb, Zagreb, Croatia|Bank of Cyprus Oncology Center, Nicosia, Cyprus|Medical Research Institute, Alexandria, Egypt|National Cancer Institute, Cairo, Egypt|Mansoura University Hospital, Dakahlia, Egypt|Gharbia Cancer Society, Tanta, Egypt|Centre Léon Bérard, Lyon, France|Institut Gustave Roussy, Villejuif, France|Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz; Apotheke, Mainz, Germany|Universitätsklinikum Wurzburg, Würzburg, Germany|University General Hospital of Heraklion, Crete, Greece|Semmelweis Egyetem, Budapest, Hungary|Orszagos Onkologiai Intezet, Budapest, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont; Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Budapest, Hungary|Debreceni Egyetem Klinikai Központ; Bőrgyógyászati Klinika, Debrecen, Hungary|Pecsi Tudomanyegyetem, Pecs, Hungary|Rambam Health Care Campus, Haifa, Israel|Hadassah University Hospital - Ein Kerem, Jerusalem, Israel|Chaim Sheba Medical Center; Allergy and Clinical Immunology Unit, Ramat Gan, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel|Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda), Milano, Lombardia, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Toscana, Italy|A.O.U. Senese Policlinico Santa Maria Alle Scotte, Siena, Toscana, Italy|Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center - Oncology, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Maastricht University Medical Center, Maastricht, Netherlands|Auckland City Hospital, Auckland, New Zealand|Christchurch Clinical Studies Trust, Christchurch, New Zealand|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|IPO de Lisboa; Servico de Oncologia Medica, Lisboa, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|Medisprof SRL, Cluj-Napoca, Romania|FSBSI "Russian Oncological Scientific Center n.a. N.N. Blokhin"; Chemotherapy Departement, Moskva, Moskovskaja Oblast, Russian Federation|Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic, Kazan, Russian Federation|SBIH " Clinical Oncological Dispensary # 1"; Chemotherapy department #1 and #2, Krasnodar, Russian Federation|Moscow city oncology hospital #62 of Moscow Healthcare Department, Moscow, Russian Federation|St. Petersburg SHI "City Clinical Oncology Dispensary", Saint-Petersburg, Russian Federation|SBIH Republican Clinical Oncological Dispensary of the MoH of Republic Bashkortostan, Ufa, Russian Federation|Institute for Oncology and Radiology of Serbia; Medical Oncology, Belgrade, Serbia|Clinical Center Bezanijska Kosa, Belgrade, Serbia|Cape Town Oncology Trials, Cape Town, South Africa|Wits Donald Gordon Clinical Trial Centre; Medical Oncology, Parktown, Johannesburg, South Africa|Cancercare Langenhoven Drive Oncology Centre, Port Elizabeth, South Africa|Hospital Universitario Marques de Valdecilla; Servicio de Oncologia, Santander, Cantabria, Spain|Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, LA Coruña, Spain|Hospital Regional Universitario de Malaga; Oncologia, Málaga, Malaga, Spain|Hospital General Universitario Santa Lucia, Cartagena (Murcia), Murcia, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Royal Marsden Hospital, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT01739764
157	NCT00434447	Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases		Completed	No Results Available	Bone Neoplasms	Drug: Zoledronic acid	Safety assessed by incidence of renal impairment, osteonecrosis of the Jaw (ONJ), adverse events and serious adverse events. Efficacy assessed by incidence of skeletal related events (SREs).	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	73	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	CZOL446EAU22	December 2006	September 2009		February 13, 2007		February 27, 2017	Novartis Investigative Site, Canberra, Australian Capital Territory, Australia|Novartis Investigative Site, Concord, New South Wales, Australia|Novartis Investigative Site, Liverpool, New South Wales, Australia|Novartis Investigative Site, Wagga Wagga, New South Wales, Australia|Novartis Investigative Site, Redcliffe, Queensland, Australia|Novartis Investigative Site, Townsville, Queensland, Australia|Novartis Investigative Site, Woolloongabba, Queensland, Australia|Novartis Investigative Site, Ballarat, Victoria, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, Frankston, Victoria, Australia		https://ClinicalTrials.gov/show/NCT00434447
158	NCT01588184	An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study		Active, not recruiting	No Results Available	Neoplasms	Drug: Bevacizumab	Percentage of Participants With Adverse Events	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	93	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MO25757|2011-002009-31	July 19, 2012	September 14, 2019	September 14, 2019	April 30, 2012		July 26, 2019	A.Ö. LKH; Abt. für Lungenkrankheiten, Steyr, Austria|Hospital Araujo Jorge; Departamento de Ginecologia E Mama, Goiania, GO, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Hospital de Cancer de Barretos, Barretos, SP, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|Hospital A. C. Camargo; Oncologia, Sao Paulo, SP, Brazil|Hospital Sao Jose, São Paulo, SP, Brazil|MBAL Serdika EOOD, Sofia, Bulgaria|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|North Estonia Medical Centre Foundation; Oncology Center, Tallinn, Estonia|HOPITAL JEAN MINJOZ; Oncologie, Besancon, France|Centre Leonard De Vinci;Chimiotherapie, Dechy, France|Centre Georges François Leclerc; Service Pharmacie, Bp 77980, Dijon, France|Hopital Roger Salengro; Service de Neurologie, Lille, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, France|Centre Paul Strauss; Oncologie Medicale, Strasbourg, France|Hopital Larrey; Pneumologie, Toulouse, France|Klinikum Joh.Wolfg.Goethe-UNI Senckenbergisches Institut für Neuroonkologie, Frankfurt am Main, Germany|LungenClinic Großhansdorf, Großhansdorf, Germany|Orszagos Onkologiai Intezet; Nogyogyaszati Osztaly, Budapest, Hungary|A.O. Universitaria Federico II Di Napoli; Oncologia Ed Endocrinologia Clinica, Napoli, Campania, Italy|Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica, Bologna, Emilia-Romagna, Italy|Azienda Ospedaliera San Camillo Forlanini; U.O.C. Pneumologia Ad Indirizzo Oncologico 1, Roma, Lazio, Italy|Fondazione IRCCS Istituto Neurologico C. Besta; Neuro-oncologia Sperimentale e Terapia Genica, Milano, Lombardia, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica, Milano, Lombardia, Italy|ASST DI MONZA; Oncologia Medica, Monza, Lombardia, Italy|ASST LARIANA; Oncologia, S. Fermo Della Battaglia (CO), Lombardia, Italy|Azienda Ospedaliera Le Molintte di Torino; Dipartimento Di Neurologia - Oncologia, Torino, Piemonte, Italy|Ospedale Antonio Perrino; Oncologia Medica, Brindisi, Puglia, Italy|Centro Catanese Di Oncologia; Oncologia Medica, Catania, Sicilia, Italy|Ospedale Nuovo Della Versilia; Divisione Di Oncologia Medica, Lido Di Camaiore, Toscana, Italy|A.O. Universitaria Pisana-Ospedale Cisanello; Dipartimento Cardio Toracico-Pneumologia Ii, Pisa, Toscana, Italy|Ospedale Misericordia E Dolce; Oncologia Medica, Prato, Toscana, Italy|National Cancer Center; Medical Oncology, Gyeonggi-do, Korea, Republic of|Severance Hospital; Internal Medicine, Seoul, Korea, Republic of|Asan Medical Center, Uni Ulsan Collegemedicine; Dept.Internal Medicine / Divisionhematology/Oncology, Seoul, Korea, Republic of|Instituto Nacional de Cancerologia; Oncology, Distrito Federal, Mexico|Fundación Rodolfo Padilla Padilla, A.C.; Oncology, Leon, Mexico|Oaxaca Site Management Organization, Oaxaca, Mexico|Leyenburg Hospital; Pulmonology, Den Haag, Netherlands|Radboud Ziekenhuis; Urologie, 659, Nijmegen, Netherlands|Prof. Dr. I. Chiricuta Institute of Oncology, Cluj Napoca, Romania|Euroclinic Center of Oncology SRL, Iasi, Romania|Altai Region Oncology Dispensory; Oncology, Barnaul, Russian Federation|Regional Oncology Hospital; Oncology, Irkutsk, Russian Federation|Blokhin Cancer Research Center; Combined Treatment, Moscow, Russian Federation|Russian Research Center of Roentgenoradiology; Dept of Chemotherapy, Moscow, Russian Federation|P.A. Gertsen Cancer Research Inst. ; Chemotherapy Dept, Moscow, Russian Federation|City Clinical Oncology Hospital, Moscow, Russian Federation|Medical Radiological Scientific Center; Department of Radiotherapy of Gynaecological Disease, Obninsk, Kaluzhskaya Region, Russian Federation|Bashkirian Republican Clinical Oncology Dispensary, UFA, Russian Federation|Vychodoslovensky onkologicky ustav, Košice, Slovakia|Wits Donald Gordon Clinical Trial Centre; Medical Oncology, Parktown, Johannesburg, South Africa|Hospital de Basurto; Servicio de Oncologia, Bilbao, Vizcaya, Spain|Hospital de Cruces; Servicio de Oncologia, Bilbao, Vizcaya, Spain|Complejo Asistencial Universitario De Burgos; Servicio de Oncologia, Burgos, Spain|Hospital Reina Sofia; Medical Oncology, Cordoba, Spain|Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia, Jaen, Spain|Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología, La Coruña, Spain|Hospital Gregorio Marañon, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Malaga, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Mälarsjukhuset, Eskilstuna, Kvinnokliniken, Eskilstuna, Sweden|Norrlands universitetssjukhus; Onkologkliniken, Umeå, Sweden|Universitetssjukhuset Örebro, Onkologiska kliniken, Örebro, Sweden|Adana City Hospital, Medical Oncology, Adana, Turkey|Addenbrooke'S Hospital; Dept of Neurosurgery, Cambridge, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom|North Wales Cancer Treatment Centre, Glan Clwyd Hospital, Rhyl, United Kingdom		https://ClinicalTrials.gov/show/NCT01588184
159	NCT00681187	Somatuline Autogel Preference and Health Economy Study	SAPHE	Completed	Has Results	Neuroendocrine Tumour With Carcinoid Symptoms	Drug: lanreotide (Autogel formulation)	Subject Preference for Self or Partner Administration|Number of Patients Stating at Least One Injection Interfered With Daily Activities|Number of Patients Stating at Least One Injection Negatively Interfered With Psychological Wellbeing|Days Sick Leave|Total Number of Visits to HCP Due to Carcinoid Symptoms|Perceived Symptom Control Evaluation in Respect to Episodes of Flushing|Perceived Symptom Control Evaluation in Respect to Episodes of Diarrhoea|Chromogranin A Levels|5-hydroxyindoleacetic Acid (5-HIAA) Levels|Healthcare Professionals With Positive Response to Specified Questions on Self or Partner Administration Method	Ipsen	All	18 Years and older   (Adult, Older Adult)	Phase 4	26	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	A-99-52030-216	June 2008	August 2010	August 2010	May 21, 2008	March 13, 2012	January 30, 2019	Aarhus University Hospital / Medisinsk afd. V, Aarhus, Denmark|Odense Univeristy Hospital / S-AMB, Odense, Denmark|Haukeland University Hospital / Kreftafd, Bergen, Norway|University Hospital North-Norway / GastroLab, Tromsø, Norway|S:t Olavs Hospital / Medisinsk Afd, Trondheim, Norway|Sahlgrenska University Hospital / Kirurgkliniken, Gothenburg, Sweden|Linköping University Hospital / Onkologen, Linköping, Sweden|Karolinska University Hospital, Huddinge / GastroCentrum Medicin, Stockholm, Sweden|Karolinska University Hospital, Solna / Kirurgmottagningen, Stockholm, Sweden|Akademiska Hospital/ Kliniken f onkologisk endokrinologi, Uppsala, Sweden		https://ClinicalTrials.gov/show/NCT00681187
160	NCT00234195	Wellbutrin XL, Major Depressive Disorder and Breast Cancer		Completed	No Results Available	Breast Cancer|Major Depressive Disorder	Drug: bupropion extended release (Wellbutrin XL)	To evaluate the efficacy of bupropion extended release (Wellbutrin XL™) in the treatment of Major Depressive Disorder in women with breast cancer.|To evaluate the tolerability of bupropion extended-release (Wellbutrin XL™) in these patients|To evaluate the effect of bupropion extended-release (Wellbutrin XL™) on fatigue, sexual functioning, and pain in these patients.	Thomas Jefferson University|GlaxoSmithKline	Female	18 Years and older   (Adult, Older Adult)	Phase 4	25	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Prot105042|29000-J08101	September 2005		January 2007	October 6, 2005		April 17, 2007	Thomas Jefferson University, Department of Psychiatry, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT00234195
161	NCT00942968	Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer		Completed	Has Results	Cancer	Drug: dalteparin	Number of Participants With Major Bleeding Events Adjudicated by Central Adjudication Committee|Number of Participants With New or Recurrent Venous Thromboembolism (VTE) Adjudicated by Central Adjudication Committee|Number of Participants With Investigator Identified Major Bleeding Events|Number of Participants With Any Bleeding Event (Major or Minor) Adjudicated by Central Adjudication Committee|Number of Participants With Fatal Bleeding Events|Time to First Occurrence of Major Bleeding Event Adjudicated by Central Adjudication Committee|Time to First Occurrence of Any Bleeding Event (Major or Minor) Adjudicated by Central Adjudication Committee|Number of Participants With Investigator Identified New or Recurrent Venous Thromboembolism (VTEs)|Number of Participants With New or Recurrent Venous Thromboembolism (VTE) or Central Venous Thrombosis (CVT) Adjudicated by Central Adjudication Committee|Number of Participants With Investigator Identified New or Recurrent Venous Thromboembolism (VTE) or Central Venous Thrombosis (CVT)|Time to First Occurrence of New or Recurrent Venous Thromboembolism (VTE) Adjudicated by Central Adjudication Committee|Time to First Occurrence of New or Recurrent VTE or CVT Adjudicated by Central Adjudication Committee	Pfizer	All	18 Years and older   (Adult, Older Adult)	Phase 4	338	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	FRAG-A001-401|A6301095	June 2009	March 2012	June 2013	July 21, 2009	February 24, 2017	February 24, 2017	Arizona Cancer Center, Tuscon, Arizona, United States|Bay Area Cancer Research Group, Pleasant Hill, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|University of CT Health Center, Farmington, Connecticut, United States|Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States|Georgetown University Hospital-Lombardi Cancer Ctr, Washington, District of Columbia, United States|Halifax Health, Daytona Beach, Florida, United States|Atlanta Institute for Medical Research, Decatur, Georgia, United States|Orchard Healthcare Research Inc., Skokie, Illinois, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|Bringham and Women's Hospital, Boston, Massachusetts, United States|Henry Ford Hospital K-15, Detroit, Michigan, United States|University of Rochester Medical Center, Rochester, New York, United States|Stony Brook University, Medical Center, Stony Brook, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|MidDakota Clinic, Bismarck, North Dakota, United States|Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Vermont Cancer Center at Fletcher Allen Health Care, Burlington, Vermont, United States|University of Virginia, Charlottesville, Virginia, United States|LKH Graz Univrsitatstklinik fur Innere Medizin, Graz, Austria|Medizinische Universitat Innsbruck Studienambulanz Hamatologie, Innsbruck, Austria|KH d. Elizabethinen Linz GmbH Servicestelle fur klin. Studien und Universitare Angelegenheiten, Linz, Austria|KH der Barmherzigen Schwestern, Linz, Austria|Dialysestation Landesklinkum St.Poelten, St. Poelten, Austria|Medizinische Universitat Wien, Vienna, Austria|University of Alberta, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|London Health Sciences Centre, London, Ontario, Canada|Ottawa Health Research Institute, Ottawa, Ontario, Canada|University Health Network-Toronto General Hospital, Toronto, Ontario, Canada|Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada|Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada|Gelre Ziekenhuizen-Locatie Apeldoorn, Apeldoorn, Netherlands|Orbis Medisch Centrum, Sittard-Geleen, Sittard-Geleen, Netherlands|Hospital clinic i Provincial de Agencia de Ensayos Clinicos, Barcelona, Spain|Hospital General Santa Maria del Rosell, Caragena (Murcia), Spain|Hospital Virgen de la Arrixaca, El Palmar (Murcia), Spain|Hospital Universitari Dr Josep Trueta, Girona, Spain|Clinica Universitaria de Navarra, Pamplona, Spain		https://ClinicalTrials.gov/show/NCT00942968
162	NCT00510354	Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate	Radix	Completed	No Results Available	Progressive Gastrointestinal Stromal Tumor	Drug: Imatinib mesylate	Tumor assessments should be performed by a CT or MRI scan after 4 months. Response to treatment with RAD001 plus Imatinib mesylate at 4 months (defined as progression-free survival (PFS) at 4 months).|Tolerability and safety assessed by AEs and SAEs. Objective tumor response rate (complete response [CR] and partial response [PR]) assessed by CT or MRI PFS at month 12 for patients with data available from follow up observation (optional)	Novartis Pharmaceuticals|Novartis	All	30 Years to 80 Years   (Adult, Older Adult)	Phase 4	28	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CRAD001C2454|2005-004837-16	October 2006	November 2012	November 2012	August 2, 2007		November 18, 2016	Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Frankfurt/M, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Mannheim, Germany|Novartis Investigative Site, Tübingen, Germany		https://ClinicalTrials.gov/show/NCT00510354
163	NCT03752216	NIraparib and Quality Of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.	NiQoLe	Recruiting	No Results Available	Ovarian Cancer	Drug: Niraparib	Toxicities inducing dose modifications of Niraparib between the start to the cycle 3 (interruption, discontinuation and dose reduction).|Self-reported fatigue by patient by FACT-F questionnaire (Functional Assessment of Cancer Therapy General - Fatigue)|Self-reported symptoms and side effects with the NCI PRO-CTCAE|Reasons of the dose modification of Niraparib|General health-related quality of life by FACT-G questionnaire (Functional Assessment of Cancer Therapy General)|Pain related to the treatment by Visual Analogic Scale (VAS)|Side effects of interest (HTA, anemia, thrombocytopenia)|Duration of Niraparib treatment|Time to first subsequent line of anti-cancer therapy|Overall response rate|Initial cognitive functions by FACT-cog (Functional Assessment of Cancer Therapy - Cognitive Function) questionnaire|Plasma level of Niraparib before Niraparib administration|Geriatric Depression Scale (score range from 0 [better outcome] to 30 [worse outcome])	ARCAGY/ GINECO GROUP|Tesaro, Inc.	Female	18 Years and older   (Adult, Older Adult)	Phase 4	141	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GINECO-OV239B|2018-002274-44	April 3, 2019	August 2020	November 2021	November 22, 2018		August 15, 2019	Institut Sainte-Catherine, Avignon, France|CHRU Jean Minjoz, Besançon, France|Clinique Tivoli, Bordeaux, France|Institut Bergonié, Bordeaux, France|Hôpital Fleyriat, Bourg-en-bresse, France|Centre François Baclesse, Caen, France|Medipole de Savoie, Challes-les-Eaux, France|ROC 37 Société de Recherche Oncologique Clinique 37, Chambray-lès-Tours, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Groupe Hospitalier Mutualiste de Grenoble - Institut Daniel Hollard, Grenoble, France|Centre Léon Bérard, Lyon, France|Hôpital Privé Jean Mermoz, Lyon, France|CH Mont-de-Marsan, Mont-de-marsan, France|ICM Val d'Aurelle, Montpellier, France|ORACLE - Centre d'Oncologie de Gentilly, Nancy, France|Centre Antoine Lacassagne, Nice, France|Centre ONCOGARD - Institut de Cancérologie du Gard, Nimes, France|Hôpital Cochin, Paris, France|Groupe Hospitalier Diaconesses-Croix Saint Simon, Paris, France|Centre CARIO - HPCA, Plérin, France|Centre Hospitalier Universitaire de Poitiers, Poitiers, France|Polyclinique Francheville, Périgueux, France|Institut Jean Godinot, Reims, France|Centre Hospitalier Saint-Malo, Saint-Malo, France|Clinique Mutualiste de l'Estuaire, Saint-nazaire, France|Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France|Hôpitaux Universitaires de Strasbourg, Strasbourg, France|Clinique Pasteur - ONCOSUD, Toulouse, France		https://ClinicalTrials.gov/show/NCT03752216
164	NCT00115206	Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy		Completed	No Results Available	Non-Small Cell Lung Cancer	Drug: Neulasta® (pegfilgrastim)	Quality of Life|Quality of Life, *Neutropenia, *Hospitalization, *Disease Response	Amgen	All	18 Years and older   (Adult, Older Adult)	Phase 4		Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20020121	July 2002		July 2004	June 22, 2005		April 6, 2009			https://ClinicalTrials.gov/show/NCT00115206
165	NCT01432015	Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting		Completed	Has Results	Ovarian Cancer|Uterine Cancer	Drug: fosaprepitant|Drug: aprepitant|Other: Oral Placebo|Other: IV placebo	Overall Complete Response Rate|Impact on Daily Living Activities	Gynecologic Oncology Associates|Merck Sharp & Dohme Corp.	Female	18 Years and older   (Adult, Older Adult)	Phase 4	20	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	GOA-NVM1	September 2011	March 2015	March 2015	September 12, 2011	May 27, 2015	March 28, 2017	Gynecologic Oncology Associates, Newport Beach, California, United States		https://ClinicalTrials.gov/show/NCT01432015
166	NCT02842749	Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China		Active, not recruiting	No Results Available	Pancreatic Neuroendocrine Tumors	Drug: everolimus	Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Overall Survival|Progression free survival	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	49	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CRAD001PCN31	March 14, 2016	December 2, 2024	December 2, 2024	July 25, 2016		May 24, 2019	Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Shanghai, Shanghai, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Guangzhou, China		https://ClinicalTrials.gov/show/NCT02842749
167	NCT00029523	DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor		Completed	No Results Available	Meningeal Neoplasms	Drug: Intrathecal (injected into the spinal fluid) DepoCyt|Drug: Intrathecal methotrexate|Drug: Intrathecal cytarabine (also known as ara-C)	Progression-free survival, defined as the time to neurological progression or death|Time to neurological progression;|Survival (all-cause and meningeal disease-specific)|Frequency of improvement in pre-existing meningeal-disease related neurological deficits|Karnofsky Performance Scores (KPS)|Quality of life|Cytological response rate|Overall safety profile	Pacira Pharmaceuticals, Inc	All	18 Years and older   (Adult, Older Adult)	Phase 4	100	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SKY0101-010	April 2001		November 2004	January 16, 2002		February 28, 2007	Barrow Neurological Institute, Phoenix, Arizona, United States|Alta Bates Comprehensive Cancer Center, Berkeley, California, United States|University of Southern California, Norris Cancer Center, Los Angeles, California, United States|University of Colorado Hospital, Anschutz Cancer Pavilion, Denver, Colorado, United States|Georgetown University Medical Center Hematology/Oncology, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory Clinic, Department of Neurosurgery, Atlanta, Georgia, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|Rush Cancer Institute, Chicago, Illinois, United States|Loyola University Medical Center, Dept. of Hematology/Oncology, Maywood, Illinois, United States|Beth Israel Deaconess Medical Center Dept. of Neurology, Boston, Massachusetts, United States|Park Nicollet Institute, Oncology Research Program, Minneapolis, Minnesota, United States|JFK Neuroscience Institute, Edison, New Jersey, United States|Bowman Gray School of Medicine/Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States|Case Western Reserve University Hospital of Cleveland, Cleveland, Ohio, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Health Science Center, San Antonio, Texas, United States|University of Utah, Hunsman Cancer Institute, Salt lake City, Utah, United States|Virginia Mason Medical Center, Seattle, Washington, United States|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT00029523
168	NCT02034799	Phase IV Bioseal Study in Brain Tumor Surgery		Completed	Has Results	Hemostasis|Meningioma Surgery	Biological: Bioseal Fibrin Sealant|Other: Standard of Care (SoC)	Hemostasis at the Target Bleeding Site (TBS) at 6 Minutes Following Treatment Application. Hemostasis is Defined as no Detectable Bleeding at the TBS.|Hemostasis at the TBS at 3 Minutes Following Treatment Application|Incidence of Neurosurgical Complications, Central Nervous System Events and Surgical Wound Complications.|Incidence of Potential Bleeding-related Adverse Events	Ethicon, Inc.|Guangzhou Bioseal Biotechnology Co., Ltd.	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	256	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	BIOS-13-002	November 1, 2013	August 1, 2014	September 1, 2014	January 14, 2014	February 26, 2018	February 26, 2018	Clinical Investigation Site #6, Zhengzhou, Henan, China|Clinical Investigation Site #5, Changsha, Hunan, China|Clinical Investigation Site #3, Chengdu, Sichuan, China|Clinical Investigation Site #4, Hangzhou, Zhejiang, China|Clinical Investigation Site #7, Beijing, China|Clinical Investigation Site #2, Shanghai, China|Clinical Investigation Site #1, Tianjin, China		https://ClinicalTrials.gov/show/NCT02034799
169	NCT00966277	Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients		Completed	Has Results	Pancreatic Cancer|Venous Thromboembolism	Drug: Dalteparin	Number of Participants With Venous Thromboembolic Events (VTE)	M.D. Anderson Cancer Center|Eisai Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 4	87	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2008-0487|NCI-2011-01773	April 2010	September 2014	September 2014	August 26, 2009	December 12, 2016	December 12, 2016	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00966277
170	NCT01066884	A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer		Completed	No Results Available	Non-Squamous Non-Small Cell Lung Cancer	Drug: erlotinib [Tarceva]	Incidence of adverse events (AEs)|Best Response Rate per investigator assessment|Time to Progression (TTP)|Overall survival	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	5	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML20569	April 2009	November 2009	November 2009	February 10, 2010		August 24, 2016	Balashikha, Russian Federation|Krasnoyarsk, Russian Federation		https://ClinicalTrials.gov/show/NCT01066884
171	NCT01107756	A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen	Grano-Tax	Completed	No Results Available	Neoplasms (no Otherwise Specified)	Drug: LENOGRASTIM (GRANOGYTE 34)	Incidence and severity of neutropenia assessed by using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.|Incidence and severity of febrile neutropenia assessed by using the Common Terminology Criteria for Adverse Events (CTCAE) version 4|Incidence and severity of anaemia assessed by using the Common Terminology Criteria for Adverse Events (CTCAE) version 4|Incidence and severity of asthenia assessed by using the Common Terminology Criteria for Adverse Events (CTCAE) version 4|Incidence and severity of anorexia assessed by using the Common Terminology Criteria for Adverse Events (CTCAE) version 4|Incidence and severity of myalgia assessed by using the Common Terminology Criteria for Adverse Events (CTCAE) version 4|Incidence and severity of nails changes, including nail disorders assessed by using the Common Terminology Criteria for Adverse Events (CTCAE) version 4|Incidence and severity of oral mucositis assessed by using the Common Terminology Criteria for Adverse Events (CTCAE) version 4|Neutropenia/febrile neutropenia associated days in hospital|Neutropenia/febrile neutropenia associated use of anti-infectives|Incidence of chemotherapy dose reduction, withdrawals or treatment delays due to neutropenia or febrile neutropenia|Infection with (or without) neutropenia|Relationship between the incidence and severity of neutropenia and the different chemotherapy regimens	Sanofi	All	21 Years to 75 Years   (Adult, Older Adult)	Phase 4	403	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DOCET_L_04775|U1111-1116-9574	March 2010	July 2012	July 2012	April 21, 2010		October 5, 2012	Investigational Site Number 53, Alberton, South Africa|Investigational Site Number 012, Amanzimtoti, South Africa|Investigational Site Number 55, Benoni, South Africa|Investigational Site Number 11, Bloemfontein, South Africa|Investigational Site Number 21, Cape Town, South Africa|Investigational Site Number 27, Cape Town, South Africa|Investigational Site Number 26, Cape Town, South Africa|Investigational Site Number 22, Cape Town, South Africa|Investigational Site Number 13, Durban, South Africa|Investigational Site Number 14, Durban, South Africa|Investigational Site Number 32, East London, South Africa|Investigational Site Number 24, George, South Africa|Investigational Site Number 51, Johannesburg, South Africa|Investigational Site Number 12387, Johannesburg, South Africa|Investigational Site Number 47, Klerksdorp, South Africa|Investigational Site Number 43, Nelspruit, South Africa|Investigational Site Number 44, Polokwane, South Africa|Investigational Site Number 31, Port Elizabeth, South Africa|Investigational Site Number 42, Pretoria, South Africa|Investigational Site Number 41, Pretoria, South Africa|Investigational Site Number 451, Pretoria, South Africa|Investigational Site Number 48, Rustenburg, South Africa|Investigational Site Number 54, Sandton, South Africa|Investigational Site Number 25, Somerset West, South Africa|Investigational Site Number 56, Vereeniging, South Africa		https://ClinicalTrials.gov/show/NCT01107756
172	NCT01041612	Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi		Completed	No Results Available	Cancer of Bile Duct|Pancreatic Cancer	Device: PTFE Covered ComVi [full covered] Biliary Stent	Obstruction of 1st C-SEMS or presence of jaundice at death without stent exchange|Death of patients	Taewoong Medical Co., Ltd.	All	18 Years and older   (Adult, Older Adult)	Phase 4	120	Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care	RaMM-BO 2.0	January 2010	September 2012	September 2012	January 1, 2010		October 21, 2016	Gifu University, Gifu, Japan|Onomichi General Hospital, Onomichi, Japan|Teine-Keijinkai Hospital, Sapporo, Japan|The University of Tokyo, Tokyo, Japan|Toho University, Tokyo, Japan|Tokyo Medical University, Tokyo, Japan|Yamaguchi University, Ube, Japan|Soon Chun Hyang University School of Medicine, Bucheon, Korea, Republic of|Soon Chun Hyang University School of Medicine, Cheonan, Korea, Republic of|Catholic University of Daegu School of Medicine, Daegu, Korea, Republic of|Inha University School of Medicine, Incheon, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Ajou University School of Medicine, Suwon, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01041612
173	NCT03432949	Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC	TRANCE	Recruiting	No Results Available	Metastatic Prostate Cancer	Drug: Dexamethasone plus Radium-223	Percentage of total doses delivered on schedule	University Health Network, Toronto|Bayer	Male	Child, Adult, Older Adult	Phase 4	24	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-5196	February 23, 2018	February 15, 2020	February 15, 2021	February 14, 2018		December 21, 2018	University Health Network, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT03432949
174	NCT01000740	A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa		Completed	No Results Available	Non-small Cell Lung Cancer	Genetic: EGFR Mutation Test|Genetic: Ki-67 protein expression	Describe the quality of life of long-term survivors who are not terminated from the EAP|To describe the current tumour control status via RECIST|To collect the risk factors related to prognosis in addition to the information already collected from EAP (age, gender, histology, smoking history, previous history of anti-cancer treatment, disease stage before starting gefitinib treatment, etc.)|To describe the treatment compliance of gefitinib in these patients|To describe the current clinical status of long-term survivors in the EAP program by clinical|To compare the key clinical features (age group, gender, histology, smoking history, disease stage, treatment-naive or pre-treated, response to prior chemotherapy,) in fast-progressors versus long-term survivals.	AstraZeneca	All	Child, Adult, Older Adult	Phase 4	59	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1839IL/0052 SubStudy	August 2009	April 2010	April 2010	October 23, 2009		May 21, 2010	Research Site, Beijing, Beijing, China|Research Site, Guangzhou, Guangdong, China|Research Site, Wuhan, Hubei, China|Research Site, Nanjing, Jiangsu, China|Research Site, Suzhou, Jiangsu, China|Research Site, Jinan, Shandong, China|Research Site, Shanghai, Shanghai, China|Research Site, Chengdu, Sichuan, China|Research Site, Hangzhou, Zhejiang, China		https://ClinicalTrials.gov/show/NCT01000740
175	NCT01083199	Global Performance Evaluation of the AMS CONTINUUM™ Device		Completed	Has Results	Prostate Cancer	Device: CONTINUUM™	Successful Device Placement|Functionally Adequate Vesico-urethral Anastomosis Within 21 Days Post-procedure in Subjects With Successful Device Placement|Intraoperative/Postoperative Parameters|Percentage of Subjects Demonstrating Functionally Adequate Anastomosis at the 1st and 2nd Device Removal Visits|Incontinence Rate and I-QOL Score|Bladder Neck Contracture (BNC) Rate	American Medical Systems	Male	40 Years and older   (Adult, Older Adult)	Phase 4	10	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PE0702	October 2007	November 2010	November 2010	March 9, 2010	April 12, 2016	April 12, 2016	University of Patras, Rio-Patras, Greece|Hospital University Gregorio Maranon, Madrid, Spain		https://ClinicalTrials.gov/show/NCT01083199
176	NCT00651911	Fasturtec TLS Treatment / Prophylysis		Completed	No Results Available	Tumor Lysis Syndrome	Drug: urate oxidase	To assess the uricolytic response to rasburicase treatment|To evaluate tumor lysis risk factors, treatments for tumor lysis syndrome and complications of treatment in patients treated prophylactically or therapeutically for tumor lysis syndrome	Sanofi	All	18 Years and older   (Adult, Older Adult)	Phase 4	45	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	L_8637	July 2003		July 2004	April 3, 2008		April 3, 2008	Sanofi-Aventis, Bridgewater, New Jersey, United States		https://ClinicalTrials.gov/show/NCT00651911
177	NCT00216541	A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy		Completed	No Results Available	Anemia|Neoplasms	Drug: epoetin alfa	Change in hemoglobin from the start of the study to 3 or 4, 8 or 9, and 12 weeks, and at the end of the treatment period|Number of patients who receive an allogenic blood transfusion during the study	Janssen-Cilag B.V.	All	18 Years and older   (Adult, Older Adult)	Phase 4	110	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CR003541	August 2003		September 2006	September 22, 2005		May 19, 2011			https://ClinicalTrials.gov/show/NCT00216541
178	NCT00762346	Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis		Completed	No Results Available	Non Small Cell Lung Cancer|Bone Metastases|High NTX Level	Drug: zometa	Skeleton-related event|OS	Sun Yat-sen University|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	156	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CZOL446ECN06T	September 2008	March 2013	March 2013	September 30, 2008		December 10, 2013	cancer center, Sun Yat-sen University, Guangzhou, Guangdong, China		https://ClinicalTrials.gov/show/NCT00762346
179	NCT02151149	Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly	ABOUND 70+	Completed	Has Results	Non-Small Cell Lung Cancer|Carcinoma|Squamous Cell Carcinoma|Adenocarcinoma|Carcinoma, Large Cell|Lung Neoplasm	Drug: nab-paclitaxel|Drug: Carboplatin	Percentage of Participants With Either Peripheral Neuropathy ≥ Grade 2 or Myelosuppression Adverse Events (AEs) ≥ Grade 3 Based on Local Laboratory Values|Number of Participants With Treatment Emergent Adverse Events During the Treatment Period|Percentage of Participants With at Least 1 Treatment Emergent Adverse Event With Action Taken as Study Drug Withdrawn|Dose Intensity Per Week of Nab-Paclitaxel During the Entire Study|Dose Intensity Per Week of Carboplatin During the Entire Study|Percentage of Participants With Dose Reductions During the Entire Study|Percentage of Participants With a Dose Delay During the Entire Study|Kaplan Meier Estimate of Progression-Free Survival (PFS)|Kaplan Meier Estimate of Overall Survival (OS)|Percentage of Participants Who Achieved a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to RECIST 1.1 Criteria	Celgene	All	70 Years and older   (Older Adult)	Phase 4	143	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ABI-007-NSCL-005	June 9, 2014	July 14, 2017	July 14, 2017	May 30, 2014	September 24, 2018	September 24, 2018	Arizona Clinical Research Center, Tucson, Arizona, United States|Genesis Cancer Center, Hot Springs, Arkansas, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Saint Jude Heritage Medical Center, Fullerton, California, United States|Global Cancer Research Institute (GCRI), Inc., Gilroy, California, United States|Ventura County Hematology-Oncology Specialists, Oxnard, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|University of California Los Angeles, Santa Monica, California, United States|Rocky Mountain Cancer Centers, LLP, Denver, Colorado, United States|St Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|Lynn Cancer Institute, Boca Raton, Florida, United States|Baptist Cancer Inst, Jacksonville, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Northshore University Healthsystem Research Institute, Evanston, Illinois, United States|Oncology Specialists, S.C., Niles, Illinois, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Western Kentucky Hematology and Oncology Group, Paducah, Kentucky, United States|West Jeffersion Medical Center, Marrero, Louisiana, United States|Ochsner Medical Institutions, New Orleans, Louisiana, United States|Medstar Health Research Institute, Baltimore, Maryland, United States|Reliant Medical Group, Worcester, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Center for Cancer and Hematologic Disease, Cherry Hill, New Jersey, United States|Regional Cancer Care Associates LLC, East Brunswick, New Jersey, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Carol G Simon Cancer Center, Morristown, New Jersey, United States|Somerset Hematology-Oncology Associates, Somerville, New Jersey, United States|Regional Cancer Care Associates LLC- Sparta division, Sparta, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Brookdale University Hospital and Medical Center, Brooklyn, New York, United States|Broome Oncology, LLC, Johnson City, New York, United States|Clinical Research Alliance, Lake Success, New York, United States|SUNY Upstate Medical University Medicine Oncology, Syracuse, New York, United States|Lineberger Cancer Center, Chapel Hill, North Carolina, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Forsyth Memorial Hospital, Inc., Winston-Salem, North Carolina, United States|St Elizabeth Hospital, Youngstown, Ohio, United States|Cancer Centres of Southwest Okahoma Research, Lawton, Oklahoma, United States|Good Samaritan Hospital Corvalis, Corvallis, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Medical College, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Texas Oncology, P.A.-Amarillo, Amarillo, Texas, United States|Baylor University Medical Center at Dallas, Dallas, Texas, United States|UTMB Galveston, Galveston, Texas, United States|Texas Oncology, PA - Longview, Longview, Texas, United States|Virginia Mason Cancer Center, Seattle, Washington, United States|Northwest Cancer Specialists, P.C., Vancouver, Washington, United States	"Statistical Analysis Plan: ABI-007-NSCL-005_SAP_AM!_Redacted.17March 2016", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02151149/SAP_000.pdf|"Study Protocol: ABI-007-NSCL-005_PA1_Redacted.09April2014", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02151149/Prot_001.pdf|"Statistical Analysis Plan: ABI-007-NSCL-005.OriginalSAP.Redacted24 June2016", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02151149/SAP_002.pdf|"Study Protocol: ABI-007-NSCL-005_PA2_Redacted.05 December 2014", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02151149/Prot_003.pdf|"Study Protocol: ABI-007-NSCL-005_PA3_Redacted.17 March 2016", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02151149/Prot_004.pdf|"Study Protocol: ABI-007-NSCL-005_Original_Redacted.06 March2014", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02151149/Prot_005.pdf	https://ClinicalTrials.gov/show/NCT02151149
180	NCT01006356	An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer		Completed	Has Results	Cancer|Pain	Drug: Hydromorphone HCl OROS	Percentage of Participants With Dosing Frequency of Analgesics for Treating Breakthrough Pain|Frequency of Experiencing Breakthrough Pain|Change From Baseline in Korean - Brief Pain Inventory (K-BPI) Score at Day 15|Pain Intensity Score|Global Assessment of Overall Efficacy of Study Drug by Investigator|Global Assessment of Overall Efficacy of Study Drug by Participant|Participant's Preferences Along With Reasons|Number of Participants With Clinical Global Impression - Improvement (CGI-I) Score|European Organisation for Research and Treatment of Cancer Quality of Life (EQRTC QLQ-C30) Score	Janssen Korea, Ltd., Korea	All	20 Years and older   (Adult, Older Adult)	Phase 4	141	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CR015694|42801PAI4006	October 2008	August 2009	August 2009	November 2, 2009	August 8, 2013	August 8, 2013			https://ClinicalTrials.gov/show/NCT01006356
181	NCT01199198	Tolvaptan in Hyponatremic Cancer Patients		Completed	No Results Available	Advanced Cancers	Drug: Tolvaptan|Drug: Placebo	Proportion of Patients whose Serum Sodium Concentration Corrected to at least 135 mEq/L on Day 14	M.D. Anderson Cancer Center|Otsuka Pharmaceutical Development & Commercialization, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 4	52	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	2009-0862	May 2011	September 2013	September 2013	September 10, 2010		January 9, 2015	UT MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT01199198
182	NCT00765687	Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates	BLEST	Completed	No Results Available	Non-small Cell Lung Cancer|Bone Metastases	Drug: bisphosphates	Skeleton-related event|overall survival	Sun Yat-sen University|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	432	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	CZOL446ECN07	August 2008	May 2012	May 2012	October 3, 2008		December 10, 2013	SunYat-senU, GuangZhou, Guangdong, China		https://ClinicalTrials.gov/show/NCT00765687
183	NCT01394991	A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia		Completed	Has Results	Anemia|Neoplasms	Drug: Epoetin alfa 450 IU/kg once a week|Drug: Epoetin alfa 150 IU/kg 3 times a week|Drug: Epoetin alfa 450 IU/kg once a week (QW)|Drug: Epoetin alfa 150 IU/kg 3 times a week (TIW)	Number of Participants With at Least 1 Clinically Relevant and Objectively Confirmed Thrombovascular Event From Randomization Through Week 16|Number of Positively Adjudicated Thrombovascular Events|Time to First Positively Adjudicated Thrombovascular Event|Number of Suspected Thrombovascular Events|Time to First Suspected Thrombovascular Event|Mortality|Number of Hemoglobin Responders|Red Blood Cell Transfusions	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	All	18 Years and older   (Adult, Older Adult)	Phase 4	504	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CR010543|EPOANE4008	January 2006	September 2009	September 2009	July 15, 2011	July 15, 2011	April 5, 2012			https://ClinicalTrials.gov/show/NCT01394991
184	NCT01774019	Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer		Recruiting	No Results Available	Pancreatic Carcinoma	Device: WallFlex™ Biliary RX Fully Covered/Uncovered Stent System	Number of serious pre-operative, operative and post-operative adverse events to 120 days post randomization or to 30 days post surgery, whichever comes last|Number of adverse events|Time to surgery|Curative Intent Surgery details pertaining to intraoperative assessment of resectability, surgical resection and reconstruction techniques.|Amount of intraoperative blood loss and number of blood transfusions, duration of surgery|Biliary obstructive symptoms assessment|Improvement of liver function test (LFT) levels as relative to baseline|Stent placement success|Stent removal success|Number, type, reason, and timing of biliary re-interventions|Number of hospital and ICU admissions|Duration of hospital and ICU admissions	Boston Scientific Corporation	All	18 Years and older   (Adult, Older Adult)	Phase 4	294	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	90914721|E7059	February 20, 2013	July 2020	January 2021	January 23, 2013		September 25, 2018	Standford University Medical Center, Stanford, California, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Westmead Hospital, Westmead, New South Wales, Australia|ULB Erasme Hospital, Brussels, Belgium|Centre hospitalier de l Université de Montréal, Montreal, Quebec, Canada|Hopital Edouard Herriot, Lyon, France|Queen Elizabeth Hospital, Kowloon, Hong Kong|Prince of Wales Hospital, the Chinese University of Hong Kong, Sha Tin, Hong Kong|Asian Institute of Gastroenterology, Hyderabad, India|Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy|Tokyo Medical University, Tokyo, Japan		https://ClinicalTrials.gov/show/NCT01774019
185	NCT03355157	A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).	PADMA	Recruiting	No Results Available	Metastatic Breast Cancer	Drug: Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)	Time-to-treatment failure (TTF)	German Breast Group|Pfizer|Advanced Medical Services	All	18 Years and older   (Adult, Older Adult)	Phase 4	260	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GBG 93|2016-004482-89	March 1, 2018	December 31, 2021	December 31, 2021	November 28, 2017		September 19, 2018	Agaplesion Markus Krankenhaus - Klinik für Gynäkologie und Geburtshilfe, Frankfurt am Main, Germany		https://ClinicalTrials.gov/show/NCT03355157
186	NCT02444572	Comparison of Thromboembolic Events in Patients Undergoing Thromboprophylactic Treatment With ENOXA® vs Lovenox®	ENOXACARE	Recruiting	No Results Available	Gastrointestinal Neoplasms|Thromboembolic Event	Drug: Enoxaparin 4000 IU	Incidence of asymptomatic Deep Venous Thrombosis (DVT)|Incidence of symptomatic thromboembolic events|Number of adverse events|Incidence of both Enoxaparin formulations immunogenicity	Les Laboratoires des Médicaments Stériles	All	19 Years to 90 Years   (Adult, Older Adult)	Phase 4	160	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	ENOXACARE_med14	October 2015	December 2019	December 2019	May 14, 2015		November 19, 2018	Charles Nicolle Hospital, Tunis, Tunis BAB Souika, Tunisia		https://ClinicalTrials.gov/show/NCT02444572
187	NCT00117039	A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia		Completed	No Results Available	Anemia|Neoplasms	Drug: Aranesp®	Hemoglobin maintenance|Quality of Life|Changes in measures of work productivity and anemia treatment convenience	Amgen	All	18 Years and older   (Adult, Older Adult)	Phase 4	1500	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20030206	January 2004		April 2005	July 4, 2005		October 15, 2008			https://ClinicalTrials.gov/show/NCT00117039
188	NCT00772681	Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma	Tax-Nazo	Completed	No Results Available	Head and Neck Neoplasms	Drug: docetaxel and cisplatin	Complete response rate after neoadjuvant chemotherapy|Percentage of patients whose is disease controlled locally or regionally|Median length of overall survival|Median length of disease free survival|Percentage of alive patients without metastatis	Sanofi	All	19 Years and older   (Adult, Older Adult)	Phase 4	57	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	XRP6976F_6007	October 2004	March 2008	March 2008	October 15, 2008		December 7, 2009	Sanofi-Aventis Administrative Office, Istanbul, Turkey		https://ClinicalTrials.gov/show/NCT00772681
189	NCT03444766	Study of Nivolumab for Advanced Cancers in India		Recruiting	No Results Available	Non-Small Cell Lung Cancer (NSCLC)|Non-Small-Cell Lung Carcinoma|Nonsmall Cell Lung Cancer|Kidney Cancer|Kidney Neoplasms|Renal Cancer|Renal Neoplasms	Drug: Nivolumab	Number of Adverse Events (AE)|Number of treatment-related Serious Adverse Events (SAE)|Number of AE that lead to discontinuation from treatment with nivolumab	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 4	100	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-887	March 6, 2018	September 1, 2019	April 29, 2020	February 23, 2018		January 15, 2019	Local Institution, Bangalore, India|Local Institution, Bangalore, India|Local Institution, Bangalore, India|Local Institution, Bengaluru, India|Local Institution, Hyderabad, India|Local Institution, Jaipur, India|Local Institution, Kolkata, India|Local Institution, Kolkata, India|Local Institution, Mumbai, India|Local Institution, New Delhi, India|Local Institution, Vellore, India		https://ClinicalTrials.gov/show/NCT03444766
190	NCT00500578	Intermittent Use of Aerosolized Ribavirin for Treatment of RSV		Completed	Has Results	Hematological Malignancies	Drug: Ribavirin	Occurrences of Pneumonia	M.D. Anderson Cancer Center|ICN Pharmaceuticals	All	5 Years and older   (Child, Adult, Older Adult)	Phase 4	51	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ID03-0010	February 2003	January 2009	January 2009	July 12, 2007	September 16, 2010	August 1, 2012	U.T.M.D. Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00500578
191	NCT03629886	Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study		Active, not recruiting	No Results Available	Cervical Intraepithelial Neoplasia	Biological: Cervarix	Number of subjects with serious adverse events (SAEs) related to the study vaccine|Number of subjects with potentially Immune Mediated Diseases (pIMDs)|Number of subjects reporting pregnancies and outcomes of reported pregnancies|Number of subjects with SAEs|Number of subjects with any adverse events (AEs)/SAEs leading to premature discontinuation from the study|Number of subjects with SAEs related to study participation|Number of subjects with incident cervical infection associated with HPV-16 and/or HPV-18|Number of subjects with incident cervical infection associated with any oncogenic HPV type	GlaxoSmithKline	Female	26 Years and older   (Adult, Older Adult)	Phase 4	6051	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	205779	August 22, 2018	March 8, 2020	March 8, 2020	August 14, 2018		May 21, 2019	GSK Investigational Site, Jintan, Jiangsu, China|GSK Investigational Site, Lianshui, Jiangsu, China|GSK Investigational Site, Xuzhou, Jiangsu, China|GSK Investigational Site, Yancheng, Jiangsu, China		https://ClinicalTrials.gov/show/NCT03629886
192	NCT00168987	Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors		Completed	No Results Available	Colorectal Neoplasms|Hepatocellular Carcinoma|Cholangiocarcinoma	Drug: oral nutritional supplement rich in eicosapentanoic acid	improvement of muscle function (hand grip strength, respiratory muscle function) at two months|improvement of cognitive function at two months|improvement of quality of life at two months|tolerance of the oral nutritional supplement|improvement of nutritional state (body weight, muscle mass, body cell mass, phase angle, serum albumin)	Charite University, Berlin, Germany|Pfrimmer Nutricia GmbH, Erlangen , Germany	All	18 Years and older   (Adult, Older Adult)	Phase 4	30	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EA1/174/05	January 2005	November 2006	June 2007	September 15, 2005		May 9, 2008	Charite University Hospital, Berlin, Germany		https://ClinicalTrials.gov/show/NCT00168987
193	NCT03859869	A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)		Not yet recruiting	No Results Available	Exocrine Pancreatic Insufficiency (EPI)	Drug: Pancrelipase|Drug: Placebo	Change in stool fat|Difference between 2 dose cohorts (Resected Dose A and Dose B) in change from baseline in stool fat|Change in stool frequency for each dose cohort|Difference between 2 dose cohorts (Resected Dose A and Dose B) in change from baseline in stool frequency	AbbVie	All	21 Years and older   (Adult, Older Adult)	Phase 4	92	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	M16-142	December 13, 2019	January 27, 2022	May 21, 2022	March 1, 2019		July 26, 2019	Alabama Oncology /ID# 207770, Mountain Brook, Alabama, United States|Banner University MC Phoenix /ID# 208402, Phoenix, Arizona, United States|University of Arizona Cancer Center - North Campus /ID# 204333, Tucson, Arizona, United States|UCSD Moores Cancer Center - LaJolla /ID# 202678, La Jolla, California, United States|Stanford Univ School of Med /ID# 208821, Stanford, California, United States|Medstar Georgetown Univ Med Ct /ID# 203363, Washington, District of Columbia, United States|University of Florida /ID# 202679, Gainesville, Florida, United States|IACT Health /ID# 211394, Columbus, Georgia, United States|Northwest Community Hospital /ID# 202270, Arlington Heights, Illinois, United States|NorthShore University HealthSystem - Evanston /ID# 209026, Evanston, Illinois, United States|Ingalls Memorial Hosp /ID# 203962, Harvey, Illinois, United States|Advocate Christ Medical Center /ID# 203132, Oak Lawn, Illinois, United States|University of Michigan Hospitals /ID# 204407, Ann Arbor, Michigan, United States|Ascension Providence Hospital /ID# 203449, Southfield, Michigan, United States|Saint Louis University School of Medicine /ID# 205769, Saint Louis, Missouri, United States|NYU Langone Winthrop Hospital /ID# 207513, Mineola, New York, United States|Northwell-Long Island Jewish Medical Ctr /ID# 207321, New Hyde Park, New York, United States|New York University Langone Me /ID# 202290, New York, New York, United States|Columbia University Medical Center /ID# 204165, New York, New York, United States|East Carolina University /ID# 206661, Greenville, North Carolina, United States|Gabrail Cancer Center Research /ID# 208030, Canton, Ohio, United States|Ohio State Cancer Center /ID# 203131, Columbus, Ohio, United States|Fox Chase Cancer Center /ID# 202288, Philadelphia, Pennsylvania, United States|Allegheny Center Digestive Health /ID# 202291, Pittsburgh, Pennsylvania, United States|Reading Hospital /ID# 206869, Reading, Pennsylvania, United States|Musc /Id# 210727, Charleston, South Carolina, United States|Tennessee Cancer Specialists /ID# 208235, Knoxville, Tennessee, United States|Vanderbilt Univ Med Ctr /ID# 204231, Nashville, Tennessee, United States|UT MD Anderson Cancer Center /ID# 202271, Houston, Texas, United States|Huntsman Cancer Institute /ID# 205297, Salt Lake City, Utah, United States|WI Center for Advanced Res /ID# 205746, Milwaukee, Wisconsin, United States|Medical College of Wisconsin /ID# 205714, Milwaukee, Wisconsin, United States|Emanuelli Research & Development Center LLC /ID# 207097, Arecibo, Puerto Rico|Auxilio Mutuo Cancer Center /ID# 203129, San Juan, Puerto Rico		https://ClinicalTrials.gov/show/NCT03859869
194	NCT00037518	A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer		Completed	No Results Available	Hyperparathyroidism|Parathyroid Neoplasms	Drug: AMG 073	Changes in serum calcium and PTH|Safety and tolerability of cinacalcet	Amgen	All	18 Years and older   (Adult, Older Adult)	Phase 4	46	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20000204	April 2001			May 20, 2002		May 8, 2013			https://ClinicalTrials.gov/show/NCT00037518
195	NCT02312960	Radium-223 Dichloride Long-term Follow-up Program		Recruiting	No Results Available	Neoplasm Metastasis / Bone and Bones	Other: Data Collection	Incidence of radium-223 dichloride related Adverse Events|Severity of radium-223 dichloride related Adverse Events|Incidence of radium-223 dichloride related Serious Adverse Events|Incidence of placebo-related Adverse Events|Severity of placebo-related Adverse Events|Incidence of placebo-related Serious Adverse Events|Incidence of leukemia|Incidence of myelodysplastic syndrome|Incidence of aplastic anemia|Incidence of primary bone cancer|Incidence of any other new primary malignancy|Incidence of bone fractures|Incidence of bone-associated events|Incidence of febrile neutropenia in subjects who receive cytotoxic chemotherapy|Incidence of hemorrhage in subjects who receive cytotoxic chemotherapy	Bayer	All	18 Years and older   (Adult, Older Adult)	Phase 4	800	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	16996|2014-002407-25	December 18, 2014	September 15, 2025	September 15, 2025	December 9, 2014		July 26, 2019	Tucson, Arizona, United States|Plantation, Florida, United States|Indianapolis, Indiana, United States|Ashland, Kentucky, United States|New Orleans, Louisiana, United States|Shreveport, Louisiana, United States|Detroit, Michigan, United States|Omaha, Nebraska, United States|Syracuse, New York, United States|Pittsburgh, Pennsylvania, United States|Watertown, South Dakota, United States|Darlinghurst, New South Wales, Australia|Westmead, New South Wales, Australia|Heidelberg, Victoria, Australia|Bruxelles - Brussel, Belgium|Edegem, Belgium|Kortrijk, Belgium|Leuven, Belgium|Montreal, Quebec, Canada|Santiago, Chile|Praha 2, Czechia|Tampere, Finland|Bordeaux Cedex, France|Nantes, France|NIMES cedex 9, France|Poitiers, France|Saint Cloud, France|Toulouse Cedex 9, France|Tours, France|Villejuif, France|Freiburg im Breisgau, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Ulm, Baden-Württemberg, Germany|Erlangen, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|Rostock, Mecklenburg-Vorpommern, Germany|Aachen, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Dresden, Sachsen, Germany|Jena, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Bremen, Germany|Hamburg, Germany|Magdeburg, Germany|Afula, Israel|Beer Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Jerusalem, Israel|Kfar Saba, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Tel Aviv, Israel|Zrifin, Israel|Bologna, Emilia-Romagna, Italy|Forlì-Cesena, Emilia-Romagna, Italy|Modena, Emilia-Romagna, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Torino, Piemonte, Italy|Cagliari, Sardegna, Italy|Trento, Trentino-Alto Adige, Italy|Matsuyama, Ehime, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Kanazawa, Ishikawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Sendai, Miyagi, Japan|Kurashiki, Okayama, Japan|Osakasayama, Osaka, Japan|Hidaka, Saitama, Japan|Kita-Adachigun, Saitama, Japan|Bunkyo-ku, Tokyo, Japan|Bunkyo-ku, Tokyo, Japan|Koto-ku, Tokyo, Japan|Chiba, Japan|Chiba, Japan|Fukuoka, Japan|Kumamoto, Japan|Miyazaki, Japan|Osaka, Japan|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Busan, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Oslo, Norway|Bialystok, Poland|Warszawa, Poland|Moscow, Russian Federation|Obninsk, Russian Federation|Singapore, Singapore|Singapore, Singapore|Badalona (Barcelona), Barcelona, Spain|Palma de Mallorca, Illes Baleares, Spain|A Coruña, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Málaga, Spain|Pamplona, Spain|Sevilla, Spain|Sevilla, Spain|Kaohsiung, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Truro, Cornwall, United Kingdom|Plymouth, Devon, United Kingdom|Nottingham, Nottinghamshire, United Kingdom|Taunton, Somerset, United Kingdom|Sheffield, South Yorkshire, United Kingdom|Bristol, United Kingdom|Cottingham, United Kingdom		https://ClinicalTrials.gov/show/NCT02312960
196	NCT00171964	Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions		Completed	No Results Available	Pain|Neoplasm Metastasis|Cancer	Drug: Zoledronic acid in combination with therapy	Pain reduction|Time to pain reduction|Duration of pain reduction|Quality of life|Changes in parameters of bone turnover	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	75	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CZOL446EDE06	May 2002	December 2008	December 2008	September 15, 2005		June 1, 2017	Novartis Investigative Site, Herne, Germany		https://ClinicalTrials.gov/show/NCT00171964
197	NCT01948960	Influence of Exceptional Patient Characteristics on Everolimus Exposure	INPRES	Completed	No Results Available	Breast Neoplasms	Drug: everolimus dose escalation	everolimus AUC|correlation between early metabolic response and PFS|correlation between early metabolic response and AUC|effect dose escalation on metabolic respons|correlation between AUC and frequency of adverse event	Radboud University|Novartis	Female	18 Years and older   (Adult, Older Adult)	Phase 4	56	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	UMCNONCO201301	August 2013	January 15, 2018	January 15, 2018	September 24, 2013		December 7, 2018	Maasziekenhuis Pantein, Boxmeer, Netherlands|Spaarne Gasthuis, Hoofddorp, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|St. Antonius Ziekenhuis, Nieuwegein, Netherlands|Radboud university medical center, Nijmegen, Netherlands|Bernhoven Ziekenhuis, Uden, Netherlands|Isala Klinieken, Zwolle, Netherlands		https://ClinicalTrials.gov/show/NCT01948960
198	NCT03138967	Investigation of Sugammadex in Outpatient Urological Procedures		Active, not recruiting	Has Results	Malignant Neoplasms of Urinary Tract|Bladder Cancer	Drug: Rocuronium|Drug: Sugammadex|Drug: Neostigmine|Drug: Glycopyrrolate	Muscle Recovery Time|PostOperative Complications|Overall Recovery Time	M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.	All	18 Years and older   (Adult, Older Adult)	Phase 4	54	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care	2015-1007	September 18, 2017	September 1, 2018	September 2020	May 3, 2017	July 26, 2019	July 26, 2019	University of Texas MD Anderson Cancer Center, Houston, Texas, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/67/NCT03138967/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03138967
199	NCT01689792	A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)		Completed	No Results Available	Colorectal Cancer	Drug: MOVIPREP|Drug: CitraFleet	Polyp detection rate|Adenoma Detection Rate (ADR)|ADR and PDR by location|Cancer detection rate|Flat lesion only detection rate|Advanced risk lesion detection rate|Colonoscopy completion rate|Colon cleansing quality|Acceptability and tolerability of medication using patient questionnaires	Norgine	All	40 Years to 80 Years   (Adult, Older Adult)	Phase 4	398	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Screening	NOR-01/2011 (PDR)	November 2011	January 2013	December 2013	September 21, 2012		March 31, 2015	Klinikum Aschaffenburg, Aschaffenburg, Germany		https://ClinicalTrials.gov/show/NCT01689792
200	NCT04005066	Study of Elunate® (Fruquintinib) in Chinese Patients With Advanced CRC		Recruiting	No Results Available	Advanced Colorectal Cancer	Drug: Elunate®	Incidence of AEs|Incidence of ADRs|Incidence of SAEs|Incidence of AESI	Hutchison Medipharma Limited	All	Child, Adult, Older Adult	Phase 4	3000	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2018-013-00CH2	April 20, 2019	November 30, 2022	February 28, 2023	July 2, 2019		July 2, 2019	Shanghai Dongfang Hospital, Shanghai, China		https://ClinicalTrials.gov/show/NCT04005066
201	NCT00576017	A Study to Evaluate the Safety and Effectiveness of Fentanyl-TTS Compared to Weak Opioids in Patients With Moderate to Severe Chronic Cancer Pain Previously Treated With NSAIDS (Non-steroidal Anti-inflammatory Drugs).		Completed	No Results Available	Pain	Drug: Fentanyl-TTS	The primary endpoint was the control of pain during treatment. Pain was assessed by the visual analogue scale. Pain severity was assessed at each follow-up visit.|The secondary endpoint was to assess the advantages of using fentanyl-TTS after the first step of the WHO analgesic ladder as compared to minor opioids.	Janssen-Cilag, S.A.	All	18 Years and older   (Adult, Older Adult)	Phase 4	19	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CR003526	October 2003		March 2005	December 18, 2007		May 19, 2011			https://ClinicalTrials.gov/show/NCT00576017
202	NCT00140036	Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).		Completed	No Results Available	Colorectal Neoplasms	Procedure: Blood draw	Correlation of genotype with safety and efficacy measures.	Pfizer	All	18 Years and older   (Adult, Older Adult)	Phase 4	137	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CPTAIV-0020-366|A5961020	September 2002		August 2005	August 31, 2005		March 3, 2008	Pfizer Investigational Site, Mobile, Alabama, United States|Pfizer Investigational Site, Tucson, Arizona, United States|Pfizer Investigational Site, Fresno, California, United States|Pfizer Investigational Site, Stamford, Connecticut, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, New Port Richey, Florida, United States|Pfizer Investigational Site, Tamarac, Florida, United States|Pfizer Investigational Site, Rockford, Illinois, United States|Pfizer Investigational Site, Terre Haute, Indiana, United States|Pfizer Investigational Site, New Orleans, Louisiana, United States|Pfizer Investigational Site, Annapolis, Maryland, United States|Pfizer Investigational Site, Pittsfield, Massachusetts, United States|Pfizer Investigational Site, Minneapolis, Minnesota, United States|Pfizer Investigational Site, Columbia, Missouri, United States|Pfizer Investigational Site, Billings, Montana, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Hooksett, New Hampshire, United States|Pfizer Investigational Site, Lebanon, New Hampshire, United States|Pfizer Investigational Site, Rockville Centre, New York, United States|Pfizer Investigational Site, Greenville, North Carolina, United States|Pfizer Investigational Site, Hendersonville, North Carolina, United States|Pfizer Investigational Site, Hickory, North Carolina, United States|Pfizer Investigational Site, Winston - Salem, North Carolina, United States|Pfizer Investigational Site, Zanesville, Ohio, United States|Pfizer Investigational Site, Charleston, South Carolina, United States|Pfizer Investigational Site, Temple, Texas, United States|Pfizer Investigational Site, Newport News, Virginia, United States|Pfizer Investigational Site, Milwaukee, Wisconsin, United States|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Kingston, Ontario, Canada|Pfizer Investigational Site, Kitchener, Ontario, Canada|Pfizer Investigational Site, Windsor, Ontario, Canada|Pfizer Investigational Site, Fleurimont, Quebec, Canada		https://ClinicalTrials.gov/show/NCT00140036
203	NCT01205230	VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK		Completed	Has Results	Cancer	Drug: pazopanib	Plasma Pazopanib Area Under the Concentration-time Curve From Zero (Pre-dose) to 24 Hours (AUC[0-24]) of Pazopanib Alone and of Pazopanib in Combination With Ketoconazole and Esomeprazole|Plasma Maximum Observed Concentration (Cmax) of Pazopanib Alone and of Pazopanib in Combination With Ketoconazole and Esomeprazole|Time of Occurrence of Cmax (Tmax) of Pazopanib Alone and of Pazopanib in Combination With Ketoconazole and Esomeprazole|Plasma Concentration at 24 Hours After Administration (C24) of Pazopanib Alone and of Pazopanib in Combination With Ketoconazole and Esomeprazole|Plasma AUC(0-24) for the Indicated Metabolites of Pazopanib When Administered Alone or in Combination With Ketoconazole and Ezomeprazole|Plasma Cmax for the Indicated Metabolites of Pazopanib When Administered Alone or in Combination With Ketoconazole and Ezomeprazole|Tmax for the Indicated Metabolites of Pazopanib When Administered Alone or in Combination With Ketoconazole and Ezomeprazole|Plasma Ketoconazole Concentration at the Indicated Time Points|Number of Participants With the Indicated Grade 3 or 4 Adverse Events (AEs)|Number of Participants With the Indicated Event of Dose Limiting Toxicity (DLT)	GlaxoSmithKline	All	18 Years and older   (Adult, Older Adult)	Phase 4	34	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	113971	September 2010	August 2011	August 2011	September 20, 2010	April 24, 2012	May 22, 2012	GSK Investigational Site, New Brunswick, New Jersey, United States|GSK Investigational Site, Greenville, South Carolina, United States		https://ClinicalTrials.gov/show/NCT01205230
204	NCT02294084	Sitagliptin and Brown Adipose Tissue	Sita01	Completed	No Results Available	Neoplasms, Adipose Tissue	Drug: Sitagliptin|Drug: placebo	The effect of sitagliptin treatment on BAT activity in overweight, pre-diabetic subjects BAT volume and activity will be measured by means of cold-induced 18F-FDG PET-CT scans|The effect of sitagliptin treatment on energy expenditure in overweight, pre-diabetic subjects indirect calorimetrie|The effect of sitagliptin treatment on muscle glucose metabolism in overweight, pre-diabetic subjects Expression and/or activation of biomarkers for insulin signaling and glucose and lipid metabolism in skeletal muscle biopsies|The effect of sitagliptin treatment on fat mass in overweight, pre-diabetic subjects Fat mass will be measured via DEXA scan|The effect of sitagliptin treatment on glucose metabolism in overweight, pre-diabetic subjects serum glucose, insulin, and HbA1c. Furthermore, insulin secretion will be determined by OGTT together with C-peptine, glucose and insulin area under the curve|The effect of sitagliptin treatment on plasma lipid levels in overweight, pre-diabetic subjects total cholesterol, HDL-C LDL-C triglycerides, and free fatty acids in plasma	Ingrid Jazet|Merck Sharp & Dohme Corp.|Leiden University Medical Center	Male	35 Years to 50 Years   (Adult)	Phase 4	30	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	P14.242	March 2014	October 2016	December 2016	November 19, 2014		July 16, 2018	Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands		https://ClinicalTrials.gov/show/NCT02294084
205	NCT00370240	Chlorhydrate of Ropivacaine and Breast Cancer Surgery		Completed	No Results Available	Breast Neoplasms|Pain,Postoperative	Drug: Chlorhydrate de Ropivacaine|Other: placebo	Comparing the frequencies of chronic breast pain 3 months after breast surgery evaluated by the Brief Pain Inventory in the two groups.|Visual Analogic Scale, Patient satisfaction with analgesic, consumption, neuropathic pain and depression/anxiety rating scale	Institut Curie|AstraZeneca|Gustave Roussy, Cancer Campus, Grand Paris	Female	18 Years to 85 Years   (Adult, Older Adult)	Phase 4	260	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	(CRH 05353A)|EudraCT 2005-005691-32	September 2006	July 2007	November 2008	August 31, 2006		November 6, 2017	René Huguenin Center, Saint-Cloud, France		https://ClinicalTrials.gov/show/NCT00370240
206	NCT02757690	Validation of 3 Dimensional Laparoscopic System in Disral Pancreatectomy and Splenectomy		Completed	No Results Available	Benign Neoplasm of Body of Pancreas|Benign Neoplasm of Tail of Pancreas	Device: 3-dimensional distal pancreatectomy|Device: 2-dimensional distal pancreatectomy	Operation time|Numbers of errors during operation|Subjective scoring in the view of operator, 1st assist	Asan Medical Center|Olympus	All	21 Years to 80 Years   (Adult, Older Adult)	Phase 4	60	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)	2D vs 3D LDPS comparison	January 2015	February 2016	February 2016	May 2, 2016		May 2, 2016			https://ClinicalTrials.gov/show/NCT02757690
207	NCT00277160	A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer		Completed	No Results Available	Neutropenia|Breast Cancer|Lung Cancer|Non-Hodgkin's Lymphoma|Ovarian Cancer	Drug: Neulasta (pegfilgrastim)	Incidence of febrile neutropenia, defined by ANC < 1.0 x 10^9/L and temperature ≥ 38o C on the same day|Incidence of grade 3 and 4 neutropenia|Dose delays or dose reductions|Incidence of febrile neutropenia with a more strict definition (ANC < 0.5 x 10^9/L and temperature ≥ 38o C), on the same day	Amgen	All	65 Years and older   (Older Adult)	Phase 4	852	Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	20020122	June 2002	November 2004	January 2005	January 16, 2006		October 8, 2010			https://ClinicalTrials.gov/show/NCT00277160
208	NCT00006864	Interleukin-2 in Treating Patients With Metastatic Kidney Cancer		Completed	No Results Available	Kidney Cancer	Biological: aldesleukin		Case Comprehensive Cancer Center|National Cancer Institute (NCI)|Chiron Corporation	All	18 Years and older   (Adult, Older Adult)	Phase 4		Other|NIH|Industry	Interventional	Primary Purpose: Treatment	CHIR1899|CWRU-CHIR-1899|CHIR-MA-99-01|CWRU-010002|NCI-G00-1875	July 2000	July 2007	July 2007	June 2, 2003		January 9, 2014	Northwestern Connecticut Oncology-Hematology Associates, Torrington, Connecticut, United States|Ireland Cancer Center, Cleveland, Ohio, United States		https://ClinicalTrials.gov/show/NCT00006864
209	NCT03039543	Neuromuscular Blockade During Transurethral Resection of Bladder Cancer		Completed	Has Results	Neuromuscular Blockade	Drug: Rocuronium|Drug: Sugammadex	Number of Participants Attaining a 5 (Optimal) Surgical Condition Score|Incidence of Postoperative Residual Curarization|Recovery Time (PACU Discharge)|the Incidence of Desaturation|Other Postoperative Adverse Events	Seoul National University Bundang Hospital|MSD Korea Ltd.	All	19 Years and older   (Adult, Older Adult)	Phase 4	108	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other	B-1701-378-006	June 1, 2017	November 10, 2017	November 10, 2017	February 1, 2017	May 22, 2018	May 22, 2018	Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of	"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03039543/SAP_000.pdf|"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03039543/Prot_001.pdf	https://ClinicalTrials.gov/show/NCT03039543
210	NCT01283906	A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients	MuGard	Completed	No Results Available	Oral Mucositis	Device: MuGard|Device: Control Rinse	To evaluate the efficacy of MuGard on reducing the symptoms of oral mucositis using an Oral Mucositis Daily Questionnaire (OMDQ)|To evaluate the efficacy of MuGard on delaying the onset of oral mucositis symptoms and reducing the impact on health and resource outcomes.	Access Pharmaceuticals, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 4	120	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	APC-10U1101	January 2011	April 2013	May 2013	January 26, 2011		September 12, 2013	Ironwood Cancer and Research Centers, Mesa, Arizona, United States|21st Century Oncology TRC Headquarters, Scottsdale, Arizona, United States|St. Joseph's Mercy Cancer Center- Hot Springs Radiation Oncology, Hot Springs, Arkansas, United States|Enloe Medical Center- Cancer Center, Chico, California, United States|John Muir Medical Center, Concord, California, United States|MD Anderson Cancer Center Orlando, Orlando, Florida, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Signature Healthcare Brockton Hospital, Brockton, Massachusetts, United States|Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|VA Western New York Health System, Buffalo, New York, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|CaroMont Health Comprehensive Cancer Center, Gastonia, North Carolina, United States|21st Century Oncology- Carolina Radiation Medicine, Greenville, North Carolina, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|PeaceHealth St. Joseph Cancer Center, Bellingham, Washington, United States|Providence Hospital - Pacific Campus; Flynn Cancer Center, Everett, Washington, United States|Columbia St. Mary's Hospital, Milwaukee, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT01283906
211	NCT00134589	CHOICE: Communicating Health Options Through Information and Cancer Education		Completed	No Results Available	Colorectal Neoplasms	Behavioral: Academic Detailing (Medical Practices)+Decision Aids (Patients)	Completion of colorectal cancer screening|Patient's intention to ask/patient asking medical provider for colorectal cancer screening	Centers for Disease Control and Prevention|University of North Carolina|Aetna, Inc.	All	52 Years to 75 Years   (Adult, Older Adult)	Phase 4	450	U.S. Fed|Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single	CDC-NCCDPHP-R-01-PH-000018	April 2005	April 2009	April 2009	August 25, 2005		August 4, 2009	Emory University Rollins School of Public Health, Atlanta, Georgia, United States		https://ClinicalTrials.gov/show/NCT00134589
212	NCT02564107	A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease		Completed	No Results Available	Pain; Bone Neoplasms; Neoplasm Metastasis	Drug: Ibandronate	Cumulative incidence of skeletal events according to Skeletal Morbidity Period Rate (SMPR)|Incidence of bone pain according to participant questionnaire|Analgesic consumption according to participant questionnaire|Change in serum pyridinoline cross-linked carboxyterminal telopeptide of collagen type I (ICTP)|Short Form 36 (SF-36) score|Incidence of adverse events (AEs)	Hoffmann-La Roche	Female	18 Years and older   (Adult, Older Adult)	Phase 4	48	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML18044	November 2004	April 2006	April 2006	September 30, 2015		November 2, 2016	Plovdiv, Bulgaria|Shumen, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Varna, Bulgaria|Veliko Tarnovo, Bulgaria		https://ClinicalTrials.gov/show/NCT02564107
213	NCT00302653	Rasburicase in Tumor Lysis Syndrome		Completed	No Results Available	Hyperuricemia	Drug: Rasburicase	Percentage of patients with uric acid greater-than-normal laboratory levels (hyperuricemia)|Adverse events occurrence	Sanofi	All	up to 18 Years   (Child, Adult)	Phase 4	33	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	L_9436	February 2006	November 2006		March 14, 2006		September 25, 2009	Sanofi-aventis administrative office, São Paulo, Brazil		https://ClinicalTrials.gov/show/NCT00302653
214	NCT01318473	The Use of the ActiSight™ Needle Guidance System in Patients Undergoing CT-Guided With Lesions Smaller Than 15 mm	ActiSight	Completed	No Results Available	Cancer	Device: ActiSight™ Needle Guidance System	Frequency of adequate sample for diagnosis obtained in the procedure as determined from the Histology / Cytology report|Frequency of target reached by the biopsy or aspiration tool, as determined by a qualified physician reviewing the CT images|Number of needle punctures through the skin|Number of needle punctures through the pleura|Number of CT scans needed|Duration of procedure: patient preparation, planning, guidance and Cytolog report.	ActiViews Ltd.|Tel-Aviv Sourasky Medical Center	All	18 Years and older   (Adult, Older Adult)	Phase 4	25	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ASNG-LFNA-102-IL|ASNG-LFNA-101-IL	June 2009	January 2010	January 2010	March 18, 2011		October 3, 2012			https://ClinicalTrials.gov/show/NCT01318473
215	NCT00158041	Subcutaneous Amifostine Safety Study		Completed	No Results Available	Head and Neck Cancer|Lung Cancer|Lymphoma	Drug: Amifostine administered subcutaneously	Incidence of nausea/vomiting|Incidence of hypotension|Incidence of generalized skin rash|Incidence of injection-site skin toxicity	Mt. Sinai Medical Center, Miami|MedImmune LLC	All	18 Years and older   (Adult, Older Adult)	Phase 4	452	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	ETH056-01D	January 2002		January 2005	September 12, 2005		September 12, 2005	Mt. Sinai Medical Center, Miami Beach, Florida, United States		https://ClinicalTrials.gov/show/NCT00158041
216	NCT00563771	Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome		Completed	No Results Available	Hyperuricemia	Drug: Rasburicase	Response will be defined as achievement of normal uric acid levels (less than or = to 7.0mg/dL)	Sanofi	All	up to 18 Years   (Child, Adult)	Phase 4	38	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	L_8720	March 2003		January 2004	November 26, 2007		January 28, 2008	Sanofi-Aventis, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT00563771
217	NCT00283465	A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy		Completed	No Results Available	Anemia|Neoplasm	Drug: Epoetin alfa	Number of patients who receive an allogenic red blood cell transfusion during the study, during each chemotherapy cycle, and at 4 weeks after the last administration of chemotherapy|Number of units transfused during each chemotherapy cycle; change in quality of life; change in hemoglobin level; relationship between change in hemoglobin and quality of life; tumor response; patient survival up to 12 months after the end of treatment	Janssen-Cilag B.V.	All	18 Years and older   (Adult, Older Adult)	Phase 4	316	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CR002047	November 1999		April 2004	January 30, 2006		January 14, 2011			https://ClinicalTrials.gov/show/NCT00283465
218	NCT00688038	Correlation of MR Thermal Imaging to Actual Size of Ablation During Laser Ablation Therapy		Completed	No Results Available	Advanced Cancer|Bone Metastases	Procedure: Laser Ablation|Procedure: Magnetic Resonance Thermal Imaging	Correlation of Maximal Dimensions of 60-degree Celsius Isotherm + Ablation Zone Dimensions as determined by MRI	M.D. Anderson Cancer Center|BioTex, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 4	24	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2007-0393|NCI-2011-00518	May 13, 2008	September 12, 2017	September 12, 2017	June 2, 2008		September 15, 2017	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00688038
219	NCT00742222	Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer	EXIBT	Completed	No Results Available	Breast Cancer|Carcinoma|Lumpectomy|Ductal Carcinoma in Situ	Radiation: Electronic Brachytherapy|Radiation: Intracavitary accelerated partial breast irradiation	The incidence of signs and symptoms of subcutaneous toxicities will be recorded at the following follow-up visits; six month, one year, two year, three year, four year, and five year.|Local-regional Breast Failure - Ipsilateral breast failure at five years, Including: Ipsilateral recurrence within the initially treated volume, Ipsilateral recurrence of cancer outside of the initially treated volume, and axillary nodal recurrence	Xoft, Inc.	Female	50 Years and older   (Adult, Older Adult)	Phase 4	63	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TPR-0186	May 2008	January 2015	January 2015	August 27, 2008		May 17, 2016	DCH Cancer Treatment Center, Tuscaloosa, Alabama, United States|Beverly Oncology, Montebello, California, United States|Florida Radiation Oncology Group, Orange Park, Florida, United States|St Elizabeth's and Memorial Cancer Center, Swansea, Illinois, United States|Cancer Institute of Cape Girardeau, Cape Girardeau, Missouri, United States|AtlantiCare Cancer Care Institute, Galloway, New Jersey, United States|Nazha Cancer Center, Northfield, New Jersey, United States|Dallas Surgical Group / Northpoint Cancer Center, Dallas, Texas, United States		https://ClinicalTrials.gov/show/NCT00742222
220	NCT01373021	The Effect of Dexmedetomidine on Postoperative Analgesia		Completed	No Results Available	Colon Cancer, Rectal Cancer	Drug: Fentanyl|Drug: Dexmedetomidine	total amount of administered fentanyl	Seoul National University Hospital|Pharmbio Korea Co., Ltd.	All	20 Years to 74 Years   (Adult, Older Adult)	Phase 4	95	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research	sunrud1129	June 2011	February 2012	February 2012	June 14, 2011		March 8, 2012	Seoul national university hospital, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01373021
221	NCT00754468	Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus.	ESODOI	Completed	Has Results	Barrett's Esophagus|Esophageal Cancer	Device: Cryo Spray Ablation	Depth of Injury|Side Effects of Subjects Receiving Cryospray Therapy.	CSA Medical, Inc.|University of Miami	All	18 Years and older   (Adult, Older Adult)	Phase 4	7	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-00017	February 2009	March 2012	March 2012	September 18, 2008	November 4, 2015	November 4, 2015	University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States		https://ClinicalTrials.gov/show/NCT00754468
222	NCT01789281	Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.		Recruiting	No Results Available	Neoplasms	Drug: Everolimus|Drug: Sandostatin LAR Depot	Frequency and severity of AEs/SAEs|Percentage of patients with clinical benefit	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	52	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CRAD001C2X01B	May 14, 2013	May 12, 2023	May 12, 2023	February 12, 2013		August 2, 2019	Hematology Oncology Services of Arkansas SC, Little Rock, Arkansas, United States|Rocky Mountain Cancer Centers SC, Greenwood Village, Colorado, United States|Stamford Hospital, Stamford, Connecticut, United States|H Lee Moffitt Cancer Center and Research Institute SC-2, Tampa, Florida, United States|Central Indiana Cancer Centers SC, Indianapolis, Indiana, United States|Crescent City Research Consortium, LLC SC-3, Metairie, Louisiana, United States|Mayo Clinic SC-2, Rochester, Minnesota, United States|Washington University School of Medicine Dept of Oncology, Saint Louis, Missouri, United States|Nebraska Cancer Specialists Onc Dept, Omaha, Nebraska, United States|Clinical Research Alliance, Lake Success, New York, United States|New York University Medical Center SC-4, New York, New York, United States|Oregon Health and Science University SC-8, Portland, Oregon, United States|Utah Cancer Specialists Utah Cancer (2), Salt Lake City, Utah, United States|Novartis Investigative Site, Praha 2, Czech Republic, Czechia|Novartis Investigative Site, Arezzo, AR, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Leningrad Region, Russia, Russian Federation|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Izmir, Turkey		https://ClinicalTrials.gov/show/NCT01789281
223	NCT03752606	Application of Tachosil During Lymphadenectomy		Completed	No Results Available	Lymphocele|Endometrial Cancer|Cervical Cancer	Biological: TACHOSIL GROUP	The incidence and volume of lymphocele.|The incidence of lymphocele after adjuvant treatment	Medical University of Lublin|Takeda	Female	18 Years to 70 Years   (Adult, Older Adult)	Phase 4	50	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	022018	November 29, 2013	December 31, 2014	December 31, 2017	November 26, 2018		November 26, 2018	IInd Department of Gynecology, Lublin, Poland		https://ClinicalTrials.gov/show/NCT03752606
224	NCT00247338	The Impact of Low Calorie and Low Nitrogen Parenteral Nutrition Support on the Clinical Outcome of Postoperative Patients		Completed	No Results Available	Gastrointestinal Neoplasms|Postoperative Complications	Drug: low calorie, low nitrogen parenteral nutrition for patient with NRS score 3	Infectious complications|Systemic inflammatory response syndrome|The length of hospital stay after operation|Post-operative nutritional cost & total treatment cost	Sino-Swed Pharmaceutical Corporation|Guangzhou S Y S Medical School hospital|Wuhan TongJi Hospital|Beijing 301 hospital|Jie-Ping Wu Medical Foundation	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 4	120	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Hypocaloric PN	April 2005	April 2006	May 2006	November 1, 2005		May 12, 2008	Department of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|Department of General Surgery, Affiliated Hospital of Medical University of Tongji, Wuhan, Hubei, China|Department of General Surgery, General Hospital of PLA, Beijing, China		https://ClinicalTrials.gov/show/NCT00247338
225	NCT03743129	Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029）	ALTER-L029	Not yet recruiting	No Results Available	Non-Small Cell Lung Cancer Stage III	Drug: Anlotinib	Progression Free Survival (PFS)|Disease Control Rate at 6 months(DCR6)|Disease Control Rate at 12 months(DCR12)|Overall Survival at 12 months (OS12)|Overall Survival at 24 months (OS24)|Recurrence rate at 12 months|Recurrence rate at 24 months	Anhui Shi, MD|Beijing Cancer Hospital|Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 4	90	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2018YJZ47	November 30, 2018	November 30, 2020	November 30, 2021	November 15, 2018		December 5, 2018			https://ClinicalTrials.gov/show/NCT03743129
226	NCT00953277	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer		Completed	No Results Available	Peripheral Nerve Injury|Prostate Cancer|Radical Prostatectomy|Nerve Reconstruction|Cavernous Nerve Injury	Other: Processed Human Nerve Tissue Scaffold	Surgeon Assessment of Technical Feasibility|Erectile Recovery Rates|Continence Rates|Quality of Life Questionnaire|Adverse Events	Axogen Corporation	Male	18 Years to 70 Years   (Adult, Older Adult)	Phase 4	12	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ANG-CP-003	August 2009	April 2015	April 2015	August 6, 2009		May 21, 2015	Vanderbilt University, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT00953277
227	NCT00067730	A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation		Completed	No Results Available	Sepsis|Hematologic Neoplasms|Hematopoietic Stem Cell Transplantation|Infection	Drug: Drotrecogin Alfa (activated)	Safety|Mortality|Bleeding incidence	Eli Lilly and Company	All	18 Years and older   (Adult, Older Adult)	Phase 4	7	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	6416|F1K-US-EVCE	March 2003		October 2003	August 27, 2003		December 7, 2007	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denver, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iowa City, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manhassaet, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durham, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winston-Salem, North Carolina, United States		https://ClinicalTrials.gov/show/NCT00067730
228	NCT01501487	MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I	MINT	Completed	No Results Available	Breast Cancer	Drug: TAC chemotherapy|Drug: TC chemotherapy|Drug: Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy|Drug: TCH chemotherapy|Drug: T + trastuzumab followed by CEF + trastuzumab|Drug: Dose dense AC followed by T + trastuzumab|Drug: Dose dense AC followed by T + trastuzumab + pertuzumab|Drug: PTH followed by dose dense AC of FEC	Determine the predictive power of chemosensitivity of MammaPrint as measured by pCR.|Determine the predictive power of chemosensitivity of the combination of MammaPrint and BluePrint as measured by pCR.|Compare TargetPrint single gene read out of ER, PR and HER2 with local and centralized IHC and/or CISH/FISH assessment of ER, PR and HER2.|Identify possible correlations between the TheraPrint Research Gene Panel outcomes and chemoresponsiveness.|Identify and/or validate predictive gene expression profiles of clinical response/resistance to chemotherapy.|Compare the three BluePrint molecular subtype categories with IHC-based subtype classification.	Agendia|University of South Florida|University of Miami|Morton Plant Mease Health Care|Florida Hospital|Plano Cancer Center|Ohio State University Comprehensive Cancer Center|University of Oklahoma|University of South Alabama	Female	18 Years and older   (Adult, Older Adult)	Phase 4	226	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	P0334	October 2011	February 2016	June 2017	December 29, 2011		June 28, 2018	University of South Alabama, Mitchell Cancer Institute, Mobile, Alabama, United States|Morton Plant Mease Health Care, Clearwater, Florida, United States|University of Miami, Miami, Florida, United States|University of South Florida Breast Cancer Program, Tampa, Florida, United States|Helen Ellis Memorial Hospital, Tarpon Springs, Florida, United States|Eastchester Center for Cancer Care, Bronx, New York, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|University of Oklahoma, Health Sciences Center, Oklahoma City, Oklahoma, United States|Texas Health, Plano Cancer Institute, Plano, Texas, United States		https://ClinicalTrials.gov/show/NCT01501487
229	NCT00606515	Pharmacokinetics Study of Liposomal Paclitaxel in Humans	LPS-PK-H	Completed	No Results Available	Cancer	Drug: Liposomal paclitaxel|Drug: Paclitaxel	Pharmacokinetic parameters	Shandong Luye Pharmaceutical Co., Ltd.|Nanjing Sike Pharmaceutical Co., Ltd.	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	16	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)	LPS-PK-01-2008	February 2008	October 2008	October 2008	February 4, 2008		February 10, 2009	Cancer Hospital of Fudan University, Shanghai, Shanghai, China|Cancer Hospital of Fudan University, Shanghai, China		https://ClinicalTrials.gov/show/NCT00606515
230	NCT02819921	Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen		Recruiting	No Results Available	Hot Flashes|Breast Neoplasms	Drug: Desvenlafaxine succinate 100mg|Drug: Desvenlafaxine succinate 50mg|Drug: Placebo	Reduction rate of hot flashes symptom score|Clinical impression state and change|Peripheral neuropathy|Depression|Anxiety|Manic or Hypomanic symptoms.|Sleep quality|Chonotype|Circadian misalignment|Fatigue|Quality of life|Beliefs about medicines|Illness perception|Social support|Body image|Resilience|Hormonal level|Genetic polymorphism	Seoul National University Hospital|Seoul National University Bundang Hospital|Korea Cancer Center Hospital|Pfizer	Female	19 Years and older   (Adult, Older Adult)	Phase 4	339	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	WI209149	November 10, 2017	December 2019	December 2020	June 30, 2016		April 19, 2018	National Cancer Center, Goyang, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT02819921
231	NCT03460678	Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.		Recruiting	No Results Available	Carcinoma, Non-Small-Cell Lung	Drug: Pemetrexed|Drug: Erlotinib	Progression-Free Survival (PFS) in eligible patients randomized to erlotinib or pemetrexed treatment arms|Median Overall Survival (OS) Time between eligible patients randomized to erlotinib or pemetrexed treatment of therapy|Overall response rate and duration between eligible patients randomized to erlotinib or pemetrexed treatment arms|Incidence of adverse events (AEs) and serious adverse events (SAEs) to erlotinib and pemetrexed	Hikma Pharmaceuticals LLC	All	18 Years and older   (Adult, Older Adult)	Phase 4	72	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MRT-JOR-LEB-KSA-2016-04	February 28, 2018	December 2019	December 2019	March 9, 2018		March 19, 2018	King Hussein Cancer Center (KHCC), Amman, Jordan|American University of Beirut Medical Center, Beirut, Lebanon		https://ClinicalTrials.gov/show/NCT03460678
232	NCT03715205	Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)		Recruiting	No Results Available	Carcinoma, Non-Small-Cell Lung|Melanoma	Drug: Pembrolizumab	Incidence of Adverse Events (AEs)|Incidence of Drug-Related AEs|Incidence of Serious Adverse Events (SAEs)|Incidence of Drug-Related SAEs|Incidence of Treatment Discontinuations|Incidence of Events of Clinical Interest (ECIs)	Merck Sharp & Dohme Corp.	All	18 Years and older   (Adult, Older Adult)	Phase 4	150	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	3475-593|MK-3475-593|KEYNOTE 593	January 31, 2019	January 1, 2026	January 1, 2026	October 23, 2018		July 11, 2019	Indraprastha Apollo Hospitals ( Site 0008), New Delhi, Delhi, India|Kokilaben Ben Dhirubhai Ambani Hosp & Med Res Inst. ( Site 0001), Mumbai, Maharashtra, India|Deenanath Mangeshkar Hospital and Research Center ( Site 0009), Pune, Maharastra, India|Rajiv Gandhi Cancer Institute and Research Centre ( Site 0003), Delhi, India|Artemis Health Institute ( Site 0007), Gurgaon, India		https://ClinicalTrials.gov/show/NCT03715205
233	NCT03285763	A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)	TAIL	Active, not recruiting	No Results Available	Carcinoma, Non-Small-Cell Lung	Drug: Atezolizumab	Percentage of Participants with Adverse Events|Percentage of Participants Alive 2 Years After Initiation of Treatment|Overall Survival (OS)|Progression-Free Survival Based on Disease Status as Evaluated By the Investigator in Accordance With Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 (v.1.1)|EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire|European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13)|Progression-Free Survival Based on Disease Status as Evaluated By the Investigator in Accordance With Modified RECIST|Percentage of Participants Alive 3 Years After Initiation of Treatment|Percentage of Participants with Objective Reponse as Assessed by the Investigator According to RECIST v1.1|Percentage of Participants with Objective Reponse as Assessed by the Investigator According to Modified RECIST|Duration of Response as Assessed by the Investigator According to RECIST v.1.1|Duration of Response as Assessed by the Investigator According to Modified RECIST	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	600	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MO39171|2017-001409-34	October 25, 2017	August 31, 2019	August 31, 2021	September 18, 2017		August 14, 2019	Hospital Aleman, Caba, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|CETUS Hospital Dia, Belo Horizonte, MG, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, Brazil|Hospital Alemao Oswaldo Cruz, Sao Paulo, SP, Brazil|Beijing Hospital, Beijing City, China|Chinese PLA General Hospital, Beijing, China|Shandong Cancer Hospital, Jinan, China|First Affiliated Hospital of Soochow University, Suzhou, China|Henan Cancer Hospital, Zhengzhou, China|Organizacion Sanitas Internacional, Bogota, Colombia|Fundacion Clinica Valle del Lili; Unidad de Investigaciones Clinicas, Cali, Colombia|Clinica CIMCA, San Jose, Costa Rica|Sjællands Universitetshospital, Næstved; Onkologisk Afdeling, Naestved, Denmark|Odense Universitetshospital, Onkologisk Afdeling R, Odense C, Denmark|Vejle Sygehus; Onkologisk Afdeling, Vejle, Denmark|Anticancer Hospital Ag Savas; 1St Dept of Internal Medicine, Athens, Greece|Uoa Sotiria Hospital; Oncology, Athens, Greece|Agioi Anargyroi; 3Rd Dept. of Medical Oncology, Athens, Greece|Univ General Hosp Heraklion; Medical Oncology, Heraklion, Greece|University Hospital of Patras Medical Oncology, Patras, Greece|Diavalkaniko Hospital, Thessaloniki, Greece|Oncomedica, Guatemala, Guatemala|Ist. Ricovero e Cura a Carattere Scientifico-Centro Rif. Oncologico della Basilica, Rionero In Vulture (PZ), Basilicata, Italy|Campus Universitario S.Venuta; Centro Oncologico T.Campanella, Catanzaro, Calabria, Italy|Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica, Bologna, Emilia-Romagna, Italy|Arcispedale Santa Maria Nuova; Oncologia, Reggio Emilia, Emilia-Romagna, Italy|Policlinico Umberto i di Roma; dip. Scienze Radiologiche, Oncologiche, Anatomopatologiche, Roma, Lazio, Italy|AZ. Ospedaliera San Giovanni - Addolorata, Roma, Lazio, Italy|Cliniche Gavazzeni S.p.A.; Dip. di Oncologia Pneumologica ed Urologica, Bergamo, Lombardia, Italy|ASST DEGLI SPEDALI CIVILI DI BRESCIA; Oncologia Medica, Brescia, Lombardia, Italy|Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia, Milano, Lombardia, Italy|Ospedali Riuniti Di Ancona; Oncology, Ancona, Marche, Italy|Ospedale Antonio Perrino; Oncologia Medica, Brindisi, Puglia, Italy|Ospedale Oncologico A.Businco; Div. Oncologia Medica II, Cagliari, Sardegna, Italy|Ospedale Cannizzaro, Oncologia, Catania, Sicilia, Italy|Azienda Ospedaliero-Universitaria Careggi; SOD Radioterapia, Firenze, Toscana, Italy|Azienda Ospedaliera Universitaria Pisana - Ospedale Cisanello; Dipartimento Cardio Toraco Vascolare, Pisa, Toscana, Italy|Ospedale Regionale Umberto Parini; S.C. Oncologia, Aosta, Valle D'Aosta, Italy|ULSS2 Marca Trevigiana; UOC Oncologia Medica - Distretto di Treviso, Treviso, Veneto, Italy|Riga East Clinical University Hospital Latvian Oncology Centre, Riga, Latvia|Pauls Stradins Clinical University Hospital, Riga, Latvia|Hotel Dieu de France; Oncology, Beirut, Lebanon|Bellevue Medical Center, El-Metn, Lebanon|Institute Kanser Negara (IKN), Putrajaya, FED. Territory OF Kuala Lumpur, Malaysia|Hospital Pulau Pinang; Jabatan Respiratori, Georgetown, Penang, Malaysia|University Malaya Medical Centre; Clinical Oncology Unit,, Kuala Lumpur, Malaysia|Hospital Umum Sarawak; Oncology and Radiotherapy, Kuching, Malaysia|Mount Miriam Cancer Hospital, Tanjung Bungah, Malaysia|Health Pharma Professional Research, CD Mexico, Mexico CITY (federal District), Mexico|Oncologico Potosino, San Luis Potosí, SAN LUIS Potosi, Mexico|Investigacion Clinica Merida, Mérida, Yucatan, Mexico|Centro Oncologico Internacional, Mexico D.F., Mexico|Oaxaca Site Management Organization, Oaxaca, Mexico|Clinique le Littoral, Casablanca, Morocco|Centre Hospitalier Universitaire Hassan II, FES, Morocco|Hopital Militaire d'Instruction Mohamed V, Rabat, Morocco|Institut National D'oncologie Sidi Med Benabdellah, Rabat, Morocco|Meander Medisch Centrum, Amersfoort, Netherlands|Ziekenhuis Rijnstate, Arnhem, Netherlands|Amphia Ziekenhuis; Afdeling Longziekten, Breda, Netherlands|Tergooiziekenhuizen, loc. Hilversum, Hilversum, Netherlands|UMC Radboud Nijmegen, Nijmegen, Netherlands|Isala, Zwolle, Netherlands|Centro Hemato Oncologico Panama, Panama, Panama|Instituto Regional de Enfermedades Neoplásicas del Sur; Centro de Inv. de Medicina Oncológica, Arequipa, Peru|Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional, Lima, Peru|University of Perpetual Help System DALTA Medical Center, Las Pinas, Philippines|The Medical City Hospital; Cancer Research Room, Pasig, Philippines|East Avenue Medical Center, Quezon City, Philippines|Centrum Onkologii w Gliwicach; II Klinika Radioterapii i Chemioterapii, Gliwice, Poland|Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc w Olsztynie, Olsztyn, Poland|Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, Otwock, Poland|Szpital Kliniczny; Przemienienia Panskiego;Uniwersytetu Medyczny im.; Karola Marcinkowskiego w Pozna, Poznan, Poland|Centrum Onkologii Instytut im.Marii Sklodowskiej-Curie; Klinika Nowotworow Pluca i Klatki Piersiowej, Warszawa, Poland|University Clinic Golnik, Golnik, Slovenia|Hospital Univ. Central de Asturias; Servicio de Oncologia, Oviedo, Asturias, Spain|Hospital Universitario Marques de Valdecilla; Servicio de Oncologia, Santander, Cantabria, Spain|Hospital Universitario Reina Sofia; Servicio de Oncologia, Córdoba, Cordoba, Spain|Hospital de Donostia; Servicio de Oncologia Medica, San Sebastian, Guipuzcoa, Spain|Hospital Universitario Son Espases; Servicio de Oncologia, Palma De Mallorca, Islas Baleares, Spain|Complejo Hospitalario Universitario Insular-Materno Infantil; Servicio de Oncologia, Las Palmas de Gran Canaria, LAS Palmas, Spain|Hospital Infanta Sofia; Servico de Oncologia, San Sebastian de Los Reyes, Madrid, Spain|Complejo Hospitalario de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain|Hospital Universitario de Canarias;servicio de Oncologia, La Laguna, Tenerife, Spain|Hospital General Univ. de Alicante; Servicio de Oncologia, Alicante, Spain|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia, Barcelona, Spain|Hospital Provincial de Castellon; Servicio de Oncologia, Castellon, Spain|Hospital Universitari de Girona Dr Josep Trueta; Departamento de Oncologia Medica, Girona, Spain|Hospital Universitario Virgen de las Nieves; Servicio de Oncologia, Granada, Spain|Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia, Jaen, Spain|Hospital Lucus Augusti; Servicio de Oncologia, Lugo, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Madrid, Spain|Hospital Quiron de Madrid; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hospital General Universitario de Valencia; Servicio de oncologia, Valencia, Spain|Hospital Universitario la Fe; Servicio de Oncologia, Valencia, Spain|Hospital Clinico Universitario de Valladolid; Servicio de Oncologia, Valladolid, Spain|Hospital Clinico Universitario Lozano Blesa; Servicio de Oncologia, Zaragoza, Spain|Sahlgrenska Universitetssjukhuset, Lungmedicinkliniken, Goeteborg, Sweden|Karolinska Universitetssjukhuset, Solna; Kliniska prövningsenheten Z:4:01, Stockholm, Sweden|Uppsala University Hospital; Department of Oncology, Uppsala, Sweden|Tawam Hospital, Al Ain, United Arab Emirates|Royal United Hospital, Bath, United Kingdom|Birmingham Heartlands Hospital ; Department of Respiratory Medicine (Rm 30), Birmingham, United Kingdom|Castle Hill Hospital; The Queen's Centre for Oncology & Haematology, Hull, United Kingdom|Forth Valley Royal Hospital ; Oncology Department, Larbert, United Kingdom|Chelsea & Westminster Hospital, London, United Kingdom|Mount Vernon Cancer Centre, Northwood, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom		https://ClinicalTrials.gov/show/NCT03285763
234	NCT02208843	Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation		Completed	Has Results	Carcinoma, Non-Small-Cell Lung	Drug: Afatinib	Objective Tumour Response (Complete Response [CR], Partial Response [PR]) as Assessed by the Investigator According to the RECIST Version 1.1|Progression-free Survival (PFS) as Assessed by the Investigator According to RECIST 1.1.|Disease Control (CR, PR, Stable Disease [SD]) as Assessed by the Investigator According to RECIST 1.1	Boehringer Ingelheim	All	18 Years and older   (Adult, Older Adult)	Phase 4	60	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1200.217|2014-001077-14	October 2, 2014	May 17, 2017	June 13, 2017	August 5, 2014	December 17, 2018	December 17, 2018	Clinical Research Center, Alexandria University Hospital, Alexandria, Egypt|National Cancer Institute, Cairo University, Cairo, Egypt|Kasr Al Ainy Hospital, Cairo, Egypt|Nilai Medical Centre, Nilai, Malaysia|Baguio General Hospital and Medical Center, Baguio City, Philippines|St. Luke's Medical Center, Taguig, Philippines|University Clinical Center, Gdansk, Gdansk, Poland|Specialist Hospital, Szczecin-Zdunowo, Szczecin-Zdunowo, Poland|Oncol Centre M Sklodowska-Curie, Dept of Lung & Chest Cancer, Warsaw, Poland|Braila County Emergency Hospital, Medical Oncology, Braila, Romania|Institute of Oncology 'Prof. Dr. Alexandru Trestioreanu', Bucharest, Romania|Sf. Nectarie Oncology Center, Craiova, Craiova, Romania|Regional Oncology Institute of Iasi, Medical Oncology, Iasi, Romania|Institute for Oncol & Radiol of Serbia, Clinic f. Med. Onco., Belgrade, Serbia|Clinical Center of Serbia, Belgrade, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|Inst. for Pulm. Diseases of Vojvodine, Clinic f. Pulm. Oncol, Sremska Kamenica, Serbia|Wattanosoth Hospital, Bangkok, Thailand|King Chulalongkorn Memorial Hospital, Bangkok, Thailand|Rajavithi Hospital, Bangkok, Thailand|Songklanagarind Hospital, Songkhla, Thailand	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02208843/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02208843/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT02208843
235	NCT00576173	An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients		Completed	No Results Available	Pain	Drug: tramadol hydrochloride; acetaminophen	Pain intensity and side effect will be assessed on entry, 10, 30 mins, and 1hour. In addition, the amount of rescue analgesic medication consumed will be recorded by the patient and summarized by the investigator at study visits.|Investigator global assessment and patient global assessment for the treatment with respect to pain control, side effects and overall using a 5-point scale at the end of the treatment phase.	Johnson & Johnson Taiwan Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 4	60	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CR014683	December 2005		February 2007	December 18, 2007		April 28, 2010			https://ClinicalTrials.gov/show/NCT00576173
236	NCT01544478	V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)		Completed	Has Results	Cervical Cancer|Cervical Intraepithelial Neoplasia|Adenocarcinoma in Situ	Biological: V501	Combined Incidence of Cervical Intraepithelial Neoplasia (CIN) 2/3 or Worse Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18	Merck Sharp & Dohme Corp.	Female	16 Years to 26 Years   (Child, Adult)	Phase 4	1030	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	V501-110|132247|2015-002932-42	November 25, 2011	August 27, 2016	August 27, 2016	March 6, 2012	July 7, 2017	November 28, 2018			https://ClinicalTrials.gov/show/NCT01544478
237	NCT02320734	Deep Neuromuscular Relaxation in Patients for Thoraco-laparoscopic Esophagectomy	DEPTH	Completed	No Results Available	Neuromuscular Block|Esophageal Cancer|Surgery	Drug: Rocuronium	Rating of surgical conditions (SRS) during the abdominal phase of the operation.|Rating of SRS during thoracic phase of the operation.|Number of on demand boluses infused, indication of on demand bolus administration|Rating of anesthesia conditions|Costs (euro's) associated with use of Rocuronium, Sugammadex, operation time and length of stay ICU.|Number of correct estimates of group randomization by surgeons	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Merck Sharp & Dohme Corp.	All	18 Years and older   (Adult, Older Adult)	Phase 4	66	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care	2014-211|2014-002147-18|MISP51412	February 2015	September 2016	September 2016	December 19, 2014		September 19, 2016	Academic Medical Center, Amsterdam, Noord-Holland, Netherlands		https://ClinicalTrials.gov/show/NCT02320734
238	NCT00747773	Cryospray Ablation of Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung	CSAir 1	Completed	No Results Available	Lung Cancer	Device: CryoSpray Ablation System	The primary safety endpoint for this study is patient safety|The primary efficay endpoint is histological effects of cryospray therapy in lobectomy patients	CSA Medical, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 4	21	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-00008-00	November 2007	June 2008	August 2008	September 5, 2008		January 9, 2014	Franklin Square Hospital Center, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT00747773
239	NCT03768063	A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study	IMbrella B	Recruiting	No Results Available	Cancer	Drug: Atezolizumab	Number of Participants With Continued Access to Atezolizumab-Based Therapy and/or Comparator Agent(s)|Percentage of Participants With Serious Adverse Events (SAEs) by Severity Determined According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0|Percentage of Participants With Adverse Events of Special Interest by Severity Determined According to NCI CTCAE Version 4.0	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	1000	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BO40729	February 28, 2019	December 28, 2028	December 28, 2028	December 7, 2018		August 14, 2019	Univ of Alabama at Birmingham; UAB Comprehensive Cancer Ctr, Birmingham, Alabama, United States|HonorHealth Research Institute - Pima - Virginia G. Piper Cancer Care Network, Scottsdale, Arizona, United States|University of Arkansas for Medical Sciences; Winthrop Rockefeller Cancer Institute, Little Rock, Arkansas, United States|Kaiser Permanente - Bellflower, Bellflower, California, United States|City of Hope, Duarte, California, United States|Reagan UCLA Medical Center, Los Angeles, California, United States|Stanford University Medical Center, Stanford, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States|Yale Cancer Center, New Haven, Connecticut, United States|Yale University School Of Medicine; Yale Cancer Center, Trumbull, Connecticut, United States|Georgetown University Medical Center Lombardi Cancer Center, Washington, District of Columbia, United States|SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States|Mercy Hospital, a Campus of Plantation General Hospital, Miami, Florida, United States|Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida, United States|SCRI Florida Cancer Specialists North; Research Office North Region., Saint Petersburg, Florida, United States|University Of Chicago Medical Center; Section Of Hematology/Oncology, Chicago, Illinois, United States|Fort Wayne Medical Oncology and Hematology, Inc, Fort Wayne, Indiana, United States|New England Cancer Specialists, Scarborough, Maine, United States|John Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|St. Joseph Mercy Hospital; Cancer Care Center., Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Montefiore Medical Center, Bronx, New York, United States|New York University School of Medicine, New York, New York, United States|Memorial Sloan Kettering - Basking Ridge, New York, New York, United States|Levine Cancer Institute-Carolinas Medical Center; Levine Cancer Institute-Carolinas Medical Center, Charlotte, North Carolina, United States|Carolina BioOncology Institute, PLCC, Huntersville, North Carolina, United States|Oncology Hematology Care Inc, Cincinnati, Ohio, United States|Ohio State University; Hemat/Onc, Columbus, Ohio, United States|St. Luke's Cancer Care Associates, Bethlehem, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Cancer Center; Investigational Drug Service, Pittsburgh, Pennsylvania, United States|SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|SCRI-Tennessee Oncology, Nashville, Tennessee, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Texas Health Sciences Center in San Antonio, San Antonio, Texas, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|The Prince Charles Hospital; Oncology Dept., Chermside, Queensland, Australia|The Townsville Hospital, Douglas, Queensland, Australia|Cabrini Hospital Malvern, Malvern, Victoria, Australia|Institut Jules Bordet, Bruxelles, Belgium|Multiprofile Hospital for Active Treatment Central Onco Hospital OOD; Dept. of Medical Oncology, Plovdiv, Bulgaria|Multiprofile Hospital for Active Treatment Serdika EOOD; Medical Oncology Department, Sofia, Bulgaria|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|Lakeridge Health, Oshawa, Ontario, Canada|Rigshospitalet, København Ø, Denmark|Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez, Lille, France|CHU Timone; Centre d'Essais Précoces en Cancérologie de Marseille (CEPCM), Marseille, France|APHP - Hospital Saint Louis, Paris, France|Hôpital d'Instruction des Armées de Sainte Anne; Service de Pneumologie, Toulon, France|Institut Gustave Roussy, Villejuif, France|St. Elisabethen Krankenhaus, Frankfurt am Main, Germany|Universitätsklinikum Freiburg;Klinik für Innere Medizin I, Freiburg, Germany|Lungenfachklinik Immenhausen; Zentrum fur Pneumologie, Immenhausen, Germany|Krankenhaus Barmherzige Bruder Regensburg, Regensburg, Germany|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Seoul National University Hospital;Cancer Clinical Trials Center, Seoul, Korea, Republic of|Asan Medical Center, Uni Ulsan Collegemedicine; Dept.Internal Medicine / Divisionhematology/Oncology, Seoul, Korea, Republic of|Asan Medical Center; Internal Dept / Gastorenterology, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Centro Universitario Contra El Cancer, Monterrey, Mexico|Centrum Onkologii - Instytut, Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow, Warszawa, Poland|Centro Hospitalar do Porto - Hospital de Santo António; Oncologia, Porto, Portugal|Centrul de Oncologie Sfantul Nectarie, Craiova, Romania|University Hospital Bratislava; Department of Oncology, Bratislava, Slovakia|Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital General Universitario Gregorio Mara, Madrid, Spain|Centro Integral Oncologico Clara Campal; Servicio de Oncología, Madrid, Spain|HM Sanchinarro - CIOCC; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Freiburger Spital; Onkologie, Fribourg, Switzerland|Chang Gung Memorial Hospital Chiayi, Putzu, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei, Taiwan|Barts Cancer Institute, London, United Kingdom		https://ClinicalTrials.gov/show/NCT03768063
240	NCT00224068	Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy		Completed	No Results Available	Anemia	Drug: Sodium ferric gluconate, ferrous sulfate, standard of care	Change in hemoglobin|Change in various iron indices	Watson Pharmaceuticals	All	18 Years and older   (Adult, Older Adult)	Phase 4	180	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	FR01008	May 2002	December 2003	December 2003	September 22, 2005		March 2, 2012	Bakersfield, California, United States|Chula Vista, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Norwich, Connecticut, United States|Port St Lucie, Florida, United States|Zephyrhills, Florida, United States|Columbus, Georgia, United States|Coeur d'Alene, Idaho, United States|Hutchinson, Kansas, United States|Lexington, Kentucky, United States|Baton Rouge, Louisiana, United States|Baltimore, Maryland, United States|Detroit, Michigan, United States|Southfield, Michigan, United States|St Joseph, Michigan, United States|Duluth, Minnesota, United States|Greenwood, Mississippi, United States|Cherry Hill, New Jersey, United States|Denville, New Jersey, United States|Manhasset, New York, United States|Bismarck, North Dakota, United States|Columbus, Ohio, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|West Chester, Pennsylvania, United States|Columbia, South Carolina, United States|Laredo, Texas, United States|Richmond, Virginia, United States|Salem, Virginia, United States|Walla Walla, Washington, United States|Milwaukee, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT00224068
241	NCT01675531	A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)		Completed	Has Results	Cancer	Drug: Targin	NRS (Numeric Rating Scale)|Mean Change in FACT-GOG/NTX From Visit1(Week 0) to Visit 4(Week 4 Post-treatment).|Physician's Overall Satisfaction|Patient's Overall Satisfaction	Mundipharma Korea Ltd	All	20 Years and older   (Adult, Older Adult)	Phase 4	73	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	OXN12-KR-402	December 2012	December 2013	June 2014	August 30, 2012	December 16, 2016	December 16, 2016	Seoul ST.Mary Hospital, Seoul, Banpogu, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01675531
242	NCT01040884	Safety And Accuracy Study Of The Actisight™ Needle Guidance System In Patients Undergoing CT-Guided Procedures		Completed	No Results Available	Cancer	Other: ActiSight Needle Guidance System	Frequency of target reached (tip of the needle location) within a radius of 8 mm from the preplanned targeted point as measured on the final CT scan|Number of needle punctures through the skin|Number of CT scans needed	ActiViews Ltd.	All	18 Years and older   (Adult, Older Adult)	Phase 4	40	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ASNG-LFNA-101-IL-H	June 2010	January 2012	January 2012	December 30, 2009		July 12, 2012	ActiViews Ltd, Haifa, Israel		https://ClinicalTrials.gov/show/NCT01040884
243	NCT02554942	A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors		Completed	No Results Available	Anemia	Drug: Epoetin beta	Incidence of adverse events|Hemoglobin response rate index	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	28	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML17912	June 2004	September 2005	September 2005	September 18, 2015		November 2, 2016	Alcoy, Spain|Barakaldo, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Caceres, Spain|El Palmar Murcia, Spain|La Laguna, Spain|Manresa, Spain|Salamanca, Spain|Valencia, Spain|Valencia, Spain|Zaragoza, Spain		https://ClinicalTrials.gov/show/NCT02554942
244	NCT00050635	STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea		Completed	No Results Available	Neoplasms|Diarrhea	Drug: Sandostatin LAR Depot	Change from baseline and at 6 months in the proportion of patients with NCI Grades 3 and/or 4 diarrhea during chemotherapy	Novartis Pharmaceuticals|Quintiles, Inc.|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	150	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	CSMS995AUS38|STOP Trial	December 2002		July 2003	December 18, 2002		November 19, 2009	Kenmar Research Institute, Burbank, California, United States|Bay Area Cancer Research Group, Concord, California, United States|Compassionate Cancer Care medical Group, Inc., Fountain Valley, California, United States|California Cancer Care, Inc., Greenbrae, California, United States|Pacific Shores Medical Center, Long Beach, California, United States|Kenmar Research Institute, Los Angeles, California, United States|Oncology Hematology Group of South Florida, Miami, Florida, United States|Pasco Hernando Oncology Associates, New Port Richey, Florida, United States|Mid-Florida Hematology & Oncology Centers, PA, Orange City, Florida, United States|Oncology & Hematology Associates of West Broward, Tamarac, Florida, United States|Creticos Cancer Center, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Cancer Care Center, Bloomington, Indiana, United States|Suniti Medical Corporation, Merrillville, Indiana, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Cancer & Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States|Delta Oncology, Greenwood, Mississippi, United States|Missouri Cancer Associates, Columbia, Missouri, United States|Heartland Hematology Oncology Associates, Kansas City, Missouri, United States|Arch Medical Services/The Center for Cancer Care and Research, St. Louis, Missouri, United States|New Mexico Cancer Care Associates, Santa Fe, New Mexico, United States|North Shore Hematology Oncology, E. Setauket, New York, United States|Raleigh Hematology Oncology Associates, Wake Practice, Raleigh, North Carolina, United States|Dakota Clinic/Odyssey Research Services, Fargo, North Dakota, United States|Nashat Y. Gabrail, MD, Canton, Ohio, United States|North Coast Cancer Care, Inc., Sandusky, Ohio, United States|Lawrence M. Stallings, MD, Wooster, Ohio, United States|Consultants in Medical Oncology-Hematology, Drexel Hill, Pennsylvania, United States|Regional Hematology Oncology Assoc, Langhorne, Pennsylvania, United States|Oncology Services of Aberdeen, Borden, South Dakota, United States|Jones Oncolgy/Hematology Clinic, Germantown, Tennessee, United States|McFaddin Ward Cancer - TOPA, Beaumont, Texas, United States|Scott & White Hospital/CCPC, Waco, Texas, United States|Oncology & Hematology Associates of SW VA, Roanoke, Virginia, United States		https://ClinicalTrials.gov/show/NCT00050635
245	NCT02092467	Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis		Active, not recruiting	No Results Available	Arthritis, Rheumatoid	Drug: tofacitinib|Biological: adalimumab|Biological: etanercept	Malignancies, excluding non-menlanoma skin cancer (NMSC)|Incidence of major adverse cardiovascular events (MACE)|Opportunistic infections|Hepatic events|Cardiovascular events other than MACE|All cause mortality|Disease Activity Score Based on 28-joints Count (DAS28)|Number of Participants With an American College of Rheumatology 20% (ACR20) Response|Clinical Disease Activity Index (CDAI)|Simplified Disease Activity Index (SDAI)|ACR-EULAR Boolean remission|Number of Participants Achieving American College of Rheumatology 50% (ACR50) Response|Number of Participants Achieving American College of Rheumatology 70% (ACR70) Response|Health Assessment Questionnaire-Disability Index (HAQ-DI)	Pfizer	All	50 Years and older   (Adult, Older Adult)	Phase 4	4414	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	A3921133|2013-003177-99	March 14, 2014	March 3, 2020	March 3, 2020	March 20, 2014		July 11, 2019	University of Alabama at Birmingham (UAB), Arthritis Clinical Intervention Program, Birmingham, Alabama, United States|Rheumatology Associates of N. Alabama, PC, Huntsville, Alabama, United States|Rheumatology Associates of North Alabama, PC, Huntsville, Alabama, United States|Clinical and Translational Research Center of Alabama, PC, Tuscaloosa, Alabama, United States|Southern Arizona VA Health Care System (SAVAHCS), Tucson, Arizona, United States|Southern Arizona VA Health Care System, Tucson, Arizona, United States|University of Arizona Clinical and Translational Science Research Center, Tucson, Arizona, United States|CHI St. Vincent Medical Group Hot Springs, Hot Springs, Arkansas, United States|Arthritis And Rheumatism Associates LLC, Jonesboro, Arkansas, United States|Medvin Clinical Research, Covina, California, United States|Med Investigations, Inc., Fair Oaks, California, United States|Talbert Medical Group, Huntington Beach, California, United States|University of California, San Diego (UCSD)- Perlman Ambulatory Clinic, La Jolla, California, United States|Valerius Medical Group And Research Center Of Greater Long Beach, Inc., Long Beach, California, United States|ProHealth Partners, Long Beach, California, United States|Keck Medicine of USC, Los Angeles, California, United States|University of Southern California (USC) Norris Comprehensive Cancer Center, Los Angeles, California, United States|California Medical Research Associates Inc, Northridge, California, United States|Medvin Clinical Research, Placentia, California, United States|Advances In Medicine, Rancho Mirage, California, United States|Sierra Rheumatology, Inc., Roseville, California, United States|San Diego Arthritis Medical Clinic, San Diego, California, United States|Dr. Orrin M. Troum, Md And Medical Associates, Santa Monica, California, United States|Investigational Drug Service, Torrance, California, United States|Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California, United States|Harbor UCLA Medical Center, Torrance, California, United States|Robin K. Dore M.D., Inc., Tustin, California, United States|Medvin Clinical Research, Van Nuys, California, United States|Ventura Clinical Trials, Ventura, California, United States|Desert Valley Medical Group, Victorville, California, United States|Medvin Clinical Research, Whittier, California, United States|Arthritis Associates and Osteoporosis Center of Colorado Springs, Colorado Springs, Colorado, United States|Pfizer BioBank - Biomedical Systems, Groton, Connecticut, United States|Howard University Hospital, Washington, District of Columbia, United States|RASF-Clinical Research Center, Inc, Boca Raton, Florida, United States|Bay Area Arthritis and Osteoporosis, Brandon, Florida, United States|Arthritis and Rheumatism Associates, Clearwater, Florida, United States|Florida Clinical Research Group, Clearwater, Florida, United States|Dr.Robert W. Levin MDOffice of, Clearwater, Florida, United States|International Medical Research, Daytona Beach, Florida, United States|Centre for Rheumatology, Immunology and Arthritis, Fort Lauderdale, Florida, United States|UF Health-Rheumatology, Jacksonville, Florida, United States|University of Florida - Rheumatology at ACC, Jacksonville, Florida, United States|University of Florida College of Medicine Jacksonville, Jacksonville, Florida, United States|University of Florida College of Medicine, Jacksonville - Rheumatology Research, Jacksonville, Florida, United States|San Marcus Research Clinic, Miami Lakes, Florida, United States|San Marcus Research Clinic, Inc., Miami, Florida, United States|Doctors Research Institute, Miami, Florida, United States|Center for Arthritis and Rheumatic Diseases, Miami, Florida, United States|Ocala Rheumatology Research Center, Ocala, Florida, United States|Advanced Clinical Research of Orlando, Ocoee, Florida, United States|Arthritis & osteoporosis treatment center,PA, Orange Park, Florida, United States|Omega Research Consultants, LLC, Orlando, Florida, United States|Rheumatology Associates of Central Florida, PA, Orlando, Florida, United States|Millennium Research, Ormond Beach, Florida, United States|Arthritis Center, Inc., Palm Harbor, Florida, United States|Arthritis Research of Florida, Inc., Palm Harbor, Florida, United States|Advanced Medical Research Center, Port Orange, Florida, United States|Advanced Urgent Care, Port Orange, Florida, United States|University of South Florida, College of Medicine, Internal Medicine-Rheumatology, Tampa, Florida, United States|USF Health Morsani Center for Advanced Healthcare, Tampa, Florida, United States|Florida Medical Clinic, P.A., Zephyrhills, Florida, United States|Arthritis and Rheumatology of GA, P.C., Atlanta, Georgia, United States|Medical Associates of North Georgia, Canton, Georgia, United States|Office of Jefrey D. Lieberman, MD, PC, Decatur, Georgia, United States|Coeur D'Alene Arthritis Clinic, Coeur d'Alene, Idaho, United States|Quincy Medical Group, Quincy, Illinois, United States|Springfield Clinic - Clinical Research, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Diagnostic Rheumatology and Research PC, Indianapolis, Indiana, United States|Professional Research Network of Kansas, LLC, Wichita, Kansas, United States|Arthritis and Diabetes Clinic, Inc., Monroe, Louisiana, United States|Klein & Associates, M.D.,P.A., Cumberland, Maryland, United States|Arthritis Treatment Center, Frederick, Maryland, United States|Klein & Associates, MD, PA, Hagerstown, Maryland, United States|The Center for Rheumatology and Bone Research, Wheaton, Maryland, United States|Phase III Clinical Research, Fall River, Massachusetts, United States|UMass Memorial Medical Center, Memorial Campus, Worcester, Massachusetts, United States|Bronson Healthcare Group - Bronson Internal Medicine and Rheumatology, Battle Creek, Michigan, United States|Bronson Healthcare Group, Battle Creek, Michigan, United States|Jasper Clinic, Inc., Kalamazoo, Michigan, United States|Western Michigan University School Of Medicine, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Borgess Research Institute, Kalamazoo, Michigan, United States|June DO,PC, Lansing, Michigan, United States|Shores Rheumatology P.C., Saint Clair Shores, Michigan, United States|St. Paul Rheumatology, PA, Eagan, Minnesota, United States|Center for Diagnostic Imaging, Mendota Heights, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Kansas City Internal Medicine, Kansas City, Missouri, United States|Clinvest Research, LLC, Springfield, Missouri, United States|Glacier View Research Institute(Regulatory/Administrative), Kalispell, Montana, United States|Glacier View Research Institute, Kalispell, Montana, United States|Physician Research Collaboration, LLC, Lincoln, Nebraska, United States|Westroads Clinical Research, Inc., Omaha, Nebraska, United States|University of Nevada School of Medicine, Las Vegas, Nevada, United States|Steinberg Diagnostics, Las Vegas, Nevada, United States|Access Health / Davis Group, Ltd., Las Vegas, Nevada, United States|Access Health / Davis Group, Ltd, Las Vegas, Nevada, United States|Arthritis Center Of Reno, Reno, Nevada, United States|Nashua Rheumatology, SNHHS, Nashua, New Hampshire, United States|Nashua Rheumatology, Nashua, New Hampshire, United States|Summit Medical Group, Clifton, New Jersey, United States|Weill Cornell Physicians at Brooklyn Heights, Brooklyn, New York, United States|Northwell Health - merge, Great Neck, New York, United States|NYU Langone Rheumatology Associates Long Island., Lake Success, New York, United States|EmergeOrtho,P.A., Durham, North Carolina, United States|Physicians East, PA, Greenville, North Carolina, United States|PMG Research of Hickory LLC, Hickory, North Carolina, United States|PMG Research of Hickory, LLC, Hickory, North Carolina, United States|Frycare outpatient imaging Center, Hickory, North Carolina, United States|PMG Research of Hickory, LLC, Hickory, North Carolina, United States|Piedmont Healthcare/Research, Statesville, North Carolina, United States|Carolina Arthritis Associates, Wilmington, North Carolina, United States|Clinical Research Services, Bismarck, North Dakota, United States|Dorothy Sander, RPh, Bismarck, North Dakota, United States|St. Alexius Medical Center Inpatient Pharmacy, Bismarck, North Dakota, United States|Trinity Health Center - Medical Arts, Minot, North Dakota, United States|Cincinnati Rheumatic Disease Study Group, Inc., Cincinnati, Ohio, United States|STAT Research, Inc., Dayton, Ohio, United States|Health Research of Oklahoma, Oklahoma City, Oklahoma, United States|Oklahoma Medical Research Foundation (OMRF), Oklahoma City, Oklahoma, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|William M. Schnitz M.D. - Private Practice, Oklahoma City, Oklahoma, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|The Arthritis Group, Philadelphia, Pennsylvania, United States|UPMC Arthritis and Autoimmunity Clinic, Pittsburgh, Pennsylvania, United States|Clinical Research Center of Reading, LLC, Wyomissing, Pennsylvania, United States|Low Country Rheumatology, PA, Charleston, South Carolina, United States|Rheumatology Associates, P.A., Charleston, South Carolina, United States|Innovative Clinical Research, LLC, Greenville, South Carolina, United States|Piedmont Arthritis Clinic, PA, Greenville, South Carolina, United States|Articluaris Healthcare Group d/b/a ACME Research, Orangeburg, South Carolina, United States|Articularis Healtchare Group, Inc. d/b/a Low Country Rheumatology, Summerville, South Carolina, United States|West Tennessee Research Institute, Jackson, Tennessee, United States|Rheumatology Consultants, PLLC, Knoxville, Tennessee, United States|Dr. Ramesh C. Gupta MD, Office of, Memphis, Tennessee, United States|Center For Inflammatory Disease, Nashville, Tennessee, United States|Amarillo Center for Clinical Research, Ltd., Amarillo, Texas, United States|Austin Regional Clinic, Austin, Texas, United States|Trinity Universal Research Associates, Inc, Carrollton, Texas, United States|Pioneer Research Solutions, Inc., Cypress, Texas, United States|Baylor Scott and White Research Institute / Arthritis Care and Research Center, Dallas, Texas, United States|Arthritis Centers of Texas, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Harold C. Simmons Comprehensive Cancer Center-University of Texas Southwestern Medical Center, Dallas, Texas, United States|University of Texas Southwestern Medical Center - Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Accurate Clinical Management, LLC, Houston, Texas, United States|Rheumatic Disease Clinical Research Center, Houston, Texas, United States|Accurate Clinical Research, Inc., Houston, Texas, United States|Houston Institute for Clinical Research, Houston, Texas, United States|Accurate Clinical Management, LLC, Houston, Texas, United States|Medical Center Research, LLC, Houston, Texas, United States|Arthritis and Osteoporosis Associates, LLP, Lubbock, Texas, United States|Southwest Rheumatology Research, LLC, Mesquite, Texas, United States|Accurate Clinical Research, Inc., Nassau Bay, Texas, United States|Trinity Universal Research Associates, Inc., Plano, Texas, United States|Center for Arthritis and Rheumatic Diseases, PC, Chesapeake, Virginia, United States|Center for Arthritis and Rheumatic Diseases, P.C., Suffolk, Virginia, United States|Rheumatic Disease Center, Glendale, Wisconsin, United States|Consultorios Reumatologicos Pampa., C.a.b.a., Buenos Aires, Argentina|I.A.R.I. Instituto de Asistencia Reumatologica Integral, San Fernando, Buenos Aires, Argentina|OMI- Organizacion Medica de Investigacion, Buenos Aires, Caba, Argentina|Centro de Educacion Medica e Investigaciones Clinicas Norberto Quirno (CEMIC), C.a.b.a., Caba, Argentina|Sanatorio Parque S.A y Consultorios Externos Asociados, Rosario, Santa FE, Argentina|Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Tucuman, Argentina|CIER - Centro de Investigaciones en Enfermedades Reumaticas, Caba, Argentina|Centro Privado de Medicina Familiar - Mindout Research S.R.L., Caba, Argentina|Hospital Privado Centro Medico de Cordoba S.A., Cordoba, Argentina|CER San Juan, San Juan, Argentina|The Queen Elizabeth Hospital, Woodville Sth, South Australia, Australia|St. Vincent's Hospital, Fitzroy, Victoria, Australia|Austin Repatriation Hospital, Heidelberg West, Victoria, Australia|RK Will Pty Ltd, Victoria Park, Western Australia, Australia|SER - Servicos Especializados em Reumatologia da Bahia, Salvador, BA, Brazil|CEDOES - Centro de Diagnostico e Pesquisa da Osteoporose do Espirito Santo, Vitoria, Espirito Santo, Brazil|CMIP- Centro Mineiro de Pesquisa Ltda/CETAL- Centro de Estudos e Tratamento do Aparelho Locomotor, Juiz De Fora, MG, Brazil|Hospital das Clinicas Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil|EDUMED - Educacao em Saude SS Ltda, Curitiba, PR, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, RIO Grande DO SUL, Brazil|CCBR Brasil - Centro de Pesquisa e Analises Clinicas LTDA, Rio de Janeiro, RJ, Brazil|Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto, Sao Jose do Rio Preto, SAO Paulo, Brazil|Clinica Medica Bonfliglioli Ltda., Campinas, SP, Brazil|CPCLin - Centro de Pesquisas Clinicas Ltda. / Clinica Dr. Freddy Goldberg Eliaschewitz LTDA EPP, Sao Paulo, SP, Brazil|AACD- Lar Escola\ Associacao de Assistencia a Crianca Deficiente, Sao Paulo, SP, Brazil|Instituto de Assistencia Medica do Hospital do Servidor Publico Estadual, Sao Paulo, SP, Brazil|Fundacao Faculdade de Medicina MECMPAS - Hospital das Clinicas da FMUSP, Sao Paulo, SP, Brazil|Hospital Israelita Albert Einstein, Sao Paulo, SP, Brazil|Hospital Moinhos de Vento, Rio Grande De Sul, Brazil|CPCLin - Centro de Pesquisas Clinicas Ltda. / Clinica Dr. Freddy Goldberg Eliaschewitz LTDA EPP, Sao Paulo, Brazil|CPClin- Centro de Pesquisas Clinicas Ltda./Clinica Dr. Freddy Goldberg Eliaschewitz, Sao Paulo, Brazil|CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda, Sao Paulo, Brazil|CPCLin - Centro de Pesquisas Clinicas Ltda. / Clinica Dr. Freddy Goldberg Eliaschewitz LTDA EPP, Sao Paulo, Brazil|UMBAL "Dr Georgi Stranski" EAD, Pleven, Bulgaria|MBAL Eurohospital Plovdiv OOD, Plovdiv, Bulgaria|MBAL RUSe AD,, Ruse, Bulgaria|UMBAL Sveti Ivan Rilski EAD, Sofia, Bulgaria|UMBAL Sveti Ivan Rilski" EAD, Sofia, Bulgaria|MBAL Sveta Marina EAD, Varna, Bulgaria|Rheumatology Research Associates, Edmonton, Alberta, Canada|PerCuro Clinical Research Limited, Victoria, British Columbia, Canada|Medicine Professional Corporation, Ottawa, Ontario, Canada|Clinical Research and Arthritis Centre, Windsor, Ontario, Canada|Centre de Rhumatologie de l'Est du Quebec, Rimouski, Quebec, Canada|Centre de Recherche Musculo-Squelettique, Trois-Rivieres, Quebec, Canada|Prosalud, Santiago, Metropolitana, Chile|Centro Medico de Reumatologia Ltda., Temuco, Region DE LA Araucania, Chile|Centro de Investigacion Clinica Universidad Catolica (CICUC), Santiago, Region Metropolitana, Chile|Guangdong General Hospital, Guangzhou, Guangdong, China|Centro Integral de Reumatologia REUMALAB S.A.S., Medellin, Antioquia, Colombia|Centro de Investigacion en Reumatologia y Especialidades Medicas S.A.S, CIREEM S.A.S, Bogota D.C., Cundinamarca, Colombia|Centro de Investigaciones Clinica del Country, Bogota, Cundinamarca, Colombia|Preventive Care S.A.S., Chia, Cundinamarca, Colombia|Servimed E.U., Bucaramanga, Santander, Colombia|Lekarna Vesalion, Ostrava, Czech Republic, Czechia|Vesalion, s.r.o., Ostrava, Czech Republic, Czechia|Mestska nemocnice Ostrava, Radiologie a zobrazovaci metody (rentgen), Ostrava, Czech Republic, Czechia|Mediscan Group, s.r.o., Praha 11, Czech Republic, Czechia|MEDIFIN a.s., Lekarna Sustova, Praha, Czech Republic, Czechia|Revmacentrum MUDr. Mostera, s.r.o., Brno - Zidenice, Czechia|Lekarna Na Lidicke, Brno, Cerna Pole, Czechia|Lekarna Zahradnikova, Brno, Czechia|REVMACLINIC s.r.o., Brno, Czechia|Revmaclinic, S.r.o., Brno, Czechia|DC- FLIPPER s.r.o., Brno, Czechia|X-MEDICA s.r.o., radiodiagnostika, Brno, Czechia|Lekarna Halasovo namesti, Brno, Czechia|Revmatologie, s.r.o., Brno, Czechia|Artroscan, s.r.o., Ostrava, Czechia|Lekarna U Revmatologickeho ustavu, Praha 2, Czechia|Revmatologicky ustav., Praha 2, Czechia|Remedis, s.r.o., Nuselska lekama, Praha 4, Czechia|Revmatologicka Ambulance, Praha 4, Czechia|Lekarna Stefanikova, Zlin, Czechia|Nemocnice ATLAS, Zlin, Czechia|PV - MEDICAL s.r.o., Zlin, Czechia|Helsingin yliopistollinen keskussairaala, Helsinki, Finland|HUS-Kuvantaminen, Helsinki, Finland|HUSLAB, Helsinki, Finland|Kiljavan Laaketutkimus Oy, Hyvinkaa, Finland|Laakarikeskus Aava Hyvinkaan Pipetti, Hyvinkaa, Finland|Pamela Youde Nethersole Eastern Hospital, Chai Wan, HKG, Hong Kong|The University of Hong Kong (HKU)-Queen Mary Hospital (QMH), Hong Kong, Hong Kong|The Chinese University of Hong Kong-Prince Of Wales Hospital, Shatin, Hong Kong|Tuen Mun Hospital, Tuen Mun, New Territories, Hong Kong|Barzilai Medical Center - Rheumatology Outpatient Clinic, Ashkelon, Israel|Bnai Zion Medical Center, Haifa, Israel|Rambam Health Care Campus, Haifa, Israel|Carmel Medical Center, Haifa, Israel|Hadassah Medical Center - Hebrew University Hospital, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Rabin Medical Center, Petah Tikva, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|The Chaim Sheba Medical Center, Tel-Hashomer, Israel|Assaf Harofeh Medical Center, Zerifin, Israel|Istishari Hospital, Amman, Jordan|King Abdullah University Hospital, Irbid, Jordan|Hotel Dieu de France Hospital, Achrafieh, Beirut, Lebanon|Ain Wazein Hospital, Lebanon, Lebanon|Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia|Sarawak General Hospital, Kuching, Sarawak, Malaysia|Hospital Selayang, Department of Medicine, Batu Caves, Selangor, Malaysia|Unidad de Enfermedades Reumaticas y Cronico Degenerativas S. C., Torreon, Coahuila, Mexico|Consultorio de Reumatologia, Mexico, Distrito Federal, Mexico|CINTRE, Centro de Investigacion y Tratamiento Reumatologico S.C., Mexico, Distrito Federal, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Distrito Federal, Mexico|Centro Integral en Reumatologia SA de CV, Guadalajara, Jalisco, Mexico|Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico|Centro de Investigacion Clinica de Morelia. S.C, Morelia, Michoacan, Mexico|Clinica de Enfermedades Cronicas y Procedimientos Especiales, SC, Morelia, Michoacan, Mexico|Centro de Investigacion de Tratamientos Innovadores de Sinaloa, S.C, Culiacan, Sinaloa, Mexico|Unidad Reumatologica Las Americas S.C.P., Merida, Yucatan, Mexico|Unidad Reumatologica Las Americas SCP, Merida, Yucatan, Mexico|Centro de Especialidades Medicas del Sureste S.A de C.V., Merida, Yucatan, Mexico|Investigacion y Biomedica de Chihuahua SC, Chihuahua, Mexico|Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi, S.C., San Luis Potosi, Mexico|Unidad de Investigaciones Reumatologicas, San Luis Potosi, Mexico|Medical Center Leeuwarden, Leeuwarden, Netherlands|Universitair Medisch Centrum (UMC) Utrecht, Utrecht, Netherlands|Counties Manukau District Health Board Radiology (X-rays only), Auckland, New Zealand|Middlemore Clinical Trials, Auckland, New Zealand|Pacific Medimaging Limited, Hamilton, New Zealand|Rheumatology Clinic, Waikato Hospital, Hamilton, New Zealand|Timaru Hospital, Timaru, New Zealand|Timaru Radiology, Timaru, New Zealand|Capital and Coast District Health Board Radiology Services, Wellington, New Zealand|Wellington Hospital, Wellington, New Zealand|Centro de Investigacion ClinicaTrujillo E.I.R.L. Clinica Peruana Americana, Trujillo, LA Libertad, Peru|ABK REUMA S.R.L. de Medicentro Biociencias- BIO CIENCIAS PERU S.R.L., Pueblo Libre, Lima, Peru|Centro de Investigación CAREINEN-Hospital Nacional Carlos Alberto Seguin Escobedo (HNCASE) Arequipa, Arequipa, Peru|Investigaciones Clinicas S.A.C, Lima, Lima, Peru|ACQ MEDIC S.A.C. - Centro de Investigacion Clinica Inmunoreumatologia, Lima, Peru|Unidad de Investigacion de la Clinica Internacional - Clinica Internacional, Lima, Peru|Instituto Peruano del Hueso y la Articulacion - Instituto Peruano del Hueso y la Articulacion S.A.C., Lima, Peru|Investigaciones en Reumatologia - Centro Medico Corpac, Lima, Peru|Investigaciones Clinicas S.A.C., Lima, Peru|Centro de Investigacion de Reumatologia - Clinica San Borja, Lima, Peru|Centro de Investigacion en Salud - Centro de Excelencia en Reumatologia, Lima, Peru|Centro de Investigacion en Salud - Centro de Excelencia en Reumatologia, Lima, Peru|Lecznica MAK-MED, NZOZ, Nadarzyn, Mazowieckie, Poland|NZOZ Lecznica MAK-MED, Nadarzyn, Mazowieckie, Poland|Rheuma-Medicus - Specjalistyczne Centrum Reumatologii i Osteoporozy, Warszawa, Mazowieckie, Poland|Zdrowie Osteo-Medic s.c. Lidia i Artur Racewicz, Agnieszka i Jerzy Supronik, Bialystok, Podlaskie, Poland|Centrum medyczne Pratia Gdynia, Gdynia, Pomorskie, Poland|Medica Pro Familia Sp. z o.o. S.K.A. Oddzial w Gdynia, Gdynia, Pomorskie, Poland|Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy, Klinika Reumatologii i Ukladowych, Bydgoszcz, Poland|Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Centrum Kliniczno-Badawcze J.Brzezicki, B.Gornikiewicz-Brzezicka Lekarze Spolka Partnerska, Elblag, Poland|Synexus Polska Sp. z o.o. Oddzial w Gdyni, Gdynia, Poland|Centrum Medyczne Pratia Katowice, Katowice, Poland|Prof. dr hab. n. med. Leszek Szczepanski, Prywatna Praktyka Lekarska, Osrodek Badan Klinicznych, Lublin, Poland|Zespol Poradni Specjalistycznych Reumed Filia Onyksowa, Lublin, Poland|PROFMEDICUS Sp. z o.o., Osrodek Badan Klinicznych, Olsztyn, Poland|Prywatna Praktyka Lekarska Prof. UM dr hab. med. Pawel Hrycaj, Poznan, Poland|Wojewodzki Zespol Reumatologiczny im. dr Jadwigi Titz-Kosko w Sopocie, Oddzial 1, Sopot, Poland|KO-MED Centra Kliniczne Sp. zo.o., Staszow, Poland|NASZ LEKARZ Przychodnie Medyczne, Torun, Poland|Niepubliczny Zaklad Opieki Zdrowotnej (NZOZ) - Nasz Lekarz, Torun, Poland|NZOZ Nasz Lekarz Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna, Torun, Poland|Rheuma Medicus Zaklad Opieki Zdrowotnej, Warsaw, Poland|Medica Pro Familia Sp. z o.o. S.K.A., Warszawa, Poland|Synexus Polska Sp. z o. o. Oddzial we Wroclawiu, Wroclaw, Poland|Akademicki Szpital Kliniczny im. J. Mikulicza - Radeckiego we Wroclawiu, Wroclaw, Poland|NZOZ Biogenes Sp. z o.o., Wroclaw, Poland|Ponce Medical School Foundation, Inc., Ponce, Puerto Rico|Ponce Medical School Foundation, Inc. CAIMED Center, Ponce, Puerto Rico|Fundacion de Investigaction de Diego, San Juan, Puerto Rico|Saint Petersburg State Healthcare Institution City Hospital 40 Of Kurort Administrative Region, Saint-Petersburg, Sestroretsk CITY, Russian Federation|Saint-Petersburg State Budgetary Institution of Healthcare Municipal hospital # 40 of the, St.Petersburg, Sestroretsk CITY, Russian Federation|SBHI City Clinical Hospital #4 of HD of Moscow, Moscow, Russian Federation|SBIH of Moscow City Clinical Hospital 1 n. a. N.I. Pirogov of the Healthcare Department of Moscow, Moscow, Russian Federation|SBIH of Nizhniy Novgorod region City Clinical Hospital #5 of Nizhniy Novgorod district, Nizhniy Novgorod, Russian Federation|Federal State Budgetary Scientific Institution "Research Institute of Fundamental and Clinical Immun, Novosibirsk, Russian Federation|LLC City Neurological Center Sibneuromed, Novosibirsk, Russian Federation|Consulting and Diagnostic Rheumatological Center Healthy Joints LLC, Novosibirsk, Russian Federation|GBUZ RK Republic Hospital n. a. V.A. Baranov, Petrozavodsk, Russian Federation|Federal State Budgetary Educational Institution of Higher Education, Smolensk, Russian Federation|Saint-Petersburg State Budget Healthcare Institution Consultative-diagnostic Center #85, St. Petersburg, Russian Federation|SBEI of HPE Ural State Medical University of the MoH of the RF, Yekaterinburg, Russian Federation|Municipal Budgetary Institution "Central City Clinical Hospital #6", Yekaterinburg, Russian Federation|Municipal Budgetary Institution Central City Clinical Hospital 6, Yekaterinburg, Russian Federation|Nestatna reumatologicka ambulancia, Bratislava, Slovakia|ROMJAN s.r.o. - Specializovana reumatologicka ambulancia, Bratislava, Slovakia|AAGS, s.r.o., Dunajska Streda, Slovakia|"KM Management spol. s.r.o.Gastroenterologicke a hepatologicke centrum Nitra, Nitra, Slovakia|ECCLESIA s.r.o, Reumatologicka ambulancia, Nove Zamky, Slovakia|REUMACENTRUM s.r.o., Reumatologicka ambulancia, Partizanske, Slovakia|Reumex s.r.o, Rimavska Sobota, Slovakia|Reuma-Global s.r.o., Reumatologicka ambulancia, Trnava, Slovakia|Greenacres Hospital, Port Elizabeth, Eastern CAPE, South Africa|WCR: Wits Clinical Research, Johannesburg, Gauteng, South Africa|Clinresco Centres ( Pty ) Ltd, Kempton Park, Gauteng, South Africa|Emmed Research, Pretoria, Gauteng, South Africa|Jakaranda Hospital, Pretoria, Gauteng, South Africa|Wilmed Park Oncology Unit-Wilmed Park Private Hospital, Wilkoppies, Klerksdorp, South Africa|St. Augustine's Hospital - Chelmsford Medical Centre 2, Durban, Kwa-zulu Natal, South Africa|Tiervlei Trial Centre, Karl Bremer Hospital, Bellville, Cape Town, Western CAPE, South Africa|Arthritis Clinical Research Trials cc, Cape Town, Western CAPE, South Africa|Panorama Medical Centre., Cape Town, Western CAPE, South Africa|Winelands Medical Research Centre, Stellenbosch, Western CAPE, South Africa|Clinical Research Centre (UCT) Groote Schuur Hospital, Cape Town, South Africa|Doctors Bungalows, Groote Schuur Hospital, Cape Town, South Africa|Hospital de Merida, Merida, Badajoz, Spain|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Hospital Nuestra Senora de la Esperanza, Santiago de Compostela, LA Coruna, Spain|Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain|Hospital Universitario de Basurto, Bilbao, Vizcaya, Spain|Hospital Plato, Barcelona, Spain|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Regional Universitario de Malaga, Malaga, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|China Medical University Hospital, Taichung City, Taiwan (r.o.c), Taiwan|Changhua Christian Hospital, Changhua, Taiwan|Buddhist Dalin Tzu Chi General Hospital, Chia-Yi, Taiwan|Chung Shan Medical University Hospital, Taichung, Taiwan|National Cheng Kung University (NCKU) Hospital, Tainan, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Medical Foundation - Linkou Branch, Taoyuan City, Taiwan|Phramongkutklao Hospital, Bangkok, Thailand|Ramathibodi Hospital, Mahidol University, Bangkok, Thailand|Faculty of Medicine , Siriraj Hospital , Mahidol University, Bangkok, Thailand|Maharaj Nakorn Chiangmai Hospital, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand|Prince of Songkla University, Songkhla, Thailand|"Ankara Universitesi Tip Fakultesi Ibn-i Sina Hastanesi, Ankara, Turkey|Ankara Universitesi Tip Fakultesi Hastanesi, Ankara, Turkey|Hacettepe Universitesi Tip Fakultesi, Ankara, Turkey|Adnan Menderes Universitesi Tip Fakultesi Hastanesi, Aydin, Turkey|Adnan Menderes Universitesi Uygulama ve Arastirma Hastanesi, Aydin, Turkey|Dicle University Medical Faculty, Diyarbakir, Turkey|Gasiantep Univ. Fac. Of Med. Sahibey Hospital. Dept of Internal Diseases, Gaziantep, Turkey|Gaziantep Universitesi Sahinbey Hastanesi, Gaziantep, Turkey|Gaziantep Universitesi, Gaziantep, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi, Istanbul, Turkey|Sifa University Faculty of Medicine, Izmir, Turkey|Izmir Tepecik Egitim ve Arastirma Hastanesi, Izmir, Turkey|Kocaeli Universitesi Tip Fakultesi Hastanesi, Kocaeli, Turkey|Manisa Celal Bayar Universitesi, Manisa, Turkey|Manisa Celal Bayar Universitesi Hafsa Sultan Hastanesi, Manisa, Turkey|Ondokuz Mayis Universitesi Tip Fakultesi Fiziksel Tip ve, Samsun, Turkey|Cumhuriyet Universitesi Tip Fakultesi Hastanesi Fiziksel Tip ve Rehabilitasyon Anabilim Dali, Sivas, Turkey|Clinical Trials, Poole, Dorset, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, Dorset, United Kingdom|Barking, Havering and Redbridge University Hospital NHS Trust, Goodmayes, Essex, United Kingdom|The Royal Wolverhampton NHS Trust-Cannock Chase Hospital, Cannock, United Kingdom|University of Liverpool Academic Rheumatology Unit, Liverpool, United Kingdom|Aintree University Hospital NHS Foundation Trust (University Hospital Aintree), Liverpool, United Kingdom|Clinical trials, Liverpool, United Kingdom|Clinical Research Facility, Royal Victoria Infirmary, Newcastle Upon Tyne, United Kingdom|drugThe Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom|Royal Victoria Infirmary - The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom|North Tyneside General Hospital, North Shields, United Kingdom|Pharmacy Department, Wolverhampton, United Kingdom		https://ClinicalTrials.gov/show/NCT02092467
246	NCT00117117	A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®		Completed	No Results Available	Anemia	Drug: Aranesp	Patient reported outcomes|Changes in hemoglobin endpoints and RBC transfusion requirements	Amgen	All	18 Years and older   (Adult, Older Adult)	Phase 4	2423	Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20020132	September 2002		December 2003	July 4, 2005		March 25, 2009			https://ClinicalTrials.gov/show/NCT00117117
247	NCT03323021	Use of Human Dehydrated Amnion/Chorion (DHACM) Allograft in Partial Nephrectomy		Completed	No Results Available	Partial Nephrectomy|Kidney Cancer|Renal Function Aggravated	Biological: Dehydrated human amnion/chorion membrane|Other: Standard of Care	Recovery of Renal Function|Preservation of Renal Parenchymal Volume|Cancer Control Rates	MiMedx Group, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 4	61	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	AFSUR001	May 23, 2017	February 21, 2019	February 21, 2019	October 26, 2017		March 8, 2019	The Mount Sinai Hospital, New York, New York, United States		https://ClinicalTrials.gov/show/NCT03323021
248	NCT01465243	Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose		Completed	No Results Available	Non-small Cell Lung Cancer	Drug: Icotinib	Progression-free Survival|Overall survival|Objective response rate|Time to progression|Health-Related Quality of Life (HR QOL)|Number of Participants with adverse events and serious adverse events (SAEs)	Betta Pharmaceuticals Co., Ltd.	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	32	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BD-IC-IV01	September 2011	October 2013	February 2014	November 4, 2011		February 17, 2014	307 Hospital of People's Liberation Army（PLA）, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT01465243
249	NCT00776425	A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies		Completed	No Results Available	Anemia	Drug: Epoetin beta	Percentage of Participants Who Achieved a Clinical Response 3-4 Weeks After Start of Treatment|Percentage of Participants Who Achieved a Clinical Response 6-8 Weeks After Start of Treatment|Percentage of Participants Who Achieved a Clinical Response 10-12 Weeks After Start of Treatment|Percentage of Participants Who Achieved a Clinical Response 3-4 Weeks After Start of Treatment with Mixed Dosing Regimen|Percentage of Participants Who Achieved a Clinical Response 6-8 Weeks After Start of Treatment with Mixed Dosing Regimen|Percentage of Participants Who Achieved a Clinical Response 10-12 Weeks After Start of Treatment with Mixed Dosing Regimen|Quality of Life of Anemic Participants Using Short Form 36 (SF-36) Questionnaire Prior To Treatment|Quality of Life of Anemic Participants Using SF-36 Questionnaire 3-4 Weeks After Start of Treatment|Quality of Life of Anemic Participants Using SF-36 Questionnaire 6-8 Weeks After Start of Treatment|Quality of Life of Anemic Participants Using SF-36 Questionnaire 10-12 Weeks After Start of Treatment|Percentage of Participants With Quality of Life Integral Value (IV) Reduction Prior To Treatment|Percentage of Participant With Quality of Life IV Reduction 3-4 Weeks After Start of Treatment|Percentage of Participant With Quality of Life IV Reduction 6-8 Weeks After Start of Treatment|Percentage of Participant With Quality of Life IV Reduction 10-12 Weeks After Start of Treatment|Percentage of Participant With Characteristics of The Quality of Life Related Response To Treatment 3-4 Weeks After Start of Treatment|Percentage of Participant With Characteristics of The Quality of Life Related Response To Treatment 6-8 Weeks After Start of Treatment|Percentage of Participant With Characteristics of The Quality of Life Related Response To Treatment 10-12 Weeks After Start of Treatment|Fatigue Severity Score at Baseline|Fatigue Severity Score 3-4 Weeks After Start of Treatment|Fatigue Severity Score 6-8 Weeks After Start of Treatment|Fatigue Severity Score 10-12 Weeks After Start of Treatment|Percentage of Participant With Various Fatigue Severity Prior To Treatment|Percentage of Participant With Various Fatigue Severity 3-4 Weeks After Start of Treatment|Percentage of Participant With Various Fatigue Severity 6-8 Weeks After Start of Treatment|Percentage of Participant With Various Fatigue Severity 10-12 Weeks After Start of Treatment|Percentage of Participant With Different Symptoms Prior to Treatment (MDASI Questionnaire)|Percentage of Participant With Different Symptoms 3-4 Weeks After Start of Treatment (MDASI Questionnaire)|Percentage of Participant With Different Symptoms 6-8 Weeks After Start of Treatment (MDASI Questionnaire)|Percentage of Participant With Different Symptoms 10-12 Weeks After Start of Treatment (MDASI Questionnaire)|Severity Score of Different Symptoms Prior toTreatment (MDASI Questionnaire)|Severity Score of Different Symptoms 3-4 Weeks After Start of Treatment (MDASI Questionnaire)|Severity Score of Different Symptoms 6-8 Weeks After Start of Treatment (MDASI Questionnaire)|Severity Score of Different Symptoms 10-12 Weeks After Start of Treatment (MDASI Questionnaire)|Percentage of Participants With Improvement in Symptoms Severity 10-12 Weeks After Start of Treatment|Percentage of Participants With Concomitant Symptoms of Various Severity Prior To Treatment|Percentage of Participants With Concomitant Symptoms of Various Severity 3-4 Weeks After Start of Treatment|Percentage of Participants With Concomitant Symptoms of Various Severity 4-6 Weeks After Start of Treatment|Percentage of Participants With Concomitant Symptoms of Various Severity 10-12 Weeks After Start of Treatment|Quality of Life of Anemic Participants With Clinical Response Using SF-36 Questionnaire Prior To Treatment|Quality of Life of Anemic Participants With Clinical Response Using SF-36 Questionnaire 3-4 Weeks After Start of Treatment|Quality of Life of Anemic Participants With Clinical Response Using SF-36 Questionnaire 6-8 Weeks After Start of Treatment|Quality of Life of Anemic Participants With Clinical Response Using SF-36 Questionnaire 10-12 Weeks After Start of Treatment|Percentage of Participants With Different Symptoms Who Had Clinical Response Prior to Treatment|Percentage of Participants With Different Symptoms Who Had Clinical Response 3-4 Weeks After Start of Treatment|Percentage of Participants With Different Symptoms Who Had Clinical Response 6-8 Weeks After Start of Treatment|Percentage of Participants With Different Symptoms Who Had Clinical Response 10-12 Weeks After Start of Treatment|Severity Score of Different Symptoms in Anemic Participants With Clinical Response Prior To Treatment|Severity Score of Different Symptoms in Anemic Participants With Clinical Response 3-4 Weeks After Start of Treatment|Severity Score of Different Symptoms in Anemic Participants With Clinical Response 6-8 Weeks After Start of Treatment|Severity Score of Different Symptoms in Anemic Participants With Clinical Response 10-12 Weeks After Start of Treatment|Percentage of Participants With Clinical Response After First 3-4 Weeks of Treatment at 30000 IU Once Weekly Dose|Percentage of Participants With Clinical Response After Second 3-4 Weeks of Treatment at 30000 IU Once Weekly Dose|Percentage of Participants With Clinical Response After Third 3-4 Weeks of Treatment at 30000 IU Once Weekly Dose|Quality of Life in Anemic Participants Receiving Treatment at 30000 IU Once Weekly (SF-36 Questionnaire) Prior to Treatment|Quality of Life in Anemic Participants Receiving Treatment at 30000 IU Once Weekly (SF-36 Questionnaire) 3-4 Weeks After Start of Treatment|Quality of Life in Anemic Participants Receiving Treatment at 30000 IU Once Weekly (SF-36 Questionnaire) 6-8 Weeks After Start of Treatment|Quality of Life in Anemic Participants Receiving Treatment at 30000 IU Once Weekly (SF-36 Questionnaire) 10-12 Weeks After Start of Treatment|Number of Participants With Lymphoproliferative Disorders and Solid Tumors Who Had Quality of Life IV Reduction Prior to Treatment|Number of Participants With Lymphoproliferative Disorders and Solid Tumors Who Had Quality of Life IV Reduction 3-4 Weeks After Start of Treatment|Number of Participants With Lymphoproliferative Disorders and Solid Tumors Who Had Quality of Life IV Reduction 6-8 Weeks After Start of Treatment|Number of Participants With Lymphoproliferative Disorders and Solid Tumors Who Had Quality of Life IV Reduction 10-12 Weeks After Start of Treatment|Percentage of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors Prior Receiving Treatment at 30000 IU Once Weekly|Percentage of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors 3-4 Weeks After Start of Treatment at 30000 IU Once Weekly|Percentage of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors 6-8 Weeks After Start of Treatment at 30000 IU Once Weekly|Percentage of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors 10-12 Weeks After Start of Treatment at 30000 IU Once Weekly|Severity Score of Different Symptoms in Participants With Lymphoproliferative Disorders and Solid Tumors Prior to Treatment at 30000 IU Once Weekly|Severity Score of Different Symptoms in Participants With Lymphoproliferative Disorders and Solid Tumors 3-4 Weeks After Start of Treatment at 30000 IU Once Weekly|Severity Score of Different Symptoms in Participants With Lymphoproliferative Disorders and Solid Tumors 6-8 Weeks After Start of Treatment at 30000 IU Once Weekly|Severity Score of Different Symptoms in Participants With Lymphoproliferative Disorders and Solid Tumors 10-12 Weeks After Start of Treatment at 30000 IU Once Weekly|Percentage of Participants With Improvement in Symptoms Severity Categorized by Lymphoproliferative Disorders and Solid Tumors 10-12 Weeks After Start of Treatment|Number of Participants Who Achieved a Clinical Response 3-4 Weeks After Start of Treatment|Number of Participants Who Achieved a Clinical Response 6-8 Weeks After Start of Treatment|Number of Participants Who Achieved a Clinical Response 10-12 Weeks After Start of Treatment|Number of Participants Who Achieved a Clinical Response With Mixed Drug Dosing Regimen, 3-4 Weeks After Start of Treatment|Number of Participants Who Achieved a Clinical Response With Mixed Drug Dosing Regimen, 6-8 Weeks After Start of Treatment|Number of Participants Who Achieved a Clinical Response With Mixed Dosing Regimen, 10-12 Weeks After Start of Treatment|Number of Participants With Quality of Life IV Reduction 3-4 Weeks After Start of Treatment|Number of Participants With Quality of Life IV Reduction 6-8 Weeks After Start of Treatment|Number of Participants With Quality of Life IV Reduction 10-12 Weeks After Start of Treatment|Number of Participants With Characteristics of the Quality of Life Related Response To Treatment 3-4 Weeks After Start of Treatment|Number of Participants With Characteristics of the Quality of Life Related Response To Treatment 6-8 Weeks After Start of Treatment|Number of Participants With Characteristics of the Quality of Life Related Response To Treatment 10-12 Weeks After Start of Treatment|Percentage of Participants With Various Fatigue Severity 3-4 Weeks After Start of Treatment|Percentage of Participants With Various Fatigue Severity 6-8 Weeks After Start of Treatment|Percentage of Participants With Various Fatigue Severity 10-12 Weeks After Start of Treatment|Number of Participants With Different Symptoms 3-4 Weeks After Start of Treatment (MDASI Questionnaire)|Number of Participant With Different Symptoms 6-8 Weeks After Start of Treatment (MDASI Questionnaire)|Number of Participants With Different Symptoms 10-12 Weeks After Start of Treatment (MDASI Questionnaire)|Number of Participants With Improvement in Symptoms Severity 10-12 Weeks After Start of Treatment|Number of Participants With Concomitant Symptoms of Various Severity 3-4 Weeks After Start of Treatment|Number of Participants With Concomitant Symptoms of Various Severity 6-8 Weeks After Start of Treatment|Number of Participants With Concomitant Symptoms of Various Severity 10-12 Weeks After Start of Treatment|Number of Participants With Different Symptoms Who Had Clinical Response 3-4 Weeks After Start of Treatment|Number of Participants With Different Symptoms Who Had Clinical Response 6-8 Weeks After Start of Treatment|Number of Participants With Different Symptoms Who Had Clinical Response 10-12 Weeks After Start of Treatment|Number of Participants With Clinical Response After First 3-4 Weeks of Treatment at 30000 IU Once Weekly Dose|Number of Participants With Clinical Response After Second 3-4 Weeks of Treatment at 30000 IU Once Weekly Dose|Number of Participants With Clinical Response After Third 3-4 Weeks of Treatment at 30000 IU Once Weekly Dose|Number of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors Before Receiving Treatment at 30000 IU Once Weekly|Number of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors 3-4 Weeks After Start of Treatment at 30000 IU Once Weekly|Number of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors 6-8 Weeks After Start of Treatment at 30000 IU Once Weekly|Number of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors 10-12 Weeks After Start of Treatment at 30000 IU Once Weekly|Number of Participants With Improvement in Symptoms Severity Categorized by Lymphoproliferative Disorders and Solid Tumors 10-12 Weeks After Start of Treatment at 30000 IU Once Weekly	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	117	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML20197	January 2007	November 2012	November 2012	October 21, 2008		July 2, 2017	Arkhangelsk, Russian Federation|Barnaul, Russian Federation|Belgorod, Russian Federation|Ivanovo, Russian Federation|Kazan, Russian Federation|Kostroma, Russian Federation|Lipetsk, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|Petrozavodsk, Russian Federation|Ryazan, Russian Federation|Salekhard, Russian Federation|Soshi, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|Surgut, Russian Federation|Tumen, Russian Federation|Tver, Russian Federation|UFA, Russian Federation|Yaroslavl, Russian Federation		https://ClinicalTrials.gov/show/NCT00776425
250	NCT01609543	A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations		Completed	Has Results	Non-Squamous Non-Small Cell Lung Cancer	Drug: erlotinib [Tarceva]	Progression-Free Survival (PFS)|Percentage of Participants With Best Overall Response (BOR)|Percentage of Participants Who Were Alive at 1 Year	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	62	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML27880|2011-002168-26	May 2012	January 2015	January 2015	June 1, 2012	February 1, 2016	February 1, 2016	Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Deszk, Hungary|Farkasgyepu, Hungary|Gyula, Hungary|Mosonmagyaróvar, Hungary|Mátraháza, Hungary|Nyiregyhaza, Hungary|Pecs, Hungary|Szekesfehervar, Hungary|Szekszard, Hungary|Szolnok, Hungary|Szombathely, Hungary|Torokbalint, Hungary|Törökbálint, Hungary|Riga, Latvia|Riga, Latvia|Ankara, Turkey|Ankara, Turkey|Antalya, Turkey|Edirne, Turkey|Istanbul, Turkey		https://ClinicalTrials.gov/show/NCT01609543
251	NCT02000531	Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population		Completed	Has Results	Carcinoma, Non-Small-Cell Lung	Drug: Erlotinib|Drug: Chemotherapy	Progression Free Survival (PFS) Based on Well-documented and Verifiable Progression Events|Participants With Adverse Events	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	45	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML29028	January 2014	December 2014	December 2014	December 4, 2013	January 13, 2016	January 13, 2016	Beijing, China|Changchun, China|Chongqing, China|ChongQing, China|Fuzhou, China|Guangzhou, China|Nanjing, China|Shanghai, China|Shanghai, China|Shantou, China|Wuhan, China		https://ClinicalTrials.gov/show/NCT02000531
252	NCT00952081	A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients		Completed	Has Results	Hypertension|Brain Tumor|Epilepsy	Drug: Clevidipine	The Primary Endpoint of This Trial is the Proportion of Patients Who Did Not Require Rescue Antihypertensive Medication to Maintain SBP Below 130 mmHg (i.e. Clevidipine is a Sole Antihypertensive Agent Used for Blood Pressure Control)	NYU Langone Health|The Medicines Company	All	21 Years and older   (Adult, Older Adult)	Phase 4	22	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	08-745	July 2009	December 2009	February 2010	August 4, 2009	October 30, 2013	February 9, 2015	NYU Langone Medical Center, Department of Anesthesiology, New York, New York, United States		https://ClinicalTrials.gov/show/NCT00952081
253	NCT03210376	Neuromuscular Blockade on Shoulder Pain of Elderly		Active, not recruiting	No Results Available	Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Urinary Tract	Drug: Deep Neuromuscular Blockade (NMB)|Drug: Moderate Neuromuscular Blockade (NMB)|Drug: Sugammadex|Drug: Neostigmine|Behavioral: Pain Assessment	Incidence of Postoperative Shoulder Pain|Cumulative Intraoperative Insufflation Pressure (mmHg min) During Surgery|Readiness to Discharge from the Post-Anesthesia Care Unit (PACU|Degree of Post-Operative Nausea|Degree of Post-Operative Vomiting	M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.	All	65 Years and older   (Older Adult)	Phase 4	100	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	2017-0046|NCI-2018-01176	November 17, 2017	November 2019	November 2020	July 6, 2017		April 8, 2019	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03210376
254	NCT00092183	An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)		Completed	No Results Available	Nausea|Vomiting|Breast Neoplasms	Drug: MK0869, aprepitant / Duration of Treatment: 3 days|Drug: Comparator: ondansetron / Duration of Treatment: 3 days	Emesis and use of rescue medication|Safety and tolerability|Quality of life	Merck Sharp & Dohme Corp.	All	18 Years and older   (Adult, Older Adult)	Phase 4	866	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	0869-071|MK0869-071|2004_063	October 10, 2002	December 1, 2003	February 11, 2004	September 24, 2004		May 5, 2017			https://ClinicalTrials.gov/show/NCT00092183
255	NCT00204373	Treatment of Zollinger-Ellison Syndrome With Prevacid		Completed	Has Results	Zollinger-Ellison Syndrome|Multiple Endocrine Neoplasia	Drug: Lansoprazole (Prevacid)	Long-term Medical(Non-surgical)Control of Gastric Acid Production Assessed From Time of Study Enrollment, up to 240 Months Post Enrollment.|The Median Survival From the Time of Diagnosis.	Charles Mel Wilcox, MD|Takeda Pharmaceuticals North America, Inc.|University of Alabama at Birmingham	All	19 Years and older   (Adult, Older Adult)	Phase 4	72	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	F030107005	March 2003	December 2010	December 2010	September 20, 2005	October 19, 2012	October 30, 2012			https://ClinicalTrials.gov/show/NCT00204373
256	NCT01053819	Can We Miss Pigmented Lesions in Psoriasis Patients?		Completed	Has Results	Psoriasis|Melanoma|Non-melanoma Skin Cancer	Drug: etanercept	The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques.|A Secondary Objective Will be to Evaluate the Identified Pigmented Lesions for Suspicious Criteria	University of Alabama at Birmingham|Amgen	All	19 Years and older   (Adult, Older Adult)	Phase 4	6	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	F070629011	September 2007	April 2012	April 2012	January 21, 2010	August 22, 2012	February 23, 2018	UAB Dermatology, Birmingham, Alabama, United States		https://ClinicalTrials.gov/show/NCT01053819
257	NCT01783236	Analgesic Efficacy of Intravenous Acetaminophen After Video-assisted Thoracic Surgery		Completed	Has Results	Lung Tumor	Drug: IV Acetaminophen|Drug: Saline Placebo	Total Morphine Consumption (mg)|Total Number of PCA Requests in First 24 Hours Post-Operation|VAS Pain Score 2 Hours Post Operation|VAS Pain Score 6 Hours Post-Operation|VAS Score 24 Hours Post-Operation	Weill Medical College of Cornell University|Mallinckrodt	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 4	16	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	1204012295	June 2013	February 2015	July 2015	February 4, 2013	May 11, 2017	May 11, 2017	Weill Cornell Medical College, New York City, New York, United States		https://ClinicalTrials.gov/show/NCT01783236
258	NCT02243735	Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion as Treatment of Anaemia	FIT	Recruiting	No Results Available	Anemia|Colorectal Carcinoma|Surgery	Drug: Ferrous fumarate|Drug: ferric(III)carboxymaltose	Normalization of Hb-level.|Difference in Morbidity score	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Vifor Pharma	All	18 Years and older   (Adult, Older Adult)	Phase 4	198	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NL50013.018.14|2014-002827-87	November 2014	November 2019	December 2019	September 18, 2014		August 28, 2018	Medisch Centrum Alkmaar, Alkmaar, Netherlands|Flevoziekenhuis, Almere, Netherlands|Meander Ziekenhuis, Amersfoort, Netherlands|Academic Medical Center, Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Sint Lucas Andreas Ziekenhuis, Amsterdam, Netherlands|Spaarne ziekenhuis, Amsterdam, Netherlands|VU medical center, Amsterdam, Netherlands|Amsterdam, Netherlands|Gelre Ziekenhuis, Apeldoorn, Netherlands|Albert Schweizer Ziekenhuis, Dordrecht, Netherlands|Tergooi ziekenhuis, Hilversum, Netherlands|Haga Ziekenhuis, The Hague, Netherlands		https://ClinicalTrials.gov/show/NCT02243735
259	NCT03340506	Dabrafenib and/or Trametinib Rollover Study		Recruiting	No Results Available	Melanoma|Non Small Cell Lung Cancer|Solid Tumor|Rare Cancers|High Grade Glioma	Drug: dabrafenib|Drug: trametinib	Occurences of adverse events to evaluate long term safety and tolerability of dabrafenib, trametinib or combination|Clinical Benefit Assessment by investigator	Novartis Pharmaceuticals|Novartis	All	Child, Adult, Older Adult	Phase 4	100	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDRB436X2X02B	December 28, 2017	July 17, 2023	July 17, 2023	November 13, 2017		July 9, 2019	Honor Health Research Institute, Scottsdale, Arizona, United States|James Cancer Hospital and Solove Research Institute Ohio State, Columbus, Ohio, United States|Mary Crowley Cancer Research, Dallas, Texas, United States|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain		https://ClinicalTrials.gov/show/NCT03340506
260	NCT03451071	Postpartum HPV Vaccination		Recruiting	No Results Available	HPV-Related Malignancy	Drug: Gardasil9	Patient indication of willingness to accept the vaccine based on survey|Uptake of the vaccine doses|serum titers of vaccine-specific HPV types	University of Alabama at Birmingham|Merck Sharp & Dohme Corp.	Female	16 Years to 26 Years   (Child, Adult)	Phase 4	100	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	000518236	April 29, 2019	December 1, 2019	June 30, 2020	March 1, 2018		July 8, 2019	University of Alabama at Birmingham, Birmingham, Alabama, United States		https://ClinicalTrials.gov/show/NCT03451071
261	NCT02911961	APAP-CYS Protein Adduct Concentrations in Patients With Liver-Directed Therapy Intended to Treat Hepatic Tumors		Recruiting	No Results Available	Acetaminophen Exposure	Drug: Acetaminophen	APAP-CYS Concentrations Over Time - Acetaminophen Group|APAP-CYS Concentrations Over Time - Non-Acetaminophen Group|Relationship between APAP-CYS and other biochemical markers of liver function	Denver Health and Hospital Authority|Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division|University of Colorado, Denver|Rocky Mountain Poison and Drug Center	All	21 Years to 80 Years   (Adult, Older Adult)	Phase 4	30	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening	16-0031	August 2019	June 2020	September 2020	September 23, 2016		August 1, 2019	University of Colorado Denver, Denver, Colorado, United States		https://ClinicalTrials.gov/show/NCT02911961
262	NCT03142542	The Efficacy and Safety of Udenafil in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy	DA8159_EDP_IIT	Not yet recruiting	No Results Available	Prostate Cancer With Radical Prostatectomy	Drug: ZYDENA TAB.75mg(Udenafil 75mg)|Drug: Placebo Oral Tablet	The proportion of patients who has IIEF-EF score ≥22|Safety evaulation: Occurrence of any adverse events|Safety evaluation: Systolic and diastolic blood pressure|Safety evaluation: 12-lead ECG|Safety evaluation: Number of Participants With Abnormal Laboratory Values|Safety evaluation:pulse rate	Samsung Medical Center|Dong-A ST Co., Ltd.	Male	20 Years to 70 Years   (Adult, Older Adult)	Phase 4	99	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	2017-02-112	May 2017	May 2019	December 2019	May 5, 2017		May 5, 2017			https://ClinicalTrials.gov/show/NCT03142542
263	NCT00616135	Study of Autologous Fat Enhanced w/ Regenerative Cells Transplanted to Reconstruct Breast Deformities After Lumpectomy	RESTORE-2	Completed	No Results Available	Breast Neoplasms|Carcinoma, Ductal, Breast|Mammaplasty|Mastectomy, Segmental, Lumpectomy, Breast Reconstruction,	Procedure: ADRC-Enhanced Autologous Fat Transplant	Patient and physician satisfaction with functional and cosmetic results. Improvement in overall breast deformity measured at 12 months compared to baseline.|Change in breast volume and shape at 6 and 12 Months compared to baseline. Improvement in skin pigmentation abnormalities at 6 and 12 months compared to Baseline. Improvement in overall breast deformity at 6 Months compared to Baseline.	Cytori Therapeutics	Female	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	71	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RESTORE-2	June 2008	November 2010	November 2010	February 15, 2008		May 17, 2011	Jules Bordet Institute of Cancer, Brussels, Belgium|Università degli Studi di Firenze, Florence, Italy|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Instituto Valenciano Oncologia, Valencia, Spain|Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom		https://ClinicalTrials.gov/show/NCT00616135
264	NCT02532634	Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone	RAPA	Completed	No Results Available	Cancer|Tumors	Drug: ramosetron, aprepitant, dexamethasone|Drug: palonosetron, aprepitant, dexamethasone	To compare the overall complete response (CR) of RAD to PAD (Overall CR defined as no emesis, no rescue medication, at cycle 1	Kangdong Sacred Heart Hospital|The Catholic University of Korea|Astellas Pharma Korea, Inc.	All	19 Years and older   (Adult, Older Adult)	Phase 4	292	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care	KJH-2015-01	August 19, 2015	May 8, 2018	May 8, 2018	August 26, 2015		May 10, 2018	St. Vincent`S Hospital, Suwon, Gyeonggi, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Chungnam National University Hospita, Daejeon, Korea, Republic of|Pusan National University Hospital, Pusan, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Kangdong Sacred Heart Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of		https://ClinicalTrials.gov/show/NCT02532634
265	NCT00160901	Complementary Therapies for the Reduction of Side Effects During Chemotherapy for Breast Cancer		Completed	No Results Available	Breast Cancer	Drug: two complex naturopathic add-on therapies, leaflet 5-a-day	Difference in the sum score of the most common side effects of a chemotherapy (fatigue, nausea, loss of appetite, constipation, diarrhea) measured by the EORTC QLQ C30 3-5 weeks after and before 3 cycles of chemotherapy|Difference in general QOL 3-5 weeks after and before three cycles of chemotherapy|Difference in anxiety and depression measured by HADS-D 3-5 weeks after and before three cycles of chemotherapy|Sensitivities measured by the perimed sensitivity questionnaire|Creatinin|ALAT|Coagulation time|Selenium	Heidelberg University|Hector-Stiftung|Cefak KG, Kempten|Ursapharm, Saarbrücken|Schwabe-Wenex International Ltd	Female	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	150	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	M16	August 2003		December 2005	September 12, 2005		April 19, 2007	Department of Complementary and Integrative Medicine, Heidelberg, Baden-Württemberg, Germany		https://ClinicalTrials.gov/show/NCT00160901
266	NCT02049112	A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study	NIAGARA	Completed	No Results Available	Xerostomia|Hyposalivation|Head and Neck Cancer|Sjögren Syndrome	Device: Salivary equivalent|Device: Aequasyal|Device: Biotene	Dry mouth discomfort|Mouth burning sensation|Speech difficulties|Chewing difficulties|Swallowing difficulties|Taste perversion|Medical device acceptability|Medical device safety assessment	Unither Pharmaceuticals, France	All	18 Years and older   (Adult, Older Adult)	Phase 4	210	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UN/2011/001	January 2012	April 2013	June 2013	January 29, 2014		January 29, 2014	Leopold Bellan Private Hospital, Magnanville, France		https://ClinicalTrials.gov/show/NCT02049112
267	NCT00106392	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy		Completed	Has Results	Erectile Dysfunction|Prostate Cancer	Drug: Tacrolimus|Drug: Placebo	Erectile Function Domain Score Between Treated and Untreated Groups|Percentage of Patients Achieving Normal Spontaneous Erectile Function as Measured by the Erectile Function (EF) Domain Score|Time Taken to Achieve Normalization of the Erectile Function (EF) Domain Score|Percentage of Patients Considered Successful Responders to Impotence Medications|Time to Achieve Response to Impotence Medications|Continence Level as Quantified by Part I of the Prostate Health-Related Quality of Life Questionnaire	Astellas Pharma Inc	Male	up to 65 Years   (Child, Adult, Older Adult)	Phase 4	131	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	20-03-001	February 2005	April 2008	November 2008	March 24, 2005	October 28, 2010	November 23, 2010	Ann Arbor, Michigan, United States|New York, New York, United States|New York, New York, United States|Cleveland, Ohio, United States|Nashville, Tennessee, United States|Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00106392
268	NCT00211211	FREE Study - Fracture Reduction Evaluation		Completed	No Results Available	Osteopenia|Osteoporosis|Multiple Myeloma|Bone Neoplasms	Device: Balloon Kyphoplasty	The primary objective of this study is to compare the effectiveness of standard medical therapy alone to kyphoplasty using the KyphX system for the treatment of acute vertebral compression fractures (VCFs).|Safety will be compared between the study groups throughout the study with focus on clinically meaningful events and subsequent VCFs including the "treated" vertebrae.|The primary study endpoint is the change in quality of life as measured by the Physical Component Summary (PCS) scale of the 36-Item Short Form (SF-36) as measured at the one-month follow-up visit.|The secondary study endpoints are: EuroQol self-report (EQ-5D) questionnaire and SF-36 scores at 1, 3, 6, 12 and 24 months|procedural safety (peri-operative clinical events)|function as measured by objective functionality tests-reaching, "get up and go" and by the subjective Roland Morris disability questionnaire at 1, 3, 6, 12 and 24 months|pain using a 10-point visual analogue scale (VAS) at 5-10 days (post enrollment for the control group and post kyphoplasty for the kyphoplasty group)|changes in spinal deformity as measured radiographically at baseline, 3, 12 and 24 months.|Maintenance of vertebral body height will be assessed from lateral spine x-rays obtained in Kyphoplasty treated subjects only at baseline and at 3, 12, and 24 month visits.|patient satisfaction at 1, 3, 6, 12, 24 months|outcome (nursing home, back to status prior to fracture) at 1, 3, 6, 12, 24 months|economic aspects (including hospital days, disabilities, etc.) at 1, 3, 6, 12, 24 months|the cost-effectiveness of kyphoplasty expressed in incremental cost/quality adjusted life year gained at different time points (1 year and 2 years)|rate of incident fractures at 3, 12 and 24 months (frequency, timing and location)|Each endpoint will be compared between the 2 groups and for its evolution over time.	Medtronic Spine LLC|Medtronic Spinal and Biologics	All	21 Years and older   (Adult, Older Adult)	Phase 4	300	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	SP0201 - FREE Study	February 2003	December 2007	December 2007	September 21, 2005		December 8, 2017	University of Alabama, Birmingham, Alabama, United States		https://ClinicalTrials.gov/show/NCT00211211
269	NCT00380965	Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy		Completed	No Results Available	Peripheral Neuropathy|Antineoplastic Combined Chemotherapy Protocols	Drug: Cesamet™ (nabilone)	The Average Pain Score at target site.|The Worst Pain Score at target site.|The Pain at Night Score at target site.|Quality of Life measures.|Patient satisfaction with treatment.|Safety will be assessed through the collection of AEs and vital signs.	NEMA Research, Inc.	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	23	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CB1 Study 003	October 2006	October 2007	October 2007	September 27, 2006		February 15, 2008	South Florida Medical Research, Aventura, Florida, United States|Naples Anesthesia and Pain Associates, Naples, Florida, United States		https://ClinicalTrials.gov/show/NCT00380965
270	NCT02006225	Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients.	GCSF	Not yet recruiting	No Results Available	Autologous Stem Cell Transplantation	Drug: Plerixafor	Peripheral blood stem cell content by means of percentage of CD34+ cells	Tel-Aviv Sourasky Medical Center|Sanofi	All	up to 30 Years   (Child, Adult)	Phase 4	30	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TASMC-13-MB-0693-12-CTIL	February 2014	February 2019	February 2020	December 10, 2013		December 10, 2013			https://ClinicalTrials.gov/show/NCT02006225
271	NCT02982954	A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer	CHECKMATE 920	Active, not recruiting	No Results Available	Renal Cell Carcinoma	Drug: Nivolumab|Drug: Ipilimumab	Incidence of high grade immune-mediated adverse events (IMAEs)|Time to onset of all high grade IMAEs|Time to resolution of all high grade IMAEs|Percentage of patients who received immune modulating medication due to high grade IMAEs|Progression-free survival at time of initial progression (PFS 1) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as assessed by the investigator|Objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as assessed by the investigator|Time to response (TTR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as assessed by the investigator|Duration of response (DOR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as assessed by the investigator	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 4	200	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-920	December 7, 2016	March 30, 2020	February 28, 2023	December 6, 2016		January 3, 2019	Northwest Alabama Cancer Center, Pc, Muscle Shoals, Alabama, United States|Alaska Urological Institute dba Alaska Clinical Research Center, Anchorage, Alaska, United States|Ironwood Cancer And Research Centers, Pc, Chandler, Arizona, United States|Highlands Oncology Group, P.A., Fayetteville, Arkansas, United States|eCare, Encinitas, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|Los Angeles Cancer Network, Los Angeles, California, United States|UCLA Hematology Oncology, Los Angeles, California, United States|Torrance Health Association, Redondo Beach, California, United States|Kaiser Permanente Medical Group - Southern California, Riverside, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|University Of Miami/Sylvester Cancer Center, Miami, Florida, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Emory University - Winship Cancer Institute, Atlanta, Georgia, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Minnesota Oncology Hematology, Minneapolis, Minnesota, United States|Southdale Cancer Clinic, Minneapolis, Minnesota, United States|Park Nicollet Clinic Cancer Center, Saint Louis Park, Minnesota, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States|HCA Midwest Division, Kansas City, Missouri, United States|St. Francis Cancer Treatment Center, Grand Island, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|University Of New Mexico, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|Broome Oncology, Johnson City, New York, United States|Laura & Isaac Perlmutter Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States|Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa, Oklahoma, United States|Va Medical Center Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Hollings Cancer Center, Charleston, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology, Austin, Texas, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology-Fort Worth 12th Ave, Fort Worth, Texas, United States|Texas Oncology-Midland Allison Cancer Center, Midland, Texas, United States|Texas Oncology, San Antonio, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Inova Research Center, Fairfax, Virginia, United States|Bon Secours St Francis Hospital, Midlothian, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Medical Oncology Associates, Spokane, Washington, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT02982954
272	NCT01794793	Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies		Recruiting	No Results Available	Cushing's Disease|Acromegaly|Neuroendocrine Tumors|Pituitary Tumors|Ectopic ACTH Secreting (EAS) Tumors|Dumping Syndrome|Prostate Cancer|Melanoma Negative for bRAF|Melanoma Negative for nRAS	Drug: Pasireotide|Drug: Cabergoline	Incidence of adverse events to evaluate long term safety data|Percentage of patients with clinical benefit as assessed by the investigator	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	500	Industry	Interventional	Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CSOM230B2412	January 14, 2013	June 9, 2023	June 9, 2023	February 20, 2013		July 15, 2019	Ximed Research SC - SOM230B2412, La Jolla, California, United States|Cedars Sinai Medical Center Cedars Sinai 4, Los Angeles, California, United States|Stanford Universtiy Medical Center Stanford Hospital & Clinics, Stanford, California, United States|University of Michigan Comprehensive Cancer Center SC-2, Ann Arbor, Michigan, United States|Icahn School of Medicine at Mount Sinai Cardiology, New York, New York, United States|Memorial Sloan-Kettering Cancer Center SC, New York, New York, United States|Virginia Endocrinology Research SC, Chesapeake, Virginia, United States|Swedish Cancer Institute Swedish Cancer Institute (SC), Seattle, Washington, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Mar del Plata, Buenos Aires, Argentina|Novartis Investigative Site, Edegem, Antwerpen, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Fortaleza, CE, Brazil|Novartis Investigative Site, Curitiba, PR, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Joinville, SC, Brazil|Novartis Investigative Site, Botucatu, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Toulouse, Cedex 9, France|Novartis Investigative Site, Angers cedex 09, France|Novartis Investigative Site, Bron Cedex, France|Novartis Investigative Site, Le Kremlin Bicetre, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Marseille cedex 05, France|Novartis Investigative Site, Pessac Cedex, France|Novartis Investigative Site, Pierre Benite Cedex, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Maebashi city, Gunma, Japan|Novartis Investigative Site, Kobe-shi, Hyogo, Japan|Novartis Investigative Site, Nankoku city, Kochi, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Suita city, Osaka, Japan|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Pulau Pinang, Malaysia|Novartis Investigative Site, Wilayah Persekutuan, Malaysia|Novartis Investigative Site, México, Distrito Federal, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Durango, Mexico|Novartis Investigative Site, Mexico City, Mexico|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Tyumen, Russian Federation|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Zuerich, Switzerland|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kocaeli, Turkey		https://ClinicalTrials.gov/show/NCT01794793
273	NCT00628901	A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE)		Completed	Has Results	Leiomyoma|Uterine Fibroids|Uterine Neoplasms|Menorrhagia|Leiomyomatosis	Procedure: Uterine Fibroid Embolization (UFE)|Device: Contour SE™ Microspheres|Device: Embosphere® Microspheres	Number of Participants With Fibroid Devascularization Measured by Contrast Enhanced Magnetic Resonance Imaging (MRI)|Visual Analog Scale (VAS) Maximum Level of Nausea|Visual Analog Scale (VAS) Maximum Level of Pain|Fluoroscopy Time|Procedure Time|Any Adverse Events That the Participant Experienced|Uterine Fibroid Symptom Quality of Life Questionaire (UFS-QOL) Score|Health Related Quality of Life (HRQL)Subscores|Health Related Quality of Life Subscores	Boston Scientific Corporation	Female	18 Years and older   (Adult, Older Adult)	Phase 4	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	M9011|ONC-PM-022005	January 2006	December 2009	January 2011	March 5, 2008	August 22, 2011	July 11, 2012	Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT00628901
274	NCT00687011	Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)		Completed	No Results Available	Neoplasms|Nausea|Vomiting	Drug: Palonosetron and Dexamethasone	Proportion of patients having achieved complete response (CR), defined as no emetic episodes and no rescue medication.|Proportion of patients who achieved a CR and of those who achieved complete control; Number of emetic episodes; Time to first emetic episode, to administration and need for rescue therapy; and to treatment failure|Severity of nausea; Patient global satisfaction; Quality of life questionnaire	Merck Sharp & Dohme Corp.	All	18 Years and older   (Adult, Older Adult)	Phase 4	118	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	P04594	October 10, 2006	October 27, 2008	October 27, 2008	May 30, 2008		May 15, 2017			https://ClinicalTrials.gov/show/NCT00687011
275	NCT00684463	Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)		Completed	No Results Available	Neoplasms|Nausea|Vomiting	Drug: Palonosetron	Proportion of patients having achieved complete response (CR), defined as no emetic episodes and no rescue medication.|Proportion of patients who achieved a CR and of those who achieved complete control|Number of emetic episodes|Time to first emetic episode; time to administration and need for rescue therapy; and to treatment failure time to first emetic episode or administration of rescue medication	Merck Sharp & Dohme Corp.	All	18 Years and older   (Adult, Older Adult)	Phase 4	59	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	P04935	April 11, 2007	February 22, 2008	February 22, 2008	May 26, 2008		May 16, 2017			https://ClinicalTrials.gov/show/NCT00684463
276	NCT00524407	Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy		Completed	No Results Available	Chemotherapy|Anemia|Cancer	Drug: Epoetin alfa	To measure the change in quality of life score as demonstrated by the FACT-An (Functional Assessment in Cancer Therapy - Anemia) and LASA (Linear Analogue Assessment Scale) tools over the 36 week study period.|Health care resource utilization. To measure transfusion requirements and change in Hb levels. All patients were followed for survival until closure of study which was the time the last patient in the entire study completed study participation.	Ortho Biotech, Inc.|Ortho Biotech Clinical Affairs, L.L.C.	All	18 Years and older   (Adult, Older Adult)	Phase 4	273	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CR005125	July 1996		November 2002	September 3, 2007		April 2, 2010			https://ClinicalTrials.gov/show/NCT00524407
277	NCT02514174	Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older		Completed	No Results Available	Carcinoma, Non-Small-Cell Lung|ErbB Receptors	Drug: Afatinib	Occurrence of AEs leading to dose reduction of afatinib|Occurrence of CTCAE grade 3 or higher diarrhoea|Occurrence of CTCAE grade 3 or higher rash/acne+ (+ represents grouped term)|Occurence of CTCAE grade 3 or higher stomatitis+ (+ represents grouped term)|Occurence of CTCAE grade 3 or higher paronychia+ (+ represents grouped term)|Time to first dose reduction of afatinib caused by AE's, defined as time from the date of the first administration of afatinib to the first dose reduction of afatinib caused by AE's.	Boehringer Ingelheim	All	70 Years and older   (Older Adult)	Phase 4	25	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1200.209	August 18, 2015	March 28, 2019	April 25, 2019	August 3, 2015		May 13, 2019	Mayo Clinic-Arizona, Scottsdale, Arizona, United States|Pacific Cancer Medical Center, Inc., Anaheim, California, United States|City of Hope, Duarte, California, United States|Compassionate Care Research Group, Inc. at Compassionate Cancer Care Medical Group, Inc., Fountain Valley, California, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States|University of Miami, Miami, Florida, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Baystate Health D'Amour Center for Cancer Care, Springfield, Massachusetts, United States|Montefiore Medical Center, Bronx, New York, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT02514174
278	NCT03449758	Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis	SariPRO	Active, not recruiting	No Results Available	Rheumatoid Arthritis	Drug: SARILUMAB|Drug: Azathioprine|Drug: Chloroquine|Drug: Hydroxychloroquine|Drug: Leflunomide|Drug: Methotrexate|Drug: Sulfasalazine	Change in the total RAID score|Patient-reported outcome (PRO): Hospital Anxiety and Depression Scale (HADS)|PRO: Multidimensional Assessment of Thymic States (MATHys)|PRO: Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue|PRO: Stanford Health Assessment Questionnaire Disability Index (HAQ-DI)|Change in duration of morning stiffness|PRO: International Physical Activity Questionnaire (IPAQ)|Change in patient global assessment of disease activity|Change in erythrocyte sedimentation rate (ESR)|Disease Activity and Functional Status Assessment: DAS28-ESR|Disease Activity and Functional Status Assessment: CDAI|Disease Activity and Functional Status Assessment: Joint counts|Assessment: DAS28-ESR Low Disease Activity (LDA) and remission|Assessment: CDAI LDA and remission|Adverse events	Sanofi|Regeneron Pharmaceuticals	All	18 Years and older   (Adult, Older Adult)	Phase 4	140	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SARILL08755|U1111-1197-7699	March 9, 2018	August 2019	August 2019	February 28, 2018		January 31, 2019	Investigational Site Number 250007, Argenteuil, France|Investigational Site Number 250006, Besancon, France|Investigational Site Number 250027, Bobigny, France|Investigational Site Number 250016, Bordeaux, France|Investigational Site Number 250014, Caen, France|Investigational Site Number 250019, Cannes, France|Investigational Site Number 250013, Cholet, France|Investigational Site Number 250002, Clermont Ferrand, France|Investigational Site Number 250009, Echirolles, France|Investigational Site Number 250005, La Roche Sur Yon, France|Investigational Site Number 250004, Lille Cedex, France|Investigational Site Number 250012, Limoges Cedex, France|Investigational Site Number 250021, Lyon, France|Investigational Site Number 250018, Montivilliers, France|Investigational Site Number 250029, MONTPELLIER Cedex 5, France|Investigational Site Number 250025, NANTES Cedex 1, France|Investigational Site Number 250026, Nice cedex 1, France|Investigational Site Number 250020, Paris Cedex 10, France|Investigational Site Number 250011, PARIS Cedex 13, France|Investigational Site Number 250010, Paris, France|Investigational Site Number 250015, Paris, France|Investigational Site Number 250028, Paris, France|Investigational Site Number 250031, Poitiers, France|Investigational Site Number 250023, Pontoise, France|Investigational Site Number 250017, RENNES Cedex, France|Investigational Site Number 250008, Rouen, France|Investigational Site Number 250001, St Etienne, France|Investigational Site Number 250022, Toulouse, France|Investigational Site Number 250003, Tours, France		https://ClinicalTrials.gov/show/NCT03449758
279	NCT01636947	A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)	KMEC	Completed	Has Results	Nausea|Vomiting	Drug: Aprepitant|Drug: Aprepitant Placebo|Drug: Ondansetron|Drug: Dexamethasone|Drug: Ondansetron Placebo|Drug: Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).	The Percentage of Participants With No Vomiting - Overall Stage|Percentage of Participants With a Complete Response - Overall, Acute, and Delayed Stages|Number of Emetic Events - Overall Stage|Percentage of Participants With No Vomiting and No Significant Nausea - Overall Stage|Percentage of Participants With No Impact on Daily Life - Overall Stage|Number of Participants With No Use of a Rescue Therapy - Overall, Acute, and Delayed Stages|Percentage of Participants With One or More Clinical Adverse Event|Percentage of Participants With No Vomiting - Acute and Delayed Stages	Merck Sharp & Dohme Corp.	All	21 Years and older   (Adult, Older Adult)	Phase 4	494	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	0869-225|MK-0869-225	December 12, 2012	August 4, 2014	August 4, 2014	July 10, 2012	July 30, 2015	September 25, 2018			https://ClinicalTrials.gov/show/NCT01636947
280	NCT00160199	Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion		Completed	Has Results	Secondary Amenorrhea	Drug: PROMETRIUM® 300 mg|Drug: PROMETRIUM® 400 mg	Secretory Conversion of the Endometrium|Number of Subjects With Withdrawal Bleeding|Maximum Intensity of Withdrawal Bleeding After Any Cycle|The Duration of Withdrawal Bleeding After the First Treatment Cycle|The Duration of Withdrawal Bleeding After Second Treatment Cycle|Time to Withdrawal Bleeding After First Treatment Cycle|Time to Withdrawal Bleeding After Second Treatment Cycle	Solvay Pharmaceuticals	Female	18 Years to 45 Years   (Adult)	Phase 4	240	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	S168.4.002	November 2004	February 2009	February 2009	September 12, 2005	June 2, 2010	July 7, 2010	Site 29, Mobile, Alabama, United States|Site 41, Montgomery, Alabama, United States|Site 26, Tucson, Arizona, United States|Site 5, Jonesboro, Arkansas, United States|Site 39, Carmichael, California, United States|Site 17, Encinitas, California, United States|Site 10, San Diego, California, United States|Site 42, Avon, Connecticut, United States|Site 3, Groton, Connecticut, United States|Site 22, New Britian, Connecticut, United States|Site 9, Waterbury, Connecticut, United States|Site 37, West Hartford, Connecticut, United States|Site 14, Aventura, Florida, United States|Site 40, Clearwater, Florida, United States|Site 1, West Palm Beach, Florida, United States|Site 30, West Palm Beach, Florida, United States|Site 46, Atlanta, Georgia, United States|Site 43, Powder Springs, Georgia, United States|Site 36, Champaign, Illinois, United States|Site 12, Chicago, Illinois, United States|Site 6, Baton Rouge, Louisiana, United States|Site 7, Baltimore, Maryland, United States|Site 2, St. Louis, Missouri, United States|Site 16, Reno, Nevada, United States|Site 45, New York, New York, United States|Site 23, New Bern, North Carolina, United States|Site 15, Winston-Salem, North Carolina, United States|Site 28, Winston-Salem, North Carolina, United States|Site 33, Cincinnati, Ohio, United States|Site 32, Erie, Pennsylvania, United States|Site 47, Hershey, Pennsylvania, United States|Site 44, Philadelphia, Pennsylvania, United States|Site 38, Pottstown, Pennsylvania, United States|Site 13, Greenville, South Carolina, United States|Site 8, Conroe, Texas, United States|Site 11, Corpus Christi, Texas, United States|Site 27, Houston, Texas, United States|Site 34, Houston, Texas, United States|Site 24, San Antonio, Texas, United States|Site 35, Salt Lake City, Utah, United States|Site 19, Norfolk, Virginia, United States|Site 4, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT00160199
281	NCT02476526	Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease		Completed	No Results Available	Chronic Kidney Disease|Pulmonary Embolism|Renal Artery Stenosis|Pulmonary Cancer	Drug: Low Volume iso-osmolar non-ionic radio contrast medium|Drug: Acetylcysteine Inhalation|Drug: Sodium Bicarbonate Solution|Procedure: 64-MDCT Scanning	Peak Serum Creatinine Level	VA Greater Los Angeles Healthcare System|General Electric	All	18 Years and older   (Adult, Older Adult)	Phase 4	50	U.S. Fed|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	Barack0001	September 2008	November 20, 2017	November 20, 2017	June 19, 2015		November 28, 2017	VA Greater Los Angeles Healthcare System, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT02476526
282	NCT03571126	Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer		Recruiting	No Results Available	Chemotherapy-induced Nausea and Vomiting|Lung Cancer	Drug: Olanzapine|Drug: Placebos	Incidence rate of no delayed nausea and vomiting|Complete response of acute nausea and vomiting|Complete response of delayed nausea and vomiting|Disease control rate|Quality of life of participants by The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 13 scale|Quality of life of participants by The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 30 scale|Quality of life of participants by Functional Assessment of Cancer Therapy-Lung cancer scale	Zunyi Medical College|Zunyi First People's Hospital|Afﬁliated Hospital of North Sichuan Medical College|Sichuan Cancer Hospital and Research Institute|Guizhou Provincial People's Hospital|Affiliated Hospital of Southwest Medical University	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 4	156	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	20180520	May 9, 2019	October 1, 2019	August 1, 2020	June 27, 2018		July 18, 2019	Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China|Afﬁliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China		https://ClinicalTrials.gov/show/NCT03571126
283	NCT02564094	A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies		Completed	No Results Available	Anemia	Drug: Epoetin beta	Response rate according to hemoglobin level|Transfusion requirement rate|Predictive value of reticulocyte increase|Incidence of adverse events (AEs)	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	54	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML18043	February 2005	June 2006	June 2006	September 30, 2015		November 2, 2016	Plovdiv, Bulgaria|Plovdiv, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Varna, Bulgaria|Varna, Bulgaria		https://ClinicalTrials.gov/show/NCT02564094
284	NCT02422745	COcoa Supplement and Multivitamin Outcomes Study	COSMOS	Active, not recruiting	No Results Available	Cardiovascular Disease|Cancer	Dietary Supplement: Cocoa extract|Dietary Supplement: Multivitamin|Dietary Supplement: Cocoa extract placebo|Dietary Supplement: Multivitamin placebo	Cardiovascular disease (CVD) events|Invasive cancer|Combined endpoint of major cardiovascular events plus all-cause mortality|Myocardial infarction|Stroke|Cardiovascular mortality|Coronary revascularization|Total mortality|Breast cancer|Colorectal cancer|Lung cancer|Blood flavonoid levels	Brigham and Women's Hospital|Fred Hutchinson Cancer Research Center|Mars, Inc.|Pfizer|Columbia University	All	60 Years and older   (Adult, Older Adult)	Phase 4	21445	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	2014D001652	June 2015	March 2020	October 2020	April 21, 2015		July 10, 2019	Brigham and Women's Hospital, Boston, Massachusetts, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT02422745
285	NCT01315015	Breast Cancer Screening With MRI in Women Aged 50-75 Years With Extremely Dense Breast Tissue: the DENSE Trial		Active, not recruiting	No Results Available	Breast Cancer	Other: Contrast enhanced breast MRI	The number of interval cancers will be compared between the MRI group and the control group|The number of MRI screen-detected tumors will be determined|Tumor size, stage and grade distributions, including their histological and molecular subtypes, diagnosed in both study groups will be compared|The referral rate in the MRI study group will be determined|The positive predictive value (and the amount of false-positive diagnoses) of MRI will be determined using the histological diagnosis as the reference test|The number of biopsies per positive MRI will be determined|The mortality rate in the MRI group will be compared with the control group using the MISCAN computer simulation program|The cost-effectiveness of MRI will be estimated using the MISCAN computer simulation program|The impact of MRI screening on quality of life will be assessed using standardized and validated questionnaires	UMC Utrecht|Dutch Breast Cancer Screening Organisations|Dutch Reference Centre for Screening|National Institute for Public Health and the Environment|Antoni van Leeuwenhoek Hospital|University Medical Center Nijmegen|Jeroen Bosch Ziekenhuis|Albert Schweitzer Hospital|Hospital Group Twente (ZGT)|VU University Medical Center|Maastricht University Medical Center|ZonMw: The Netherlands Organisation for Health Research and Development|Dutch Cancer Society|Pink Ribbon Inc.|A Sister's Hope|Bayer|Stichting Kankerpreventie Midden-West|Matakina	Female	49 Years to 75 Years   (Adult, Older Adult)	Phase 4	36185	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening	UMCU DENSE|ZONMW-200320002-UMCU|Pink Ribbon-10074|BSP-DENSE|DCS-UU-2009-4348|DCS-UU-2014-6859	November 2011	December 2019	December 2019	March 15, 2011		October 12, 2018	Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands|Hospital Group Twente (ZGT), Almelo And Hengelo, Netherlands|Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands|VU University Medical Center, Amsterdam, Netherlands|Albert Schweitzer Hospital, Dordrecht, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|UMC Utrecht, Utrecht, Netherlands		https://ClinicalTrials.gov/show/NCT01315015
286	NCT02246023	Fractionated Versus Target-controlled Propofol Administration in Bronchoscopy		Completed	No Results Available	Lung Cancer|Sarcoidosis|Interstitial Pneumonia	Device: Flexible bronchoscopy in moderate sedation|Device: Oxygen saturation|Device: Blood pressure|Device: Propofol dosage|Device: Recovery time after bronchoscopy	Mean arterial oxygen saturation|Number of occasions with recorded an oxygen saturation of < 90%|Number of an oxygen desaturation of > 4% from baseline|Number of occasions with a systolic blood pressure < 90 mmHg during bronchoscopy, maximum oxygen requirement,|Frequency of dose adjustments|Cumulative propofol dose|Recovery time after bronchoscopy	Daniel Franzen|B. Braun Melsungen AG|University of Zurich	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 4	78	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	BronchoPropTCI|SNCTP000000706	January 2015	December 2015	February 2016	September 22, 2014		April 14, 2016	University Hospital Zurich, Zurich, Switzerland		https://ClinicalTrials.gov/show/NCT02246023
287	NCT00608868	SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients	SELINE	Completed	Has Results	Non Small Cell Lung Carcinoma	Drug: Gefitinib	Objective Response Rate(ORR)|Period of Progression-Free Survival|Quality of Life and Symptom Improvement Based on Functional Assessment of Cancer Therapy-Lung (FACT-L)|Overall Survival|Adverse Event	AstraZeneca	All	19 Years to 80 Years   (Adult, Older Adult)	Phase 4	156	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D7913L00067	January 2007	January 2009	January 2009	February 6, 2008	September 28, 2012	September 28, 2012	Research Site, Daegu, Korea, Republic of		https://ClinicalTrials.gov/show/NCT00608868
288	NCT01490892	Quantitative Subharmonic Breast Imaging		Completed	No Results Available	Breast Cancer	Drug: 3D HI and SHI of UCA	Breast lesion characterization with 3D SHI|Quantitative SHI measures for breast lesion characterization	Thomas Jefferson University|National Cancer Institute (NCI)|Lantheus Medical Imaging|University of California, San Diego	Female	18 Years and older   (Adult, Older Adult)	Phase 4	236	Other|NIH|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	11F.438|R01CA140338	November 2011	April 5, 2019	April 5, 2019	December 13, 2011		April 10, 2019	University of California, San Diego, La Jolla, California, United States|Thomas Jefferson University, Dept of Radiology, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT01490892
289	NCT03934684	Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma		Not yet recruiting	No Results Available	Relapsed Refractory Multiple Myeloma	Drug: Drug: Carfilzomib + Dexamethasone|Drug: Drug: Carfilzomib + Lenalidomide + Dexamethasone	Number of participants with treatment-emergent adverse events as assessed by CTCAE v4.03|Progression Free Survival|Overall Response Rate|Clinical Benefit Rate|Time to Response|Duration of Response	Amgen	All	18 Years and older   (Adult, Older Adult)	Phase 4	100	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20160372	September 1, 2019	April 6, 2022	July 10, 2024	May 2, 2019		June 20, 2019			https://ClinicalTrials.gov/show/NCT03934684
290	NCT03768960	A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent		Recruiting	No Results Available	Multiple Myeloma	Drug: Daratumumab	Incidence of Treatment Emergent Adverse Events (TEAE)|Overall Response Rate (ORR)|Percentage of Participants with Very Good Partial Response (VGPR) or better|Percentage of Participants with Progression Free Survival (PFS)|Time to Response|Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score|Change from Baseline in EuroQol-5 Dimensions (EQ-5D-5L) Score	Johnson & Johnson Private Limited	All	18 Years and older   (Adult, Older Adult)	Phase 4	150	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CR108556|54767414MMY4008	June 10, 2019	October 31, 2020	June 20, 2021	December 7, 2018		July 26, 2019	Vedanta Institute of Medical Science, Ahmedabad, India|Sparsh Hospitals & Critical Care (Pvt) Ltd, Bhubaneshwar, India|Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh, India|Basavatarakam Indo-American Hospital, Hyderabad, India|Tata Medical Center, Kolkata, India|Christian Medical College, Ludhiana, India|Shatabdi Super Speciality Hospital, Mumbai Naka, India|Apex Wellness Rishikesh Hospital, Nashik, India|All India Institute of Medical Sciences, New Delhi, India|Deenanath Mangeshkar Hospital and Research Centre, Pune, India|Noble Hospital Pvt Ltd, Pune, India|Regional Cancer Centre, Thiruvananthapuram, India|Christian Medical College, Vellore, India		https://ClinicalTrials.gov/show/NCT03768960
291	NCT03416374	A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy		Recruiting	No Results Available	Relapsed and/or Refractory Multiple Myeloma	Drug: Ixazomib|Drug: Bortezomib|Drug: Carfilzomib|Drug: Lenalidomide|Drug: Dexamethasone	Progression-Free Survival (PFS) Rate at 12 Months from the Start of Study Treatment|Overall Survival (OS) from the Start of Study Treatment|PFS from the Start of Study Treatment|Percentage of Participants who Achieved VGPR or Better (CR + VGPR)|Rate of Minimal Residual Disease (MRD) in Bone Marrow in Participants who Achieved CR|Percentage of Participants who Achieve or Maintain Any Best Response|Overall Response Rate (ORR)|Percentage of Participants Continuing Treatment with Ixazomib at 12 Months from the Start of Study Treatment|Duration of Response (DOR)|Patient-Reported Outcome Health-Related Quality of Life (HRQoL) based on European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-C30 (EORTC QLQ-C30)|Patient-Reported Outcome HRQoL based on EORTC Multiple Myeloma Module (EORTC QLQ-MY20) Score|Evaluation of modified Quality-Adjusted Life-Years (QALYs)|Healthcare Resource Utilization (HCRU)|Relative Dose Intensity (RDI)|Percentage of Participants with Bone Lesions (Bone Evaluation)|Number of Participants Reporting One or More Treatment-Emergent AEs (TEAEs)	Takeda	All	20 Years and older   (Adult, Older Adult)	Phase 4	47	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	C16043|U1111-1207-0061|JapicCTI-183839	March 12, 2018	August 31, 2020	May 31, 2021	January 31, 2018		March 21, 2019	Kameda Medical Center, Kamogawa, Chiba, Japan|The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan|Ogaki Municipal Hospital, Ogaki, Gifu, Japan|Gunma University Hospital, Maebashi, Gunma, Japan|Shibukawa Medical Center, Shibukawa, Gunma, Japan|Kobe city Medical Center General Hospital, Kobe, Hyogo, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Iwate Medical University, Morioka, Iwate, Japan|Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan|Suwa Red Cross Hospital, Suwa, Nagano, Japan|Dokkyo Medical University, Koshigaya, Saitama, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan|Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan|Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|The Jikei University Hospital, Minato-ku, Tokyo, Japan|Kyorin University Hospital, Mitaka, Tokyo, Japan|Japanese Red Cross Medical Center, Shibuya-ku, Tokyo, Japan|Tokyo Disaster Medical Center, Tachikawa, Tokyo, Japan|Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan|Kyoto Kuramaguchi Medical Center, Kyoto, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Osaka Red Cross Hospital, Osaka, Japan		https://ClinicalTrials.gov/show/NCT03416374
292	NCT03173092	An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma (MM) Previously Receiving a Bortezomib-based Induction Regimen (US MM-6)		Recruiting	No Results Available	Multiple Myeloma	Drug: Ixazomib|Drug: Lenalidomide|Drug: Dexamethasone	Progression Free Survival (PFS)|Percentage of Participants with Partial Response (PR), Very Good Partial Response (VGPR) and Complete Response (CR)|Duration of Response|Duration of Therapy (DoT)|Duration of Ixazomib Therapy|Relative Dose Intensity (RDI) for Each Study Drug	Millennium Pharmaceuticals, Inc.|Takeda	All	18 Years and older   (Adult, Older Adult)	Phase 4	160	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	C16038|U1111-1192-7696	September 20, 2017	November 30, 2023	November 30, 2023	June 1, 2017		August 13, 2019	Arizona Oncology Associates, P.C., Tucson, Arizona, United States|CARTI Cancer Center, Little Rock, Arkansas, United States|Pacific Cancer Medical Center, Anaheim, California, United States|Compassionate Care Research Group, Inc., Fountain Valley, California, United States|The Oncology Institute of Hope & Innovation, Whittier, California, United States|US Oncology Research, Colorado Springs, Colorado, United States|Woodlands Medical Specialists - Pensacola, Pensacola, Florida, United States|Illinois Cancer Specialists - Niles, Niles, Illinois, United States|American Health Network, Greenfield, Indiana, United States|Hematology Oncology Of Indiana, Indianapolis, Indiana, United States|Saint Agnes Hospital, Baltimore, Maryland, United States|Regional Cancer Care Associates, Bethesda, Maryland, United States|Karmanos Cancer Institute, Bloomfield Hills, Michigan, United States|Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, United States|St. Vincent Frontier Cancer Center, Billings, Montana, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|TriHealth Cancer Institute - Medical Oncology and Hematology Westside, Cincinnati, Ohio, United States|Willamette Valley Cancer Institute and Research Center - Springfield, Springfield, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee, United States|Texas Oncology - Austin Midtown, Austin, Texas, United States|Texas Oncology - Presbyterian Cancer Center Dallas, Dallas, Texas, United States|Texas Oncology - El Paso Cancer Treatment Center Grandview, El Paso, Texas, United States|South Texas Veterans Health Care System, San Antonio, Texas, United States|Texas Oncology - San Antonio Northwest, San Antonio, Texas, United States|Millennium Physicians Association, Shenandoah, Texas, United States|Texas Oncology - Tyler, Tyler, Texas, United States		https://ClinicalTrials.gov/show/NCT03173092
293	NCT00104104	A Multiple Myeloma Trial in Patients With Bone Metastases		Completed	Has Results	Multiple Myeloma	Drug: zoledronic acid	The Number of Participants With a Significant Increase in Serum Creatinine at 12 Months|The Number of Participants With Disease Progression|The Number of Participants With a Significant Increase in Serum Creatinine at 24 Months|Time to First Significant Increase in Serum Creatinine|Zoledronic Acid Concentrations	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	179	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CZOL446EUS97|US97	October 2004	October 2007	October 2007	February 23, 2005	June 6, 2011	June 29, 2011	Hematology Oncology Specialists, Huntsville, Alabama, United States|Palo Verde Hematology Oncology, Glendale, Arizona, United States|US Oncology, Tucson, Arizona, United States|Myeloma Institute For Research Therapy, Little Rock, Arkansas, United States|University of Arkansas, Little Rock, Arkansas, United States|Pacific Cancer Medical Center, Anaheim, California, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Southbay Oncology Hematology Partners, Campbell, California, United States|Bay Area Cancer Research Group, Concord, California, United States|California Oncology of the Central Valley, Fresno, California, United States|Dr. Robert P. Brouillard Inc., LaJolla, California, United States|Antelope Valley Cancer Center, Lancaster, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|North Valley H/O, Mission Hills, California, United States|Hematology/Oncology Group of Orange County, Orange, California, United States|Desert Hematology Oncology Medical Group, Rancho Mirage, California, United States|Camino Medical Group, Sunnyvale, California, United States|Oncotherapeutics, West Hollywood, California, United States|Greeley Medical Center, Greeley, Colorado, United States|Florida Cancer Specialists, Fort Meyers, Florida, United States|South Florida Oncology Hematology, Hollywood, Florida, United States|Osceola Cancer Center, Kissimmee, Florida, United States|Miami Cancer Care, Miami, Florida, United States|Pasco Hernado Oncology, New Port Richey, Florida, United States|MetCare Oncology, Ormond Beach, Florida, United States|Hematology Oncology Associates PA, Pensacola, Florida, United States|Hem/Onc Associates of Central Brevard, Rockledge, Florida, United States|Augusta Oncology Associates, Augusta, Georgia, United States|Georgia Cancer Specialists, Tucker, Georgia, United States|Cancer Care Center, New Albany, Indiana, United States|Hutchinson Clinic, PA, Hutchinson, Kansas, United States|Hematology and Oncology Specialists, New Orleans, Louisiana, United States|Maine Center for Cancer Medicine - Blood Disorders, Scarborough, Maine, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Oncology Hematology Associates, PA, Clinton, Maryland, United States|Maryland Oncology-Hematology PA, Columbia, Maryland, United States|Hematology Oncology Associates of Ohio & Michigan, Lambertville, Michigan, United States|Providence Cancer Center, Clinical Trials Dept, Southfield, Michigan, United States|Kansas City Cancer Center, Kansas City, Missouri, United States|St. Joseph Oncology, Inc., St. Joseph, Missouri, United States|The Center for Cancer Care and Research, St. Louis, Missouri, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Nevada Cancer Center, Las Vegas, Nevada, United States|Center for Cancer & Hematology Disease, Cherry Hill, New Jersey, United States|Central Jersey Oncology Center, East Brunswick, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|CINJ at Cooper University Hospital, Voorhees, New Jersey, United States|New Mexico Cancer Care Associates, Santa Fe, New Mexico, United States|Hematology Oncology of Western Suffolk, Bay Shore, New York, United States|New York Presbyterian Hospital, New York, New York, United States|Syracuse Hematology/Oncology PC, Syracuse, New York, United States|Dayton Oncology & Hematology, PA, Kettering, Ohio, United States|University of Pennsylvania, Philadelphia, Philadelphia, Pennsylvania, United States|Pennsylvania Oncology Associates, Philadelphia, Pennsylvania, United States|Berks Oncology and Hematology Associates, West Reading, Pennsylvania, United States|Hematology & Oncology Associates of RI, Cranston, Rhode Island, United States|Roger Williams Hospital Medical Center, Providence, Rhode Island, United States|Charleston Hematology Oncology, Charleston, South Carolina, United States|Baptist Regional Cancer Center, Knoxville, Tennessee, United States|Center for Oncology Research & Treatment, PA, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|Utah Hematology Oncology, Ogden, Utah, United States|Oncology Hematology Associates of Southwest VA, Salem, Virginia, United States|Western Washington Oncology, Lacey, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|Fox Valley Hematology Oncology SC, Appleton, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT00104104
294	NCT02268890	A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma		Completed	No Results Available	Multiple Myeloma	Drug: Bortezomib	Initial Observed Plasma Drug Concentration (Co)|Maximum Observed Plasma Concentration (Cmax)|Area Under Plasma Concentration-Time Curve From Time 0 to Last Quantifiable Time Point|Area Under Plasma Concentration-Time Curve From Time 0 to Infinity (AUC-Infinity)|Terminal Half-life (t1/2)|Terminal rate constant (lamda[z])|Systemic clearance (CL)|Apparent Volume of Distribution (Vd)	Johnson & Johnson Taiwan Ltd	All	20 Years and older   (Adult, Older Adult)	Phase 4	18	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CR104583|26866138MMY4073	December 2014	July 2015	July 2015	October 20, 2014		July 11, 2016	Changhua, Taiwan|Kaohsiung, Taiwan|Taichung City, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan		https://ClinicalTrials.gov/show/NCT02268890
295	NCT00622505	Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Patients	Z-MARK	Completed	No Results Available	Multiple Myeloma	Drug: zoledronic acid	Proportion of patients with ≥1 SRE at the end of one year on study.|Time to first SRE on study, proportion of each type of SRE, SRE rate, biomarker changes, and survival.	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	159	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	CZOL446EUS129	November 2007	April 2012	April 2012	February 25, 2008		November 18, 2016	TriValley Cancer Research and Treatment Center, Casa Grande, Arizona, United States|Wilshire Oncology Medical Group, La Verne, California, United States|Cedars Sinai Medical Center Outpatient Cancer Ctr. (4), Los Angeles, California, United States|Palo Alto Medical Foundation Hematology/Oncology, Mountain View, California, United States|Oncology Care Medical Associates, San Gabriel, California, United States|Santa Clara Valley Health & Hospital System, San Jose, California, United States|University of Colorado U of Colorado Cancer Center, Aurora, Colorado, United States|Hematology Oncology PC, Stamford, Connecticut, United States|Washington Hospital Center, Washington, District of Columbia, United States|Palm Beach Institute of Hematology Oncology, Boynton Beach, Florida, United States|Innovative Medical Research of South Florida Innovative Med Research, Miami Shores, Florida, United States|Cancer Centers of Florida PA Cancer Centers of Central FL, Ocoee, Florida, United States|Integrated Community Oncology Network Florida Oncology Associates, Orange Park, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Loyola University Medical Center /Cardinal Bernardin Cancer Loyola Univ Med Ctr, Maywood, Illinois, United States|University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States|Center for Cancer & Blood Disorders, Bethesda, Maryland, United States|Oncology - Hematology Associates, PA Oncology Hematology Assoc, Clinton, Maryland, United States|Dana Farber Cancer Institute Clinical Research Coordinator, Boston, Massachusetts, United States|Boston VA Healthcare Boston VA, Boston, Massachusetts, United States|Berkshire Hematology Oncology, Pittsfield, Massachusetts, United States|N MS Hematology & Oncology, Tupelo, Mississippi, United States|Hematology & Oncology Consultants, PC Hematology & Oncology, Omaha, Nebraska, United States|Somerset Hematology Oncology Associates Somerset Hema Oncol Assoc (2), Somerset, New Jersey, United States|Cooper Cancer Center, Voorhees, New Jersey, United States|Rochester General Hospital / Lipson Cancer Center Lipson Cancer Center, Rochester, New York, United States|University of Rochester MC / James P. Wilmot Cancer Center James P. Wilmot Cancer Center, Rochester, New York, United States|SUNY - Upstate Medical University Div. of Hematology-Oncology, Syracuse, New York, United States|Carolina Oncology Specialists, PC, Hickory, North Carolina, United States|Regional Hematology-Oncology Associates PC, Langhorne, Pennsylvania, United States|Temple University Temple University, Philadelphia, Pennsylvania, United States|Medical Associates, PA, Charleston, South Carolina, United States|Low Country Hematology Oncology Dept of Lowcountry Hem/Onc, Mt. Pleasant, South Carolina, United States|Lexington Oncology Associates, West Columbia, South Carolina, United States|Avera Research Institute, Sioux Falls, South Dakota, United States|Blood and Cancer Center of East Texas, Tyler, Texas, United States|East Texas Medical Center Cancer Institute, Tyler, Texas, United States|Northern Utah Cancer Associates Dept.ofNorthernUtahAssoc., Ogden, Utah, United States|Central Utah Clinic Central Utah Clinic (8), Provo, Utah, United States|Peninsula Cancer Institute, Newport News, Virginia, United States|Swedish Cancer Institute, Seattle, Washington, United States|West Virginia University Health Research Center Clinical Trial Research Unit, Morgantown, West Virginia, United States		https://ClinicalTrials.gov/show/NCT00622505
296	NCT01316393	Effects of Mucoprotective Product on Xerostomia		Completed	No Results Available	Xerostomia	Other: XER2020	OHIP questionaire health impact profile	Camurus AB|Liselott Lindh, Principal Investigator, Prosthetic Dentistry, Malmö University, Malmö, Sweden	All	18 Years to 90 Years   (Adult, Older Adult)	Phase 4	20	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care	HS-10-404	February 2011	May 2011	June 2011	March 16, 2011		November 9, 2011	Department of Prosthetic Dentistry, Malmö University, Malmö, Sweden		https://ClinicalTrials.gov/show/NCT01316393
297	NCT00257114	Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability		Completed	No Results Available	Multiple Myeloma	Drug: bortezomib		Millennium Pharmaceuticals, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 4		Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	C05004		March 2007		November 22, 2005		February 11, 2008	Sinai Hospital of Baltimore, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT00257114
298	NCT01374373	Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia		Completed	No Results Available	Antineoplastic Chemotherapy Induced Anemia	Biological: Epoetin alfa	Number of subjects with adverse events and percentage of therapy withdrawals due to treatment emergent adverse events|Hemoglobin levels and percentage of responders|Quality of life|Hemoglobin levels ≥ 2 g/dl	Bio Sidus SA|IC RESEARCH GROUP	All	18 Years and older   (Adult, Older Adult)	Phase 4	30	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BIOS-012010	June 2011	November 2014	November 2014	June 16, 2011		April 7, 2016	Centro Oncologico de Investigaciones Buenos Aires, Berazategui, Buenos Aires, Argentina|Hospital Zonal Especializado en Oncología de Lanus, Lanus Este, Buenos Aires, Argentina|Centro de Medicina Integral e Investigación Clínica, Buenos Aires, Argentina		https://ClinicalTrials.gov/show/NCT01374373
299	NCT03672643	Long Term Safety Observation of Crizotinib in Chinese NSCLC Population		Recruiting	No Results Available	ALK-positive NSCLC	Drug: Crizotinib	long term safety of crizotinnib in patients with advanced NSCLC harboring a translocation or inversion of the ALK gene or ROS1 gene locus	Pfizer	All	18 Years and older   (Adult, Older Adult)	Phase 4	75	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	A8081067	January 28, 2019	January 30, 2022	January 30, 2022	September 14, 2018		July 31, 2019	Fujian Province Oncology Hospital, Fuzhou, Fujian, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|Jilin Provincial Cancer Hospital, Changchun, Jilin, China|Sichuan Province Cancer Hospital/Department of Pulmonary Tumor, Chengdu, Sichuan, China|Department of Respiratory, The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|Beijing Cancer Hospital, Internal Department, Beijing, China|Zhongshan Hospital Fudan University, Shanghai, China		https://ClinicalTrials.gov/show/NCT03672643
300	NCT00315484	Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia		Completed	No Results Available	Anemia|Chemotherapy	Drug: Epoetin alfa and Darbepoetin alfa	The primary efficacy endpoint will evaluate the proportion of patients achieving >1 g/dL hemoglobin increase by week 5.|1) time to hemoglobin (Hgb) increase of 1g/dL; 2) proportion of pts achieving a >1 g/dL Hgb increase by Wk 9; 3) proportion of pts achieving a >2g/dL Hgb increase by Wk 9; 4) Hgb values over time; 5) cumulative RBC transfusion Wk 5 to end of study	Ortho Biotech Products, L.P.	All	18 Years and older   (Adult, Older Adult)	Phase 4	358	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CR004609	February 2003		October 2004	April 18, 2006		May 19, 2011			https://ClinicalTrials.gov/show/NCT00315484
301	NCT02446223	Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%		Completed	No Results Available	Actinic Keratosis	Drug: Inggenol Mebutate 0.015%	complete clearance of all clinically visible Actinic Keratosis (AK)	Goldman, Butterwick, Fitzpatrick and Groff|LEO Pharma	All	18 Years and older   (Adult, Older Adult)	Phase 4	23	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PICATO-2013-01	January 2015	September 2016	September 2016	May 18, 2015		March 1, 2017	Cosmetic Laser Dermatology, San Diego, California, United States		https://ClinicalTrials.gov/show/NCT02446223
302	NCT01203917	Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC	IFUM	Completed	Has Results	Caucasian Patients With EGFR Mutation Positive Advanced NSCLC	Drug: Gefitinib	Objective Response Rate (ORR) (Investigator)|Disease Control Rate (DCR) (Investigator)|Progression - Free Survival (PFS) (Investigator)|Overall Survival (OS)	AstraZeneca	All	18 Years to 130 Years   (Adult, Older Adult)	Phase 4	1060	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D791AC00014	September 2010	August 2012	June 2016	September 17, 2010	October 14, 2013	January 2, 2017	Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Vratza, Bulgaria|Research Site, ANGERS Cedex 9, France|Research Site, Saint Herblain Cedex, France|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Larissa, Greece|Research Site, Thessaloniki, Greece|Research Site, Budapest, Hungary|Research Site, Deszk, Hungary|Research Site, Edelény, Hungary|Research Site, Győr, Hungary|Research Site, Mosdós, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Ancona, Italy|Research Site, Carpi, Italy|Research Site, Livorno, Italy|Research Site, Perugia, Italy|Research Site, Oslo, Norway|Research Site, Stavanger, Norway|Research Site, Trondheim, Norway|Research Site, Gdańsk, Poland|Research Site, Kraków, Poland|Research Site, Lubin, Poland|Research Site, Olsztyn, Poland|Research Site, Otwock, Poland|Research Site, Szczecin, Poland|Research Site, Toruń, Poland|Research Site, Warszawa, Poland|Research Site, Wrocław, Poland|Research Site, Coimbra, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Vila Nova de Gaia, Portugal|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj Napoca, Romania|Research Site, Constanta, Romania|Research Site, Lugo, Spain|Research Site, Lérida, Spain|Research Site, Madrid, Spain|Research Site, Majadahonda, Spain|Research Site, Málaga, Spain|Research Site, Basel, Switzerland|Research Site, Chur, Switzerland|Research Site, Rapperswil-Jona, Switzerland|Research Site, Sursee, Switzerland|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Aberdeen, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Burnley, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Wolverhampton, United Kingdom		https://ClinicalTrials.gov/show/NCT01203917
303	NCT00333099	INEC Study: Immuno-modulating Enteral Nutrition in Cancer		Completed	No Results Available	Malnutrition|Esophageal Cancer|Head and Neck Cancer	Dietary Supplement: Impact (R) Enteral Nutrition|Other: impact	Frequency and grade of mucositis|Effect on treatment conditions (interruption, doses)|Other complications linked to chemoradiotherapy|Nutritional and immune status|Life quality|Cost	University Hospital, Clermont-Ferrand|Fonds National d'Aménagement et de Développement du territoire (FNADT)|European Regional Development Fund|Centre Jean Perrin|Centre Leon Berard|Institut de Cancérologie de la Loire|Centre Hospitalier Universitaire de Saint Etienne|Hôpital Edouard Herriot|University Hospital, Grenoble|Orkyn'|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	250	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)	CHU63-0012	May 2006	September 2010	September 2011	June 2, 2006		September 14, 2012	Hotel Dieu, Clermont-Ferrand, Auvergne, France		https://ClinicalTrials.gov/show/NCT00333099
304	NCT03799601	Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC	ALTER-L013	Not yet recruiting	No Results Available	NSCLC	Drug: Anlotinib|Drug: Docetaxel|Drug: Carboplatin	progression-free survival|Overall Survival|Disease Control Rate|Overall Response Rate	Tongji Hospital|Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	45	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TJCC-LC-20190108	March 1, 2019	December 1, 2019	December 1, 2020	January 10, 2019		January 10, 2019	Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology,, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT03799601
305	NCT01302951	Penetration of Moxifloxacin Into Liver Tissue of Patients Undergoing Liver Resection.	MOXI	Completed	No Results Available	Side-effect of Antibiotic	Drug: Moxifloxacin 400 mg	Concentration (mg/L) of moxifloxacin in liver tissue|Maximum concentration (mg/L) of moxifloxacin in serum|Number of participants with adverse events|Area under the plasma concentration versus time curve (AUC) of moxifloxacin (mg*h/L)	University Hospital, Saarland|Bayer	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 4	34	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	24/06|2008-001902-18	July 2008	July 2010	July 2010	February 24, 2011		February 24, 2011	University hospital of the Saarland, Homburg/Saar, Germany		https://ClinicalTrials.gov/show/NCT01302951
306	NCT03123406	Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT	ACTIVE	Active, not recruiting	No Results Available	Hyperparathyroidism; Secondary, Renal	Drug: Cinacalcet HCl	Compared with baseline data, the proportion of subjects reaching iPTH target at 20th week|Compared with baseline data, the proportion of subjects reaching iPTH target at 32nd week|Compared with baseline data, the proportion of patients reaching Ca & P target simultaneously at 32nd week|Compared with baseline data, the proportion of patients with ≥ 30% reduction in iPTH level at 20th week|Compared with baseline data, the proportion of patients with ≥ 30% reduction in iPTH level at 32nd week|The proportion of patients once reaching iPTH target during 1st~32nd week|The proportion of patients once reaching iPTH target during 33rd~52nd week|Compared with baseline data, the change of Ca × P at 20th week|Compared with baseline data, the change of Ca × P at 32nd week|Compared with baseline data, the change of alkaline phosphatase (ALP) at 20th week|Compared with baseline data, the change of alkaline phosphatase (ALP) at 32nd week|Compared with baseline data, the change of fibroblast growth factor 23(FGF23) at 20th week|Compared with baseline data, the change of fibroblast growth factor 23(FGF23) at 32nd week|Compared with baseline data, the adjustment (type or amount) of calcium agents at 20th week|Compared with baseline data, the adjustment (type or amount) of calcium agents at 32nd week|Compared with baseline data, the adjustment (type or amount) of phosphate binders at 20th week|Compared with baseline data, the adjustment (type or amount) of phosphate binders at 32nd week|Compared with baseline data, the adjustment (type or amount) of vitamin D and its analogues at 20th week|Compared with baseline data, the adjustment (type or amount) of vitamin D and its analogues at 32nd week|Compared with baseline data, the adjustment (type or amount) of diphosphonic acid salts at 20th week|Compared with baseline data, the adjustment (type or amount) of diphosphonic acid salts at 32nd week|Compared with the data at 32nd week, the proportional change of patients reaching iPTH target at 52nd week who continue Cinacalcet treatment during 20-week real world period|Compared with the data at 32nd week, the proportional change of patients reaching iPTH target at 52nd week who discontinue Cinacalcet treatment after 20-week real world period|Compared with the data at 32nd week, the proportional change of patients reaching Ca target at 52nd week who continue Cinacalcet treatment after 20-week real world period|Compared with the data at 32nd week, the proportional change of patients reaching Ca target at 52nd week who discontinue Cinacalcet treatment after 20-week real world period|Compared with the data at 32nd week, the proportional change of patients reaching P target at 52nd week who continue Cinacalcet treatment after 20-week real world period|Compared with the data at 32nd week, the proportional change of patients reaching P target at 52nd week who discontinue Cinacalcet treatment after 20-week real world period|Compared with the data at 32nd week, the proportional change of patients reaching Ca × P target at 52nd week who continue Cinacalcet treatment after 20-week real world period|Compared with the data at 32nd week, the proportional change of patients reaching Ca × P target at 52nd week who discontinue Cinacalcet treatment after 20-week real world period|The dose change of calcium agents which were used by patients for chronic kidney disease-mineral and bone disorder(CKD-MBD) treatment during 20-week real world period|The dose change of phosphate binders which were used by patients for chronic kidney disease-mineral and bone disorder(CKD-MBD) treatment during 20-week real world period|The dose change of vitamin D and its analogues which were used by patients for chronic kidney disease-mineral and bone disorder(CKD-MBD) treatment during 20-week real world period|The dose change of diphosphonic acid salts which were used by patients for chronic kidney disease-mineral and bone disorder(CKD-MBD) treatment during 20-week real world period|The reasons of patients discontinuing Cinacalcet in 20-week real world	Kyowa Hakko Kirin China Pharmaceutical Co., LTD.	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	750	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	KKCN201601	March 31, 2017	August 27, 2019	September 30, 2019	April 21, 2017		June 18, 2019	Nanjing Jinling Hospital, Nanjing, Jiangsu, China		https://ClinicalTrials.gov/show/NCT03123406
307	NCT01770431	Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy		Completed	Has Results	Hepatic Carcinoma	Drug: Huaier Granule	Incidence of Recurrence and Metastasis After Hepatectomy|Postoperative Survival Period	Qidong Gaitianli Medicines Co., Ltd|Huazhong University of Science and Technology	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	1044	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	HE-201101	August 2011	August 2016	August 2016	January 17, 2013	October 2, 2017	October 2, 2017	Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT01770431
308	NCT01181531	Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis		Completed	Has Results	Hyperparathyroidism, Secondary	Drug: Traditional Vitamin D Therapy|Drug: Cinacalcet	Percent Change From Baseline in Mean PTH During Efficacy Assessment Phase (EAP)|Treatment Comparison of >=30% Reduction From Baseline in Mean PTH During the Efficacy Assessment Phase (EAP)|Treatment Comparison of Plasma PTH < 300 pg/mL During Efficacy Assessment Phase (EAP)	Amgen	All	18 Years and older   (Adult, Older Adult)	Phase 4	312	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20090686|PARADIGM	October 1, 2010	July 17, 2012	August 14, 2012	August 13, 2010	April 25, 2014	October 17, 2018			https://ClinicalTrials.gov/show/NCT01181531
309	NCT02996214	Lipusu Advanced Squamous Cell Carcinoma of Lung Study Carboplatin in Advanced Squamous Cell Carcinoma of Lung	LIPUSU	Not yet recruiting	No Results Available	Lung Squamous Cell Carcinoma	Drug: Paclitaxel Liposome|Drug: Gemcitabine|Drug: Cisplatin	progression free survival (PFS)|Objective Response Rate (ORR)|Regional lymph node remission rate|Overall Survival (OS)|Safety Assessment|Quality of Life	Nanjing Luye Sike Pharmaceutical Co., Ltd.	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	536	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LY-TM-LPS-2016-01	November 2016	December 2019	June 2020	December 19, 2016		December 19, 2016			https://ClinicalTrials.gov/show/NCT02996214
310	NCT00537979	Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis		Completed	Has Results	Secondary Hyperparathyroidism|Dialysis	Drug: Paricalcitol injection|Drug: Paricalcitol capsules	Proportion of Subjects Who Achieve at Least a 50% Reduction in iPTH Compared to Baseline Level|Analysis of Episodes of Hypercalcemia (> 11.5 mg/dL), Hyperphosphatemia (> 7.0 mg/dL) and Elevations of Calcium x Phosphorus Product (> 75)|Proportion of Subjects Who Achieve an iPTH <300 pg/mL|Time Required to Achieve: (1) a Reduction in iPTH Less Than <300 pg/mL;(2) a 50% Reduction in iPTH Compared to the Baseline Level; and (3) Either a Reduction in iPTH Less Than <300 pg/mL or a 50% Reduction in iPTH Compared to the Baseline Level|Duration of Response to Treatment|Health-related Quality of Life With Paricalcitol Injection or Oral Treatment	Abbott	All	18 Years and older   (Adult, Older Adult)	Phase 4	147	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	W10-129	September 2007	July 2010	July 2010	October 2, 2007	October 25, 2011	October 25, 2011	Site Ref # / Investigator 19391, Jojutla Morelos, Mexico|Site Ref # / Investigator 19389, Mexico City, Mexico|Site Ref # / Investigator 19390, Mexico City, Mexico|Site Ref # / Investigator 19393, Mexico City, Mexico|Site Ref # / Investigator 19395, Mexico City, Mexico|Site Ref # / Investigator 19392, Mexico D.F., Mexico|Site Ref # / Investigator 19397, Mexico D.F., Mexico|Site Ref # / Investigator 19396, Mexico D.F., Mexico|Site Ref # / Investigator 19394, Mexico D.F., Mexico|Site Ref # / Investigator 19399, Puebla, Mexico|Site Ref # / Investigator 19398, Zapopan, Mexico|Site Ref # / Investigator 19388, Zapopan, Mexico		https://ClinicalTrials.gov/show/NCT00537979
311	NCT00463021	A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection		Completed	No Results Available	Secondary Hyperparathyroidism	Drug: Hectorol (doxercalciferol capsules)|Drug: Zemplar (paricalcitol injection)	Dose Conversion	Genzyme, a Sanofi Company|Sanofi	All	18 Years and older   (Adult, Older Adult)	Phase 4	36	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HECT00306	April 2007		December 2007	April 19, 2007		May 5, 2015	Downey, California, United States|Paramount, California, United States|Hudson, Florida, United States|Augusta, Georgia, United States|Decatur, Georgia, United States|Pittsburgh, Pennsylvania, United States|Nashville, Tennessee, United States|Norfolk, Virginia, United States		https://ClinicalTrials.gov/show/NCT00463021
312	NCT00135304	ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism		Completed	No Results Available	Secondary Hyperparathyroidism	Drug: Sensipar®|Drug: Vitamin D	Achieving the NKF-K/DOQI targets for both biPTH (80-160 pg/mL, equivalent to iPTH 150-300 pg/mL) and Ca x P (less than 55 mg^2/dL^2) during the assessment phase|Absolute Change from Baseline for P During the Assessment Phase|Proportion of Participants with ≥ 30% Reduction from Baseline in Mean iPTH During the Assessment Phase|Percent Change from Baseline for Calcium During the Assessment Phase|Percent Change from Baseline for Phosphorus During the Assessment Phase|Percent Change from Baseline for Ca x P During the Assessment Phase|Percent Change from Baseline for iPTH During the Assessment Phase|Proportion of Participants who Attained the K/DOQI Target Range for Ca x P During the Assessment Phase.|Proportion of Participants who Attained the K/DOQI Target Range for Ca During the Assessment Phase|Proportion of Participants who Attained the K/DOQI Target Range for iPTH During the Assessment Phase|Proportion of Participants who Attained the K/DOQI Target Range for P During the Assessment Phase.|Absolute Change from Baseline for iPTH During the Assessment Phase|Absolute Change from Baseline for Ca During the Assessment Phase|Absolute Change from Baseline for Ca x P During the Assessment Phase	Amgen	All	18 Years and older   (Adult, Older Adult)	Phase 4	170	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20050102	August 2005	October 2006	December 2006	August 26, 2005		February 11, 2014			https://ClinicalTrials.gov/show/NCT00135304
313	NCT01968798	ASPREE Cancer Endpoints Study	ACES	Active, not recruiting	No Results Available	Cancer	Drug: Aspirin|Drug: Placebo	To examine the effect of daily low-dose aspirin (100 mg) compared to placebo, on specific DNA biomarkers and selected specific incident and recurrent cancer and metastases.	Hennepin Healthcare Research Institute.|National Cancer Institute (NCI)|National Institute on Aging (NIA)|Monash University|Berman Center for Outcomes and Clinical Research|National Health and Medical Research Council, Australia|Bayer	All	65 Years and older   (Older Adult)	Phase 4	14500	Other|NIH|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	3U01AG029824-02S1	September 2013	January 2019	April 2024	October 24, 2013		May 30, 2019	The University of Alabama at Birmingham, Birmingham, Alabama, United States|Palo Alto Medical Foundation Research Institute, Palo Alto, California, United States|Howard University, Washington, District of Columbia, United States|University of Florida Department of Aging and Geriatrics, Gainesville, Florida, United States|Morehouse School of Medicine, Atlanta, Georgia, United States|Emory/ Atlanta VAMC, Atlanta, Georgia, United States|Georgia Health Sciences University, Augusta, Georgia, United States|Rush Alzheimer's Disease Center, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Kansas University Medical Center, Kansas City, Kansas, United States|Baton Rouge General, Baton Rouge, Louisiana, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Mary Bird Perkins Our Lady of the Lake Cancer Center, Baton Rouge, Louisiana, United States|Mary Bird Perkins St. Tammany Parish Hospital, Covington, Louisiana, United States|Mary Bird Perkins Terrebonne General Hospital, Houma, Louisiana, United States|LSU Health Sciences- New Orleans, New Orleans, Louisiana, United States|Tulane Medical Center, New Orleans, Louisiana, United States|LSU Health Sciences- Shreveport, Shreveport, Louisiana, United States|University of Michigan, Ann Arbor, Michigan, United States|Wayne State University, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Detroit Clinical Research Center, Novi, Michigan, United States|Health Partners Research Foundation, Minneapolis, Minnesota, United States|Phalen Village Clinic, Saint Paul, Minnesota, United States|Central Jersey Medical Center, Elizabeth, New Jersey, United States|New Jersey Medical College, Newark, New Jersey, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Queens Cancer Medical Center, Queens, New York, United States|Wake Forest University Baptist Medical Center, Greensboro, North Carolina, United States|The Brody School of Medicine at ECU, Greenville, North Carolina, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Health Sciences Research Center, Pittsburgh, Pennsylvania, United States|Memorial Hospital of Rhode Island, Pawtucket, Rhode Island, United States|University of Tennessee Health Science Center, Memphis, Tennessee, United States|Meharry Medical College, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of TX Medical Branch, Galveston, Texas, United States|Regional Academic Health Center, Harlingen, Texas, United States|UT Health Science Center at San Antonio, San Antonio, Texas, United States		https://ClinicalTrials.gov/show/NCT01968798
314	NCT01087008	Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse	AZABACHE	Active, not recruiting	No Results Available	Multiple Myeloma	Drug: zoledronic acid|Other: No treatment control	Time to next need treatment|Time to symptom relapse|disease progression|prognostic factors|antitumour effect of ZOL|Overall survival	PETHEMA Foundation|Dynamic Solutions|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	103	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	AZABACHE: 2009-017440-13	April 2010	May 2013	December 2019	March 15, 2010		May 14, 2019	Hospital Universitari Germans Trias I Pujol, Badalona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Jose María Morales Meseguer, Murcia, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Hospital Universitario Son Dureta, Palma de Mallorca, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario de Canarias, Tenerife, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Universitario Dr. Peset., Valencia, Spain|Hospital Universitario La Fe, Valencia, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Spain		https://ClinicalTrials.gov/show/NCT01087008
315	NCT03229200	Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.		Enrolling by invitation	No Results Available	Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Leukemia, B-cell|Graft Vs Host Disease|Solid Tumor	Drug: Ibrutinib	The objective of protocol PCYC-1145-LT is to provide long-term access to ibrutinib for subjects who meet the selection criteria.|Characterize the drug safety profile by collecting long-term safety data for ibrutinib.	Pharmacyclics Switzerland GmbH	All	18 Years and older   (Adult, Older Adult)	Phase 4	500	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PCYC-1145-LT	May 22, 2017	July 2, 2027	July 2, 2027	July 25, 2017		July 22, 2019	Providence Health System - Southern California d/b/a Roy and Patricia Disney Family Cancer Center, The Roy & Patricia Disney Family Cancer Center, Burbank, California, United States|City Of Hope National Medical Center, Duarte, California, United States|UCSD Moores Cancer Center, La Jolla, California, United States|University of California Los Angeles (UCLA), Los Angeles, California, United States|Stanford University, Stanford, California, United States|University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Norton Medical Plaza II, 3991 Dutchmans Lane, Louisville, Kentucky, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|TRIO - Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|John Theurer Cancer Center, Hackensack UMC, Hackensack, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Clinical Research Alliance, Lake Success, New York, United States|Northwell Health, New Hyde Park, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States|University of Rochester, Rochester, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Mid Ohio Oncology/Hematology Inc., DBA The Mark H. Zangmeister Center, Columbus, Ohio, United States|Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States|Texas Oncology, Tyler, Texas, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Northwest Cancer Specialists, Compass Oncology, Vancouver, Washington, United States|Yakima Valley Memorial Hospital, Yakima, Washington, United States|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Ballarat Health Services, Ballarat, Victoria, Australia|Eastern Health, Box Hill, Victoria, Australia|St Vincent Hospital, Fitzroy, Victoria, Australia|UZ Leuven, Leuven, Belgium|AZ Turnhout, Turnhout, Belgium|University Hospital Hradec Kralove, Hradec Králové, Kralovehradecky Kraj, Czechia|Hematology and Oncology Masaryk University Hospital Brno, Brno, Czechia|University Hospital Pilsen, Pilsen, Czechia|Charles University Hospital, Prague, Prague, Czechia|IHK FNKV Praha, Praha, Czechia|Centre Henri Becquerel, Rouen Cedex, France|General Hospital of Athens "Laiko", Athens, Attica, Greece|Hadassah Medical Center, Jerusalem, Israel|Rabin Dedical Center, Petach Tikva, Israel|Sourasky Medical Center, Tel Aviv, Israel|Middlemore Hospital, Papatoetoe, Auckland, New Zealand|North Shore Hospital, Auckland, New Zealand|Szpital Specjalistyczny w Brzozowie, Oddział Hematologii Onkologicznej z Klinicznym Oddziałem Przeszczepiania Szpiku, Brzozów, Podkarpackie, Poland|Klinika Hematologii i Transplantologii, Gdańsk, Pomorskie, Poland|SPZOZ ZSM w Chorzowie, Chorzów, Silesia, Poland|Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika, Łódź, Poland|Nizhniy Novgorod Regional Clinical Hospital n.a. N.A. Semashko, Nizhniy Novgorod, Nizhegorodskaya, Russian Federation|SBI of Ryazan region "Regional Clinical Hospital", Ryazan', Ryazan Region, Russian Federation|Russian Scientific and Research Institute of Hematology and Transfusiology of Federal Medical Biological Agency, Saint Petersburg, Russian Federation|Almazov National Medical Research Centre, Saint Petersburg, Russian Federation|Yaroslavl Regional Clinical Hospital, Yaroslavl, Russian Federation|Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital de Sanata Creus i Sant Pau, Barcelona, Spain|ICO l'Hospitalet - Hospital Duran i Reynals, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|University Hospital of Salamanca, Salamanca, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Sunderby hospital, Luleå, Norrbotten, Sweden|Södra Älvsborg Hospital Borås, Borås, Sweden|Karolinska University Hospital, Solna, Sweden|Gazi University, Ankara, Turkey		https://ClinicalTrials.gov/show/NCT03229200
316	NCT01101113	Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level	CUPID	Completed	No Results Available	Secondary Hyperparathyroidism	Drug: cinacalcet|Drug: control	> 30% reduction from baseline of intact parathyroid hormone (iPTH)|Achievement of treatment goal of intact parathyroid hormone (iPTH) (150~300 pg/ml)|Achievement of targets for mean Ca x P (<55 mg2/dL2), Ca (<9.5 mg/dL), P (<5.5 mg/dL)|Achieving targets for intact PTH (150-300 pg/ml) and calcium-phosphorus product (Ca x P) (<55 mg2/dl2) simultaneously|Vascular calcification score|Normalization of serum alkaline phosphatase|Serum FGF-23	Seoul National University Hospital|Jeil-Kirin Pharmaceutical Inc.	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 4	66	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CINA-Kor-01	September 2010	March 2012	June 2012	April 9, 2010		June 8, 2012	Seoul National University Hospital, Seoul, Korea, Korea, Republic of|Kyungpook National University, Daegu, Korea, Republic of|Gil Hospital, Incheon, Korea, Republic of|Hallym University Sacred Hospital, Pyungchon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Eulji University, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01101113
317	NCT01347996	Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia		Completed	No Results Available	Acute Myeloid Leukemia	Drug: histamine dihydrochloride and IL-2	Minimal residual disease (MRD) in AML patients receiving Ceplene/IL-2|Pharmacodynamic effects of Ceplene plus low dose IL-2 (Ceplene/IL-2) by monitoring T and NK cell phenotypes and their functionality after the first and third cycles of treatment|Duration of LFS	Cytovia, Inc.|EpiCept Corporation	All	18 Years and older   (Adult, Older Adult)	Phase 4	84	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EPC2008-02	July 2009	June 2014	June 2014	May 5, 2011		November 29, 2017	Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden		https://ClinicalTrials.gov/show/NCT01347996
318	NCT01939977	Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.	PARIDOINAL	Completed	Has Results	Secondary Hyperparathyroidism Due to Renal Causes	Drug: Paricalcitol|Drug: Calcifediol	Percentage of Patients With iPTH Serum Concentration >110 pg/mL.|Change on iPTH Serum Concentration. Intention to Treat Analysis.|Percentage of Patients That Reach at Least a 30% iPTH Reduction at the End of the Study.|Percentage of Patients With iPTH Levels Between 70-110 pg/mL at the End of the Study. ITT.|Percentage of Patient With Presence of Calcifications on Protocol Renal Biopsies at 6 Months After Treatment in Each Treatment Group.|Patients That Suffered the Following Events: Acute Rejection, Acute Rejection Confirmed With Biopsy and/or Subclinic Rejection and/or Chronic Damage.|Change on Concentration of Bone Markers (Osteocalcin) at 6 Months After Transplantation on Each Treatment Group.|Percentage of Patients With Acute Rejection at 6 Months After Transplantation and Treatment on Each Treatment Group.|Percentage of Patients With Microalbuminuria on Months 1, 3 and 6 Post Transplantation.|Percentage of Patients on Each Stage of Renal Function on Months 1, 3 and 6 Post Transplantation.|Evolution of Speed of Pulse Wave From Month 1 to Month 6 Post Transplantation.|Percentage of Patients With Hypercalcemia on Each Treatment Group at 6 Months Post Transplantation.|Evolution of Anti-HLA Antibodies (PRA) From Basal to Month 6 Post-transplantation.|Frequency of Adverse Events or Serious Adverse Events That Occurs During the Study on Each Treatment Group.|Change on Concentration of Bone Markers (Alkaline Phosphatase) at 6 Months After Transplantation on Each Treatment Group.|Change on Concentration of Bone Markers (FGF-23) at 6 Months After Transplantation on Each Treatment Group	Fundación Senefro|AbbVie|Effice Servicios Para la Investigacion S.L.	All	18 Years and older   (Adult, Older Adult)	Phase 4	148	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ACA-SPAI-11-24|2013-001326-25	January 2014	September 2015	December 2015	September 11, 2013	November 19, 2018	November 19, 2018	Hospital Universitari Germans Trias I Pujol de Badalona, Badalona, Barcelona, Spain|Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain|Hospital Del Mar, Barcelona, Spain|Fundació Puigvert-Iuna, Barcelona, Spain|Hospital Universitari Vall D'Hebron, Barcelona, Spain|Hospital Puerta Del Mar, Cádiz, Spain|Hospital Reina Sofía, Córdoba, Spain|Complexo Hospitalario Universitario A Coruna, La Coruna, Spain|Complejo Hospitalario Universitario de Canarias, Las Palmas De Gran Canaria, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Complejo Hospitalario Regional de Málaga, Málaga, Spain|Hospital Virgen Del Rocío, Sevilla, Spain|Hospital Universitari I Politècnic La Fe, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain		https://ClinicalTrials.gov/show/NCT01939977
319	NCT00362544	PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia		Completed	No Results Available	Leukemia	Drug: Ambisome	The primary endpoint will be the safety defined by the incidence of adverse events occurring during the course of prophylaxis treatment (4 weeks for AL patients and 8 weeks for SCT patients).|The secondary endpoints for assessing efficacy will be the following:|Incidence of probable or proven invasive fungal infection according to EORTC-MSG 35 criteria within the12 weeks following the initiation of prophylaxis treatment.|Incidence of fever of unknown origin requiring empirical antifungal treatment within 12 weeks after trial initiation.|Incidence of superficial fungal infections within 3 months after trial initiation.|Time differential for commencement of empirical antifungal treatment measured within 3 months after trial initiation.|Evidence of colonisation by fungal organisms observed within 3 months after trial initiation.|Survival rate at the end of treatment and incidence of mortality related to fungal infection within 12 weeks and 24 weeks after study drug initiation.|Renal toxicity|The incidence and grade of nephrotoxicity will be assessed.|Hepatotoxicity|The incidence and grade hepatotoxicity will be assessed.|Patients whose AST or ALT becomes > 10 times the ULN will be withdrawn from the study.|Ionic analysis|Hypokalaemia: its incidence and grade will be evaluated. Potassium supplements received by the patient will be recorded in the Case Report Form.|Hypomagnesaemia: its incidence and grade will be evaluated as well.|Laboratories used by both sites will provide a list of their reference ranges.|Ionic disorders should be corrected throughout the trial.|Cardiovascular toxicity|The most commonly reported cardiovascular adverse events are rhythm disorders. There is a risk of seeing their incidence increase if the infusion is given too quickly.|Vital signs and ECG will be monitored throughout the trial.|Patients will be withdrawn from the trial, if in the investigator's opinion, further participation may put them at risk.|General safety|All adverse events occurring during the trial will be reported in the CRFs.	Gilead Sciences	All	18 Years and older   (Adult, Older Adult)	Phase 4	30	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	GS-FR-131-104|GS-FR-131-0119	October 2003		March 2006	August 10, 2006		July 9, 2015	Gilead Sciences, Paris, France		https://ClinicalTrials.gov/show/NCT00362544
320	NCT00304447	Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia		Completed	No Results Available	Leukemia, Myelocytic, Acute|Infusions, Intravenous	Drug: Mylotarg	The effect of corticosteroids on the frequency and severity of Mylotarg® infusion-related adverse events.|The effect of corticosteroids on the efficacy of Mylotarg® induced complete response (CR) and complete response with incomplete platelets recovery (CRp) at one-month post treatment.	Wyeth is now a wholly owned subsidiary of Pfizer	All	18 Years and older   (Adult, Older Adult)	Phase 4	30	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	0903X-100863	April 2002		January 2004	March 17, 2006		July 29, 2009			https://ClinicalTrials.gov/show/NCT00304447
321	NCT03975829	Pediatric Long-Term Follow-up and Rollover Study		Not yet recruiting	No Results Available	Diffuse Astrocytoma|Anaplastic Astrocytoma|Astrocytoma|Oligodendroglioma, Childhood|Anaplastic Oligodendroglioma|Glioblastoma|Pilocytic Astrocytoma|Giant Cell Astrocytoma|Pleomorphic Xanthoastrocytoma|Anaplastic Pleomorphic Xanthoastrocytoma|Angiocentric Glioma|Chordoid Glioma of Third Ventricle|Gangliocytoma|Ganglioglioma|Anaplastic Ganglioglioma|Dysplastic Gangliocytoma of Cerebrellum|Desmoplastic Infantile Astrocytoma and Ganglioglioma|Papillary Glioneuronal Tumor|Rosette-forming Glioneurona Tumor|Central Neurocytoma|Extraventricular Neurocytoma|Cerebellar Liponeurocytoma|Neurofibromatosis Type 1	Drug: dabrafenib|Drug: trametinib	Number of participants with Adverse Events and Serious Adverse Events (SAEs)|Percentage of participants with height (measured by cm or in) changes over time|Percentage of participants with weight (measured by kg or lb) changes over time|Percentage of participants with skeletal maturation (measured by bone age on x-ray or MRI) changes over time|Percentage of participants with sexual maturation (measured by tanner staging criteria) changes over time|Percentage of participants with cardiac function (measured by ECG) changes over time|Clinical Benefit (measured by CT/MRI)	Novartis Pharmaceuticals|Novartis	All	1 Year and older   (Child, Adult, Older Adult)	Phase 4	250	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDRB436G2401|2018-004459-19	August 27, 2019	May 29, 2026	May 29, 2026	June 5, 2019		June 5, 2019			https://ClinicalTrials.gov/show/NCT03975829
322	NCT02399124	Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma	ICE-SECRET	Recruiting	No Results Available	Renal Cell Carcinoma	Device: PROSENSE™	Success in creating an ice ball that engulfs the whole tumor with 5 mm margins using the ProSense™ as seen under laparoscopic, US or CT imaging during the procedure.|Recurrence free survival|Success in verification of the ProSense™ safety as demonstrated by having no complications related to the cryoablation procedure other than the well-known ones.	IceCure Medical Ltd.|Bnai Zion Medical Center	All	18 Years and older   (Adult, Older Adult)	Phase 4	100	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ICMRC-01	July 2014	June 2019	January 2022	March 26, 2015		March 16, 2018	Bnei Zion Medical Center, Haifa, Israel|Asaf Harofe Medical center, Zrifin, Israel		https://ClinicalTrials.gov/show/NCT02399124
323	NCT03588884	Repeated-dose Safety, Efficacy, PK and PD of CTAP101, IR Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With SHPT, CKD 3-4 and VDI		Recruiting	No Results Available	Secondary Hyperparathyroidism Due to Renal Causes|Vitamin D Deficiency|CKD Stage 3|CKD Stage 4	Drug: Calcifediol Oral Capsule|Drug: Calcifediol Oral Product|Drug: Cholecalciferol|Drug: Paricalcitol Oral Capsule	Incidence and Severity of Treatment-Emergent Adverse Events as assessed by CTCAE version 5.0	OPKO Ireland Global Holdings Ltd.	All	18 Years and older   (Adult, Older Adult)	Phase 4	80	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTAP101-CL-4001	June 8, 2018	March 17, 2020	May 22, 2020	July 17, 2018		June 3, 2019	National Institute of Clinical Research, Inc., Garden Grove, California, United States|Research by Design, LLC, Chicago, Illinois, United States|Spaulding Clinical Research, West Bend, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT03588884
324	NCT02953938	Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety	ZIPANGU	Completed	No Results Available	Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)	Biological: Ranibizumab|Radiation: Grid&Direct short pulse laser photocoagulation	Difference in mean number of ranibizumab injections|The mean change in BCVA using decimal chart and ETDRS compared to baseline|The mean average change in BCVA from Month 1 through Month 12 compared to Baseline (Day 1) by the treatment arms|The proportion of patients achieving BCVA improvement of ≥5, ≥10, ≥15, and ≥30 letters and proportion of patients experiencing a loss of <15 letters. The proportion of patients reaching BCVA values ≥73, ≥80, and ≥85 letters.|The mean change in CSFT from Month 1 through Month12 compared to Baseline (Day1) by the treatment arms|The mean average change in CSFT from Month 1 through Month12 compared to Baseline (Day1) by the treatment arms|To evaluate the safety of ranibizumab monotherapy and ranibizumab combined with Grid&Direct short pulse laser photocoagulation therapy in Japanese patients as assessed by the type, frequency, and severity of ocular and non-ocular AEs	Novartis Pharmaceuticals|Novartis	All	20 Years and older   (Adult, Older Adult)	Phase 4	59	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CRFB002EJP09	December 15, 2016	December 28, 2018	December 28, 2018	November 3, 2016		July 16, 2019	Novartis Investigative Site, Nagakute-city, Aichi, Japan|Novartis Investigative Site, Fukuoka city, Fukuoka, Japan|Novartis Investigative Site, Kita-gun, Kagawa, Japan|Novartis Investigative Site, Tsu-city, Mie, Japan|Novartis Investigative Site, Matsumoto-city, Nagano, Japan|Novartis Investigative Site, Mitaka-city, Tokyo, Japan|Novartis Investigative Site, Hokkaido, Japan		https://ClinicalTrials.gov/show/NCT02953938
325	NCT04033081	Registry of Retroperitoneal, Abdominal, Pelvic and Truncal Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet® to Evaluate the Safety and Feasibility Over 5 Years		Not yet recruiting	No Results Available	Sarcoma	Device: CivaSheet	Rate of acute toxicity|Local control rate|Reoperation rate|Complication rate|Dose to target and OAR	CivaTech Oncology|TAB Clinical	All	Child, Adult, Older Adult	Phase 4	100	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CT007	August 2019	March 2021	August 2025	July 25, 2019		July 25, 2019	Rush University Cancer Center, Chicago, Illinois, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04033081
326	NCT00504959	Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration		Completed	No Results Available	Subfoveal Choroidal Neovascularization (CNV)|Secondary to Age-related Macular Degeneration (AMD)	Drug: ranibizumab	Safety assessed by incidence and severity of treatment emergent ocular and non-ocular adverse events over 24 month study period with ranibizumab monthly prn (0.5mg/0.05ml)|Efficacy assessed by mean change in BCVA from Baseline at M 6, 12, 18, and 24. Number of injections with ranibizumab. Safety assessed by AEs and SAEs leading to premature discont. of study drug, vital signs, and ophthalmic exams.	Novartis	All	50 Years and older   (Adult, Older Adult)	Phase 4	234	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CRFB002A2402	July 2007	January 2010	January 2010	July 20, 2007		March 4, 2016	Novartis Investigational Site, Melbourne, Australia|Novartis Investigative Site, Laeken, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Bremen, Germany|Novartis Investigative Site, Chemnitz, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Marburg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Siegburg, Germany|Novartis Investigative Site, Tubingen, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Petach-Tikva, Israel|Novartis Investigative Site, Tel - Hashomer, Israel|Novartis Investigative Site, Tel-Aviv, Israel|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Nijmegen, Netherlands|Novartis Investigative Site, Coimbra, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Alicante, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Santiago de Compostela, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative SIte, Ankara, Turkey|Novartis Investigative Site, Bristol, United Kingdom|Novartis Investigative Site, Southampton, United Kingdom|Novartis Investigative Site, West Midlands, United Kingdom|Novartis Investigative Site, Wolverhampton, United Kingdom		https://ClinicalTrials.gov/show/NCT00504959
327	NCT00947115	Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects		Completed	Has Results	Infections, Papillomavirus	Procedure: Blood sampling|Procedure: Cervico-vaginal secretion (CVS) samples	Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum|Number of Seroconverted Subjects.|Total Immunoglobulin G (IgG) Antibody Titers in Serum|Anti-HPV-16/18 Secretion Antibody Titers in Cervico-vaginal Secretion (CVS)|Total Immunoglobulin G (IgG) Secretion Antibody Titers in CVS|Number of Subjects With Any Fatal or Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).|Number of Subjects With Any Fatal or Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication)	GlaxoSmithKline	Female	20 Years to 60 Years   (Adult)	Phase 4	525	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	112772	September 2009	February 2015	February 2015	July 27, 2009	May 2, 2011	February 23, 2017	GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Wuerzburg, Bayern, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Bydgoszcz, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Poznan, Poland		https://ClinicalTrials.gov/show/NCT00947115
328	NCT02958969	Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma		Completed	No Results Available	Venous Thromboembolism|Multiple Myeloma	Drug: Apixaban|Drug: Placebo Oral Tablet	Symptomatic venous thromboembolism|Major and clinically relevant non-major bleeding|All-cause mortality|Atherothrombotic events	Gregory Piazza|Bristol-Myers Squibb|Dana-Farber Cancer Institute	All	18 Years and older   (Adult, Older Adult)	Phase 4	50	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	18-493	February 28, 2018	June 30, 2018	June 30, 2019	November 8, 2016		July 17, 2019	Brigham and Women's Hospital, Boston, Massachusetts, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT02958969
329	NCT02052024	Myobloc Atrophy Study	MAS	Completed	No Results Available	Spasticity Secondary to Either a Disorder or Trauma|Spinal Cord Injury (SCI)|Brain Injury|Tumor|Stroke	Drug: Botox|Drug: MYOBLOC	Volume and Cross-Sectional Area of Muscle|Modified Ashworth Scale	Georgetown University|Solstice Neurosciences	All	18 Years and older   (Adult, Older Adult)	Phase 4	10	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	USWM-206-1010	May 2014	August 2015	August 2015	January 31, 2014		December 16, 2015	Medstar Georgetown University Hospital, Washington, District of Columbia, United States		https://ClinicalTrials.gov/show/NCT02052024
330	NCT01034358	Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease		Completed	Has Results	Inflammatory Bowel Disease|Uterine Cervical Dysplasia	Biological: Human Papillomavirus Vaccine	Twelve Month Antibody Response to the Human Papillomavirus (HPV) Vaccine (Geometric Mean Titers [GMT])	Mayo Clinic|Merck Sharp & Dohme Corp.	Female	9 Years to 26 Years   (Child, Adult)	Phase 4	15	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	09-000485	February 2010	June 2011	June 2011	December 17, 2009	October 23, 2012	October 23, 2012	Mayo Clinic, Rochester, Minnesota, United States		https://ClinicalTrials.gov/show/NCT01034358
331	NCT00420927	Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis	OPTIMA	Completed	Has Results	Rheumatoid Arthritis	Biological: adalimumab|Drug: methotrexate|Biological: placebo	Number of Subjects With Low Disease Activity (DAS28 Less Than 3.2) and No Radiographic Progression From Baseline (Change in mTSS Less Than or Equal to 0.5) at Week 78, Arm 2 vs. Arm 4|Number of Subjects With Low Disease Activity (DAS28 Less Than 3.2) and No Radiographic Progression From Baseline (Change in mTSS Less Than or Equal to 0.5) at Week 78, Arm 2 vs. Arm 1|Number of Subjects With DAS28 Low Disease Activity (DAS28 Less Than 3.2) at Week 78|Number of Subjects With DAS28 Remission (DAS28 Less Than 2.6) at Week 78|Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS Less Than or Equal to 0.5) at Week 78|Number of Subjects Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 78|Number of Subjects Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 78|Number of Subjects Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 78|Change From Baseline in DAS28 Score at Week 78|Number of Subjects With Clinical Disease Activity Index (CDAI) Low Disease Activity (CDAI Less Than or Equal to 10) at Week 78|Number of Subjects With Simplified Disease Activity Index (SDAI) Low Disease Activity (SDAI Less Than or Equal to 11) at Week 78|Number of Subjects With Clinical Disease Activity Index (CDAI) Remission (CDAI Less Than or Equal to 2.8) at Week 78|Number of Subjects With Simplified Disease Activity Index (SDAI) Remission (SDAI Less Than or Equal to 3.3) at Week 78|Change From Baseline in CDAI Score at Week 78|Change From Baseline in SDAI Score at Week 78|Change From Baseline in Synovitis Score According to the Rheumatoid Arthritis Magnetic Resonance Imaging (RA MRI) Scoring System (RAMRIS) at Week 78|Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5) and Normal Function (HAQ-DI Less Than 0.5) at Week 78|Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5), Normal Function (HAQ-DI Less Than or Equal to 0.5), and ACR70 Response at Week 78|Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5), Normal Function (HAQ-DI Less Than 0.5), and DAS28 Remission (DAS28 Less Than 2.6) at Week 78	Abbott	All	18 Years and older   (Adult, Older Adult)	Phase 4	1032	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	M06-810|2006-004139-31	December 2006	July 2010	July 2010	January 11, 2007	September 29, 2011	April 18, 2012	Site Reference ID/Investigator# 4560, Birmingham, Alabama, United States|Site Reference ID/Investigator# 4547, Birmingham, Alabama, United States|Site Reference ID/Investigator# 6222, Huntsville, Alabama, United States|Site Reference ID/Investigator# 4537, Mobile, Alabama, United States|Site Reference ID/Investigator# 6758, Tuscaloosa, Alabama, United States|Site Reference ID/Investigator# 9323, Hemet, California, United States|Site Reference ID/Investigator# 4568, La Jolla, California, United States|Site Reference ID/Investigator# 4535, Palm Desert, California, United States|Site Reference ID/Investigator# 4571, Santa Monica, California, United States|Site Reference ID/Investigator# 9271, Torrance, California, United States|Site Reference ID/Investigator# 10746, Victorville, California, United States|Site Reference ID/Investigator# 4559, Denver, Colorado, United States|Site Reference ID/Investigator# 6229, Aventura, Florida, United States|Site Reference ID/Investigator# 10603, Lake Mary, Florida, United States|Site Reference ID/Investigator# 9325, Orange Park, Florida, United States|Site Reference ID/Investigator# 4550, Palm Harbor, Florida, United States|Site Reference ID/Investigator# 4570, Sarasota, Florida, United States|Site Reference ID/Investigator# 4601, Tampa, Florida, United States|Site Reference ID/Investigator# 4552, Vero Beach, Florida, United States|Site Reference ID/Investigator# 10745, Meridian, Idaho, United States|Site Reference ID/Investigator# 4548, Chicago, Illinois, United States|Site Reference ID/Investigator# 4557, Springfield, Illinois, United States|Site Reference ID/Investigator# 4605, Wichita, Kansas, United States|Site Reference ID/Investigator# 10741, Wheaton, Maryland, United States|Site Reference ID/Investigator# 6417, Fall River, Massachusetts, United States|Site Reference ID/Investigator# 4561, Dover, New Hampshire, United States|Site Reference ID/Investigator# 11222, Freehold, New Jersey, United States|Site Reference ID/Investigator# 6228, Passaic, New Jersey, United States|Site Reference ID/Investigator# 4544, Albuquerque, New Mexico, United States|Site Reference ID/Investigator# 12821, Bronx, New York, United States|Site Reference ID/Investigator# 4534, Orchard Park, New York, United States|Site Reference ID/Investigator# 9324, Plainview, New York, United States|Site Reference ID/Investigator# 4600, Smithtown, New York, United States|Site Reference ID/Investigator# 4549, Mayfield Village, Ohio, United States|Site Reference ID/Investigator# 6227, Bend, Oregon, United States|Site Reference ID/Investigator# 4546, Duncansville, Pennsylvania, United States|Site Reference ID/Investigator# 4564, West Reading, Pennsylvania, United States|Site Reference ID/Investigator# 4558, Wexford, Pennsylvania, United States|Site Reference ID/Investigator# 4533, Charleston, South Carolina, United States|Site Reference ID/Investigator# 7482, Greenville, South Carolina, United States|Site Reference ID/Investigator# 10743, Jackson, Tennessee, United States|Site Reference ID/Investigator# 4562, Nashville, Tennessee, United States|Site Reference ID/Investigator# 4536, Dallas, Texas, United States|Site Reference ID/Investigator# 4538, Houston, Texas, United States|Site Reference ID/Investigator# 6899, San Antonio, Texas, United States|Site Reference ID/Investigator# 6381, Tyler, Texas, United States|Site Reference ID/Investigator# 10744, Seattle, Washington, United States|Site Reference ID/Investigator# 4545, Glendale, Wisconsin, United States|Site Reference ID/Investigator# 4572, Oak Creek, Wisconsin, United States|Site Reference ID/Investigator# 3886, Buenos Aires, Argentina|Site Reference ID/Investigator# 3888, Buenos Aires, Argentina|Site Reference ID/Investigator# 6346, Buenos Aires, Argentina|Site Reference ID/Investigator# 3887, Quilmes, Argentina|Site Reference ID/Investigator# 3889, San Miguel de Tucuman, Argentina|Site Reference ID/Investigator# 8380, Campsie, Sydney, Australia|Site Reference ID/Investigator# 6954, Clayton, Australia|Site Reference ID/Investigator# 6940, Malvern East, Australia|Site Reference ID/Investigator# 3915, Graz, Austria|Site Reference ID/Investigator# 3911, Graz, Austria|Site Reference ID/Investigator# 3880, Vienna, Austria|Site Reference ID/Investigator# 3885, Vienna, Austria|Site Reference ID/Investigator# 3916, Vienna, Austria|Site Reference ID/Investigator# 7792, Vienna, Austria|Site Reference ID/Investigator# 3914, Brussels, Belgium|Site Reference ID/Investigator# 3909, Genk, Belgium|Site Reference ID/Investigator# 3881, Gilly, Belgium|Site Reference ID/Investigator# 3376, Liege, Belgium|Site Reference ID/Investigator# 6720, Mechelen, Belgium|Site Reference ID/Investigator# 6718, Sint-Niklaas, Belgium|Site Reference ID/Investigator# 3910, Yvoir, Belgium|Site Reference ID/Investigator# 6701, Burlington, Canada|Site Reference ID/Investigator# 6834, Edmonton, Canada|Site Reference ID/Investigator# 7197, Halifax, Canada|Site Reference ID/Investigator# 3883, Hamilton, Canada|Site Reference ID/Investigator# 3884, Hamilton, Canada|Site Reference ID/Investigator# 3907, Montreal, Canada|Site Reference ID/Investigator# 3903, Montreal, Canada|Site Reference ID/Investigator# 5178, Ottawa, Canada|Site Reference ID/Investigator# 3904, Richmond, Canada|Site Reference ID/Investigator# 3912, Sainte-Foy, Quebec, Canada|Site Reference ID/Investigator# 3901, Sarnia, Canada|Site Reference ID/Investigator# 3906, St. John's, Canada|Site Reference ID/Investigator# 6542, Toronto, Canada|Site Reference ID/Investigator# 3882, Victoria, Canada|Site Reference ID/Investigator# 5616, Windsor, Canada|Site Reference ID/Investigator# 5847, Winnipeg, Canada|Site Reference ID/Investigator# 3905, Winnipeg, Canada|Site Reference ID/Investigator# 3968, Brno, Czech Republic|Site Reference ID/Investigator# 3971, Hradec Kralove, Czech Republic|Site Reference ID/Investigator# 5559, Ostrava, Czech Republic|Site Reference ID/Investigator# 3969, Prague 2, Czech Republic|Site Reference ID/Investigator# 5548, Uherske Hradiste, Czech Republic|Site Reference ID/Investigator# 3982, Amiens, France|Site Reference ID/Investigator# 3979, Le Mans, France|Site Reference ID/Investigator# 3983, Paris Cedex 14, France|Site Reference ID/Investigator# 3918, Strasbourg, France|Site Reference ID/Investigator# 3926, Bad Nauheim, Germany|Site Reference ID/Investigator# 3928, Berlin-Buch, Germany|Site Reference ID/Investigator# 3978, Damp, Germany|Site Reference ID/Investigator# 3924, Duesseldorf, Germany|Site Reference ID/Investigator# 3927, Frankfurt/Main, Germany|Site Reference ID/Investigator# 3965, Frankfurt, Germany|Site Reference ID/Investigator# 3925, Freiburg, Germany|Site Reference ID/Investigator# 4291, Halle, Germany|Site Reference ID/Investigator# 8489, Hofheim, Germany|Site Reference ID/Investigator# 3923, Munich, Germany|Site Reference ID/Investigator# 8483, Osnabrueck, Germany|Site Reference ID/Investigator# 8486, Ratingen, Germany|Site Reference ID/Investigator# 3919, Vogelsang-Gommern, Germany|Site Reference ID/Investigator# 6637, Zerbst, Germany|Site Reference ID/Investigator# 3921, Budapest, Hungary|Site Reference ID/Investigator# 3922, Budapest, Hungary|Site Reference ID/Investigator# 3920, Debrecen, Hungary|Site Reference ID/Investigator# 3824, Aguascallentes, Mexico|Site Reference ID/Investigator# 3822, Leon, Guanajuato, Mexico|Site Reference ID/Investigator# 3825, Mexico City, Mexico|Site Reference ID/Investigator# 3951, Mexico City, Mexico|Site Reference ID/Investigator# 3890, Mexico City, Mexico|Site Reference ID/Investigator# 3823, Mexico City, Mexico|Site Reference ID/Investigator# 3891, Mexico City, Mexico|Site Reference ID/Investigator# 3947, Arnem, Netherlands|Site Reference ID/Investigator# 3948, Hilversum, Netherlands|Site Reference ID/Investigator# 8485, Auckland 6, New Zealand|Site Reference ID/Investigator# 8488, Hamilton, New Zealand|Site Reference ID/Investigator# 8496, Timaru, New Zealand|Site Reference ID/Investigator# 8511, Wellington, New Zealand|Site Reference ID/Investigator# 7607, Alesund, Norway|Site Reference ID/Investigator# 7935, Kristiansand S, Norway|Site Reference ID/Investigator# 7506, Levanger, Norway|Site Reference ID/Investigator# 7511, Lillehammer, Norway|Site Reference ID/Investigator# 7500, Trondheim, Norway|Site Reference ID/Investigator# 3963, Bydgoszcz, Poland|Site Reference ID/Investigator# 3962, Katowice, Poland|Site Reference ID/Investigator# 5560, Lublin, Poland|Site Reference ID/Investigator# 3961, Wroclaw, Poland|Site Reference ID/Investigator# 3944, Caguas, Puerto Rico|Site Reference ID/Investigator# 3937, Ponce, Puerto Rico|Site Reference ID/Investigator# 3934, San Juan, Puerto Rico|Site Reference ID/Investigator# 3935, San Juan, Puerto Rico|Site Reference ID/Investigator# 3959, Piestany, Slovakia|Site Reference ID/Investigator# 3960, Piestany, Slovakia|Site Reference ID/Investigator# 7177, Berea, Durban, South Africa|Site Reference ID/Investigator# 7175, Cape Town, South Africa|Site Reference ID/Investigator# 7178, Cape Town, South Africa|Site Reference ID/Investigator# 7176, Port Elizabeth, South Africa|Site Reference ID/Investigator# 7172, Pretoria, South Africa|Site Reference ID/Investigator# 7174, Soweto, South Africa|Site Reference ID/Investigator# 3955, A Coruna, Spain|Site Reference ID/Investigator# 13661, Bilbao, Spain|Site Reference ID/Investigator# 3930, Elche (Alicante), Spain|Site Reference ID/Investigator# 8524, Madrid, Spain|Site Reference ID/Investigator# 3956, Madrid, Spain|Site Reference ID/Investigator# 3943, Madrid, Spain|Site Reference ID/Investigator# 3931, Madrid, Spain|Site Reference ID/Investigator# 3957, Oviedo, Spain|Site Reference ID/Investigator# 3954, Santiago de Compostela, Spain|Site Reference ID/Investigator# 3932, Zaragoza, Spain|Site Reference ID/Investigator# 4015, Eskilstuna, Sweden|Site Reference ID/Investigator# 3984, Falun, Sweden|Site Reference ID/Investigator# 4016, Malmoe, Sweden|Site Reference ID/Investigator# 4014, Stockholm, Sweden|Site Reference ID/Investigator# 4017, Uppsala, Sweden|Site Reference ID/Investigator# 4012, Bath, United Kingdom|Site Reference ID/Investigator# 8495, Huddersfield, United Kingdom|Site Reference ID/Investigator# 4048, Leeds, United Kingdom|Site Reference ID/Investigator# 4013, London, United Kingdom|Site Reference ID/Investigator# 4046, Newcastle upon Tyne, United Kingdom|Site Reference ID/Investigator# 4047, Oxford, United Kingdom|Site Reference ID/Investigator# 3985, Southampton, United Kingdom|Site Reference ID/Investigator# 7977, York, United Kingdom		https://ClinicalTrials.gov/show/NCT00420927
332	NCT00110682	Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses		Completed	No Results Available	Keratosis|Actinic Keratosis	Drug: Imiquimod used as an adjunct to cryotherapy	Recurrence rate and time to recurrence of lesions|Time to reach treatment success|Percentage of patients who clear|Patient improvement assessment	Derm Research @ 888 Inc.|3M	All	18 Years and older   (Adult, Older Adult)	Phase 4	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	DR 2004-05	April 2005	October 2006	December 2006	May 13, 2005		April 24, 2008	DermResearch @ 888 Inc, Vancouver, British Columbia, Canada|Windsor Clinical Research, Windsor, Ontario, Canada|Centre de Recherche Dermatologique, CRDQ, Sainte-Foy, Quebec, Canada		https://ClinicalTrials.gov/show/NCT00110682
333	NCT00977080	Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D	IMPACT SHPT	Completed	Has Results	Chronic Kidney Disease|Secondary Hyperparathyroidism|Hemodialysis	Drug: Paricalcitol|Drug: Cinacalcet	The Number of Participants Who Achieve a Mean Intact Parathyroid Hormone (iPTH) Value Between 150 to 300 pg/mL During the Evaluation Period (Weeks 21 to 28).|Number of Participants Who Achieve at Least 30% Reduction From Baseline in Intact Parathyroid Hormone (iPTH) as Assessed by the Mean iPTH Obtained During the Evaluation Period (Weeks 21 to 28).|Number of Participants Who Achieve at Least 50% Reduction From Baseline in iPTH as Assessed by the Mean iPTH Obtained During the Evaluation Period (Weeks 21 to 28).|Analysis of the Number of Participants Who Achieve a Mean iPTH Value Between 150 and 300 pg/mL During the Evaluation Period (Weeks 21 to 28) Using a Cochran-Mantel-Haenszel Test Controlling for IV and Oral Site Randomization Strata|Number of Participants With Hypocalcemia Defined as < 8.4 mg/dL and Based on the Mean of at Least 2 Values Obtained During the Evaluation Period (Weeks 21 to 28)|Number of Participants With Hypercalcemia Defined as Calcium > 10.5 mg/dL and Based on the Mean of at Least 2 Values Obtained During the Evaluation Period (Weeks 21 to 28)	Abbott	All	18 Years and older   (Adult, Older Adult)	Phase 4	272	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	M10-967|2009-011378-14	November 2009	May 2011	May 2011	September 15, 2009	June 20, 2012	June 20, 2012	Site Reference ID/Investigator# 22781, Tempe, Arizona, United States|Site Reference ID/Investigator# 24342, Chula Vista, California, United States|Site Reference ID/Investigator# 21142, Los Angeles, California, United States|Site Reference ID/Investigator# 22762, Los Angeles, California, United States|Site Reference ID/Investigator# 22758, Riverside, California, United States|Site Reference ID/Investigator# 21442, San Diego, California, United States|Site Reference ID/Investigator# 23688, Arvada, Colorado, United States|Site Reference ID/Investigator# 21370, Coral Springs, Florida, United States|Site Reference ID/Investigator# 25902, Hudson, Florida, United States|Site Reference ID/Investigator# 21146, Lauderdale Lakes, Florida, United States|Site Reference ID/Investigator# 26743, Lauderdale Lakes, Florida, United States|Site Reference ID/Investigator# 22788, Miami, Florida, United States|Site Reference ID/Investigator# 22722, Orlando, Florida, United States|Site Reference ID/Investigator# 23147, Tampa, Florida, United States|Site Reference ID/Investigator# 22778, Meridian, Idaho, United States|Site Reference ID/Investigator# 21369, Detroit, Michigan, United States|Site Reference ID/Investigator# 22786, Detroit, Michigan, United States|Site Reference ID/Investigator# 21144, St. Louis, Missouri, United States|Site Reference ID/Investigator# 21443, St. Louis, Missouri, United States|Site Reference ID/Investigator# 21145, Omaha, Nebraska, United States|Site Reference ID/Investigator# 22505, Flushing, New York, United States|Site Reference ID/Investigator# 22759, Toledo, Ohio, United States|Site Reference ID/Investigator# 22796, Lancaster, Pennsylvania, United States|Site Reference ID/Investigator# 22770, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 22772, Aiken, South Carolina, United States|Site Reference ID/Investigator# 21147, Orangeburg, South Carolina, United States|Site Reference ID/Investigator# 22982, Houston, Texas, United States|Site Reference ID/Investigator# 21143, Houston, Texas, United States|Site Reference ID/Investigator# 22506, San Antonio, Texas, United States|Site Reference ID/Investigator# 22776, Bluefield, West Virginia, United States|Site Reference ID/Investigator# 22311, Brno, Czech Republic|Site Reference ID/Investigator# 22310, Jilemnice, Czech Republic|Site Reference ID/Investigator# 21624, Usti nad Labem, Czech Republic|Site Reference ID/Investigator# 22363, Aalborg, Denmark|Site Reference ID/Investigator# 23105, Copenhagen, Denmark|Site Reference ID/Investigator# 23909, Fredericia, Denmark|Site Reference ID/Investigator# 22462, Holstebro, Denmark|Site Reference ID/Investigator# 21748, Coburg, Germany|Site Reference ID/Investigator# 33268, Darmstadt, Germany|Site Reference ID/Investigator# 35903, Duesseldorf, Germany|Site Reference ID/Investigator# 21742, Frankfurt, Germany|Site Reference ID/Investigator# 21744, Heilbronn, Germany|Site Reference ID/Investigator# 21368, Luedenscheid, Germany|Site Reference ID/Investigator# 22362, Athens, Greece|Site Reference ID/Investigator# 38970, Thessaloniki, Greece|Site Reference ID/Investigator# 22322, Thessaloniki, Greece|Site Reference ID/Investigator# 22463, Thessaloniki, Greece|Site Reference ID/Investigator# 22323, Thessaloniki, Greece|Site Reference ID/Investigator# 39262, Thessaloniki, Greece|Site Reference ID/Investigator# 22312, Bergamo, Italy|Site Reference ID/Investigator# 21746, Genova, Italy|Site Reference ID/Investigator# 39180, Lucca, Italy|Site Reference ID/Investigator# 22314, Milan, Italy|Site Reference ID/Investigator# 21367, Pavia, Italy|Site Reference ID/Investigator# 21745, Pesaro, Italy|Site Reference ID/Investigator# 21842, Alkmaar, Netherlands|Site Reference ID/Investigator# 22309, Delft, Netherlands|Site Reference ID/Investigator# 21843, Dordrecht, Netherlands|Site Reference ID/Investigator# 38903, Beja, Portugal|Site Reference ID/Investigator# 38531, Faro, Portugal|Site Reference ID/Investigator# 22464, Lisbon, Portugal|Site Reference ID/Investigator# 23910, Vila Franca de Xira, Portugal|Site Reference ID/Investigator# 24643, Moscow, Russian Federation|Site Reference ID/Investigator# 24642, Moscow, Russian Federation|Site Reference ID/Investigator# 21361, Barcelona, Spain|Site Reference ID/Investigator# 21364, Cordoba, Spain|Site Reference ID/Investigator# 22366, L'Hospitalet, Barcelona, Spain|Site Reference ID/Investigator# 38343, Madrid, Spain|Site Reference ID/Investigator# 21362, Madrid, Spain|Site Reference ID/Investigator# 21363, Palma de Mallorca, Spain|Site Reference ID/Investigator# 22367, Pamplona, Spain|Site Reference ID/Investigator# 38462, Puerto de la Cruz, Spain|Site Reference ID/Investigator# 21365, Seville, Spain|Site Reference ID/Investigator# 23913, Linkoping, Sweden|Site Reference ID/Investigator# 23782, Stockholm, Sweden|Site Reference ID/Investigator# 22364, Uppsala, Sweden|Site Reference ID/Investigator# 23912, Birmingham, United Kingdom|Site Reference ID/Investigator# 21747, Coventry, United Kingdom|Site Reference ID/Investigator# 23102, London, United Kingdom|Site Reference ID/Investigator# 23104, London, United Kingdom|Site Reference ID/Investigator# 23103, Manchester, United Kingdom|Site Reference ID/Investigator# 41982, Omagh, Northern Ireland, United Kingdom|Site Reference ID/Investigator# 40222, Sheffield, United Kingdom		https://ClinicalTrials.gov/show/NCT00977080
334	NCT00803712	20070360 Incident Dialysis		Completed	Has Results	Chronic Kidney Disease|Secondary Hyperparathyroidism	Drug: Cinacalcet|Drug: Vitamin D	Achievement of a ≥ 30% Reduction in Mean PTH From Baseline to During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26)|Achievement of a Mean PTH <= 300 pg/mL During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26)|Achievement of a ≥ 30% Reduction in Mean PTH From Baseline to During the Efficacy Assessment Phase at Month 12 (Weeks 48 to 52)|Achievement of a Mean PTH <= 300 pg/mL During the Efficacy Assessment Phase at Month 12 (Weeks 48 to 52)|Achievement of a Mean Corrected Serum Calcium < 10.2 mg/dL During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26)|Achievement of a Mean Corrected Serum Calcium < 10.2 mg/dL During the Efficacy Assessment Phase at Month 12 (Weeks 48 to 52)|Achievement of a Mean Serum Phosphorus < 5.5 mg/dL During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26)|Achievement of a Mean Serum Phosphorus < 5.5 mg/dL During the Efficacy Assessment Phase at Month 12 (Weeks 48 to 52)|Achievement of a >= 30% Reduction in Mean iPTH From Baseline to During Both Efficacy Assessment Phases at Month 6 (Weeks 22 to 26) and Month 12 (Weeks 48 to 52)|Achievement of a Mean iPTH <=300 pg/mL During Both Efficacy Assessment Phases at Month 6 (Weeks 22 to 26) and Month 12 (Weeks 48 to 52)|Achievement of a Mean Corrected Serum Calcium < 10.2 mg/dL During Both Efficacy Assessment Phases at Month 6 (Weeks 22 to 26) and Month 12 (Weeks 48 to 52)|Achievement of a Mean Serum Phosphorus < 5.5 mg/dL During Both Efficacy Assessment Phases at Month 6 (Weeks 22 to 26) and Month 12 (Weeks 48 to 52)|Summary of iPTH (pg/mL) at Month 6 Efficacy Assessment Phase|Summary of Percent Change From Baseline in iPTH (pg/mL) at Month 6 Efficacy Assessment Phase|Summary of iPTH (pg/mL) at Month 12 Efficacy Assessment Phase|Summary of Percent Change From Baseline in iPTH (pg/mL) at Month 12 Efficacy Assessment Phase|Summary of Corrected Serum Calcium (mg/dL) at Month 6 Efficacy Assessment Phase|Summary of Percent Change From Baseline in Corrected Serum Calcium at Month 6 Efficacy Assessment Phase|Summary of Corrected Serum Calcium (mg/dL) at Month 12 Efficacy Assessment Phase|Summary of Percent Change From Baseline in Corrected Serum Calcium at Month 12 Efficacy Assessment Phase|Summary of Serum Phosphorus (mg/dL) at Month 6 Efficacy Assessment Phase|Summary of Percent Change From Baseline in Serum Phosphorus at Month 6 Efficacy Assessment Phase|Summary of Serum Phosphorus (mg/dL) at Month 12 Efficacy Assessment Phase|Summary of Percent Change From Baseline in Serum Phosphorus at Month 12 Efficacy Assessment Phase|Subject Incidence of Hypercalcemia During the Efficacy Assessment Phase at Month 6|Subject Incidence of Hypercalcemia During the Maintenance Phase|Subject Incidence of Hypercalcemia During the Efficacy Assessment Phase at Month 12|Subject Incidence of Hyperphosphatemia During the Efficacy Assessment Phase at Month 6|Subject Incidence of Hyperphosphatemia During the Maintenance Phase|Subject Incidence of Hyperphosphatemia During the Efficacy Assessment Phase at Month 12	Amgen	All	18 Years and older   (Adult, Older Adult)	Phase 4	313	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20070360	February 1, 2009	December 9, 2010	July 5, 2011	December 5, 2008	March 12, 2014	October 17, 2018			https://ClinicalTrials.gov/show/NCT00803712
335	NCT00132431	START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism		Completed	No Results Available	Kidney Disease|Secondary Hyperparathyroidism|Chronic Kidney Disease	Drug: Sensipar	Proportion of subjects with a mean bio-intact parathyroid hormone (biPTH) >/= 80 pg/mL and </= 160 pg/mL (comparable to K/DOQI Guideline target range for intact parathyroid hormone [iPTH] of >/= 150 pg/mL and </= 300 pg/mL) during the assessment phase|Proportion of subjects with mean calcium-phosphorus product (Ca x P) < 55 mgÂ²/dLÂ² during the assessment phase	Amgen	All	18 Years and older   (Adult, Older Adult)	Phase 4	300	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	20040123	July 2004		July 2005	August 22, 2005		February 13, 2009			https://ClinicalTrials.gov/show/NCT00132431
336	NCT01453179	Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2)	LEIDA 2	Completed	No Results Available	Actinic Keratosis	Drug: Imiquimod|Drug: Diclofenac	Long-term outcome with respect to the risk of progression to SCC (in situ and/or invasive) of treatment with Aldara® 5% cream (IMIQ) and Solaraze® 3% gel (DIC) with increased precision (meta-analysis with study 3271).|Recurrence rate|Time to recurrence|Need of rescue treatment|Cosmetic outcome	MEDA Pharma GmbH & Co. KG|Siro Clinpharm Germany GmbH (until June 2013)|Accovion GmbH	All	18 Years and older   (Adult, Older Adult)	Phase 4	221	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	X-03016-3284|2010-022054-16	October 2011	March 2015	March 2015	October 17, 2011		April 14, 2017	Medical University Graz, University Clinic for Dermatology and Venerology Graz, Graz, Austria|Medical Practice, Maria Enzersdorf, Austria|Medical University Vienna, Department for General Dermatology, Vienna, Austria|Medical Supply Center, Augsburg, Germany|Licca Clinical Research Institute, Clinic for Dermatolgy and Surgery, Augsburg, Germany|Medical Practice, Berlin, Germany|Medical Practice, Duelmen, Germany|Medical Practice, Germering, Germany|Medical Department of Otto-von-Guericke-University Magdeburg, University Clinic for Dermatology and Venerology, Magdeburg, Germany|Medical Practice, Mahlow, Germany|Department of Dermatology Johannes Gutenberg-University Mainz, Clinical Research Center, Mainz, Germany|Medical Practice, Markkleeberg, Germany|Medical Practice for Dermatology and Medical Cosmetics, Mönchengladbach, Germany|Medical Practice, Münster, Germany|Derma Center Vechta, Clinic for Dermatology, Vechta, Germany|Centrovital, Medical Practice for Dermatology, Witten, Germany|Medical Practice for Dermatology and Venerology, Wuppertal, Germany		https://ClinicalTrials.gov/show/NCT01453179
337	NCT02088515	Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma		Completed	No Results Available	Squamous Cell Carcinoma	Drug: Nedaplatin|Drug: Cisplatin|Drug: Docetaxel	progress free survival|Objective Response Rate	Jiangsu Simcere Pharmaceutical Co., Ltd.	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	290	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	5501068	December 2013	October 2016	February 2017	March 17, 2014		March 3, 2017	Hunan Xiangya Hospital, Changsha, Hunan, China|Nanjing Military General Hospital, Nanjing, Jiangsu, China|Shanghai Chest hospital, Shanghai, Shanghai, China|Xijing Hospital, Xian, Shanxi, China		https://ClinicalTrials.gov/show/NCT02088515
338	NCT00171886	Octreotide Efficacy and Safety in First-line Acromegalic Patients		Completed	No Results Available	Acromegaly	Drug: Octreotide	To evaluate the ability of Sandostatin® LAR® to decrease GH and IGF-I levels in acromegaly patients with micro- or macroadenomas not previously treated|To evaluate efficacy of Sandostatin® LAR® to reduce the size of micro- or macroadenomas in acromegaly patients with micro- or macroadenomas not previous treated|To evaluate the effect of Sandostatin® LAR® on Health Related Quality of Life.|To evaluate the ability of Sandostatin® LAR® to relieve acromegaly signs and symptoms	Novartis Pharmaceuticals|Novartis	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 4	20	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CSMS995BES02	July 2002	May 2006	May 2006	September 15, 2005		February 24, 2017	Novartis Investigative site, Alicante, Spain|Novartis Investigative site, Barcelona, Spain|Novartis Investigative site, Burgos, Spain|Novartis Investigative site, Cordoba, Spain|Novartis Investigative site, Coruna, Spain|Novartis Investigative site, Madrid, Spain|Novartis Investigative site, Malaga, Spain|Novartis Investigative site, Tarragona, Spain		https://ClinicalTrials.gov/show/NCT00171886
339	NCT00352703	PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation		Completed	No Results Available	Non-Hodgkin's Lymphoma|Multiple Myeloma	Drug: Kepivance (Palifermin)	The primary efficacy endpoints are the incidence (%) and duration of severe oral mucositis (WHO grades 3 or 4).	Swedish Orphan Biovitrum	All	18 Years and older   (Adult, Older Adult)	Phase 4	145	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	20050100	April 2006	April 2007	May 2007	July 17, 2006		November 3, 2014			https://ClinicalTrials.gov/show/NCT00352703
340	NCT03350698	Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination		Recruiting	No Results Available	Papillomavirus Vaccines	Biological: Gardasil-9	# of participants with elevated HPV antibody titers from baseline to 7 months	Eastern Virginia Medical School|Merck Sharp & Dohme Corp.	All	27 Years to 69 Years   (Adult, Older Adult)	Phase 4	100	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	17-09-FB-0176	April 6, 2018	June 14, 2020	November 15, 2020	November 22, 2017		July 18, 2019	EVMS Otolaryngology, Norfolk, Virginia, United States		https://ClinicalTrials.gov/show/NCT03350698
341	NCT01990534	A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma		Active, not recruiting	Has Results	Hodgkin Lymphoma	Drug: Brentuximab vedotin	Objective Response Rate (ORR)|Duration of Response (DOR)|Progression Free Survival (PFS)|Complete Remission Rate|Duration of Complete Remission (CR)|Overall Survival (OS)|Percentage of Participants Who Received Stem Cell Transplantation (SCT)|Number of Participants With Adverse Events (AEs), Drug-Related AEs, Grade 3 or Higher AEs, Serious Adverse Events (SAEs), Drug-Related SAEs and Grade 3 or Higher SAEs|Number of Participants With Abnormal Clinical Laboratory Values Reported as AEs|Antibody-drug Conjugate (ADC) Serum Concentrations|Serum Concentration of Total Antibodies (Conjugated and Unconjugated)|Monomethyl Auristatin E (MMAE) Serum Concentrations|Number of Participants With Antitherapeutic Antibodies (ATA)	Millennium Pharmaceuticals, Inc.|Takeda	All	18 Years and older   (Adult, Older Adult)	Phase 4	60	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	C25007|2013-000232-10|U1111-1154-2250|NMRR-13-1246-18099|REec-2014-0619	March 2014	March 2016	March 2020	November 21, 2013	May 5, 2017	May 5, 2017	Praha, Prague, Czech Republic|Brno, Czech Republic|Heidelberg, Baden Wuerttemberg, Germany|Koeln, Germany|Georgetown, Penang, Malaysia|Ampang, Selangor, Malaysia|Kuala Lumpur, Malaysia|Gdansk, Poland|Krakow, Poland|Warszawa, Poland|Pamplona, Navarra, Spain|Madrid, Spain|Bangkoknoi, Bangkok, Thailand|Patumwan, Bangkok, Thailand|Ratchathewi, Bangkok, Thailand|Izmir, Bornova, Turkey|Ankara, Turkey|Izmir, Turkey		https://ClinicalTrials.gov/show/NCT01990534
342	NCT03511326	PRO With Luxerm® in the Field Treatment of Thin and Non-hyperkeratotic Non-pigmented AK	SESAME 2	Completed	No Results Available	Actinic Keratoses	Drug: Methyl Aminolaevulinate 16% Cream	Subject reported outcomes	Galderma|GCP services	All	18 Years and older   (Adult, Older Adult)	Phase 4	50	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	RD.03.SPR.114384	June 7, 2017	November 28, 2017	November 28, 2017	April 27, 2018		April 27, 2018	University Hospital Regensburg, Regensburg, Germany		https://ClinicalTrials.gov/show/NCT03511326
343	NCT03487588	An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses	SK-FAN	Completed	No Results Available	Seborrheic Keratosis	Drug: A-101 Topical Solution	Subject Satisfaction|Effectiveness of treatment|Comparison of Physician Lesion Assessment Score (PLA) to Subject Satisfaction	Aclaris Therapeutics, Inc.	All	30 Years to 75 Years   (Adult, Older Adult)	Phase 4	41	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	A-101-SEBK-402	March 21, 2018	November 14, 2018	November 14, 2018	April 4, 2018		May 13, 2019	Aclaris Investigational Site, Fort Washington, Pennsylvania, United States|Aclaris Investigational Site, Knoxville, Tennessee, United States|Aclaris Investigational Site, Austin, Texas, United States		https://ClinicalTrials.gov/show/NCT03487588
344	NCT02406014	Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp		Completed	No Results Available	Actinic Keratosis (AK)	Drug: Ingenol Mebutate Gel, 0.015%|Drug: Diclofenac sodium gel 3%	Complete clearance of all AKs|Complete clearance of all AKs at Week 17	LEO Pharma	All	18 Years and older   (Adult, Older Adult)	Phase 4	502	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LP0041-1120	April 2015	June 2016	June 2016	April 1, 2015		May 9, 2017	Gemain, Weber & Craninic, Schweinfurt, Germany		https://ClinicalTrials.gov/show/NCT02406014
345	NCT00123461	Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism		Completed	No Results Available	Secondary Hyperparathyroidism|Renal Failure|Chronic Renal Insufficiency	Drug: Hectorol (doxercalciferol capsules), 0.5mcg	Laboratory measurement of intact parathyroid hormone (iPTH)|Laboratory measurement of serum bone markers	Genzyme, a Sanofi Company|Sanofi	All	18 Years and older   (Adult, Older Adult)	Phase 4	70	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	BCI-CH-151	July 2005	October 2007	October 2007	July 25, 2005		May 5, 2015	AKDHC Medical Research Services, Phoenix, Arizona, United States|UCLA Diabetes Reseach Center, Alhambra, California, United States|Apex Research of Riverside, Riverside, California, United States|George Washington University Hospital, Washington, District of Columbia, United States|Discovery Medical Research Group, Ocala, Florida, United States|Nephrology Associates, Palm Beach Gardens, Florida, United States|Georgia Kidney Associates, Inc., Marietta, Georgia, United States|Michigan Kidney Consultants, P.C., Pontiac, Michigan, United States|Twin Cities Clinical Research, Brooklyn Center, Minnesota, United States|Montefiore Medical Center, Bronx, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Wake Nephrology Associates, PA, Raleigh, North Carolina, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|Altru Health System Research Center, Grand Forks, North Dakota, United States|DaVita Lewiston Dialysis Center, Lewiston, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Instituto Renal del Este, Caguas, Puerto Rico|Jose Cangiano, MD, San Juan, Puerto Rico		https://ClinicalTrials.gov/show/NCT00123461
346	NCT01926496	Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%		Active, not recruiting	No Results Available	Actinic Keratosis (AK)	Drug: Ingenol Mebutate Gel, 0.015%|Drug: Imiquimod Cream, 5%	Incidence of SCC|Incidence of neoplasia	LEO Pharma	All	18 Years and older   (Adult, Older Adult)	Phase 4	579	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LP0041-63|2012-003112-31	September 11, 2013	July 2019	July 2019	August 21, 2013		May 23, 2019	CHU Angers - Service de Dermatologie, Angers, France|CHU Besançon - Hôpital Jean Minjoz, Besançon, France|HOPITAL AVICENNE - Service de Dermatologie, Bobigny, France|CHRU de Brest - Hôpital Morvan - Service de Dermatologie, Brest, France|CHU Albert Michallon - Service de Dermatologie, Pôle Pluridisciplinaire de Médecine, Grenoble, France|Hôpital Claude Huriez - CHRU de Lille - Clinique de Dermatologie, Lille, France|Hôpital de la Timone - Service de Dermatologie Vénérologie, Marseille, France|CHU de Nantes - Hôtel Dieu - Unité Fonctionnelle de Dermatologie Cancérologie, Nantes, France|HOPITAL DE L ARCHET II - Service de Dermatologie-Vénérologie, Nice, France|Hôpital Caremeau, Nimes, France|HOPITAL COCHIN TARNIER - Service de Dermatologie, Paris, France|Hôpital Saint Louis - Service de Dermatologie, Paris, France|CHU BORDEAUX - Hôpital Haut-Lévêque, Pessac, France|CHU Poitiers - Service de Dermatologie, Poitiers, France|C.H.U. de Saint-Etienne - Hôpital Nord, Saint-Etienne, France|Hôpital d'instruction des Armées Bégin - Clinique Dermatologique, St Mandé, France|Hautarztpraxis Simon, Berlin, Germany|Hauttumorzentrum Bochum Universitätsklinikum der Ruhr-Universität-Bochum, Bochum, Germany|Praxis Streit Bucholz, Buchholz, Germany|Dermatologisches Zentrum, Am Krankenhaus 1, Buxtehude, Germany|Klinikum Dortmund - Hautklinik, Dortmund, Germany|Mensingderma, Hamburg, Germany|Universitätsklinikum Leipzig Klinik für Dermatologie, Venerologie und Allergologie, Leipzig, Germany|Hautpraxis Dr. Ina Schulze, Markkleeberg, Germany|Hauttumorzentrum Münster, Münster, Germany|Klinik für Dermatologie und Allergologie, Klinikum Vest, Behandlungszentrum, Knappschaftskrankenhaus Recklinghausen,, Recklinghausen, Germany|Universitätklinikum Regensburg, Regensburg, Germany|Praxis Dr. Hoffmann, Witten, Germany|Praxis Derma Hübinger, Wuppertal, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Ninewells Hospital, Dundee, Angus, United Kingdom|Cumberland Infirmary, Carlisle, Cumbria, United Kingdom|Heavitree Hospital, Exeter, Devon, United Kingdom|Brighton General Hospital, Brighton, East Sussex, United Kingdom|Manchester Royal Infirmary, Manchester, Greater Manchester, United Kingdom|Monklands Hospital, Airdrie, Lanarkshire, United Kingdom|Scunthorpe General Hospital, Scunthorpe, Lincolnshire, United Kingdom|Royal Gwent Hospital, Newport, Monmouthshire, United Kingdom|Harrogate District Hospital, Harrogate, North Yorkshire, United Kingdom|Scarborough Hospital, Scarborough, North Yorkshire, United Kingdom|Cannock Chase Hospital, Cannock, Staffordshire, United Kingdom|East Surrey Hospital, Redhill, Surrey, United Kingdom|Southlands Hospital, Shoreham-by-Sea, West Sussex, United Kingdom|St Luke's Hospital, Bradford, West Yorkshire, United Kingdom|Chapel Allerton Hospital, Leeds, West Yorkshire, United Kingdom|Hull Royal Infirmary, Hull, United Kingdom		https://ClinicalTrials.gov/show/NCT01926496
347	NCT01000636	Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT)		Completed	No Results Available	Actinic Keratosis	Procedure: Metvix PDT	Skin biopsies to be performed in lesional, peri-lesional skin and in healthy skin to assess gene's expression in each condition.|Clinical assessment of the AKs present on the target area treated with Metvix PDT.	Galderma	All	18 Years and older   (Adult, Older Adult)	Phase 4	9	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	RD.03.SPR.29061|Eudract # :2008-001603-30	October 2009	October 2011	October 2011	October 23, 2009		February 24, 2012	Department of Dermatology of Manchester Royal Infirmary, Manchester, United Kingdom		https://ClinicalTrials.gov/show/NCT01000636
348	NCT00777127	Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses	LEIDA	Completed	No Results Available	Actinic Keratosis	Drug: Imiquimod|Drug: Diclofenac	Recurrence with respect to the study treatment area until month 12|Time to recurrence|Long-term outcome with respect to development of SCC (in situ and/or invasive)|Need of rescue treatment|Haematological changes|Cosmetic outcome.	MEDA Pharma GmbH & Co. KG	All	18 Years and older   (Adult, Older Adult)	Phase 4	258	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	X-03016-3271|2007-004884-24	December 2008	November 2012	November 2012	October 22, 2008		February 1, 2013	Hospital Feldkirch, Department for Dermatology and Venereology, Feldkirch, Austria|Medical University Graz, University Clinic for Dermatology and Venereology, Graz, Austria|Medical University Innsbruck, University Clinic for Dermatology and Venereology, Innsbruck, Austria|Medical University Vienna, Department for General Dermatology, Vienna, Austria|CHU St Jacques, Department for Dermatology, Besancon Cedex, France|Hospital Sainte Marguerite, Department for Dermatology and Venereology, Pavilion 3, First Floor, Marseille, France|CHU Nice - Hospital Archet 2, Department for Dermatology, Nice, France|Hospital Saint-Louis, Derpartment for Dermatology, Paris, France|Hospital Center Lyon South, Department for Dermatology and Immuno-Allergology, Pierre Benite, France|Licca Clinical Research Institute, Augsburg, Germany|Charite - Medicine University Berlin, Dermatoma Center, Clinic for Dermatology, Allergology and Venereology, Berlin, Germany|Medical Practice Dominicus / Bockhorst, Duelmen, Germany|Medical practice, Düsseldorf, Germany|University Clinic Düsseldorf, Clinic for Dermatology, Düsseldorf, Germany|Clinic and Medical Faculty of Johann Wolfgang Goethe-University, Center for Dermatology and Venereology, Frankfurt am Main, Germany|SCiderm GmbH, Hamburg, Germany|Medical Practice, Hannover, Germany|University Clinic Schleswig-Holstein, Campus Kiel, Clinic for Dermatology, Venereology and Allergology, Kiel, Germany|Medical Department of Otto-von-Guericke-University Magdeburg, University Clinic for Dermatology and Venereology, Magdeburg, Germany|Department of Dermatology J. Gutenberg-University Mainz, Clinical Research Center, Mainz, Germany|Science, Onco & Beauty GbR, Practice for Dermatology and Medical Cosmetics, Mönchengladbach, Germany|University Clinic Münster, Clinic and Polyclinic for Skin Diseases, Münster, Germany|Clinic University Regensburg, Clinic and Polyclinic for Dermatology, Regensburg, Germany|Derma Center Vechta, Vechta, Germany|Centrovital, Witten, Germany|Medical practice for Dermatology and Venerology, Wuppertal, Germany		https://ClinicalTrials.gov/show/NCT00777127
349	NCT00377273	An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses		Completed	No Results Available	Actinic Keratoses	Drug: fluorouracil cream 0.5%	The reduction in Actinic Keratosis lesion counts on other body sites from pretreatment to post-treatment and AK clearance of other body site lesions for Treatment Cycle 1.|The reduction in Actinic Keratosis lesion counts of the face (including anterior scalp, if applicable) from pretreatment to post-treatment and AK clearance of facial lesions for each Treatment Cycle|The recurrence of facial lesions at 12 and 18 months post initial treatment, and the need for re-treatment.	Sanofi	All	18 Years and older   (Adult, Older Adult)	Phase 4	250	Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DL6025-0201	November 2003		October 2005	September 18, 2006		April 10, 2008	Sanofi-Aventis, Bridgewater, New Jersey, United States		https://ClinicalTrials.gov/show/NCT00377273
350	NCT00116649	Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis		Completed	Has Results	Keratosis	Drug: imiquimod cream	Number of Participants Who Experienced an Adverse Event|Percent Reduction From Baseline to the Final Follow-up in Total Actinic Keratosis Lesion Count	Graceway Pharmaceuticals, LLC	All	18 Years and older   (Adult, Older Adult)	Phase 4	551	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1520-IMIQ	June 2005	May 2007	May 2007	July 1, 2005	November 25, 2008	July 20, 2010	Phoenix, Arizona, United States|Encino, California, United States|Los Angeles, California, United States|Riverside, California, United States|San Diego, California, United States|Santa Monica, California, United States|Denver, Colorado, United States|New Britain, Connecticut, United States|Coral Gables, Florida, United States|Hollywood, Florida, United States|Miami, Florida, United States|West Palm Beach, Florida, United States|Arlington Heights, Illinois, United States|Indianapolis, Indiana, United States|Metairie, Louisiana, United States|Boston, Massachusetts, United States|Chaska, Minnesota, United States|Henderson, Nevada, United States|Henderson, Nevada, United States|Reno, Nevada, United States|Reno, Nevada, United States|New York, New York, United States|High Point, North Carolina, United States|Raleigh, North Carolina, United States|Winston-Salem, North Carolina, United States|Portland, Oregon, United States|Flourtown, Pennsylvania, United States|Arlington, Texas, United States|San Antonio, Texas, United States|Woodbridge, Virginia, United States|Spokane, Washington, United States|Milwaukee, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT00116649
351	NCT00115154	Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands		Completed	No Results Available	Keratosis	Drug: Aldara (imiquimod) cream, 5%	The primary objective of this study is to evaluate the efficacy of imiquimod 5% cream compared to vehicle cream in the treatment of AK on the upper extremities when the cream is applied once daily 2 days per week for 16 weeks.|The secondary objective is to evaluate the safety of treatment with imiquimod 5% cream in subjects with AK lesions on the upper extremities.	Graceway Pharmaceuticals, LLC	All	18 Years and older   (Adult, Older Adult)	Phase 4	270	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	1516-IMIQ	May 2005		September 2006	June 22, 2005		February 19, 2007	Tucson, Arizona, United States|Vista, California, United States|Atlanta, Georgia, United States|Newnan, Georgia, United States|Buffalo Grove, Illinois, United States|Evansville, Indiana, United States|Delran, New Jersey, United States|New York, New York, United States|Rochester, New York, United States|Greenville, North Carolina, United States|Portland, Oregon, United States|Providence, Rhode Island, United States|Knoxville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|Virginia Beach, Virginia, United States|Wenatchee, Washington, United States|Milwaukee, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT00115154
352	NCT00125723	FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy		Completed	No Results Available	Neutropenia	Other: PI Discretion	dose delays and dose reductions and neutropenic events	Amgen	All	18 Years and older   (Adult, Older Adult)	Phase 4	2252	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20030218	May 2004	December 2005	December 2005	August 2, 2005		December 23, 2010			https://ClinicalTrials.gov/show/NCT00125723
353	NCT00891813	Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose		Completed	Has Results	Secondary Hyperparathyroidism|Renal Insufficiency, Chronic|Parathyroid Hormone|Hemodialysis|Hypercalcemia	Drug: Zemplar (paricalcitol)	The Percentage of Patients Reaching at Least a 30% Reduction in PTH and/or Values in Range 150-300 pg/mL|Time to Reach the First 30% Reduction in PTH and/or a Value Between 150-300pg/mL|Number of Participants With Hypercalcemia (>10.5mg/dL), Hyperphosphatemia (>6.5mg/dL) and/or Elevations of the Ca X P Product (>65).	Abbott	All	18 Years and older   (Adult, Older Adult)	Phase 4	100	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	W10-677	May 2009	September 2010	September 2010	May 1, 2009	October 31, 2011	October 31, 2011	Site Reference ID/Investigator# 21401, Callao, Peru|Site Reference ID/Investigator# 23857, Lima, Peru|Site Reference ID/Investigator# 10941, Lima, Peru		https://ClinicalTrials.gov/show/NCT00891813
354	NCT00844675	Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection		Completed	No Results Available	Early Gastric Adenocarcinoma|Adenocarcinoma, Tubular	Drug: rabeprazole|Drug: placebo	Frequency of bleeding after EMR is performed|Number (No./cm2) of visible vessels on the fundus of ulcer on endoscopy performed within 24 hours after EMR|Percentage of a pH change with intragastric pH greater than 6 in 24 hours after EMR|Measurement of a change in the size of ulcer	The Catholic University of Korea|Janssen Korea, Ltd., Korea	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 4	120	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	RAB-KOR-9035	October 2007	December 2011	March 2012	February 16, 2009		October 18, 2012	Catholic University, Gangnam St. Mary's Hospital, Seoul, Ban-po dong 505, Korea, Republic of		https://ClinicalTrials.gov/show/NCT00844675
355	NCT01514448	Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib		Completed	Has Results	Metastatic Renal Cell Carcinoma (mRCC)	Drug: Everolimus (RAD001)	Percentage of Progression-free Patients by Month 6|Percentage of Patients With Overall Response Rate (ORR) Treated With Everolimus After Failure of First-line Sunitinib or Pazopanib Therapy at Month 6|Progression-Free Survival (PFS) as the Time Interval Between First Intake of Everolimus and First Documented Disease Progression or Death Due to Any Cause at 24 Months|Overall Survival (OS) of Patients Treated With Everolimus After Failure of First-line Sunitinib or Pazopanib Therapy up to 48 Months|Duration of Response (DOR) in Patients Treated With Everolimus After Failure of First-line Sunitinib or Pazopanib Therapy up to 48 Months	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	29	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CRAD001LDE43|2011-003416-23	May 21, 2012	April 1, 2016	April 1, 2016	January 23, 2012	July 19, 2017	July 19, 2017	Novartis Investigative Site, Chemnitz, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Hof, Germany|Novartis Investigative Site, Kassel, Germany|Novartis Investigative Site, Langen, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, Ravensburg, Germany|Novartis Investigative Site, Velbert, Germany|Novartis Investigative Site, Wiesbaden, Germany|Novartis Investigative Site, Wolfsburg, Germany		https://ClinicalTrials.gov/show/NCT01514448
356	NCT01064947	Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis		Completed	Has Results	Atopic Dermatitis|Secondary Infection	Drug: Retapamulin 1%	Bacteriological Culture|Skin Infection Rating Scale (SIRS)|Investigator Assessment of Clinical Cure|Local Tolerability	Derm Research, PLLC|GlaxoSmithKline	All	2 Years and older   (Child, Adult, Older Adult)	Phase 4	29	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ALT113706	February 2010	January 2012	January 2012	February 9, 2010	July 4, 2013	September 22, 2016	DermResearch, PLLC, Louisville, Kentucky, United States		https://ClinicalTrials.gov/show/NCT01064947
357	NCT00958451	Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients		Completed	No Results Available	Secondary Hyperparathyroidism|Chronic Kidney Disease	Drug: Paricalcitol|Drug: Ergocalciferol	To achieve 2 consecutive iPTH measurements with 30% or greater decrease from baseline|To achieve 25OHD level above 30 ng/ml and change cardiovascular markers	Salem Veterans Affairs Medical Center|Abbott	All	18 Years and older   (Adult, Older Adult)	Phase 4	80	U.S. Fed|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CK0023	July 2009	January 2011	January 2011	August 13, 2009		March 24, 2011	VA Medical Center, Salem, Virginia, United States		https://ClinicalTrials.gov/show/NCT00958451
358	NCT02812186	Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery		Enrolling by invitation	No Results Available	Cholecystitis|Endometriosis|Bowel Obstruction|Fibroids|Prostate Cancer|Chronic Kidney Disease|Uterine Prolapse	Procedure: deep neuromuscular blockade|Procedure: moderate neuromuscular blockade|Drug: Rocuronium	Peak Airway Pressures|Heart rate|Blood Pressure	Stony Brook University|Merck Sharp & Dohme Corp.	All	18 Years and older   (Adult, Older Adult)	Phase 4	100	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	823925	December 27, 2016	January 11, 2019	May 2019	June 24, 2016		March 21, 2019	Stony Brook University Hospital, Stony Brook, New York, United States		https://ClinicalTrials.gov/show/NCT02812186
359	NCT00454272	Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients		Completed	No Results Available	Infection|Febrile Neutropenia	Drug: Teicoplanin|Drug: Vancomycin	The primary efficacy parameter will be the Response|Safety will be assessed for all randomized patients who received at least one dose	Sanofi	All	2 Years and older   (Child, Adult, Older Adult)	Phase 4	197	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	M000507_6004	January 2005	August 2007	August 2007	March 30, 2007		March 6, 2009	Sanofi aventis administrative office, Istanbul, Turkey		https://ClinicalTrials.gov/show/NCT00454272
360	NCT00526331	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy		Completed	Has Results	Esophageal Diseases|Gastrointestinal Diseases|Disorder of the Genitourinary System|Gynecologic Diseases|Kidney Diseases|Liver Diseases|Pancreatic Diseases|Prostate Cancer|Spinal Disease	Device: Vigileo Monitor|Device: FloTrac Sensor	Length of Hospital Stay (LOS) by Participant	M.D. Anderson Cancer Center|Edwards Lifesciences	All	18 Years and older   (Adult, Older Adult)	Phase 4	49	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	2007-0231	August 2007	September 2008	September 2008	September 10, 2007	January 16, 2012	January 16, 2012	U.T.M.D. Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00526331
361	NCT01201811	Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)		Completed	Has Results	Myelodysplastic Syndromes	Drug: Azacitidine	Percentage of Participants With a Hematologic Response Using International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS) and Assessed by Investigator|Percentage of Participants Showing Hematologic Improvement Using International Working Group (IWG Criteria for Hematologic Improvement Cheson 2000) Criteria for Myelodysplastic Syndrome (MDS) and Assessed by Sponsor|Number of Red Blood Cell (RBC) Transfusions by Cycle|Number of Platelet Transfusions by Cycle|Number of Infections (Post-baseline Average) Requiring Intravenous Antibiotics, Anti-fungals, or Antivirals Per 28 Days|Number of Participants With Adverse Events (AE)|Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Azacitidine|Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of Azacitidine|Maximum Observed Plasma Concentration (Cmax) of Azacitidine|Time to Maximum Plasma Concentration (Tmax) of Azacitidine|Terminal Phase of Half-life (T1/2) of Azacitidine|Apparent Total Plasma Clearance (CL/F) of Azacitidine|Apparent Volume of Distribution (Vd/F) of Azacitidine	Celgene Corporation	All	18 Years and older   (Adult, Older Adult)	Phase 4	44	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AZA-MDS-001	October 2010	May 2013	May 2013	September 15, 2010	June 24, 2014	April 22, 2016	Changhua Christian Hospital, Changhua, Taiwan|Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan|Buddhist Tzu Chi General Hospital-Hualien Tzu Chi Medical Center, Hualien, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan|Kaohsiung Medical Hospital University, Kaohsiung, Taiwan|Shuang-ho Hospital, New Taipei City, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT01201811
362	NCT01660906	Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib		Completed	Has Results	Chronic Phase Chronic Myeloid Leukemia	Drug: Dasatinib	The Number of Imatinib-related Adverse Events (AEs) That Were Resolved, Improved, Remained Unchanged, or Worsened After 3 Months of Dasatinib Treatment|Mean Change From Baseline in Patient Reported CML Symptom Severity and Interference by MD Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) Score After Switching to Dasatinib|Mean Change From Baseline in Patient Reported Quality of Life Measurements by The European Organization for Research and Treatment of Cancer - Quality of Life (QoL) Questionnaire (EORTC QLQ) Score After Switching to Dasatinib|Number of Participants With at Least 1 AE, Discontinuations Due to AE, Treatment-related AE, Serious Adverse Event (SAE), Treatment-related SAE, or Death as Outcome|The Percentage of Participants With at Least 1 Imatinib-related Grade 1 or Grade 2 Chronic Adverse Events (AEs) That Improved Without Worsening Within 3 Months of Switching to Dasatinib	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 4	39	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA180-400|2011‐006180‐21	December 2012	October 2015	October 2015	August 9, 2012	November 22, 2016	November 22, 2016	Pacific Cancer Medical Center, Anaheim, California, United States|Cancer Center Of Central Connecticut, Southington, Connecticut, United States|St. Agnes Healthcare, Inc., Baltimore, Maryland, United States|Promedica Hematology & Oncology Assoicates, Sylvania, Ohio, United States|The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States|Local Institution, Creteil Cedex, France|Local Institution, Lille CEDEX, France|Local Institution, Pierre Benite cedex, France|Local Institution, Pringy Cedex, France|Local Institution, Vandoeuvre les Nancy, France|Local Institution, Jena, Germany|Local Institution, Koln, Germany|Local Institution, Lubeck, Germany|Local Institution, Mannheim, Germany|Local Institution, Rostock, Germany|Local Institution, Catania, Italy|Local Institution, Firenze, Italy|Local Institution, Napoli, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, Torino, Italy|Local Institution, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01660906
363	NCT01227577	CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib	MACS1428	Completed	Has Results	Chronic Myelogenous Leukemia in Chronic Phase	Drug: Nilotinib	Number of Participants With Confirmed Complete Molecular Response (CMR)|Number of Participants With Complete Cytogenetic Response (CCyR) and Major Molecular Response (MMR)|Time to CMR, CCyR and MMR|Duration of CMR, CCyR and MMR|Number of Participants With Progression to Accelerated Phase/Blastic Crisis (AP/BC)|Time to Progression of AP/BC|Number of Participants With Loss of CCyR, MMR and CMR|Number of Participants With CMR Who Were Dosed to 400 mg b.i.d.|Event-free Survival, Progression-free Survival and Overall Survival	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	128	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CAMN107AUS28	November 2010	November 2014	November 2014	October 25, 2010	February 8, 2016	February 8, 2016	Pacific Cancer Medical Center, Inc., Anaheim, California, United States|Providence St. Joseph Medical Center Roy&Patricia Disney Fam Cancer, Burbank, California, United States|Bay Area Cancer Research Dept.ofBayAreaCancerResearch, Concord, California, United States|St. Jude Heritage Medical Group Virginia Crosson Cancer Center, Yorba Linda, California, United States|Sarah Cannon Research Institute SCRI, Jacksonville, Florida, United States|Advanced Medical Specialties, Miami, Florida, United States|Pasco Hernando Oncology, New Port Richey, Florida, United States|Georgia Regents University MedCollege of GA Cancer Ctr 2, Augusta, Georgia, United States|Stroger Cook County Hospital Division of Hematology & Onc, Chicago, Illinois, United States|Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States|Indiana Blood and Marrow Institute, Beach Grove, Indiana, United States|Cancer Center of Kansas, Witchita, Kansas, United States|LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center(3), New Orleans, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|St. Louis University Cancer Center, St. Louis, Missouri, United States|University of Nebraska Medical Center University of Nebraska Med Ctr, Omaha, Nebraska, United States|Hackensack University Medical Center Dept.of HackensackUniv.MedCtr., Hackensack, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|University of Rochester Medical Ct James P Wilmot Cancer Ctr, Rochester, New York, United States|Duke University Medical Center Duke University Med Ctr, Durham, North Carolina, United States|Oregon Health & Science University, Portland, Oregon, United States|Cancer Centers of the Carolinas Cancer Center, Greenville, South Carolina, United States|Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology, Chattanooga, Tennessee, United States|The Jones Clinic, Germantown, Tennessee, United States|Tennessee Oncology Sarah Cannon Research Inst., Nashville, Tennessee, United States|Baylor Research Institute Baylor Research Institute (17), Dallas, Texas, United States|Oncology Consultants Oncology Consultants, P.A., Houston, Texas, United States|Millennium Oncology, Houston, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Providence Regional Cancer Partnership, Everett, Washington, United States		https://ClinicalTrials.gov/show/NCT01227577
364	NCT00980018	An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment	MACS0999	Completed	No Results Available	Chronic Myelogenous Leukemia	Drug: Nilotinib	Improvement of (CTCAE grading scale) of imatinib related chronic low grade non hematologic Adverse Event after switch to treatment with nilotinib at End of Cycle 3|Rate of Complete Cytogenetic Response (CCyR) present at baseline|Rate of a Major Molecular Response (MMR) after the switch in the therapy|Magnitude of Bcr-Abl change after the switch in therapy|Durability of cytogenetic and molecular response|Time to optimal imatinib-related adverse event improvement	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	52	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CAMN107AUS17	December 2009	December 2012	December 2012	September 18, 2009		April 15, 2015	Highlands Oncology Group, Fayetteville, Arkansas, United States|Hematology Oncology Services of Arkansas SC, Little Rock, Arkansas, United States|USC Norris Cancer Center LAC & USC Medical Center, Los Angeles, California, United States|Southwest Cancer Care Murrieta, Poway, California, United States|Rocky Mountain Cancer Centers RMCC - Aurora, Greenwood Village, Colorado, United States|Florida Cancer Institute, New Port Richey, Florida, United States|Cancer Centers of Florida PA Cancer Centers of FL-Orlando-4, Ocoee, Florida, United States|Stroger Cook County Hospital John H. Stroger Hospital, Chicago, Illinois, United States|St. Francis Hospital and Health Centers IndianaBlood&MarrowTransplantn, Beech Grove, Indiana, United States|St. Agnes Hospital, Baltimore, Maryland, United States|St. Louis University Cancer Center, St. Louis, Missouri, United States|Northwest Cancer Specialists Salmon Creek Office, Portland, Oregon, United States|Oregon Health Sciences University, Portland, Oregon, United States|The Jones Clinic, Germantown, Tennessee, United States|Texas Oncology, P.A., Bedford, Texas, United States|Presbyterian Hospital of Dallas TexasOncology@PresbyterianHosp, Dallas, Texas, United States|Texas Oncology Texas Oncology - Sugar Land, Dallas, Texas, United States|MD Anderson Cancer Center/University of Texas, Houston, Texas, United States|Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio(2), San Antonio, Texas, United States|Novartis Investigative Site, Brampton, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT00980018
365	NCT00081926	Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia		Completed	No Results Available	Chronic Myelogenous Leukemia	Drug: Gleevec		Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	112	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CSTI571AUS177|US177|RIGHT Trial	October 2003		March 2007	April 29, 2004		November 23, 2009	Novartis RIGHT Trial Hotline, East Hanover, New Jersey, United States		https://ClinicalTrials.gov/show/NCT00081926
366	NCT02631499	Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation		Not yet recruiting	No Results Available	Carcinoma, Hepatocellular|Neoplastic Cells, Circulating	Procedure: TACE|Drug: Epirubicin|Drug: lipiodol	Early recurrence rates|Overall Survival	Fudan University|Shanghai Zhongshan Hospital|Johnson & Johnson Medical, China	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	256	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTC-HE-TACE	December 2015	December 2018	December 2019	December 16, 2015		December 22, 2015	Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China|Nantong Tumor Hospital, Nantong, Jiangsu, China|The First Affiliated Hospital of Soochow University, Soochow, Jiangsu, China|Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, Shanghai, China|Xinhua Hospital, Affliated with Shanghai Jiao Tong University, School of Medicine, Shanghai, Shanghai, China|Zhongshan hospital, Fudan University, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT02631499
367	NCT03332511	Efficacy and Safety of Nilotinib in CML-CP	ENESTKorea	Completed	No Results Available	Chronic Myeloid Leukemia, Chronic Phase	Drug: Nilotinib	Cumulative rate of molecular response 4.5 by 24 months|Cumulative rate of molecular response 3 by 24 months|Cumulative rate of molecular response 3 by 12 months|Cumulative rate of molecular response 4 by 24 months|Cumulative rate of molecular response 4 by 12 months|Progression-free survival|Overall survival	Seoul National University Hospital|Novartis Pharmaceuticals	All	19 Years and older   (Adult, Older Adult)	Phase 4	110	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1110-124-383	May 6, 2013	October 24, 2016	October 24, 2016	November 6, 2017		November 6, 2017			https://ClinicalTrials.gov/show/NCT03332511
368	NCT02251652	Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses		Completed	Has Results	Actinic Keratoses	Drug: Ingenol Mebutate|Procedure: Cryotherapy	Safety of Combination Therapy vs Cryotherapy Alone|Change in Number of All Actinic Keratoses|Change in Actinic Keratoses by Anatomic Site	Icahn School of Medicine at Mount Sinai|LEO Pharma	All	18 Years and older   (Adult, Older Adult)	Phase 4	16	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	GCO 13-0142	April 2013	December 2014	August 2015	September 29, 2014	April 26, 2017	April 26, 2017	Icahn School of Medicine at Mount Sinai, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02251652
369	NCT01521715	First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma	FLIPPER	Completed	No Results Available	Locally Advanced and/or Metastatic Renal Cell Carcinoma|Carcinoma, Renal Cell|Clear-cell Metastatic Renal Cell Carcinoma	Drug: Pazopanib	Rate of poor risk patients as defined by the Memorial Sloan-Kettering Cancer Center (MSKCC) criteria who are free of disease progression at 6 months after start of first line treatment with pazopanib.|Overall survival of poor risk patients treated with pazopanib.|Number, characteristics and severity of Adverse Events|Progression free survival of patients treated with pazopanib|Overall response rate and duration of response according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1|Relation between biomarkers and clinical outcome (response, stable disease, progression of disease)	iOMEDICO AG|Novartis Pharmaceuticals	All	18 Years and older   (Adult, Older Adult)	Phase 4	44	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	iOM-605|2011-001138-40	January 24, 2012	June 30, 2017	July 31, 2017	January 31, 2012		August 23, 2017	Urolog. Klinik im Waldkrankenhaus St. Marien, Friedrich-Alexander-Universität, Erlangen, Germany|Universitätsklinikum Essen, Klinik f. Urologie, Essen, Germany|Med. Klinik II, Johann-Wolfgang-Goethe-Universität, Frankfurt, Germany|Medizinisches Versorgungszentrum (MVZ) Osthessen GmbH, Fulda, Germany|Universitätsmedizin Greifswald, Greifswald, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Ludwig-Maximilians-Universität (LMU) München, Klinikum Grosshadern, München, Germany|Universitätsklinikum Münster, Münster, Germany		https://ClinicalTrials.gov/show/NCT01521715
370	NCT01266837	Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)	MARC-2	Completed	No Results Available	Metastatic Renal Cell Carcinoma|Failure of Exactly One Prior VEGF-targeted Therapy	Drug: Everolimus	Rate of patients progression free 6 months after start of study treatment|Relation between biomarkers and clinical benefit (response, stable disease and progression/ no clinical benefit) of patients	iOMEDICO AG|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	64	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CRAD001LDE36T|2010-021370-11	March 2011	September 26, 2017	October 31, 2017	December 24, 2010		November 14, 2017	Charitè Campus Benjamin Franklin, Berlin, Germany|Klinik und Poliklinik für Urologie , Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden, Dresden, Germany|Urologie - Waldkrankenhaus St. Marien, Erlangen, Germany|Klinik für Innere Medizin (Tumorforschung), Universitätsklinikum Essen, Essen, Germany|Zentrum Innere Medizin, Medizinische Hochschule Hannover, Hannover, Germany|Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes, Homburg, Germany|Klinik für Urologie, Universitätsklinikum Jena, Jena, Germany|5. Medizinische Klinik, Klinikum Nürnberg, Nürnberg, Germany		https://ClinicalTrials.gov/show/NCT01266837
371	NCT00858104	Percutaneous Laser Ablation in Benign Thyroid Nodules.Long Term Results		Completed	No Results Available	Thyroid Nodule	Procedure: Percutaneous Laser Ablation	Short- (1-year) and long- (3-year) term evolution of the thyroid nodules volume and symptoms after the treatment vs. simple clinical observation.(Strong Endpoint: %nodules with greater than 50% base volume reduction and %patients free of symptoms)|Assessment of short-term and long-term PLA safety, tolerability and reproducibility.	Elesta S.R.L.	All	18 Years and older   (Adult, Older Adult)	Phase 4	200	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IALT-07	November 2008	March 2010	May 2013	March 9, 2009		May 26, 2014	Ospedale Regina Apostolorum, Albano Laziale, Roma, Italy|Azienda Ospedaliera di Perugia - Osp. S.Maria della Misericordia, Perugia, Italy|Azienda Ospedaliero-Universitaria di Pisa - Presidio di Cisanello, Pisa, Italy|Arcispedale S. Maria Nuova, Reggio Emilia, Italy		https://ClinicalTrials.gov/show/NCT00858104
372	NCT03616444	Clinical Study on Prevention Colorectal Adenomatous Polyp Recurrence After Polypectomy Under Colonoscopy by Xiaoai Jiedu Decoction		Not yet recruiting	No Results Available	Gastroenterology	Drug: Xiaoai Jiedu Decoction	Colorectal Adenomatous Polyp Recurrence|Malignant Colorectal Adenomatous Polyp	Jiangsu Famous Medical Technology Co., Ltd.	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 4	400	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	2017YFC1700602	August 19, 2018	August 18, 2020	October 18, 2020	August 6, 2018		August 6, 2018	Affiliated Hospital of Nanjing University of TCM, Nanjing, Jiangsu, China		https://ClinicalTrials.gov/show/NCT03616444
373	NCT00743080	Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue Morcellators		Completed	No Results Available	Uterine Myomas	Procedure: Laparoscopic myomectomy and supracervical hysterectomy with GYNECARE MORCELLEX|Procedure: Laparoscopic myomectomy and supracervical hysterectomy with ROTOCUT G1	Morcellament time|Total operative time|Feasibility [subjective score of difficulty]|Blood loss|Post-operative complications|Postoperative pain|Hospital stay|Time to return to full activity and/or work	University Magna Graecia|Johnson & Johnson	Female	18 Years to 80 Years   (Adult, Older Adult)	Phase 4		Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	300-07-015	January 2008		January 2010	August 28, 2008		November 3, 2010	University Magna Graecia, Catanzaro, Italy		https://ClinicalTrials.gov/show/NCT00743080
374	NCT00159328	Efficacy Study of Magnetic Resonance (MR) Guided Focused Ultrasound in the Treatment of Large Fibroids		Completed	No Results Available	Uterine Fibroids	Procedure: Magnetic Resonance Guided Focused Ultrasound	Symptom improvement as judged by validated disease specific questionnaire|Change in fibroid and uterine volume.	Imperial College London|InSightec-TxSonics	Female	18 Years and older   (Adult, Older Adult)	Phase 4	50	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	UF008	March 2003		December 2006	September 12, 2005		August 13, 2008	Department of Interventional Magnetic Resonance, St Mary's Hospital, London, United Kingdom		https://ClinicalTrials.gov/show/NCT00159328
375	NCT03677596	A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients		Recruiting	No Results Available	Leukemia|Precursor b-Cell Lymphoblastic Leukemia-Lymphoma|ACUTE LYMPHOBLASTIC LEUKEMIA	Drug: inotuzumab ozogamicin-dose level 2|Drug: Inotuzumab ozogamicin-dose level 1	Percentage of Participants With Hematologic Remission (Complete Remission [CR]/Complete Remission With Incomplete Hematologic Recovery [CRi])|Rate of veno-occlusive disease (VOD)|Frequency of adverse events|Minimal residual disease (MRD) negativity|Duration of remission (DoR) for Participants Who Achieved CR/CRi|Progression free survival (PFS)|Overall survival (OS)|Rate of hematopoietic stem cell transplantation (HSCT)|Post HSCT relapse|Post HSCT mortality|Post HSCT non relapse mortality|Post HSCT relapse related mortality|Pharmacokinetics, Cmax|Percentage of patients with positive anti-drug antibody response|Percentage of patients with laboratory abnormalities (NCI CTCAE grade)|Pharmacokinetics, Ctrough|Pharmacokinetics, Clearance|Pharmacokinetics, Area under the curve (AUC)	Pfizer	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	102	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	B1931030|2018-001557-27	July 1, 2019	June 17, 2024	June 23, 2025	September 19, 2018		August 1, 2019	Keck Hospital of USC-Norris Comprehensive Cancer Center (HC3), Los Angeles, California, United States|Keck Hospital of USC, Los Angeles, California, United States|LAC+USC Medical Center, Los Angeles, California, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|University of Maryland- Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Alfred Health, Melbourne, Victoria, Australia|Klinika Hematologii i Transplantologii, Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|National University Hospital, Singapore, Singapore|Pharmacy @ NCIS, National University Hospital, Singapore, Singapore|Raffles Hospital, Singapore, Singapore|Raffles Radiology, Singapore, Singapore|Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital Clinical Research Center, Ankara, Turkey|Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital Hematology Department, Ankara, Turkey|Hacettepe University Medical Faculty Internal Diseases Department Hematology Div, Ankara, Turkey|Ankara University Faculty of Medicine Cebeci Hospital Hematology Department, Ankara, Turkey|Private Medstar Antalya Hosp. Hematology and Stem Cell Transplantation Center, Antalya, Turkey|Marmara University Pendik Training and Research Hospital Hematology Unit, Istambul, Turkey|Erciyes University Medical Faculty Hematology Department, Kayseri, Turkey|Anadolu Medical Center Hospital, Kocaeli, Turkey		https://ClinicalTrials.gov/show/NCT03677596
376	NCT03646123	A Safety Study of Growth Factor Use in Treatment With Brentuximab Vedotin Plus Chemotherapy		Recruiting	No Results Available	Hodgkin Lymphoma	Drug: brentuximab vedotin|Drug: doxorubicin|Drug: vinblastine|Drug: dacarbazine|Drug: G-CSF	Febrile Neutropenia (FN) Rate|Primary Refractory Disease Rate|CR Rate|Physician-reported Progression Free Survival (PFS)|Subsequent Anticancer Therapy Utilization Rate|Mean Dose Intensity|Rate of Dose Reduction and Delays	Seattle Genetics, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 4	180	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SGN35-027	January 28, 2019	March 2021	March 2023	August 24, 2018		July 29, 2019	Compassionate Care Research Group, Fountain Valley, California, United States|Florida Cancer Specialists - North Region, Saint Petersburg, Florida, United States|New Jersey Hematology Oncology Associates, LLC, Brick, New Jersey, United States|Regional Cancer Care Associates - Freehold, Freehold, New Jersey, United States|Regional Cancer Care Associates - Howell, Howell, New Jersey, United States|Regional Cancer Care Associates - Mount Holly, Mount Holly, New Jersey, United States|Regional Cancer Care Associates - Central Jersey, Somerville, New Jersey, United States|Regional Cancer Care Associates - Sparta, Sparta, New Jersey, United States|Clinical Research Alliance - Morton Coleman, MD, Lake Success, New York, United States|CareMount Medical Group, Mount Kisco, New York, United States|Clinical Research Alliance - Abraham Mittelman, MD, LLC, Purchase, New York, United States|Case Western Reserve University / University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Tennessee Oncology - Nashville, Nashville, Tennessee, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03646123
377	NCT02805218	PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy		Completed	No Results Available	Lymphoma	Drug: PEG-rhG-CSF	The occurrence rate of adverse event|The severity of adverse event|the occurrence rate of grade III/ IV neutropenia during chemotherapy cycles	CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.	All	18 Years and older   (Adult, Older Adult)	Phase 4	410	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	CSPC-PGC-IV-02-1	September 2013	February 2016	February 2016	June 17, 2016		June 20, 2016			https://ClinicalTrials.gov/show/NCT02805218
378	NCT02782845	An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)		Completed	No Results Available	Non-Hodgkin's Lymphoma	Drug: Chemotherapy|Drug: Immunochemotherapy|Drug: Pegfilgrastim	Percentage of Participants with Febrile Neutropenia (Absolute Neutrophil Count [ANC] <0.5x10^9/L and Temperature ≥38 degrees Celsius) And/Or Grade IV Neutropenia (ANC<0.5x10^9/L) in Cycle 1|Percentage of Participants with Febrile Neutropenia (ANC <0.5x10^9/L and temperature ≥38 degrees Celsius) And/Or Grade IV Neutropenia (ANC<0.5x10^9/L) in Cycles 2 to 6|Percentage of Participants with Adverse Events	Hoffmann-La Roche	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 4	53	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML19812	June 2006	October 2007	October 2007	May 25, 2016		November 21, 2016	Bogota, Colombia|Chihuahua, Mexico|Chihuahua, Mexico|Estado de Mexico, Mexico|Guadalajara, Mexico|Leon, Mexico|Leon, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Obregon, Mexico|Puebla, Mexico|Queretaro, Mexico|Tepic, Mexico|Toluca, Mexico|Veracruz, Mexico		https://ClinicalTrials.gov/show/NCT02782845
379	NCT02546674	Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.	NILOdeepR	Active, not recruiting	No Results Available	Chronic Myeloid Leukemia	Drug: Nilotinib	Proportion of patients that achieve deep molecular response MR4.5 (IS) at 24 months of study treatment, measured in a standardized EUTOS MR4.5 laboratory|Proportion of patients with MMR at 12 months of study treatment|Proportion of patients with CCyR at 6 months of study treatment|Progression-free survival|Proportion of patients with MR4 at 24 months of study treatment|Individual reduction of BCR-ABL transcripts	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	171	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CAMN107ADE20	February 18, 2016	February 18, 2020	April 30, 2021	September 11, 2015		July 8, 2019	Novartis Investigative Site, Mannheim, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Herne, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Luebeck, Schleswig-holstein, Germany|Novartis Investigative Site, Aschaffenburg, Germany|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Bad Mergentheim, Germany|Novartis Investigative Site, Bad Reichenhall, Germany|Novartis Investigative Site, Bad Saarow, Germany|Novartis Investigative Site, Bad Soden, Germany|Novartis Investigative Site, Bamberg, Germany|Novartis Investigative Site, Bayreuth, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Biberach, Germany|Novartis Investigative Site, Bremerhaven, Germany|Novartis Investigative Site, Chemnitz, Germany|Novartis Investigative Site, Donauwoerth, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Erfurt, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Georgsmarienhuette, Germany|Novartis Investigative Site, Giessen, Germany|Novartis Investigative Site, Goslar, Germany|Novartis Investigative Site, Göppingen, Germany|Novartis Investigative Site, Halberstadt, Germany|Novartis Investigative Site, Halle S, Germany|Novartis Investigative Site, Halle, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Kassel, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Memmingen, Germany|Novartis Investigative Site, Minden, Germany|Novartis Investigative Site, Moers, Germany|Novartis Investigative Site, Muelheim, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, Mutlangen, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, Offenburg, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Paderborn, Germany|Novartis Investigative Site, Passau, Germany|Novartis Investigative Site, Potsdam, Germany|Novartis Investigative Site, Rostock, Germany|Novartis Investigative Site, Rotenburg, Germany|Novartis Investigative Site, Saarbruecken, Germany|Novartis Investigative Site, Schorndorf, Germany|Novartis Investigative Site, Schweinfurt, Germany|Novartis Investigative Site, Schwäbisch-Hall, Germany|Novartis Investigative Site, Stuttgart, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Velbert, Germany|Novartis Investigative Site, Weiden, Germany|Novartis Investigative Site, Westerstede, Germany|Novartis Investigative Site, Wiesbaden, Germany|Novartis Investigative Site, Wilhelmshaven, Germany|Novartis Investigative Site, Wolfsburg, Germany|Novartis Investigative Site, Worms, Germany|Novartis Investigative Site, Wuerzburg, Germany		https://ClinicalTrials.gov/show/NCT02546674
380	NCT01180049	Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma		Completed	Has Results	Non-Hodgkin's Lymphoma	Drug: temsirolimus	Independently Assessed Progression-free Survival (PFS)|Overall Survival (OS)|Independent Assessment - Objective Response Rate (ORR = CR + PR)|Investigator's Assessment ORR (ORR = CR + PR)|Investigator Assessed PFS|Percentage of Participants With Treatment-Emergent Infection- Related Adverse Events (AEs) With Grade 2 or Higher as Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)|Percentage of Participants With Treatment-Emergent Bleeding-Related AEs With Grade 2 or Higher as Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)|Quantify the Potential Effect of TEMSR on AUC and Cmax	Pfizer	All	18 Years and older   (Adult, Older Adult)	Phase 4	101	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	3066K1-4438|B1771007|2009-015498-11	March 2011	November 2015	June 2018	August 11, 2010	May 19, 2017	May 20, 2019	Mercy Research Institute, Miami, Florida, United States|Veterans Affairs New Jersey Healthcare System-Hematology/Oncology Section (111), East Orange, New Jersey, United States|Mercy Clinic Oklahoma Communities dba Mercy Clinic Oncology/Hematology-McAuley, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City-Oncology Infusion, Oklahoma City, Oklahoma, United States|Amy Shen, RPh, Seattle, Washington, United States|VA Puget Sound Health Care System, Seattle, Washington, United States|St George Hospital, Kogarah, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, Czech Republic, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|CHU de Nancy, Vandoeuvre les Nancy, France|Klinik fuer Onkologie und Haematologie, Medizinische Klinik IV, Aachen, Germany|Klinikum Johannes-Gutenberg -Universitaet, III. Medizinische Klinik und Poliklinik, Mainz, Germany|Presidio Ferrarotto - A.O.U. - PoliclinicoVittorio Emanuele, Catania, Italy|Dipartimento di Medicina Diagnostica, Clinica e di Sanità Pubblica, Modena, Italy|Struttura Complessa di Ematologia, Dipartimento di Oncologia ed Ematologia-, Torino, Italy|Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Malopolskie Centrum Medyczne S.C., Krakow, Poland|Institutul Clinic Fundeni Bucuresti, Sectia II Hematologie, Bucuresti, Romania|Spitalul Clinic Coltea, Clinica de Hematologie, Bucuresti, Romania|Spitalul Universitar de Urgenta Bucuresti, Clinica de Hematologie, Bucuresti, Romania|Republican Clinical Oncology Dispensary of the Ministry of Healthcare of Tatarstan Republic, Kazan, Russian Federation|GBOU VPO "First Saint-Petersburg State Medical University n.a. I.P.Pavlov", Saint-Petersburg, Russian Federation|Institute of Pediatric Hematology and Transplantology R.M.Gorbacheva, Saint-Petersburg, Russian Federation|Clinical Centre of Serbia,Clinic for Hematology, Belgrade, Serbia|Oncology Institute of Vojvodina, Sremska Kamenica, Serbia		https://ClinicalTrials.gov/show/NCT01180049
381	NCT01164475	Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms		Completed	Has Results	Non-Hodgkin's Lymphoma	Drug: Granulocyte-colony stimulating factor (G-CSF)|Drug: Fixed Dose Plerixafor|Drug: Weight-Based Plerixafor	Proportion of Patients Who Achieved at Least 5*10^6 Cluster of Differentiation 34+ (CD34+) Cells Per Kilogram (Cells/kg)|Area Under the Concentration-time Curve From Time 0 to 10 Hours (AUC [0-10])|Proportion of Patients Who Achieved at Least 2*10^6 CD34+ Cells/kg in Less Than or Equal to 4 Days of Apheresis|Median Number of Days of Apheresis to Collect at Least 2*10^6 CD34+ Cells/kg|Median Number of Days of Apheresis to Collect at Least 5*10^6 CD34+ Cells/kg|Total Number of CD34+ Cells/kg Collected Over up to 4 Aphereses|Mean Fold Increase in Peripheral Blood CD34+ Cell Count Following Plerixafor|Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Plasma Concentration (Tmax)|Terminal Elimination Half-life (T1/2)	Genzyme, a Sanofi Company|Sanofi	All	18 Years to 78 Years   (Adult, Older Adult)	Phase 4	61	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MOZ11809|MSC12830	October 2010	February 2013	February 2013	July 16, 2010	January 31, 2014	February 25, 2014	City of Hope National Medical Center, Duarte, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Princess Margaret Hospital, Toronto, Ontario, Canada|Samsung Medical Center, Seoul, Korea, Republic of|St. Mary's Hospital, Seoul, Korea, Republic of|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT01164475
382	NCT00430352	MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.		Completed	Has Results	Non-Hodgkin's Lymphoma	Drug: rituximab [MabThera/Rituxan]	Percentage of Participants With an Adverse Event (AE) - Overall Summary|Progression-Free Survival - Percentage of Participants With an Event|Progression-Free Survival - Time to Event|Event-Free Survival (EFS) - Percentage of Participants With an Event|Event-Free Survival (EFS) - Time to Event|Overall Survival (OS) - Percentage of Participants With an Event|Overall Survival (OS) - Time to Event|Time to Next Lymphoma Treatment (NLT) - Percentage of Participants With an Event|Time to NLT - Time to Event|Percentage of Participants With Response by Best Response to Study Treatment|Percentage of Participants With PR Who Converted to CRu	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	545	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MO19872	September 4, 2006	May 26, 2011	May 26, 2011	February 1, 2007	June 8, 2015	August 14, 2017	University "Mother Theresa" Hospital Center; Oncology Department, Tirana, Albania|Instituo Lavalle de Oncologia; Hematology, Bahia Blanca, Argentina|Academia Nacional de Medicina; Inst. de Cardiologia, Buenos Aires, Argentina|Fundaleu; Haematology, Buenos Aires, Argentina|Hospital Churruca Visca; Haematology, Buenos Aires, Argentina|Hospital Jr Vidal; Jefe de Servicio de Clinica Medica/Hematologia, Corrientes, Argentina|Sanatorio Allende; Haematology, Córdoba, Argentina|HOSPITAL PRIVADO - CENTRO MEDICO DE CÓRDOBA; Dpto Oncología, Córdoba, Argentina|Hospital General San Martin; Haematology, La Plata, Argentina|Liverpool Hospital; Haematology, Liverpool, New South Wales, Australia|Wollongong Hospital; Cancer Services, Wollongong, New South Wales, Australia|Royal Brisbane Hospital; Oncology Department, Brisbane, Queensland, Australia|Haematology & Oncology Clinics of Australia, Mater Medical Centre, South Brisbane, Queensland, Australia|Mount Medical Center, Perth, Western Australia, Australia|University Clinical Center of the Republic of Srpska, Clinic for Internal Disease, Hematology Dept, Banja Luka, Bosnia and Herzegovina|Inst. of Hematology, Kasindo, Bosnia and Herzegovina|Uni Hospital Mostar, Mostar, Bosnia and Herzegovina|Clinic of Oncology, University Clinical Center Sarajevo, Sarajevo, Bosnia and Herzegovina|Nucleo de Oncologia da Bahia - NOB, Salvador, Bahia, BA, Brazil|CEHON, Salvador, BA, Brazil|ONCOMED, Belo Horizonte, MG, Brazil|Centro de Tratamento Oncologico - Oncoclinica, Rio de Janeiro, RJ, Brazil|Hospital das Clinicas - UFRGS; Medicina Interna, Porto Alegre, RS, Brazil|Hospital Mae de Deus, Porto Alegre, RS, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, Brazil|Hospital das Clinicas - UNICAMP; Hemoterapia, Campinas, SP, Brazil|Clinica Oncologica De Piracicaba Sc, Piracicaba, SP, Brazil|Hospital Alemao Oswaldo Cruz; Oncologia, Sao Paulo, SP, Brazil|Hospital Estadual do Servidor Publico; Hematologia, Sao Paulo, SP, Brazil|Hospital das Clinicas - FMUSP, Oncologia, Sao Paulo, SP, Brazil|UMHAT Dr Georgi Stranski; Hematology, Pleven, Bulgaria|Umhat S. George; Hematology, Plovdiv, Bulgaria|UMHAT Alexandrovska EAD; Hematology, Sofia, Bulgaria|National Center of Hematology & Transfusiology; Clinical Unit, Clinic of Hematology, Sofia, Bulgaria|Mhat Sveta Marina; Dept. of Haematology, Varna, Bulgaria|Centro Médico Carlos Ardila Lule, Bucaramanga, Colombia|Hospital Pablo Tobon Uribe, Medellin-Antioquia, Colombia|Clinical Hospital Centre Split; Dept Of Hematology, Split, Croatia|Clinical Hospital Centre Dubrava; Hematology Department, Zagreb, Croatia|University Hospital Center Zagreb; Haematology Department, Zagreb, Croatia|Hospital José Carrasco; Oncology Service, Cuenca, Ecuador|Hospital Carlos Andrade Marin; Servicio de Oncología, Quito, Ecuador|Oncology & Radiotherapy Centre; Oncology, Cairo, Egypt|Kanta-Hämeen Keskussairaala; Dept of Internal Medicine, Hematology, Haemeenlinna, Finland|Kymenlaakson keskussairaala, Kotka, Finland|Päijät-Hämeen Keskussairaala; Dept of Internal Medicine, Hematology, Lahti, Finland|Satakunnan Keskussairaala; Sisaetauti Osasto, Pori, Finland|Internist; Praxis Für Haemotologie & Onkologie, Bad Soden, Germany|Dres.Christian Sperling und Claudia Schelenz, Berlin, Germany|Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany|Universitätsklinikum Bonn; Medizinische Klinik und Poliklinik I; Allgemeine Innere Medizin, Bonn, Germany|Dres. Matthias Adler Oliver Marschal und Andreas Pies, Braunschweig, Germany|Gemeinschaftspraxis, Duisburg, Germany|Internistische Praxis Dr. Plingen, Düsseldorf, Germany|Internistische Schwerpunktpraxis Erlangen, Erlangen, Germany|Praxis für Interdisziplinäre Onkologie und Hämatologie GbR, Freiburg, Germany|Onkologische Gemeinschaftspraxis, Prof. Dr. Gropp, Dr. Depenbusch und Dr. Rösel, Gütersloh, Germany|Überörtliche Gemeinschaftspraxis Schwerpunkt Hämatologie, internistische Onkologie & Palliativmed., Hamburg, Germany|Onkologische Schwerpunktpraxis; Herrn Dr. Med. Bertram, Hamburg, Germany|Dres.Andreas Karcher und Stefan Fuxius, Heidelberg, Germany|Uniklinik Heidelberg, Medizinische Klinik & Poliklinik V, Heidelberg, Germany|Onkologische Schwerpunktpraxis (Eps-Gmbh), Jena, Germany|Märkische Kliniken GmbH, Klinikum Lüdenscheid; Hämatologie / Onkologie, Lüdenscheid, Germany|Stauferklinikum Schwäb.Gmünd, Mutlangen, Germany|Gemeinschaftspraxis Dres. Schröder, Sieg, Mülheim, Germany|Onko. Gemeinschaftspraxis Dres. Tigges/ Böning/ Abenhardt/ Bosse, München, Germany|Dres.Ulrich Hutzschenreuter und Uwe Sauer, Nordhorn, Germany|Onkologische Praxis Oldenburg; Dres. Otremba, Reschke, Zirpel, Kühn und Ruff, Oldenburg, Germany|Praxis für Onkologie und Hämatologie, Recklinghausen, Germany|Diakonie-Klinikum Klinik für Innere Medizin III Abt.Hämatologie, intern. Onkologie und Palliativmedi, Schwäbisch-Hall, Germany|Internistische Gemeinschaftspraxis Dres. Hoering/Von Ehr/Responde, Stuttgart, Germany|Haematologisch-Onkologische Praxis; Dr. med. Christoph Maintz und Matthias Groschek, Wuerselen, Germany|Laiko General Hospital - Uni of Athens; 1St Dept. of Internal Medicine, Athens, Greece|Attiko Hospital; Haematology Clinic, Athens, Greece|Theagenio Anticancer Hospital; Dept. of Haematology, Thessaloniki, Greece|Rambam Medical Center; Heamatology & Bone Marrow Transplantation, Haifa, Israel|Wolfson Mc; Haematology, Holon, Israel|Hadassah Ein Karem Hospital; Haematology, Jerusalem, Israel|Chaim Sheba Medical Center; Hematology BMT & CBB, Ramat Gan, Israel|Ichilov Sourasky Medical Center; Heamatology, Tel Aviv, Israel|Ospedale Civile Dello Spirito Santo; Divisione Di Ematologia, Pescara, Abruzzo, Italy|Az. Osp. Pugliese; Dh Oncologico, Catanzaro, Calabria, Italy|Ospedale S. Gennaro; Divisione Di Ematologia, Napoli, Campania, Italy|Ospedale Cardarelli; Divisione Di Ematologia, Napoli, Campania, Italy|A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna, Bologna, Emilia-Romagna, Italy|Arcispedale S. Anna; Sezione Di Ematologia, Ferrara, Emilia-Romagna, Italy|A.O. Universitaria Policlinico Di Modena; Ematologia, Modena, Emilia-Romagna, Italy|A.O.U. Policlinico di Modena-Dipartimento di Medicina Diagnostica, Clinica e di Sanità pubblica, Modena, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica, Aviano, Friuli-Venezia Giulia, Italy|Az. Osp. Uni Ria Policlinico Tor Vergata; Unita Di Ematologia, Roma, Lazio, Italy|Ospedale S. Eugenio; Divisione Di Ematologia, Roma, Lazio, Italy|Univ. Cattolica La Sapienza; Cattedra Di Ematologia, Roma, Lazio, Italy|Uni Cattolica; Divisione Di Ematologia, Roma, Lazio, Italy|A.O. Universitaria S. Martino Di Genova; Ematologia 1, Genova, Liguria, Italy|A.O. Spedali Civili Di Brescia-P.O. Spedali Civili;U.O. Ematologia, Brescia, Lombardia, Italy|Istituto S. Raffaele Monte Tabor; Divisione Ematologia E Utmo, Milano, Lombardia, Italy|Ist. Nazionale Per Lo Studio E Cura Dei Tumori; Div. Ematologia Trapianto Midollo Osseo Allogenico, Milano, Lombardia, Italy|Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia, Milano, Lombardia, Italy|ASST DI MONZA; Ematologia, Monza, Lombardia, Italy|Irccs Policlinico San Matteo; Divisione Di Ematologia, Pavia, Lombardia, Italy|Ospedale Civile; S.C. Ematologia, Pesaro, Marche, Italy|A.O. Univ.Ospedali Riuniti Umerto I -G.M.Lancisi G.Salesi; U.O. Clinica Di Ematologia, Torrette Di Ancona, Marche, Italy|Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico, Candiolo, Piemonte, Italy|Az. Osp. S. Croce Ospedale Generale; Sezione Di Ematologia, Cuneo, Piemonte, Italy|Univ. Piemonte Est Amedeo Avogadro; Div.Ematologia- Dip.Clinica Med.Sperim.& Ircad, Novara, Piemonte, Italy|A.O. Universitaria S. Giovanni Battista-Molinette Di Torino; Ematologia 1, Torino, Piemonte, Italy|A.O.U. Citta' Della Salute E Della Scienza-P.O. Molinette;S.C. Ematologia, Torino, Piemonte, Italy|Uni Degli Studi Di Bari, Policlinico; Cattedra Di Ematologia,Dipart. Di Medicina Interna E Publica, Bari, Puglia, Italy|Ospedale Vito Fazzi; Div. Oncoematologia, Lecce, Puglia, Italy|Az. Osp. C. Panico; Rep. Ematologia E Trapianto, Tricase - Le, Puglia, Italy|Ospedale Oncologico A Businco-Cagliari; Ematologia Sez., Cagliari, Sardegna, Italy|Ospedale V. Cervello; U.O. Ematologia E Trapianti, Palermo, Sicilia, Italy|Ospedale Ferrarotto; Divisione Di Ematologia, Via S. Sofia 78, Sicilia, Italy|Az. Osp. Di Careggi; Divisione Di Ematologia, Firenze, Toscana, Italy|Ospedale Santa Chiara; Unita Operativa Di Ematologia, Pisa, Toscana, Italy|A.O. Universitaria Senese; Ematologia, Siena, Toscana, Italy|Azienda Ospedaliera S. Maria della Misericordia; Ematologia, Perugia, Umbria, Italy|Uni Degli Studi; Dip.Med.Clinica E Sperim. Ematologia, Padova, Veneto, Italy|Ospedale Di Vicenza; Nefrologia, Ematologia, Vicenza, Veneto, Italy|Issste; Haematology, Chihuahua, Mexico|Hospital Cima (Centro Internacional de Medicina) ; Haematology, Chihuahua, Mexico|Hospital Central de Pemex Norte Azcapotzalco, Mexico City, Mexico|Hospital Español de Mexico, Mexico City, Mexico|Hospital Regional Issste; Oncologia, Monterrey, Mexico|Clinca San Jose; Haematology, Obregon, Mexico|Issstep Puebla, ; Haematology, Puebla, Mexico|Spitalul Clinic Judetean de Urgenta Brasov,Clinica de Hematologie, Brasov, Romania|Fundeni Clinical Inst. ; Hematology Dept, Bucharest, Romania|Spitalul Clinic Coltea; Clinica de Hematologie, Bucuresti, Romania|Oncology Inst. Cluj-Napoca; Cancer Dept, Cluj-Napoca, Romania|Spitalul Clinic Judetean de Urgenta Sf. Spiridon Iasi, Clinica de Hematologie, Iasi, Romania|Spitalul Clinic Judetean de Urgenta Targu-Mures; compartiment Hematologie, Targu-mures, Romania|Regional Clinical Hospital; Hematology, Belgorod, Russian Federation|Clinical Oncology Dispensary of Ministry of Health of Tatarstan, Kazan, Russian Federation|Blokhin Cancer Research Center; Clinical Oncology, Moscow, Russian Federation|City Clinical Hospital After Botkin; Hematology, Moscow, Russian Federation|Vladimirskiy Regional Scientific Research Inst. ; Hematology, Moscow, Russian Federation|Regional Clinical Hospital N.A. Semashko; Hematology, Nizhny Novgorod, Russian Federation|City Hematological Center of Clinical Hospital #2; Hematology, Novosibirsk, Russian Federation|Rostov State Medical Uni ; Hematology, Rostov-na-donu, Russian Federation|Research Inst. of Hematology & Blood Transfusion ; Hematology, St Petersburg, Russian Federation|Pavlov State Medical Uni ; Bone Marrow Transplantation Clinic, St Petersburg, Russian Federation|Leningrad Regional Clinical Hospital; Hematology #1, St Petersburg, Russian Federation|Stavropol Clinical Oncology Dispansary, Stavropol, Russian Federation|Bashkirian Republican Clinical Oncology Dispensary, UFA, Russian Federation|Ulyanovsk Regional Oncology Dispensary; Chemotherapy, Ulyanovsk, Russian Federation|Regional Oncology Center; Chemotherapy, Volgograd, Russian Federation|Regional Clinical Hospital; Hematology, Yaroslavl, Russian Federation|Fakultna Nemocnica Roosevelta; Dept. of Haematology, Banska Bystrica, Slovakia|National Oncology Inst. ; Dept. of Haematology, Bratislava, Slovakia|Uni Hospital; Clinic of Haematology, Kosice, Slovakia|Uni Hospital ; Dept. of Haematol. & Transfusion Medicine, Martin, Slovakia|Institute of Oncology Ljubljana, Ljubljana, Slovenia|Complejo Asistencial Universitario De Burgos; Servicio de Oncologia, Burgos, Spain|Hospital General de Castellon; Servicio de Hematologia, Castellon, Spain|Hospital Generla de Ciudad Real; Servicio de Oncologia, Ciudad Real, Spain|Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia, Jaen, Spain|Hospital El Bierzo; Servicio de Oncologia, Leon, Spain|Hospital Costa del Sol; Servicio de Hematologia, Malaga, Spain|Hospital Universitario Virgen de Arrixaca; Servicio de Oncologia, Murcia, Spain|Hospital Universitario Virgen Macarena; Servicio de Hematologia, Sevilla, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Laenssjukhuset; Medicinkliniken/Hematologsektionen, Halmstad, Sweden|Sunderby Sjukhus; Medicinkliniken, Luleå, Sweden|Skånes Universitetssjukhus; Kliniska Forskningsenheten Onkologimottagning medicinsk behandling, Malmö, Sweden|Länssjukhuset Sundsvall-Härnösand, Medicinkliniken, Sundsvall, Sweden|Uddevalla Sjukhus; Medicinkliniken, Uddevalla, Sweden|Akademiska sjukhuset, Onkologkliniken, Uppsala, Sweden|Andreas Klinik; Onko-Hämatologisches Zentrum Cham Zug, Cham, Switzerland|Kantonsspital Graubünden;Onkologie und Hämatologie, Chur, Switzerland|Clinica Santa Chiara; Oncologia / Ematologia, Locarno, Switzerland|UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie, Zürich, Switzerland|Ankara Numune Egitim Ve Arastirma Hastanesi; Hematoloji Klinigi, Ankara, Turkey|Hacettepe Uni Medical Faculty; Hematology, Ankara, Turkey|Gazi Uni Medical School; Hematology, Ankara, Turkey|Istanbul Uni Capa Hospital; Hematology, Istanbul, Turkey|Ege Uni Medical School; Hematology, Izmir, Turkey		https://ClinicalTrials.gov/show/NCT00430352
383	NCT00802737	Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)		Completed	Has Results	Leukaemia, Lymphocytic, Chronic	Drug: Ofatumumab	Number of Participants (Par.) Classified as Responders (Rs) and Non-responders (NRs) for Objective Response in Accordance With the National Cancer Institute Working Group (NCIWG) 1996 Guidelines|Duration of Response|Progression-Free Survival (PFS)|Time to Next Chronic Lymphocytic Leukemia (CLL) Treatment|Overall Survival (OS)|Median Percent Change of Tumor Size (Sum of Products Dimensions [SPD]) From Baseline (Visit 2) at Month 4|Median Percent Change of Tumor Size (Sum of Products Dimensions [SPD]) From Baseline (Visit 2) at Month 12|Median Percent Change of Tumor Size (Sum of Products Dimensions [SPD]) From Baseline (Visit 2) at Month 24|Number of Participants With Negative and Positive Human Anti-human Antibody (HAHA) Results at the Time of Screening and Post Ofatumumab|Number of Participants Who Experienced Any Adverse Event|Number of Participants With the Indicated Major Infections|Number of Participants With Infections Requiring Hospitalization or Intravenous Antibiotics|Cmax and Ctrough at Visit 2 (Week 0) and at Visit 14 (Month 4)	GlaxoSmithKline|Genmab	All	18 Years and older   (Adult, Older Adult)	Phase 4	29	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	111827|GEN416	January 2009	September 2011	May 2013	December 5, 2008	June 26, 2012	May 14, 2014	GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Örebro, Sweden		https://ClinicalTrials.gov/show/NCT00802737
384	NCT00168727	Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma		Completed	No Results Available	Lymphoma, Non-Hodgkin|Lymphoma, Low-Grade	Drug: ibritumomab tiuxetan (Zevalin®)	Determine overall response rate, event-free survival, time-to-progression, time-to-next-therapy, and freedom-from-relapse in pts with low-grade lymphoma in first or second relapse treated with Zevalin® followed by 2 yrs of Rituxan maintenance therapy|Evaluate relative response rates in populations with and without prior rituximab therapy, in first versus second relapse, and with and without bulky (> 5 cm in greatest diameter) disease.	Biogen	All	18 Years and older   (Adult, Older Adult)	Phase 4	12	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	001-03-ZEV|Former Biogen Idec: 106-I001	June 2003		October 2005	September 15, 2005		October 19, 2006	Loma Linda University, Loma Linda, California, United States|North County Oncology, Oceanside, California, United States|Medical Specialists of Fairfield, Fairfield, Connecticut, United States|Queens Hospital, Honolulu, Hawaii, United States|Northwest Oncology and Hematology, Elk Grove Village, Illinois, United States|Horizon Oncolgy Center, Lafayette, Indiana, United States|Specialists in Hematology/Oncology, St. Louis, Missouri, United States|Presbyterian Hospital Cancer Center, Charlotte, North Carolina, United States		https://ClinicalTrials.gov/show/NCT00168727
385	NCT00090038	Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma		Completed	No Results Available	Non-Hodgkin's Lymphoma	Drug: rituximab	To determine whether treatment with rituximab causes a clinically significant effect on immunological recall response to tetanus vaccine in NHL patients|To determine whether NHL patients can mount a primary response to KLH after treatment with rituximab|To determine whether NHL subjects treated with rituximab experience clinically significant changes in antibody titers to a panel of specific antigens	Biogen	All	40 Years and older   (Adult, Older Adult)	Phase 4	168	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	102-12	October 2003	June 2007	November 2007	August 24, 2004		October 20, 2009	USC KECK School of Medicine, Los Angeles, California, United States|Radiant Research, Honolulu, Hawaii, United States|Carle Clinic Association, Urbana, Illinois, United States|Tufts - New England Medical Center, Boston, Massachusetts, United States|Our Lady of Mercy Medical Center, Bronx, New York, United States|University of Pittsburth Cancer Centers, Pittsburgh, Pennsylvania, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Research Site, Graz, Austria|Research Site, Brno, Czech Republic|Research Site, Hradec Kralove, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Praha 10, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Dijon, France|Research Site, Lyon, France|Research Site, Paris, France|Research Site, Strasbourg, France|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Frankfurt, Germany|Research Site, Giessen, Germany|Research Site, Hamburg, Germany|Research Site, Koblenz, Germany|Research Site, Mainz, Germany|Research Site, Mutlangen, Germany|Research Site, Tubingen, Germany|Research Site, Kaunas, Lithuania|Research Site, Klaipeda, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Craiova, Romania|Research Site, Ekaterinburg, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Stockholm, Sweden|Research Site, Gaziantep, Turkey|Research Site, Izmir, Turkey|Research Site, Kayseri, Turkey|Research Site, Leeds, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Sheffield, United Kingdom		https://ClinicalTrials.gov/show/NCT00090038
386	NCT02596035	An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma	CheckMate 374	Active, not recruiting	No Results Available	Renal Cell Carcinoma	Drug: Nivolumab	Incidence of high grade (Grade 3-4 and Grade 5) IMAEs in subjects with advanced or metastatic renal cell carcinoma (RCC) who are treated with nivolumab monotherapy|Median time to onset of high grade (Grade 3-4) IMAEs|Median time to resolution of high grade (Grade 3-4) IMAEs|Percentage of subjects who receive immune modulating medication for the immune-mediated event|Percentage of subjects who receive hormonal replacement therapy for the immune-mediated event|Percentage of subjects who receive ≥ 40 mg prednisone equivalents for the immune-mediated event|Total duration of all immune modulating medications given for the immune-mediated event	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 4	197	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	CA209-374|2015-003286-28	November 30, 2015	May 1, 2018	December 1, 2021	November 4, 2015		November 1, 2018	Arizona Oncology Associates, Phoenix, Arizona, United States|St. Jude Hospital Yorba Linda, Fullerton, California, United States|Cancer Care Associates Medical Group, Inc., Los Angeles, California, United States|Comprehensive Blood And Cancer Center, Los Angeles, California, United States|Local Institution, Los Angeles, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|University Of Colorado, Aurora, Colorado, United States|St. Mary's Hospital Regional Cancer Center, Grand Junction, Colorado, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Baptist Health Medical Group Oncology, Miami, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Center For Cancer And Blood Disorders, Bethesda, Maryland, United States|HCA Midwest Division, Kansas City, Missouri, United States|Southeast Nebraska Hematology & Oncology Consultants, P.C., Lincoln, Nebraska, United States|Urology Cancer Center Laboratory, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Local Institution, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Broome Oncology, Johnson City, New York, United States|Weill Cornell Medical College, New York, New York, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa, Oklahoma, United States|Northwest Cancer Specialists - East DBA Compass Oncology - East, Portland, Oregon, United States|Local Institution, Springfield, Oregon, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|The West Clinic, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Local Institution, Dallas, Texas, United States|Blue Ridge Cancer Care, DFW Airport, Texas, United States|Cancer Centers of South Texas, DFW Airport, Texas, United States|Nebraska Methodist Hospital, DFW Airport, Texas, United States|Sansum Santa Barbara Medical Foundation Clinic, DFW Airport, Texas, United States|Texas Cancer Center - Sherman, DFW Airport, Texas, United States|The Center For Cancer And Blood Disorders, Fort Worth, Texas, United States|Texas Oncology, P.A., Fort Worth, Texas, United States|Texas Oncology, Houston, Texas, United States|Texas Oncology, Paris, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|University Of Washington, Seattle, Washington, United States|Local Institution, Spokane, Washington, United States		https://ClinicalTrials.gov/show/NCT02596035
387	NCT03525834	Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.		Recruiting	No Results Available	Renal Angiomyolipoma	Drug: everolimus	Number of Adverse Events as a Measure of Safety and TolerabilitySafety|Percentage of patients with angiomyolipoma response up to 48 weeks|Percentage of patients with angiomyolipoma progression up to 48 weeks|Change of renal function from baseline (change of creatinine clearance) up to 48 weeks|Change of renal function from baseline (patients with serum creatinine abnormalities)	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	40	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CRAD001M2401	November 9, 2018	January 6, 2022	January 6, 2022	May 16, 2018		January 23, 2019	Novartis Investigative Site, Wuhan, Hubei, China|Novartis Investigative Site, Shanghai, Shanghai, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China		https://ClinicalTrials.gov/show/NCT03525834
388	NCT00637988	Barrett's Esophagus - 315 - 3 Way Cross Over		Completed	No Results Available	Barrett's Esophagus	Drug: Esomeprazole|Drug: Aspirin|Drug: Rofecoxib	Measure PGE production in Barrett's metastatic tissue & determine the reduction from baseline of PGE production would be equivalent on Day 10 in esomeprazole 40mg bid + aspirin treatment compared to esomeprazole 40 mg bid + rofecoxib 25 mg qd treatment|To determine in which of the four treatment groups the reduction in the baseline in PGE2 production, COX-2 enzyme activity and PCNA expression in Barrett's metaplastic tissue is the greatest.	AstraZeneca	All	18 Years and older   (Adult, Older Adult)	Phase 4	32	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	316|D9612L00057	April 2002	June 2003	June 2003	March 18, 2008		January 21, 2011			https://ClinicalTrials.gov/show/NCT00637988
389	NCT00637559	Barrett's Esophagus - 315 - 3 Way Cross-Over		Completed	No Results Available	Barrett's Esophagus	Drug: Esomeprazole Magnesium	To compare the total percent time during the 24-hour monitoring period that gastric pH is above 4.0 at steady state in patients when taking: esomeprazole 40mg twice daily, esomeprazole 40mg three times daily, esomeprazole 20 mg three times daily.|Compare total percent time distal esophageal pH is above 4.0 at steady state for each treatment period.	AstraZeneca	All	18 Years and older   (Adult, Older Adult)	Phase 4	50	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment	315|D9612L00056	March 2002	April 2003	April 2003	March 18, 2008		January 25, 2011			https://ClinicalTrials.gov/show/NCT00637559
390	NCT01898585	An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma		Active, not recruiting	No Results Available	Malignant Melanoma	Drug: Zelboraf	Safety: Incidence of adverse events|Overall response rate according to Response evaluation criteria in solid tumors (RECIST v1.1)|Progression free survival	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	60	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML28711	October 17, 2013	December 10, 2019	December 10, 2019	July 12, 2013		June 10, 2019	National Hospital; Oncotherapy Dept, Bloemfontein, South Africa|Groote Schuur Hospital ( Uni of Capetown ); Oncology Dept, Cape Town, South Africa|Cape Town Oncology Trials, Cape Town, South Africa|Cancercare, Cape Town, South Africa|Cancercare, George, South Africa|Mary Potter Oncology Centre, Groenkloof, South Africa|Medical Oncology Centre of Rosebank; Oncology, Johannesburg, South Africa|University of Pretoria; Department of Medical Oncology, Pretoria, South Africa|Sandton Oncology Medical Group, Sandton, South Africa		https://ClinicalTrials.gov/show/NCT01898585
391	NCT00352261	An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients		Completed	No Results Available	Barrett's Esophagus	Drug: Esomeprazole|Drug: Lansoprazole	Compare pharmacodynamic efficacy of esomeprazole 40 mg & lansoprazole 30 mg once daily in controlling intragastric pH in Barrett's Esophagus patients by evaluation of the percentage of time that intragastric pH is >4.0 over a 24 hr period steady state|Compare pharmacodynamic efficacy of esomeprazole 40 mg & lansoprazole 30 mg bid in controlling intragastric pH in BE patients by evaluation of the % of time intragastric pH is >4.0 over 24 hr period at steady state	AstraZeneca	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 4	80	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D9612L00082	January 2006		April 2007	July 14, 2006		March 26, 2009	Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, North Chicago, Illinois, United States|Research Site, Rochester, Minnesota, United States|Research Site, Kansas City, Missouri, United States|Research SIte, Springfield, Missouri, United States|Research Site, Butte, Montana, United States|Research Site, Cleveland, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Norfolk, Virginia, United States		https://ClinicalTrials.gov/show/NCT00352261
392	NCT01639703	Hepatic Xenetix-CT Perfusion		Completed	Has Results	Hepatocellular Carcinoma	Drug: Xenetix-CT perfusion imaging	Blood Volume (BV) According to Degree of Lesions Differentiation|Blood Flow (BF) According to Degree of Lesions Differentiation|Permeability Surface (PS) According to Degree of Lesions Differentiation|Arterial Liver Perfusion (ALP) According to Degree of Lesions Differentiation|Portal Venous Liver Perfusion (PVP) According to Degree of Lesions Differentiation|Total Liver Perfusion (TLP) According to Degree of Lesions Differentiation|Hepatic Perfusion Index (HPI) According to Degree of Lesions Differentiation|Blood Volume According to Immunohistochemistry Parameter (Glutamine Synthetase)|Blood Volume According to Immunohistochemistry Parameter (CD31)|Blood Flow According to Immunohistochemistry Parameter (Glutamine Synthetase)|Blood Flow According to Immunohistochemistry Parameter (CD31)|Permeability Surface According to Immunohistochemistry Parameter (Glutamine Synthetase)|Permeability Surface According to Immunohistochemistry Parameter (CD31)	Guerbet	All	18 Years and older   (Adult, Older Adult)	Phase 4	96	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	ISO-44-013	April 2012	October 2014	October 2014	July 13, 2012	July 13, 2017	July 13, 2017	AKH, Vienna, Austria|Universitätsklinikum Erlangen, Erlangen, Germany|SMC, Seoul, Korea, Republic of|SNUH, Seoul, Korea, Republic of|Zurich University Hospital, Zurich, Switzerland		https://ClinicalTrials.gov/show/NCT01639703
393	NCT01206764	A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.		Completed	Has Results	Renal Cell Carcinoma	Drug: RAD001	PFS (Progression-Free Survival)|Disease Control Rate (Stable Disease [SD] + Partial Response [PR] + Complete Response [CR]);|Objective Response Rate (ORR; Where ORR = CR + PR)|Duration of Response (DOR)|Overall Survival	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	143	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CRAD001LIC01	November 11, 2009	June 6, 2017	July 1, 2017	September 22, 2010	June 24, 2019	June 24, 2019	Novartis Investigative Site, Alger, Algeria|Novartis Investigative Site, Oran, Algeria|Novartis Investigative Site, Alexandria, Egypt|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Mansoura, Egypt|Novartis Investigative Site, Indore, Madhya Pradesh, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Amman, Jordan|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Samara, Russian Federation|Novartis Investigative Site, Riyadh, Saudi Arabia|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Durban, South Africa|Novartis Investigative Site, Parktown, South Africa|Novartis Investigative Site, Songkhla, Hat Yai, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiang Mai, Thailand|Novartis Investigative Site, Tunis, Tunisie, Tunisia|Novartis Investigative Site, Ariana, Tunisia|Novartis Investigative Site, Sousse, Tunisia	"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/64/NCT01206764/SAP_000.pdf|"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/64/NCT01206764/Prot_001.pdf	https://ClinicalTrials.gov/show/NCT01206764
394	NCT01263002	A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCC		Completed	No Results Available	Hepatitis B Associated Hepatocellular Carcinoma	Drug: clevudine, Adefovir	Proportion of patients with HBV DNA levels ＜ 60 IU/mL	Bukwang Pharmaceutical	All	18 Years and older   (Adult, Older Adult)	Phase 4	33	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CLV-413	June 2010	January 2013	September 2013	December 20, 2010		December 18, 2014	Seoul National University Hospital, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01263002
395	NCT01098760	Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients	HATT	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment	Time to progression|Progression-free survival|Overall survival|Adverse event and serious adverse event (SAE) profiles|Child-Pugh status progression|Plasma Sorafenib exposure (AUC0-12)|For subjects randomized into HFSR study subgroup: overall HFSR incidence in the first 3 weeks of Sorafenib treatment|For HFSR study subgroup: a mean HFSR grade determined at the end of the first 3 weeks of sorafenib treatment.	Bayer	All	18 Years and older   (Adult, Older Adult)	Phase 4	151	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	14898|HATT	August 2010	March 2013	October 2013	April 5, 2010		October 31, 2013	Chia Yi, Taiwan|Hualien county, Taiwan|Kaohsiung City, Taiwan|Kaohsiung City, Taiwan|Taichung City, Taiwan|Taipei City,, Taiwan|Taoyuan, Taiwan		https://ClinicalTrials.gov/show/NCT01098760
396	NCT00706706	Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma	MRCC RCC	Completed	Has Results	Carcinoma, Renal Cell	Drug: Sunitinib Malate (SU011248)	Progression-free Survival (PFS)|Percentage of Participants With Objective Response (OR)|Overall Survival (OS)|One Year Survival Probability	Pfizer	All	18 Years and older   (Adult, Older Adult)	Phase 4	105	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	A6181132	July 2008	August 2011	August 2011	June 27, 2008	December 20, 2012	January 18, 2013	Pfizer Investigational Site, Guangzhou, Guangdong, China|Pfizer Investigational Site, Wuhan, Hubei, China|Pfizer Investigational Site, Nanjing, Jiangsu, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Chong qing, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Tianjin, China|Pfizer Investigational Site, Xi'an, China		https://ClinicalTrials.gov/show/NCT00706706
397	NCT02625389	Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization.	In-Live	Recruiting	No Results Available	Congenital Hemangioma|Hemangioendothelioma|Angiosarcoma|Arteriovenous Malformation	Drug: Lipiodol® Ultra Fluid with surgical glues	Adverse drug reactions during any session of embolization|Adverse drug reactions up to one month follow-up|Adverse events up to one month follow-up|Obliteration rate	Guerbet	All	18 Years and older   (Adult, Older Adult)	Phase 4	125	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LUF-44-001|CTRI/2017/05/008607|EUPAS15045	November 29, 2017	December 2019	December 2019	December 9, 2015		September 5, 2018	Division of Peripheral Vascular & Endovascular sciences, Medanta-The Medicity Hospital, Gurgaon, Haryana, India|Christian Medical College Hospital, Vellore, Tamil Nadu, India		https://ClinicalTrials.gov/show/NCT02625389
398	NCT02060383	Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly		Completed	Has Results	Cushing's Disease|Acromegaly	Drug: Pasireotide s.c.|Drug: Sitagliptin|Drug: Liraglutide|Drug: Insulin|Drug: Pasireotide LAR|Drug: Metformin	Change in HbA1c From Randomization to Approximately 16 Weeks|Change in HbA1c From Randomization (R) Over Time Per Randomized Arm|Change in FPG (Fasting Plasma Glucose) From Randomization Until End of Core Phase|Percentage of Participants in the Incretin-based Arm Who Required Anti-diabetic Rescue Therapy With Insulin|Absolute Change in HbA1c From Baseline to End of Core Phase|Absolute Change in FPG From Baseline to End of Core Phase|Percentage of Participants With ≤ 0.3% HbA1c Increase to End of Core Phase	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	249	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	CSOM230B2219|2012-002916-16	May 23, 2014	February 5, 2018	March 26, 2018	February 12, 2014	May 29, 2019	May 29, 2019	Diabetes and Endocrine Associates La Mesa Location, Multiple Locations, California, United States|LA Biomedical Research at Harbor UCLA Medical Center SC - SOM230B2219, Torrance, California, United States|Coastal Metabolic Research Centre SC, Ventura, California, United States|East Coast Institute for Research East Coast Inst. for Res(ECIR), Jacksonville, Florida, United States|Washington University SC - SOM230B2411, Saint Louis, Missouri, United States|Great Falls Clinic, Great Falls, Montana, United States|Robert Wood Johnson Medical School - Rutgers SC, New Brunswick, New Jersey, United States|The Mount Sinai Hospital SC, New York, New York, United States|Columbia University Medical Center New York Presbyterian Neuroendocrine Unit, New York, New York, United States|Lenox Hill Hospital/Manhattan Eye, Ear and Throat Hospital SC, New York, New York, United States|Allegheny Endocrinology Associates SC, Pittsburgh, Pennsylvania, United States|Vanderbilt Clinical Trials Center SOM230B2219, Nashville, Tennessee, United States|Baylor College of Medicine Ben Taub General Hosp., Houston, Texas, United States|Virginia Endocrinology Research SC-2, Chesapeake, Virginia, United States|Swedish Medical Center Dept.ofSeattle Neuroscience(2), Seattle, Washington, United States|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Joinville, SC, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Aalborg, Denmark|Novartis Investigative Site, Aarhus, Denmark|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Odense C, Denmark|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Altunizade, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02060383/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02060383/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT02060383
399	NCT00686725	Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)		Completed	Has Results	Glioblastoma	Drug: Temozolomide|Radiation: Radiotherapy	Overall Survival (OS)|Progression-Free Survival (PFS)|Objective Tumor Assessment After Surgery: Overall Response|Relationship Between O6-methylguanine-DNA Methyltransferase (MGMT) Status and Therapy Response: Overall Survival for the MGMT Positive Group|Relationship Between MGMT Status and Therapy Response: Overall Survival for the MGMT Negative Group|Relationship Between MGMT Status and Therapy Response: Overall Survival Rate for the MGMT Positive Group|Relationship Between MGMT Status and Therapy Response: Overall Survival Rate for the MGMT Negative Group|Relationship Between MGMT Status and Therapy Response: PFS for the MGMT Positive Group|Relationship Between MGMT Status and Therapy Response: PFS for the MGMT Negative Group	Merck Sharp & Dohme Corp.	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 4	99	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P05572	June 24, 2008	September 28, 2011	September 28, 2011	May 30, 2008	April 4, 2013	June 14, 2017			https://ClinicalTrials.gov/show/NCT00686725
400	NCT04042376	A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)		Not yet recruiting	No Results Available	Waldenstrom Macroglobulinemia	Drug: Ibrutinib	Overall Response Rate (ORR)|Percentage of Participants Achieving Clinical Response Rate (CRR)|Percentage of Participants Achieving Very Good Partial Response (VGPR) or Better Response|Duration of Response (DOR)|Time to Response (TTR)|Progression Free Survival (PFS)|Overall Survival (OS)|Trough Plasma Concentration (Ctrough) of Ibrutinib|Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability	Janssen Research & Development, LLC	All	18 Years and older   (Adult, Older Adult)	Phase 4	17	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CR108654|54179060WAL4001	November 15, 2019	December 31, 2023	December 31, 2023	August 1, 2019		August 1, 2019	The First Hospital of Jilin University, Changchun, China|Peking Union Medical College Hospital, Dongcheng, China|Fujian Meidical University Union Hospital, Fuzhou, China|Guangdong General Hospital, Guangzhou, China|First affiliated Hospital of Zhejiang University, Hangzhou, China|The People's Hospital of Jiangsu Province, Nanjing, China|Institute of Hematology & Blood Diseases Hospital, Tianjin, China|Wuhan Union Hospital, Wuhan, China|Henan Cancer Hospital, Zhengzhou, China		https://ClinicalTrials.gov/show/NCT04042376
401	NCT01388907	Efficacity Assessment of PREVADH® in Adhesion Prevention in Gynaecologic Surgery		Completed	Has Results	Uterine Fibroids|Fertility Disorders	Other: Ringer lactate solution|Device: Prevadh film	Number of Patients With Adhesions to Uterine Scars|Fertility|Adnexal Adhesions|mAFS Abdominopelvic Adhesion Score	Medtronic - MITG|Registrat-Mapi	Female	20 Years to 42 Years   (Adult)	Phase 4	61	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	CLI 9821-2	May 2006	June 2008	June 2011	July 7, 2011	November 17, 2016	November 17, 2016	University Hospital, Angers, France|Clinique du Tondu, Bordeaux, France|Béclère Hospital (Public Assistance of Paris Hospital), Clamart, France|UNIVERSITY HOSPITAL Estaing, Clermont-ferrand, France|University Carémeau Hospital, Nimes, France|TENON Hospital (Public Assistance of Paris Hospital), Paris, France|TROUSSEAU Hospital (Public Assistance of Paris Hospital), Paris, France|Bichat Hospital - Claude Bernard (Public Assistance of Paris Hospital), Paris, France|South University Hospital, Rennes, France|Centre Hospitalier des quatre villes, Sevres, France|Versailles Hospital, Versailles, France		https://ClinicalTrials.gov/show/NCT01388907
402	NCT01498640	Retreatment of Recurrent Dupuytren's Contractures		Completed	Has Results	Dupuytren's Disease	Biological: Collagenase clostridium histolyticum	Clinical Success|Percent Change From Baseline in Degree of Contracture|Change in Range of Motion|Physician Global Assessment of Improvement|Subject Global Assessment of Satisfaction|Recurrence of Contracture	Endo Pharmaceuticals	All	18 Years and older   (Adult, Older Adult)	Phase 4	52	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AUX-CC-862	March 2012	October 2013	October 2013	December 23, 2011	February 20, 2015	October 5, 2017	HOPE Research Institute, Phoenix, Arizona, United States|Rockford Orthopedic Associates, Rockford, Illinois, United States|The Indiana Hand to Shoulder Center, Indianapolis, Indiana, United States|Marquette General Health System, Marquette, Michigan, United States|East River Professional Building, New York, New York, United States|Health Reserarch Institute, Oklahoma City, Oklahoma, United States|Hand Microsurgery and Reconstructive Orthopaedics, Erie, Pennsylvania, United States|Peninsula Private Hospital, Kippa Ring, Queensland, Australia|AusTrials Sherwood, Sherwood, Queensland, Australia|Emeritus Research, Malvern East, Victoria, Australia|Uppsala Akademiska University Hospital, Uppsala, SE, Sweden|Pulvertaft Hand Center, Derby, GB, United Kingdom|Newcastle Upon Tyne Hospitals, Newcastle, GB, United Kingdom		https://ClinicalTrials.gov/show/NCT01498640
403	NCT00925288	Acceptability of Human Papillomavirus (HPV) Vaccine in Female Sex Workers	Girasol	Completed	Has Results	Human Papillomavirus Infection	Biological: Gardasil	Antibody Response to HPV Vaccine for HPV 6,11,16,18.|Proportion of Female Sex Workers Who Complete the Three Dose (0, 2, 6 Month) HPV Schedule in a Timely Manner Compared to the Modified (0, 3, 6 Month) Schedule.|Prevalence of Infection With HPV Subtypes (6,11,16,18) Among Female Sex Workers|Identify Barriers to Acceptance of HPV Vaccine Among Female Sex Workers	Johns Hopkins Bloomberg School of Public Health|Merck Sharp & Dohme Corp.|NGO Via Libre|Universidad Peruana Cayetano Heredia	Female	18 Years to 26 Years   (Adult)	Phase 4	200	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	Merck IISP 35706|IRB00001625	October 2009	August 2011	August 2011	June 22, 2009	October 11, 2012	October 11, 2012	NGO Via Libre, Lima, Peru		https://ClinicalTrials.gov/show/NCT00925288
404	NCT01416025	A Trial Comparing Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing	VoriTDM	Completed	Has Results	Fungal Infection	Drug: Prospective TDM Arm	Number of Participants With Treatment Failure	Johns Hopkins University|Pfizer	All	12 Years to 100 Years   (Child, Adult, Older Adult)	Phase 4	29	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NA_00041916	January 2012	December 2014	December 2014	August 12, 2011	May 23, 2016	August 18, 2016	Johns Hopkins, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT01416025
405	NCT00211198	Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)		Completed	No Results Available	Lymphoma, T-Cell, Cutaneous	Drug: ONTAK (denileukin difitox, DAB389IL-2)	To estimate response rates (CR + CCR + PR) according to CD25 status (CD25 positive and negative) after 4 cycles of ONTAK.|Physician's Global Assessment (PGA)|Time to Event Variables - Time to response, remission, treatment failure|Response based on the CD25 status|Response based on patient demographics: stage of disease, age, sex, performance status, total dose|Number of cycles completed|6. Assess safety and tolerability of ONTAK	Eisai Inc.|Tufts Medical Center|National Cancer Institute (NCI)|Ligand Pharmaceuticals	All	18 Years and older   (Adult, Older Adult)	Phase 4	60	Industry|Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	#33	May 2001	January 2005	January 2006	September 21, 2005		March 5, 2008	City of Hope National Medical Center, Duarte, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|The University of Iowa, Iowa City, Iowa, United States|New England Medical Center, Boston, Massachusetts, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00211198
406	NCT03181984	Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain		Recruiting	No Results Available	Port-Wine Stain	Drug: Hemoporfin	Number of participants with treatment-related adverse events|Satisfaction rating of the overall treatment by subjects|Satisfaction rating of the overall treatment by investigators|Response rate	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.	All	14 Years to 65 Years   (Child, Adult, Older Adult)	Phase 4	1500	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HMME-S1612	August 31, 2017	December 2021	December 2021	June 9, 2017		July 8, 2019	The 2nd Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China|Affiliated Hospital of Hebei Medical College of traditional Chinese Medicine, Shijiazhuang, Herbei, China|Wuxi People's Hospital, Wuxi, Jiangsu, China|West China Hospital, Sichuan University, Chengdu, Sichuan, China|Peking University First Hospital, Beijing, China|PLA Army General Hospital, Beijing, China|Shanghai Dermatology Hospital, Shanghai, China		https://ClinicalTrials.gov/show/NCT03181984
407	NCT03125057	A Pilot Study of Hemoporfin PDT in Children With Port-wine Stain		Recruiting	No Results Available	Port-wine Stain	Drug: Hemoporfin PDT	Response rate	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.	All	7 Years to 14 Years   (Child)	Phase 4	40	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	HMME-C1610	August 2, 2017	February 2020	February 2020	April 24, 2017		July 8, 2019	Beijing Children's Hospital, Capital Medical University, Beijing, China		https://ClinicalTrials.gov/show/NCT03125057
408	NCT03212625	The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction		Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Urea Cream 20%|Drug: Placebos	Cumulative incidence of Hand-Foot Skin Reaction(HFSR) on each group|Cumulative incidence of severe HFSR on each group|Incidence of dose reduction or discontinuation of sorafenib due to HFSR on each group|Assessment of Quality Of Life (QOL)|Overall survival|Tumor response|Other side effect|Incidence of HFSR on 2, 4, 8, and 12 weeks on each group	Korea University Guro Hospital|Hanmi Pharmaceutical Company Limited	All	Child, Adult, Older Adult	Phase 4	288	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	KUGH15337	January 28, 2016	January 31, 2019	January 31, 2019	July 11, 2017		January 4, 2019	Korea University Guro Hospital, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT03212625
409	NCT02227316	Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure		Completed	Has Results	Symptomatic Uterine Fibroids and Adenomyosis	Drug: IV Ibuprofen|Drug: IV Acetaminophen|Drug: Intravenous placebo/Intravenous placebo	Evaluation of Maximum Pain Intensity Change Over 24 Hours With the Addition of IV Acetaminophen and IV Ibuprofen|Evaluation of Mean Pain Intensity Over 24 Hours With the Addition of IV Acetaminophen and IV Ibuprofen|Mean Nausea Intensity|Opioid Consumption|Anti-Emetic Consumption|Maximum Nausea Intensity	University of California, Los Angeles|Sponsor Name Pending	Female	21 Years to 60 Years   (Adult)	Phase 4	40	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care	14000359	August 2014	September 2016	September 2016	August 28, 2014	June 8, 2018	June 8, 2018	Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|Santa Monica/UCLA Medical Center and Orthopaedic Hospital, Santa Monica, California, United States		https://ClinicalTrials.gov/show/NCT02227316
410	NCT00376064	Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly		Completed	No Results Available	Acromegaly	Drug: Octreotide acetate and cabergoline/Octrotide and Somavert	Biochemical control (% of patients) as measured by GH- and IGF-1-values (baseline, EOS)|Effect of tumor size|Biochemical control (mean, normalization) as measured by GH- and/or IGF-1-values|Control clinical of symptoms of acromegaly|Quality of Life assessment|Safety and tolerability as assessed by frequency of AEs	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	20	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CSMS995BDE16	March 2006	January 2010		September 14, 2006		March 6, 2017	Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Greifswald, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Koln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Marburg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Regensburg, Germany|Novartis Investigative Site, Tubingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wurzburg, Germany		https://ClinicalTrials.gov/show/NCT00376064
411	NCT00324272	Post-Operative Drainage Following Lymph Node Dissection		Completed	Has Results	Malignant Melanoma|Carcinoma, Squamous Cell	Drug: Fibrin Sealant (Tisseel) used in the Experimental Arm.	Post-operative Wound Drainage.|Length of Hospital Inpatient Stay.|Length of Time Drains Remain in Situ.|Number of Patients With Post-operative Complications (Excluding Lymphoedema).|Post Operative Pain Score Measured on 1st Post-operative Day.|Disease Recurrence.|Death.	Oxford University Hospitals NHS Trust|Baxter Healthcare Corporation	All	18 Years and older   (Adult, Older Adult)	Phase 4	74	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	C02.240	January 2003	December 2006	June 2010	May 10, 2006	August 11, 2011	August 11, 2011			https://ClinicalTrials.gov/show/NCT00324272
412	NCT00978939	Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter	ASAP	Completed	No Results Available	Pleural Effusion, Malignant	Other: Standard Drainage Instructions|Other: Aggressive Drainage Instructions	To compare the incidence of auto-pleurodesis utilizing aggressive drainage versus standard drainage protocols with the PleuRx® catheter|To determine the median time to auto-pleurodesis utilizing aggressive drainage versus standard drainage protocols with the PleuRx® catheter|To assess the effects of aggressive drainage versus standard drainage protocols with the PleuRx® catheter on functional health status|To determine predictors of auto-pleurodesis (volume and rate of pleural fluid drainage, biochemical, and radiographic) using post-hoc analysis in both the aggressive and standard drainage protocols|To determine patient and caregivers' satisfaction with the PleuRx® catheter using a questionnaire	Duke University|CareFusion	All	19 Years and older   (Adult, Older Adult)	Phase 4	150	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	Pro00016092	August 2009	March 2013	October 2013	September 17, 2009		December 30, 2013	National Jewish Medical Center, Denver, Colorado, United States|Johns Hopkins University, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Utah, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT00978939
413	NCT03817853	An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma		Recruiting	No Results Available	Advanced Follicular Lymphoma	Drug: Obinutuzumab|Drug: Bendamustine|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Prednisone/Prednisolone/Methylprednisolone|Drug: Vincristine	Percentage of Grade ≥3 Infusion-Related Reactions (IRRs) During Cycle 2 in Patients Who Had Previously Received Obinutuzumab at the Standard Infusion Rate During Cycle 1 Without Experiencing a Grade 3 or 4 IRR|Percentage of Participants With Adverse Events (AEs)|Percentage of IRRs Regardless of Grade by Cycle|Time to IRR From Infusion to Onset of the IRR During Cycle 2|Duration (In Minutes) of Obinutuzumab Administration by Cycle|Duration of Grade ≥3 IRRs Associated with the obinutuzumab Administered as an SDI by Cycle|Overall Response Rate at the End of Induction Therapy|Progression-Free Survival Rate at the End of the Study|Overall Survival at the End of the Study|Complete Response (CR) Rate at 30 Months (CR30), as Assessed by the Investigator and According to the Guidelines Used at the Site	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	112	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MO40597	February 26, 2019	May 1, 2020	August 9, 2022	January 28, 2019		July 4, 2019	Scripps Clinical Research Center, La Jolla, California, United States|Rocky Mountain Cancer Center - Aurora, Aurora, Colorado, United States|Rocky Mountain Cancer Center - Boulder, Boulder, Colorado, United States|Rocky Mountain Cancer Center; Medical Oncology, Denver, Colorado, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|Summit Medical Center, Florham Park, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Presbyterian Hospital, Charlotte, North Carolina, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Texas Onc-Central Austin CA Ct, Austin, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|NOHC - Núcleo de Oncologia e Hematologia do Ceará, Fortaleza, CE, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, Brazil|Hospital Amaral Carvalho, Jau, SP, Brazil|Städtisches Klinikum Dessau, Dessau-Roßlau, Germany|Universitatsklinikum Frankfurt, Frankfurt, Germany|OncoResearch Lerchenfeld GmbH, Hamburg, Germany|Klinik der Uni zu Köln; I. Med. Klinik, Köln, Germany|Onkologische Schwerpunktpraxis Lübeck, Lübeck, Germany|Gemeinschaftspraxis für Hämatologie und Onkologie, Münster, Germany|Chiba Cancer Center, Chiba, Japan|Hokkaido University Hospital, Hokkaido, Japan|Kobe City Medical Center General Hospital, Hyogo, Japan|Kindai University Hospital, Osaka, Japan|National Cancer Center Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Albert Schweitzer Ziekenhuis; Inwendige Geneeskunde, Dordrecht, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Ikazia Ziekenhuis, Rotterdam, Netherlands|Hospital De Txagorritxu; Servicio de Hematologia, Vitoria, Alava, Spain|Hospital Universitario Puerta del Mar; Servicio de Hematologia, Cádiz, Cadiz, Spain|Hospital del Mar; Servicio de Hematologia, Barcelona, Spain|Hospital Universitario la Paz; Servicio de Hematologia, Madrid, Spain|Hospital General Universitario J.M Morales Meseguer; Servicio de Hematología, Murcia, Spain|University Hospital of Wales, Cardiff, United Kingdom|Kings College Hospital NHS Foundation Trust, London, United Kingdom|Portsmouth Hospitals NHS Trust - Queen Alexandra Hospital, Portsmouth, United Kingdom		https://ClinicalTrials.gov/show/NCT03817853
414	NCT00868088	Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip		Completed	No Results Available	Actinic Cheilitis|Squamous Cell Carcinoma In-situ (SCC-is)|Squamous Cell Carcinoma (SCC)|Photodynamic Therapy (PDT)|Mohs Surgery	Procedure: PDT prior to Mohs surgery	To determine whether pre-operative treatment of the lips with ALA PDT can reduce the size of post-surgical defects (scars) in patients with AC and lip SCC.|To determine whether ALA PDT applied to the lips can effectively clear actinic cheilitis (AC) and SCC in-situ (SCC-is) of the lip.|To assess the tolerability of ALA PDT for treatment of AC and SCC-is of the lips	Tufts Medical Center|DUSA Pharmaceuticals, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 4	34	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	PDT for Lip	July 2009	July 2010	September 2010	March 24, 2009		July 6, 2011	Tufts Medical Center, Department of Dermatology, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT00868088
415	NCT00696059	Humira in Rheumatoid Arthritis - Do Bone Erosions Heal?	HURRAH	Completed	No Results Available	Rheumatoid Arthritis|Arthritis|Joint Diseases	Drug: Adalimumab (Humira)	By means of computed tomography and magnetic resonance imaging to investigate if repair of bone erosion occurs in rheumatoid arthritis joints during adalimumab (Humira) therapy	Hvidovre University Hospital|Abbott	All	18 Years to 90 Years   (Adult, Older Adult)	Phase 4	52	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HUM 04-20	August 2004	July 2007	July 2007	June 12, 2008		June 12, 2008	Department of Rheumatology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark|Department of Rheumatology, Bispebjerg University Hospital, Copenhagen, Denmark|Department of Rheumatology, Gentofte University Hospital, Hellerup, Denmark|Department of Rheumatology, Herlev University Hospital, Herlev, Denmark|Department of Rheumatology, Hvidovre University Hospital, Hvidovre, Denmark		https://ClinicalTrials.gov/show/NCT00696059
416	NCT00521300	Preoperative Octreotide Treatment of Acromegaly	POTA	Completed	No Results Available	Acromegaly	Drug: Octreotide|Procedure: Direct surgery for acromegaly	Surgical cure by transsphenoidal surgery|Effect of treatment on surgical complications and duration of hospital stay, pituitary function, quality of life, and the need for postsurgical medical treatment of acromegaly	St. Olavs Hospital|Novartis	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 4	62	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	S-71-98 (REK)|S-71-98|SLKNR 98-5560	September 1999	June 2005	May 2010	August 27, 2007		June 2, 2014	Endocrinology Unit, Department of Medicine, Haukeland University Hospital, Bergen, Norway|Endocrinology Unit, Department of Medicine, Aker University Hospital, Oslo, Norway|Endocrinology Unit, Department of Medicine, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway|Endocrinology Unit, Department of Medicine, University Hospital of North Norway, Tromsø, Norway|Department of Endocrinology, St. Olavs Hospital, Trondheim, Norway		https://ClinicalTrials.gov/show/NCT00521300
417	NCT03190330	A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion		Recruiting	No Results Available	Leukemia, Lymphocytic, Chronic, B-Cell|Lymphoma, Mantle-Cell	Drug: Ibrutinib 420 mg|Drug: Ibrutinib 560 mg	Number of Participants With Adverse Events as a Measure of Safety and Tolerability	Johnson & Johnson Private Limited	All	18 Years and older   (Adult, Older Adult)	Phase 4	75	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	CR108316|54179060LYM4005	June 26, 2019	September 29, 2021	December 11, 2021	June 16, 2017		July 26, 2019	Vedanta Institute of Medical Science, Ahmedabad, India|Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh, India|Basavatarakam Indo-American Hospital, Hyderabad, India|Bhagwan Mahaveer Cancer Hospital & Research Centre, Jaipur, India|Apollo Gleneagles Hospital, Kolkata, India|Tata Medical Center, Kolkata, India|Apex Wellness Rishikesh Hospital, Nashik, India|Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India|Noble Hospital Pvt Ltd, Pune, India|Regional Cancer Centre, Thiruvananthapuram, India|Christian Medical College, Vellore, India		https://ClinicalTrials.gov/show/NCT03190330
418	NCT03150602	A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy		Recruiting	No Results Available	Peripheral T Cell Lymphoma|Progression, Disease	Drug: Pralatrexate	Objective Response Rate|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Overall survival|Progression-free survival|Completion response rate|Partial response rate|Duration of CR and PR|Treatment duration|Hematopoietic stem cell transplant (HSCT)|1-year OS rate after HSCT|1-year PFS rate after HSCT|1-year relapse rate after HSCT|2-year OS rate after HSCT|2-year PFS rate after HSCT|2-year relapse rate after HSCT	Taiwan Mundipharma Pharmaceuticals Ltd.	All	20 Years and older   (Adult, Older Adult)	Phase 4	22	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	FOT14-TW-401	August 30, 2016	December 31, 2020	December 31, 2020	May 12, 2017		May 12, 2017	Ntional Taiwan University Hospital, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT03150602
419	NCT01450397	MRI Results in Dupuytren's Contracture Before and After Injection With Xiaflex		Completed	Has Results	Dupuytren's Disease	Biological: XIAFLEX	The Measured Change in Volume of the Cord by MRI Before and After XIAFLEX Injection and Manual Manipulation.	Hospital for Special Surgery, New York|Auxilium Pharmaceuticals, Inc.	All	35 Years and older   (Adult, Older Adult)	Phase 4	5	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	11052	March 2011	January 2012	February 2012	October 12, 2011	May 15, 2014	April 17, 2017	Hosptial for Special Surgery, New York, New York, United States		https://ClinicalTrials.gov/show/NCT01450397
420	NCT02228382	Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors		Active, not recruiting	No Results Available	Previously Treated PH + CML	Drug: Bosutinib	Percentage of Participants with Major Cytogenetic Response (MCyR) by Week 52 in Chronic Phase Second-line Population and Chronic Phase Third-line Population of Philadelphia Chromosome Positive Chronic Myeloid Leukemia patients.|Percentage of Participants with Major Cytogenetic Response (MCyR) by Week 52 in Chronic Phase Fourth-line and later-line Population of Philadelphia Chromosome Positive Chronic Myeloid Leukemia patients.|Percentage of Participants with Overall Hematologic Response (OHR) by Week 52 in Advanced Leukemia Population patients.|Estimate cumulative probability of Percentage of Participants with Major Cytogenetic Response in Chronic Phase and Advanced Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia patient populations.|Estimate cumulative probability of Percentage of Participants with Overall Hematologic Response in the Accelerated Phase and Blast Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia patient population by number of lines of prior therapy.|Characterize distribution of best response (molecular, cytogenetic, or hematologic) in the Chronic Phase, Accelerated Phase and Blast Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia patient populations.|Estimating probability of Percentage of Participants with Major Cytogenetic Response at 3, 6, 12, 18, and 24 months in the Chronic Phase, Accelerated Phase and Blast Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia patient populations.|Estimating the probability of confirmed Overall Hematologic Response at 3, 6, 9, 12, 18, and 24 months in the Accelerated Phase and Blast Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia patient populations.|Estimating the probability of cumulative confirmed Complete Hematologic Response in the Chronic Phase, Accelerated Phase and Blast Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia patient populations.|Estimating the probability of cumulative major molecular response in the Chronic Phase, Accelerated Phase and Blast Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia patient populations.	Pfizer|Developmental Therapeutics Consortium	All	18 Years and older   (Adult, Older Adult)	Phase 4	163	Industry|Other	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	B1871039|2013-003250-25|BYOND	November 7, 2014	September 18, 2021	September 18, 2021	August 29, 2014		March 7, 2019	Keck Hospital of USC, Los Angeles, California, United States|LAC+USC Medical Center, Los Angeles, California, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Sylvester at Deerfield Beach, Deerfield Beach, Florida, United States|University of Miami Hospital & Clinics, Miami, Florida, United States|Indiana Blood and Marrow Transplantation-Administrative Offices, Indianapolis, Indiana, United States|Indiana Blood and Marrow Transplantation-Clinic, Indianapolis, Indiana, United States|Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Siteman Cancer Center - West County, Creve Coeur, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center - South County, Saint Louis, Missouri, United States|Weill Cornell Medical College - New York-Presbyterian Hospital, New York, New York, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Medizinische Universitaet Innsbruck, Innsbruck, Austria|Ordensklinikum Linz Gmbh Barmherzige Schwestern, Linz, Austria|CHU Nice-Hopital Archet I, Nice cedex 3, Alpes Maritimes, France|Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse Cedex 9, Cedex 9, France|Institut Bergonie, Bordeaux Cedex 09, France|Centre Hospitalier de Versailles (CHV) - Hopital Andre Mignot, Le Chesnay Cedex, France|Centre Regional De Lutte Contre Le Cancer, Marseille, France|CHU Brabois, Vandoeuvre-les-Nancy cedex, France|Universitaetsklinikum Koeln (AoeR), Koeln, Koln, Germany|RWTH Uniklinik Aachen, Aachen, Germany|Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK), Berlin, Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitaetsklinikum Jena, Jena, Germany|III. Medizinische Klinik, Mannheim, Germany|AOU Policlinico Consorziale di Bari - UO Ematologia con Trapianto, Bari, BA, Italy|A.O.U. Policlinico S. Orsola-Malpighi, Bologna, BO, Italy|AOU Policlinico Vittorio Emanuele - P.O. Ferrarotto - UOC Ematologia, Catania, CT, Italy|Azienda Socio Sanitaria Territoriale - ASST Monza, Monza, MB, Italy|Ospedale S. Eugenio - UOC Ematologia, Rome, RM, Italy|AOU San Luigi Gonzaga SCDU Medicina Interna II ad indirizzo Ematologico, Orbassano, TO, Italy|SOD Ematologia, Firenze, Italy|A.O. Ospedale Niguarda Ca Granda - SC Ematologia, Milano, Italy|Haukeland Universitetssjukehus, Bergen, Norway|St Olav Hospital, Trondheim, Norway|Hospital Universitario Quiron de Madrid, Pozuelo de Alarcon, Madrid, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic De Barcelona, Barcelona, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Hospital de Dia Quiron Zaragoza, Zaragoza, Spain|Hospital Quiron de Zaragoza Servicio de Hematologia, Zaragoza, Spain|Hematologiskt centrum, Stockholm, Sweden|Akademiska Sjukhuset, Uppsala, Sweden		https://ClinicalTrials.gov/show/NCT02228382
421	NCT01909934	Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma		Recruiting	No Results Available	Anaplastic Large-cell Lymphoma	Drug: brentuximab vedotin	Objective Response Rate (ORR) as assessed by an independent review facility (IRF) according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma|Duration of response|Progression-free survival (PFS)|Complete remission rate (CR)|Overall Survival	Millennium Pharmaceuticals, Inc.|Takeda	All	18 Years and older   (Adult, Older Adult)	Phase 4	45	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	C25006|2012-004128-39|U1111-1154-9784|REec-2014-0649|13/NI/0072	October 1, 2013	October 30, 2019	April 23, 2020	July 29, 2013		June 17, 2019	ZNA Stuivenberg, Antwerpen, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|Clinical Hospital Centre Rijeka, Rijeka, Croatia|Clinical Hospital Centre Zagreb, Zagreb, Croatia|Clinical Hospital Dubrava, Zagreb, Croatia|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice Olomouc, Olomouc, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Semmelweis Egyetem, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|Pecsi Tudomanyegyetem, Pecs, Hungary|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Malopolskie Centrum Medyczne s.c., Krakow, Poland|SPZOZ MSW zWarminsko-MazurskimCen.Onko.wOlsztynie, Olsztyn, Poland|Centrum Onkologii-Instytut im. M. Sklodowskiej Curie, Warszawa, Poland|Hospital de Braga, Braga, Portugal|Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital de Santa Maria, Lisboa, Portugal|Centro Hospitalar do Porto, E.P.E. - Hospital de Santo Antonio, Porto, Portugal|Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE, Porto, Portugal|Policlinica de Diagnostic Rapid SA, Brasov, Romania|Spitalul Clinic Colentina, Bucuresti, Romania|Spitalul Clinic Coltea, Bucuresti, Romania|Spitalul Clinic Judetean de Urgenta Targu Mures, Targu Mures, Romania|ICO lHospitalet Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Ankara University Medical Faculty, Ankara, Turkey|Pamukkale Uni. Med. Fac., Denizli, Turkey|Istanbul Bilim University Medical Fac., Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|Dokuz Eylul University Faculty of Medicine, Izmir, Turkey|Erciyes University Medical Faculty, Kayseri, Turkey|Royal Cornwall Hospital, Truro, Cornwall, United Kingdom|The Christie, Manchester, Greater Manchester, United Kingdom|Birmingham Heartlands Hospital, Birmingham, West Midlands, United Kingdom		https://ClinicalTrials.gov/show/NCT01909934
422	NCT01804166	A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)		Recruiting	No Results Available	Hepatosplenic T-Cell Lymphoma	Drug: Infliximab|Drug: Golimumab	Identify Biomarkers for Early Evaluation of Risk of Developing Hepatosplenic T-cell Lymphoma (HSTCL)	Janssen Scientific Affairs, LLC	All	Child, Adult, Older Adult	Phase 4	40	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	CR100938	March 21, 2013	June 25, 2020	June 25, 2020	March 5, 2013		April 19, 2019	Childrens Hospital of Boston, Boston, Massachusetts, United States|Thomas Jefferson University Ho, Philadelphia, Pennsylvania, United States|Childrens Hospital of the Kings Daughters, Norfolk, Virginia, United States		https://ClinicalTrials.gov/show/NCT01804166
423	NCT01368523	Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial		Completed	No Results Available	Chronic Myelogenous Leukemia	Drug: nilotinib	hematologic response|cytogenetic response	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	19	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CAMN107APL01|EUDRACT 2008-000755-10	December 2008	January 2010		June 8, 2011		November 16, 2016	Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Warsaw, Poland		https://ClinicalTrials.gov/show/NCT01368523
424	NCT01056510	A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)		Completed	Has Results	Lymphocytic Leukemia, Chronic	Drug: bendamustine|Drug: chlorambucil|Drug: rituximab [MabThera/Rituxan]	Percentage of Participants Achieving Confirmed Complete Response (CR) According to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 Guidelines in the First-Line Subpopulation After 6 Cycles of Therapy|Percentage of Participants Achieving Confirmed CR According to IWCLL 2008 Guidelines in the Pooled Population After 6 Cycles of Therapy|Percentage of Participants Achieving Confirmed CR According to IWCLL 2008 Guidelines in the Second-Line Subpopulation After 6 Cycles of Therapy|Percentage of Participants Achieving a Best Overall Response of CR, CR With Incomplete Marrow Recovery (CRi), Partial Response (PR), or Nodular PR (nPR) in the First-Line Subpopulation|Percentage of Participants by Disease Response Category in the First-Line Subpopulation|Percentage of Participants Experiencing PD or Death in the First-Line Subpopulation|Progression-Free Survival (PFS) in the First-Line Subpopulation|Percentage of Participants With Tumor Response of CR or CRi Experiencing PD or Death in the First-Line Subpopulation|Disease-Free Survival (DFS) in the First-Line Subpopulation|Percentage of Participants Experiencing PD, Documented Intake of New Leukemia Therapy, or Death in the First-Line Subpopulation|Event-Free Survival (EFS) in the First-Line Subpopulation|Percentage of Participants With Documented Intake of New Leukemia Therapy in the First-Line Subpopulation|Time to Next Leukemia Treatment (TNLT) in the First-Line Subpopulation|Percentage of Participants With Tumor Response of CR, CRi, PR, or nPR Experiencing PD or Death in the First-Line Subpopulation|Duration of Response in the First-Line Subpopulation|Percentage of Participants Experiencing Death in the First-Line Subpopulation|Overall Survival (OS) in the First-Line Subpopulation|Percentage of Participants Achieving Molecular Response in the First-Line Subpopulation|Number of Participants With Positive and Negative Outcome for MRD in the First-Line Subpopulation|Proportion of Malignant B-cells in Normal B-cells Among Participants With a Positive Outcome for MRD in the First-Line Subpopulation	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	357	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MO22468|2009-012072-28	March 2010	March 2014	March 2014	January 26, 2010	June 25, 2015	June 25, 2015	Pori, Finland|Vantaa, Finland|Argenteuil, France|Avignon, France|Blois, France|Bordeaux, France|Brest, France|La Roche Sur Yon, France|La Tronche, France|Le Mans, France|Lens, France|Limoges, France|Lyon, France|Marseille, France|Mulhouse, France|Nice, France|Nimes, France|Paris, France|Paris, France|Perpignan, France|Pierre Benite, France|Salouel, France|Coimbra, Portugal|Lisboa, Portugal|Lisboa, Portugal|Porto, Portugal|Porto, Portugal|Vitoria, Alava, Spain|Elche, Alicante, Spain|Jerez de La Frontera, Cadiz, Spain|Torrelavega, Cantabria, Spain|La Coruna, La Coruña, Spain|Alcorcon, Madrid, Spain|Cartagena, Murcia, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Huelva, Spain|Leon, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Murcia, Spain|Murcia, Spain|Salamanca, Spain|Sevilla, Spain|Tarragona, Spain|Valencia, Spain|Zaragoza, Spain|Falun, Sweden|Kristianstad, Sweden|Luleå, Sweden|Sundsvall, Sweden|Uddevalla, Sweden|Umea, Sweden|Uppsala, Sweden|Tunis, Tunisia|Ankara, Turkey|Ankara, Turkey|Ankara, Turkey|Bursa, Turkey|Edirne, Turkey|Istanbul, Turkey|Istanbul, Turkey|Izmir, Turkey|Kayseri, Turkey|Kocaeli, Turkey|Samsun, Turkey|Blackpool, United Kingdom|Bournemouth, United Kingdom|Edinburgh, United Kingdom|Leeds, United Kingdom|London, United Kingdom|Maidstone, United Kingdom|Manchester, United Kingdom|Manchester, United Kingdom|Oxford, United Kingdom|Romford, United Kingdom|Somerset, United Kingdom|Truro, United Kingdom		https://ClinicalTrials.gov/show/NCT01056510
425	NCT01043874	Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response	MACS0911	Completed	Has Results	Philadelphia Chromosome Positive|Chronic Myelogenous Leukemia in Chronic Phase	Drug: Nilotinib	MMR Rate at 12 Mos. of Nilotinib Treatment on Study in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have a Suboptimal Molecular Response to Imatinib at 18 Months or Later.|MMR Rate at 24 Months of Nilotinib Treatment on Study in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)|Time to First MMR of Nilotinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) .|Duration of MMR of Nilotinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) .	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	45	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CAMN107FJP01	December 2009	December 2013	January 2014	January 7, 2010	February 9, 2015	April 8, 2016	Novartis Investigative Site, Nagoya-city, Aichi, Japan|Novartis Investigative Site, Nagoya-city, Aichi, Japan|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Fukuoka-city, Fukuoka, Japan|Novartis Investigative Site, Kitakyushu, Fukuoka, Japan|Novartis Investigative Site, Hiroshima-city, Hiroshima, Japan|Novartis Investigative Site, Kumamoto City, Kumamoto, Japan|Novartis Investigative Site, Sendai-city, Miyagi, Japan|Novartis Investigative Site, Nagasaki-city, Nagasaki, Japan|Novartis Investigative Site, Okayama-city, Okayama, Japan|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, OsakaSayama, Osaka, Japan|Novartis Investigative Site, Suita-city, Osaka, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan|Novartis Investigative Site, Aomori, Japan|Novartis Investigative Site, Gifu, Japan|Novartis Investigative Site, Kyoto, Japan|Novartis Investigative Site, Saga, Japan		https://ClinicalTrials.gov/show/NCT01043874
426	NCT01007448	Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)		Completed	No Results Available	Refractory Cutaneous T-cell Lymphoma	Drug: bexarotene	Tumor responses (clinical complete and partial): Composite Assessment of Index Lesion Disease Severity (CA); Physician's Global Assessment of Clinical Condition (PGA); Percent Body Surface Area Involvement (BSA)|Time to cutaneous tumor response; Response duration; Time to cutaneous tumor progression	Bausch Health Americas, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 4	59	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	E7273-G000-401	December 2009	December 2014	December 2014	November 4, 2009		June 3, 2015	University of Alabama at Birmingham, Birmingham, Alabama, United States|Florida Academic Dermatology Centers, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Rush University, Chicago, Illinois, United States|Tulane, New Orleans, Louisiana, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota Medical School, Minneapolis, Minnesota, United States|Washington University, St. Louis, Missouri, United States|University of Rochester, Rochester, New York, United States|Duke University, Durham, North Carolina, United States|Wake Forest University Health, Winston-Salem, North Carolina, United States|University Hospitals-Case Medical Center, Cleveland, Ohio, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute At the University of Utah, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT01007448
427	NCT03226119	MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study		Completed	No Results Available	HTLV-I Infections|HTLV-II Infections|Human T-lymphotropic Virus 1|Human T-lymphotropic Virus 2|HTLV I Associated T Cell Leukemia Lymphoma|HTLV I Associated Myelopathies	Diagnostic Test: MP Diagnostics HTLV Blot 2.4	To demonstrate ≥95% agreement of HTLV Blot 2.4 results with the Reference Core Laboratory HTLV Algorithm in 100 Neurological Disorder Specimens|To demonstrate HTLV Blot 2.4 sensitivity of ≥97.5% in 50 HTLV Known Positive Specimens	MP Biomedicals, LLC|MP Biomedicals Asia Pacific Pte. Ltd.	All	18 Years and older   (Adult, Older Adult)	Phase 4	150	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic	MP-EIA-HTLV-002B	January 15, 2018	July 10, 2018	August 31, 2018	July 21, 2017		September 13, 2018	LABS, Inc., Philadelphia, Pennsylvania, United States|Qualtex Laboratories, San Antonio, Texas, United States|Eastern Virginia Medical School (EVMS), Norfolk, Virginia, United States		https://ClinicalTrials.gov/show/NCT03226119
428	NCT00786812	Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase	MACS0439	Completed	No Results Available	Chronic Myeloid Leukemia	Drug: Nilotinib	Disease response (complete hematologic response, cytogenetic response) and progression at or until 24 months, depending of the case every 3 months	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	89	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CAMN107ABR03	August 2008	January 2012	January 2012	November 6, 2008		February 23, 2017	Novartis Investigative Site, Belo Horizonte, MG, Brazil|Novartis Investigative Site, Curitiba, PR, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Campinas, SP, Brazil|Novartis Investigative Site, Jaú, SP, Brazil|Novartis Investigative Site, Ribeirao Preto, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil		https://ClinicalTrials.gov/show/NCT00786812
429	NCT00644878	Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib	MACS0254	Completed	No Results Available	Chronic Myelogenous Leukemia - Chronic Phase	Drug: Nilotinib	Bcr-Abl levels measured by polymerase chain reaction testing|Rate of major molecular response, measured by PCR|Rate of log reduction in Bcr-Abl transcripts, measured by PCR|Time to and duration of the best molecular response, measured by PCR	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	18	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CAMN107AUS09	October 2008	March 2012	March 2012	March 27, 2008		November 18, 2016	USC Norris Cancer Center Jane Anne Nohl, Los Angeles, California, United States|Innovative Medical Research of South Florida Dept.ofInnovativeMedResearch, Miami Shores, Florida, United States|Georgia Health Sciences University Dept. of MCG, Augusta, Georgia, United States|Kootenai Medical Center Dept.ofKootenai Med.Ctr., Coeur d'Alene, Idaho, United States|Indiana Blood and Marrow Institute, Beach Grove, Indiana, United States|University of Iowa Hospitals & Clinics Univ of Iowa Hosp & Clinic, Iowa City, Iowa, United States|LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center, New Orleans, Louisiana, United States|St. Agnes Hospital, Baltimore, Maryland, United States|Montefiore Medical Center Medical Center, Bronx, New York, United States|SUNY Upstate Medical Center, Syracuse, New York, United States|Westchester Medical Center Munger Pavillion (2), Valhalla, New York, United States|Wake Forest University Baptist Medical Center Hematology and Oncology, Winston-Salem, North Carolina, United States|Cancer Centers of the Carolinas, Greenville, South Carolina, United States|University of Tennessee Cancer Institute Cancer Institute, Memphis, Tennessee, United States|South Texas Institute of Cancer S. Tex Inst.- Corpus Christi, Corpus Christi, Texas, United States|Baylor College of Medicine - Breast Care Dan L Duncan Cancer Ctr, Houston, Texas, United States|Central Utah Clinic Central Utah Clinic (7), Provo, Utah, United States|Froedert Memorial Lutheran Hospital Dept.ofFroedert Memorial, Milwaukee, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT00644878
430	NCT00220311	A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia		Completed	No Results Available	Leukemia, Lymphocytic, Chronic, B-Cell	Drug: Fludarabine Phosphate (Fludara)	Response rate of final overall evaluation up to 6 treatment cycles (at about 6 months)|Response rate for measurable lesions / evaluable lesions / peripheral blood findings / bone marrow findings|Duration of response and change of peripheral blood findings	Genzyme, a Sanofi Company|Sanofi	All	15 Years to 80 Years   (Child, Adult, Older Adult)	Phase 4	10	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	303530|90699	November 2000	September 2005	September 2005	September 22, 2005		December 4, 2013			https://ClinicalTrials.gov/show/NCT00220311
431	NCT00171899	Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)		Completed	No Results Available	Chronic Myelogenous Leukemia	Drug: imatinib mesylate	Percent of patients achieving major molecular response at baseline and at last visit|Complete cytogenetic response at baseline and at last visit|Overall survival|Disease progression-free survival|Quality of Life assessment at baseline, last visit|Safety: adverse events and lab parameters, vital signs, physical exam, electrocardiogram, concomitant medications	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	80	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CSTI571ACA09	April 2005	June 2007	June 2007	September 15, 2005		February 23, 2017	Novartis Investigative Site, Toronto, Canada		https://ClinicalTrials.gov/show/NCT00171899
432	NCT00823303	Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)	PACE	Completed	Has Results	Secondary Hyperparathyroidism|Chronic Kidney Disease	Drug: Paricalcitol|Drug: Calcitriol	Confirmed Hypercalcemia	Washington University School of Medicine|Henry Ford Hospital|Feinberg School of Medicine, Northwestern University|NorthShore University HealthSystem|Abbott	All	18 Years and older   (Adult, Older Adult)	Phase 4	110	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	22095	February 2009	May 2013	September 2013	January 15, 2009	August 5, 2014	August 7, 2014	Northwestern University, Chicago, Illinois, United States|Northshore University Health System, Evanston, Illinois, United States|Henry Ford Hospital, Detroit, Michigan, United States|Washington University, St. Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT00823303
433	NCT00686543	Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)		Completed	Has Results	Fungal Infection|Acute Myelogenous Leukemia|Neutropenia	Drug: Posaconazole	Mean POS Plasma Concentrations on Days 2, 3, and 8.|Mean POS Plasma Concentrations on Days 8 and 15 Stratified by Randomized Dosing Regimen|Participants With a Mean POS Plasma Concentration ≥/<250 ng/mL on Day 3 and ≥/<500 ng/mL on Day 8|Participants With a Mean POS Plasma Concentration ≥/<350 ng/mL on Day 3 and ≥/<700 ng/mL on Day 8|Participants With a Mean POS Plasma Concentration ≥/<250 ng/mL on Day 8 and ≥/<500 ng/mL on Day 15|Participants With a Mean POS Plasma Concentration ≥/<350 ng/mL on Day 8 and ≥/<700 ng/mL on Day 15	Merck Sharp & Dohme Corp.	All	18 Years and older   (Adult, Older Adult)	Phase 4	75	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	P05115|EudraCT No. 2007-003148-31	December 2007	April 2009	April 2009	May 30, 2008	May 14, 2010	April 7, 2017			https://ClinicalTrials.gov/show/NCT00686543
434	NCT00051012	Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients		Completed	No Results Available	Lymphoma, T-Cell, Cutaneous|Mycosis Fungoides|Sezary Syndrome	Drug: ONTAK	Objective Rate of Response (ORR), defined as CR + CCR + PR|Time-to-Treatment Failure|Time-to-Progression|Duration of Response	Eisai Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 4	86	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	93-04-14	September 1995	October 2006	December 2006	January 3, 2003		March 5, 2008	University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States|Level 4 Department of Haematology Royal North Shore Hospital, St. Leonard's, New South Wales, Australia|Westmead Hospital, Department of Haematology, Westmead, New South Wales, Australia|Mater Misericordiae Adult Hospital, South Brisbane, Queensland, Australia|Oncology Haematology Radiation Oncology Unit, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia|LKH Universitatsklinikum Graz, Graz, Austria|Allgemeines Krankenhaus der Stadt Wien, Vienna, Austria|Cross Cancer Centre, Edmonton, Alberta, Canada|Hamilton Regional Cancer Center, Hamilton, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Universitatsklinikum Charite, Berlin, Germany|University of Erlangen, Erlangen, Germany|Universitatsklinikum Essen, Essen, Germany|J.W. Goethe University Frankfurt, Frankfurt, Germany|Universitatskrankenhaus Eppendorf, Hamburg, Germany|Universitatsklinikum Mannheim, Mannheim, Germany|Universitatsklinikum Munster, Munster, Germany|Medical Academy in Gdansk, Dept. of Hematology, Gdansk, Poland|Regional Oncological Center, Dept. of Chemotherapy, Lodz, Poland|Klinika Hematoonkologii Akademii Medycznej w Lublinie, Lublin, Poland|Oddzial Chorob Wewnetrznych i Hematologii, Poznan, Poland|The Medical University of Warsaw, Central Clinical Hospital, Warsaw, Poland|Centrum Onkologii-Instytut im. Marii Sklodoskiej-Curie, Warsaw, Poland|Blokhin Russian Cancer Research Center, RAMS, Moscow, Russian Federation|Burdenko Main Military Clinical Hospital, Moscow, Russian Federation|Central Research Institute of Skin and Venereal Diseases, Moscow, Russian Federation|Haematology Research Center RAMS, Moscow, Russian Federation|Samara Regional Clinical Hospital, Samara, Russian Federation|St. Petersburg Pavlov State Medical University, St. Petersburg, Russian Federation|Universitatsspital Zurich Dermatologische Klinik, Zurich, Switzerland|St. John's Institute of Dermatology, London, United Kingdom|City Hospital, Nottingham, United Kingdom|Southampton General Hospital, Southampton, United Kingdom		https://ClinicalTrials.gov/show/NCT00051012
435	NCT00050999	Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients		Completed	No Results Available	Lymphoma, T-Cell, Cutaneous|Mycosis Fungoides|Sezary Syndrome	Drug: ONTAK	Objective Rate of Response (ORR), defined as CR + CCR + PR|Time-to-Treatment Failure|Time-to-Progression|Duration of Response	Eisai Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 4	195	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	93-04-11	June 1995	September 2006	December 2006	January 3, 2003		March 5, 2008	University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States|Level 4 Department of Haematology Royal North Shore Hospital, St. Leonard's, New South Wales, Australia|Westmead Hospital, Department of Haematology, Westmead, New South Wales, Australia|Mater Misericordiae Adult Hospital, South Brisbane, Queensland, Australia|Oncology Haematology Radiation Oncology Unit, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|LKH Universitatsklinikum Graz, Graz, Austria|Allgemeines Krankenhaus der Stadt Wien, Vienna, Austria|Cross Cancer Centre, Edmonton, Alberta, Canada|Hamilton Regional Cancer Center, Hamilton, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Universitatsklinikum Charite, Berlin, Germany|University of Erlangen, Erlangen, Germany|Universitatsklinikum Essen, Essen, Germany|J.W. Goethe University Frankfurt, Frankfurt, Germany|Universitatskrankenhaus Eppendorf, Hamburg, Germany|Universitatsklinikum Mannheim, Mannheim, Germany|Universitatsklinikum Munster, Munster, Germany|Sektion Dermatologische Onkologie, Tubingen, Germany|LUMC, Department of Dermatology, Leiden, Netherlands|Medical Academy in Gdansk, Dept. of Hematology, Gdansk, Poland|Regional Oncological Center, Dept. of Chemotherapy, Lodz, Poland|Klinika Hematoonkologii Akademii Medycznej w Lublinie, Lublin, Poland|Oddzial Chorob Wewnetrznych i Hematologii, Poznan, Poland|The Medical University of Warsaw, Central Clinical Hospital, Warsaw, Poland|Centrum Onkologii-Instytut im. Marii Sklodoskiej-Curie, Warsaw, Poland|Blokhin Russian Cancer Research Center, RAMS, Moscow, Russian Federation|Burdenko Main Military Clinical Hospital, Moscow, Russian Federation|Central Research Institute of Skin and Venereal Diseases, Moscow, Russian Federation|Haematology Research Center RAMS, Moscow, Russian Federation|Samara Regional Clinical Hospital, Samara, Russian Federation|St. Petersburg Pavlov State Medical University, St. Petersburg, Russian Federation|Universitatsspital Zurich Dermatologische Klinik, Zurich, Switzerland|St. John's Institute of Dermatology, London, United Kingdom|City Hospital, Nottingham, United Kingdom|Southampton General Hospital, Southampton, United Kingdom		https://ClinicalTrials.gov/show/NCT00050999
436	NCT01206088	Tasigna in Glivec-resistant or Intolerant Patients in CML		Completed	No Results Available	CML|Nilotinib|Imatinib Resistant|Imatinib Intolerant	Drug: nilotinib	Complete cytogenetic response (CCyR) rate|evaluation of safety by NCI-CTCAE version 3.0	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	93	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CAMN107AKR02	February 2009	September 2012	September 2012	September 21, 2010		February 28, 2017	St. Mary hospital, Catholic medical center, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01206088
437	NCT00304291	A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease)		Completed	No Results Available	Neuromyelitis Optica|Myelitis, Transverse|Demyelinating Autoimmune Diseases, CNS|Autoimmune Diseases of the Nervous System	Drug: Mitoxantrone	Relapse rate|Safety	State University of New York at Buffalo|EMD Serono	All	18 Years to 55 Years   (Adult)	Phase 4	5	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	JNI-NMO-101	August 2001		May 2004	March 17, 2006		November 28, 2006	Baird Multiple Sclerosis Center, Buffalo, New York, United States		https://ClinicalTrials.gov/show/NCT00304291
438	NCT00179478	Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis	CHAMPIONS10	Completed	Has Results	Multiple Sclerosis|Optic Neuritis|Transverse Myelitis|Acute Brainstem/Cerebellar Syndrome	Drug: interferon beta 1a 30 ug IM once weekly	Rate of Development of Clinical Definite Multiple Sclerosis (CDMS) Over 10 Years|Annualized Relapse Rate|Number of Participants With an EDSS > 3.5 at Study Completion|The Number of New or Enlarging MRI T2 Lesions at 10 Years	Beth Israel Deaconess Medical Center|Biogen	All	18 Years and older   (Adult, Older Adult)	Phase 4	155	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	2003P000086|C-850 Extension study	February 2001	March 2009	March 2009	September 16, 2005	September 6, 2017	September 6, 2017	MS Treatment Center at Griffin Hospital, Derby, Connecticut, United States|Jaeb Center for Health Research, Tampa, Florida, United States|MS Center of Atlanta, Atlanta, Georgia, United States|Beta Research, Inc, Elk Grove, Illinois, United States|University of Iowa College of Medicine, Iowa City, Iowa, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Michigan State University, East Lansing, Michigan, United States|St. Louis University Health Sciences Center, Saint Louis, Missouri, United States|Jacobs Neurological Institute, Buffalo, New York, United States|University of Rochester, Rochester, New York, United States|Carolinas Medical Center - MS Center, Charlotte, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|The Neurology Group, Norristown, Pennsylvania, United States|Univeristy of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|Allegheny Neurological Associates, Pittsburgh, Pennsylvania, United States|Univeristy of Texas Houston Health Science Center, Houston, Texas, United States|Virginia Commonwealth University/Medical College of Virginia, Richmond, Virginia, United States|Neurological Associates, Inc., Richmond, Virginia, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Vancouver Hospital Health Sciences Centre, Vancouver, British Columbia, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Ottawa General Hospital, Ottawa, Ontario, Canada|University of Toronto - St. Michael's Hospital, Toronto, Ontario, Canada|Hospital Notre Dame, Montreal, Quebec, Canada|Montreal Neurological Institute, Montreal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT00179478
439	NCT00534638	Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents		Completed	Has Results	Infections, Papillomavirus	Biological: GSK Biologicals' HPV Vaccine GSK580299|Biological: Engerix-B™	Number of Female Subjects With Vaccine Overall Effectiveness Against Genital Infection With Human Papilloma Virus (HPV) 16/18 Serotypes|Number of Female Subjects With Vaccine Effectiveness Against Oropharyngeal Infection With HPV-16/18 Serotypes|Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms, in a Subset of Subjects.|Number of Subjects Reporting Any, Grade 3 and Related to Vaccination Solicited General Symptoms, in a Subset of Subjects.|Number of Subjects Reporting Any, Grade 3 and Related to Vaccination Unsolicited Adverse Events (AEs), in a Subset of Subjects.|Number of Subjects Reporting Rash and Urticaria, in a Subset of Subjects.|Number of Subjects Reporting Medically Significant Conditions (MSCs), in a Subset of Subjects.|Number of Subjects Reporting Any Serious Adverse Events (SAEs) and SAEs Causally Related to Vaccination, in a Subset of Subjects|Number of Subjects Reporting SAEs Assessed by the Investigator as Possibly Related to Vaccination.|Number of Subjects With HPV-16 and HPV-18 Antibody Concentrations Equal to or Above the Cut-off Values, by Gender, in a Subset of Subjects.|Titres for Anti-HPV-16 and Anti-HPV-18 Antibodies, by Gender, in a Subset of Subjects.|Number of Subjects Reporting Pregnancies With Onset During the Study|Number of Female Subjects With New Onset of Autoimmune Diseases (NOADs).|Number of Female Subjects Reporting Any SAEs That Are Causally Related to Vaccination, in a Female Subjects|Number of Male Subjects Reporting Any SAEs That Are Causally Related to Vaccination, in All Male Subjects	GlaxoSmithKline	All	12 Years to 15 Years   (Child)	Phase 4	34206	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	106636|2007-001731-55	October 4, 2007	December 17, 2014	December 17, 2014	September 26, 2007	January 26, 2016	June 5, 2017	GSK Investigational Site, Kotka, Finland|GSK Investigational Site, Kuopio, Finland|GSK Investigational Site, Lahti, Finland|GSK Investigational Site, Rauma, Finland|GSK Investigational Site, Tampere, Finland|GSK Investigational Site, Turku, Finland		https://ClinicalTrials.gov/show/NCT00534638
440	NCT01031069	Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females		Completed	Has Results	Infections, Papillomavirus	Biological: GSK Biologicals' HPV vaccine 580299|Biological: Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms|Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms|Number of HIV+ Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)|Number of HIV+ Subjects With Serious Adverse Events (SAEs)|Number of HIV+ Subjects With Medically Significant Conditions (MSCs)|Number of HIV+ Subjects With Potential Immune-mediated Diseases (pIMDs)|Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies|Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities|Cluster of Differentiation 4 (CD4+) Cell Count in HIV+ Subjects at Month 7|HIV Viral Load (VL) in HIV+ Subjects at Month 7|Number of HIV+ Subjects by World Health Organization (WHO) HIV Clinical Staging|Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV+ Subjects, Based on Adapted According-to-protocol (ATP) Cohort for Immunogenicity|Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV+ Subjects, Based on Total Vaccinated Cohort (TVC)|Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms|Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms|Number of HIV- Subjects With Unsolicited Adverse Events (AEs)|Number of HIV- Subjects With Serious Adverse Events (SAEs)|Number of HIV- Subjects With Medically Significant Conditions (MSCs)|Number of HIV- Subjects With Potential Immune-mediated Disease (pIMDs)|Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies|Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters|Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters|Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters|Number of Subjects With SAEs|Number of Subjects With Medically Significant Conditions (MSCs)|Number of Subjects With Potential Immune-mediated Diseases (pIMDs)|Cluster of Differentiation 4 (CD4+) Cell Count in HIV+ Subjects at Months 12, 18 and 24|HIV Viral Load (VL) in HIV+ Subjects at Months 12, 18 and 24|Number of HIV+ Subjects by WHO HIV Clinical Staging|Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV- Subjects, Based on TVC|Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum|Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)|Frequency of Specific B-cells for HPV-16/18 Antigens|Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	GlaxoSmithKline	Female	15 Years to 25 Years   (Child, Adult)	Phase 4	873	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	109823|2013-003429-28	October 26, 2010	January 13, 2016	April 19, 2017	December 14, 2009	July 24, 2019	July 24, 2019	GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|GSK Investigational Site, Ribeirão Preto, São Paulo, Brazil|GSK Investigational Site, Campinas, Brazil|GSK Investigational Site, Rio de Janeiro, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, Kohtla-Järve, Estonia|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Chennai, India|GSK Investigational Site, Kolkata, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Chiangmai, Thailand|GSK Investigational Site, Khon Kaen, Thailand		https://ClinicalTrials.gov/show/NCT01031069
441	NCT00926757	Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B	HBVNHL	Completed	No Results Available	Non Hodgkin's Lymphoma|Hepatitis B	Drug: Entecavir prophylaxis|Drug: Therapeutic entecavir	The primary endpoint is the incidence of HBV reactivation during and within 12 months after chemotherapy|The incidence of HBsAg reverse seroconversion during and within 12 months after completing chemotherapy.	Taipei Veterans General Hospital, Taiwan|Bristol-Myers Squibb	All	16 Years and older   (Child, Adult, Older Adult)	Phase 4	80	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	VGHUST98-P1-07|VGHIRB98-01-08	April 2009	November 2012	November 2012	June 24, 2009		May 29, 2013	Taipei Veterans General Hospital-Division of Gastroenterology, Division of Oncology, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT00926757
442	NCT01200355	Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome		Completed	Has Results	Acute Myelogenous Leukemia|Myelodysplastic Syndrome	Drug: micafungin|Drug: posaconazole	Time to Failure|To Compare the Number of Days on Study Drug Between Patients Who Receive Posaconazole and Patients Who Receive Micafungin.|To Compare the Incidence of Possible, Probable or Proven Invasive Fungal Infections Between Patients Who Receive Posaconazole and Those Who Receive Micafungin During Treatment Phase|Prophylaxis Failure of Study Medication for Any Reason Between Patients Who Receive Posaconazole and Those Who Receive Micafungin.|To Compare Overall Survival Rates at 6 Weeks	Memorial Sloan Kettering Cancer Center|Astellas Pharma US, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 4	113	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	10-038	September 9, 2010	April 20, 2017	April 3, 2018	September 13, 2010	July 24, 2017	May 7, 2018	Memorial Sloan Kettering Cancer Center, New York, New York, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/55/NCT01200355/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT01200355
443	NCT02145026	A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)		Completed	No Results Available	Myelodysplastic Syndromes	Drug: Epoetin beta	Percentage of Participants Achieving Erythroid Response at Week 12 as Assessed by International Working Group (IWG) 2006 Response Criteria|Percentage of Participants With Platelet Response (in Participants With Pre-Treatment Platelets <100*10^9 per Liter) at Week 12 as Assessed by IWG 2006 Response Criteria|Percentage of Participants With Neutrophil Response (in Participants With Pre-Treatment Neutrophil <1.0*10^9 per Liter) at Week 12 as Assessed by IWG 2006 Response Criteria|Percentage of Participants With Adverse Events	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 4	120	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML29005	August 6, 2014	April 9, 2019	April 9, 2019	May 22, 2014		April 24, 2019	King Chulalongkorn Memorial Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand|Rajavithi Hospital; Medicine, Bangkok, Thailand|Ramathibodi Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand|Siriraj Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand|Chiang Mai Uni Hospital; Division of Hematology,Dept of Medicine,Faculty of Medicine, Chiang Mai, Thailand|Srinagarind Hospital, Khon Kaen Uni ; Dept of Medicine, Khon Kaen, Thailand|Khonkean Regional Hospital; Medicine, Khon Kean, Thailand|Thammasart Chalermprakiert Hospital, Thammasart Uni; Hematology, Pathumthani, Thailand|Naresaun University hospital, Phitsanulok, Thailand|Sapprasitthiprasong Hospital, Ubon Ratchathani, Thailand		https://ClinicalTrials.gov/show/NCT02145026
444	NCT02768532	Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease	VEDO-PREDIRESP	Recruiting	No Results Available	Crohn Disease	Drug: Vedolizumab	Vedolizumab concentration at week 6|Vedolizumab concentration at week 14|Concentration of Vedolizumab at week 2|Presence of specific antibodies (anti-integrins) at week 2|Concentration of Vedolizumab at week 14|Presence of specific antibodies (anti-integrins) at week 14|Vedolizumab and calprotectin levels at week 2|Vedolizumab and calprotectin levels at week 14|Intra and inter-individual heterogeneity of Vedolizumab levels|Proportion of loss of clinical response|Vedolizumab serum levels|Concentration of Vedolizumab at week 54|Specific antibodies (anti-integrins) level at week 54	Centre Hospitalier Universitaire de Saint Etienne|Theradiag|Takeda	All	18 Years and older   (Adult, Older Adult)	Phase 4	93	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1608051|2016-001587-11	July 1, 2016	July 2021	June 2022	May 11, 2016		July 26, 2019	CHU Kremlin Bicetre, Paris, Le Kremlin-Bicêtre, France|CHU d'Amiens, Amiens, France|CHU L'Archet, Nice, France|CHU Lyon-Sud, Hospices Civils de Lyon, PIERRE-BENITE, Pierre Bénite, France|Chu Saint Etienne, Saint Etienne, France		https://ClinicalTrials.gov/show/NCT02768532
445	NCT01082302	Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage		Completed	No Results Available	Genital Warts|Perianal Warts	Drug: Polyphenon E (Veregen) 15% ointment|Other: Green Tea Beverage with defined catechin content	Pharmacokinetic profile of green tea catechins	MediGene|Charité Research Organization GmbH	All	18 Years and older   (Adult, Older Adult)	Phase 4	43	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CT 1022|2007-005432-88	January 2010	August 2010	August 2010	March 8, 2010		September 8, 2010	Charité Research Organisation, Berlin, Germany		https://ClinicalTrials.gov/show/NCT01082302
446	NCT02500641	Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout	FORWARD	Completed	Has Results	Gout	Drug: Febuxostat 80/120mg/day|Drug: Allopurinol 100 up to 600mg/day|Drug: Colchicine|Drug: Naproxen|Drug: Omeprazole	Pulse Wave Velocity	Menarini International Operations Luxembourg SA	All	18 Years and older   (Adult, Older Adult)	Phase 4	196	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	MEIN/14/FEB-PWV/001|2014-005567-33	August 17, 2015	May 10, 2017	May 10, 2017	July 16, 2015	June 21, 2019	June 21, 2019	Medizinische Klinik und Poliklinik III/Rheumatologie Universitätsklinikum "Carl Gustav Carus" Der Technischen Universität, Dresden, Germany|Presidio Ospedaliero San Filippo e Nicola Università degli Studi dell'Aquila U.O.C Geriatria e Lungodegenza Geriatrica, Avezzano, L'Aquila, Italy|Ospedale San Salvatore U.O.C. Medicina Interna e Nefrologia Dipartimento MeSVA Università degli Studi dell'Aquila, Coppito, L'Aquila, Italy|Azienda Ospedaliero-Universitaria Policlinico Sant'Orsola-Malpighi, Bologna, Italy|Ospedale Policlinico SS. Annunziata Università degli Studi "G. d'Annunzio". Dipartimento di Medicina e Scienze dell'Invecchiamento., Chieti, Italy|Reade Clinic, Amsterdam, Netherlands|Gdańskie Centrum Zdrowia Sp.z o.o., Gdańsk, Poland|Specjalistyczna Praktyka Lekarska Piotr Kubalski, Grudziądz, Poland|Centrum Medyczne Pratia Katowice, Katowice, Poland|Centrum Medyczne Plejady, Kraków, Poland|Krakowski Szpital Specjalistyczny im. Jana Pawła II w Krakowie, Kraków, Poland|Specjalistyczny Gabinet Dermatologiczno-Kosmetyczny, Kraków, Poland|Pratia S,A, Warsaw, Poland|Reumatika- Centrum Reumatologii, Warsaw, Poland|Oddział Kardiologiczny, WSS im. W. Biegańskiego w Łodzi, Łódź, Poland|Polimedica, Łódź, Poland|Clinica Medicală Data Plus SRL, Bucharest, Romania|Institutul Clinic Fundeni, Bucharest, Romania|S.C. Centrul Medical Sana S.R.L., Bucharest, Romania|S.C. Cardiomed S.R.L., Craiova, Romania|Institutul de Boli Cardiovasculare Clinica de Cardiologie si Recuperare Cardiovasculara, Timisoara, Romania|Cabinet Medical Medicina Interna, Timişoara, Romania|Institut za kardiovaskularne bolesti Dedinje, Belgrade, Serbia|Institut za reumatologiju, Belgrade, Serbia|Kliničko-bolnički centar "Bežanijska kosa" Klinika za imunologiju i alergologiju, Belgrade, Serbia|Vojnomedicinska akademija Klinika za reumatologiju, Belgrade, Serbia	"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/41/NCT02500641/SAP_000.pdf|"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/41/NCT02500641/Prot_001.pdf	https://ClinicalTrials.gov/show/NCT02500641
447	NCT01753154	The Effect of Balance PD Solution on the Peritoneal Membrane in Patients on Automated Peritoneal Dialysis		Completed	No Results Available	Chronic Renal Failure	Drug: Solution B (balance PD solution)|Drug: Solution A (conventional PD solution)	CA 125 (cancer antigen 125) appearance rate in the 24 hours effluent and estimated hydration	Fresenius Medical Care Deutschland GmbH	All	18 Years and older   (Adult, Older Adult)	Phase 4	25	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PD-NL-04-EU	July 2011	March 2013	December 2013	December 20, 2012		May 2, 2016	Centrum Dializ Fresenius Nephrocare, Gdańsk,, Poland|Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie, Lublin, Poland|Uniwersytecki Szpital Kliniczny nr 1, Łódź, Poland|Complejo hospitalario universitario de Albacete, Albacete, Spain|Fundación Hospital Alcorcón, Madrid, Spain|Hospital Universitario Puerta de Hierro, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain		https://ClinicalTrials.gov/show/NCT01753154
448	NCT02789488	Clinical Evaluation of Furocyst in Patients With Poly Cystic Ovary Syndrome		Completed	No Results Available	Poly Cystic Ovary Syndrome	Dietary Supplement: Fenugreek seeds extract 500 mg	Reduction in Ovary volume as assessed by ultrasound	Chemical Resources	Female	18 Years to 45 Years   (Adult)	Phase 4	50	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	CR001/PCOS-5-13	September 2013	July 2014	July 2014	June 3, 2016		June 3, 2016			https://ClinicalTrials.gov/show/NCT02789488
449	NCT00420628	Pediatric Zylet Safety and Efficacy Study		Completed	Has Results	Chalazion|Hordeolum	Drug: loteprednol etabonate/tobramycin opthalmic suspension|Drug: vehicle	Treatment Emergent Adverse Events|Investigators Global Assessment of the Clinical Condition|Assessment of Ocular Signs in the Study Eye - Visit 1|Assessment of Ocular Signs in the Study Eye - Visit 2|Assessment of Ocular Signs in the Study Eye - Visit 3	Bausch & Lomb Incorporated	All	up to 6 Years   (Child)	Phase 4	108	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	459	November 2006	January 2009	June 2009	January 11, 2007	September 22, 2010	October 7, 2011	Pediatric Ophthalmology of Erie, Erie, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT00420628
450	NCT01250951	This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.		Completed	No Results Available	Myelodysplastic Syndrome|Thalassemia	Drug: Deferasirox	changes in ferritin level, compared to baseline, in patients with transfusion-induced iron overload treated with Exjade|changes in clinical manifestations of iron overload by means of echocardiogram (ECHO), electrocardiogram (ECG), routine laboratory assessments and physical examination|changes in iron overload evidence on cardiac and liver magnetic resonance imaging (MRI) T2*, compared to baseline, in patients with transfusion-induced iron overload treated with Exjade|Number of participants with adverse events. Safety is evaluated through the continuous monitoring and recording of adverse events, as well as though routine laboratory assessments and physical examination.	Novartis Pharmaceuticals|Novartis	All	2 Years and older   (Child, Adult, Older Adult)	Phase 4	111	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CICL670ARU01	December 2009	July 2011	September 2011	December 1, 2010		December 12, 2016	Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation		https://ClinicalTrials.gov/show/NCT01250951
451	NCT00673608	Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload		Completed	No Results Available	Hemoglobinopathies|Myelodysplastic Syndromes|Other Inherited or Acquired Anaemia|MPD Syndrome|Diamond-Blackfan Anemia|Other Rare Anaemias|Transfusional Iron Overload	Drug: deferasirox	Change in cardiac iron load and cardiac ejection fraction by MRI recorded at baseline and after 53 weeks.|Change in ventricular ejection fraction values, ventricular volumes and masses from baseline values after 53 weeks.|Change in cardiac T2* from baseline to 53 weeks in the MDS and other anaemias subgroup, compared to the thalassaemia subgroup.|Changes in serum ferritin from baseline values to 53 weeks.|Changes in Liver Iron Content (LIC) by MRI from baseline values to 53 weeks|The relationship between the dosing regimen of Exjade® and changes in cardiac T2* and LIC R2 MRI|Changes in markers of iron load levels between baseline and 53 weeks.|The safety and tolerability of deferasirox therapy from baseline to 53 weeks	Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	118	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CICL670AAU01	November 2007	September 2011	September 2011	May 7, 2008		February 23, 2017	Novarts Investigative Site, Adelaide, Australia|Novarts Investigative Site, Brisbane, Australia|Novarts Investigative Site, Melbourne, Australia|Novarts Investigative Site, Sydney, Australia		https://ClinicalTrials.gov/show/NCT00673608
452	NCT00805935	Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)		Completed	Has Results	Polycystic Ovarian Syndrome|Infertility	Drug: Menotropin|Drug: Progesterone vaginal insert|Drug: Follitropin beta|Drug: Progesterone in oil|Drug: leuprolide acetate	Participants With Cycle Cancellation Due to Risk of Ovarian Hyperstimulation Syndrome (OHSS) Between Weeks 1 - 3|Number of Follicles Observed at Day 15|Number of Oocytes Retrieved at Day 18|Percentage of Oocytes Fertilized of the Total Number of Oocytes Retrieved|Number of Embryos Transferred at Three Stages of Development Before Implantation|Number of Embryos Frozen|Percentage of Participants With Biochemical Pregnancy at Approximately Day 38|Percentage of Participants With Clinical Pregnancy at Week 7|Percentage of Participants With Ongoing Pregnancy at Week 9|Estradiol Levels at Day 6|Human Chorionic Gonadotropin (hCG) Levels at Day 6|Progesterone Levels at Human Chorionic Gonadotropin (hCG) Administration|Number of Live Births Resulting From the In Vitro Fertilization Process|Participants With Treatment Emergent Adverse Events	Ferring Pharmaceuticals	Female	18 Years to 42 Years   (Adult)	Phase 4	110	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2008-05	January 2009	July 2010	September 2010	December 10, 2008	January 25, 2012	January 27, 2012	Conceptions Reproductive Associates of Colorado, Littleton, Colorado, United States|Women's Medical Research Group LLC, Florida, Clearwater, Florida, United States|Fertility Center of Illinois, Chicago, Illinois, United States|Weill Cornell Medical College, New York, New York, United States|Women & Infants' Hospital of RI, Providence, Rhode Island, United States|Center for Assisted Reproduction, Bedford, Texas, United States		https://ClinicalTrials.gov/show/NCT00805935
453	NCT00564941	Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload		Completed	No Results Available	Myelodysplastic Syndromes|Beta-Thalassemia	Drug: deferasirox	This study will evaluate the safety and efficacy of deferasirox in transfusion dependent Myelodysplastic Syndrome, Beta-thalassaemia major patients with chronic iron overload|patient's compliance during the study assessed by the number of the unused tablets returned by the patient safety assessed by patient laboratory data, adverse events, serious adverse events	Novartis Pharmaceuticals|Novartis	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 4	309	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CICL670AHU02	December 2007	July 2011	July 2011	November 29, 2007		February 24, 2017	Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Szeged, Hungary		https://ClinicalTrials.gov/show/NCT00564941
454	NCT00481143	Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload		Completed	No Results Available	Myelodysplastic Syndromes|Transfusion Dependent Iron Overload	Drug: ICL670/Deferasirox	To assess iron chelation by comparing serum ferritin values at baseline vs. 52 weeks of treatment with deferasirox|Safety and tolerability of deferasirox assessed by monitoring and recording all adverse events (AEs) and serious adverse events (SAEs)	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 4	63	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CICL670ADE03	May 2007	November 2010		June 1, 2007		May 31, 2017	Novartis Investigative Site, Berlin, Germany		https://ClinicalTrials.gov/show/NCT00481143
455	NCT03977753	Study to Evaluate 2LVERU® JUNIOR and 2LVERU® on the Treatment of Warts.	EVAsION	Not yet recruiting	No Results Available	Common Wart|Flat Wart|Plantar Wart	Drug: 2LVERU® or 2LVERU® JUNIOR|Device: Cryotherapy	Total disappearance of warts at the end of treatment visit (6-month visit) in the 2LVERU® JUNIOR or 2LVERU® arm.|Proportion of patients with disappearance of warts at the end of treatment visit between the 2LVERU® JUNIOR or 2LVERU® and cryotherapy arms.|Pain evaluation during the study by VAS and consumption of antalgic medication.|Numbers of warts disappeared at 4-month visit in 2LVERU® JUNIOR or 2LVERU® arm.|Proportion of patients according to 4 levels (total disappearance, partial disappearance (50%), no modification, increase of number of warts) between 2LVERU® JUNIOR or 2LVERU® and cryotherapy on the treatment of warts at the end of treatment.|Warts recurrence at 9-month visit between 2LVERU® JUNIOR or 2LVERU® vs cryotherapy,|Safety: frequency of adverse events (AEs) and frequency of severe adverse events (SAEs), considered as related or not to the study drug.|Numbers of warts disappeared at 4-month visit in 2LVERU® JUNIOR or 2LVERU®.|Total disappearance of warts at the end of treatment visit (6-month visit) in the 2LVERU® JUNIOR or 2LVERU®.	Labo'Life	All	3 Years and older   (Child, Adult, Older Adult)	Phase 4	280	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LLB-2019-02	October 15, 2019	October 15, 2020	September 30, 2021	June 6, 2019		August 13, 2019	Private Practice, Arlon, Belgium|Clinique Saint-Luc (Bouge), Bouge, Belgium|Private Practice, Brussel, Belgium|Grand Hopital de Charleroi - Site Notre Dame, Charleroi, Belgium|Private Practice, Ecaussinnes-d'enghien, Belgium|Private Practice, Genval, Belgium|Grand Hôpital de Charleroi, Loverval, Belgium|Private Practice, Mons, Belgium|Private Practice, Namur, Belgium|Private Practice, Namur, Belgium|Private Practice, Oisquercq, Belgium|Centre Médical de Perwez, Perwez, Belgium|Private Practice, Saint-Symphorien, Belgium|Private Practice, Uccle, Belgium|Private Practice, Wavre, Belgium		https://ClinicalTrials.gov/show/NCT03977753
456	NCT00761371	Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients		Completed	No Results Available	Warts	Drug: Imiquimod 5% cream	The percentage of subjects with total clearance of initially treated external genital or perianal warts.|Total clearance|Percentage of subjects with a partial reduction of initial wart area;|Time to achieve reduction in wart area;|Reduction in wart number|Appearance of new warts|Recurrence rate|HPV DNA|CD4+ lymphocyte and HIV RNA levels	MEDA Pharma GmbH & Co. KG|ORION Sante	All	18 Years to 69 Years   (Adult, Older Adult)	Phase 4	52	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1456-IMIQ|X-03016-9359000001	August 2002	February 2004	February 2004	September 29, 2008		April 10, 2015	Départment de Gynécologie-Obstétrique CHU Saint-Pierre, Brussels, Belgium|Service de Dermatologie CHU Saint-Pierre, Brussels, Belgium|Service Dermatologie C.H. François Rabelais (César de Paepe), Brussels, Belgium|Service de Dermatologie Hôpital Erasme, Brussels, Belgium|Service de Dermatologie et Vénéréologie Hôpital Saint Jacques, Besancon Cedex, France|Cabinet Médical, Bordeaux, France|Service de Dermatologie, Hôpital Ambroise Paré, Boulogne Billancourt, France|Service de Maladies Infectieuses Hôpital de la Conception, Marseille, France|Service de Dermatologie Hôtel Dieu, Nantes, France|Service de Dermatologie Hôpital de l'Archet II, Nice, France|Service Dermatologie Hopital COCHIN - Pavillon Tarnier, Paris, France|Cabinet Médical, Paris, France|Institut Alfred Fournier, Paris, France|Cabinet Médical, Paris, France|Service de Dermatologie Groupe Hospitalier Bichat Claude Bernard, Paris, France|Service de Dermatologie Hopital Tenon, Paris, France|Service de Dermatologie Groupe Hospitalier La Grave, Toulouse, France|Service de Dermatologie Centre Hospitalier de Valence, Valence, France		https://ClinicalTrials.gov/show/NCT00761371
457	NCT01593332	Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis		Completed	No Results Available	DMARD Resistant Rheumatoid Arthritis	Drug: Rituximab	change in 28-joint disease activity index( DAS28)|Change in European league against rheumatism(EULAR) response criteria|Rituximab side effects	Mashhad University of Medical Sciences|Roche Pharma AG	All	19 Years to 75 Years   (Adult, Older Adult)	Phase 4	44	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	87549	July 2010	September 2011	October 2011	May 8, 2012		May 8, 2012	Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Khorasan Razavi, Iran, Islamic Republic of		https://ClinicalTrials.gov/show/NCT01593332
458	NCT00189293	Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts		Completed	No Results Available	Genital Warts	Drug: Imiquimod|Other: vehicle cream	recuurence rate 24 weeks after ablative therapy|Time to recurrence|Recurrence rate at 4 and 12 weeks post ablation|Reduction of EGW area|Healing and cosmetic outcome|Local and general tolerability|Percent of complete clearance after initial topical treatment|Occurrence of new lesions	MEDA Pharma GmbH & Co. KG	All	18 Years and older   (Adult, Older Adult)	Phase 4	128	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	1526-IMIQ|2004-004654-19	June 2005	December 2007	December 2007	September 19, 2005		January 6, 2011	Clinica Ostetrica e Ginecologica Università Politecnica delle Marche, Ancona, Italy|Struttura Complessa di Ostetricia e Ginecologia Ospedale Cardinal Massaia, Asti, Italy|Unità Operativa di Ginecologia Oncologica, RCCS Ospedale Oncologico, Bari, Italy|Servizio Autonomo di Diagnosi Precoce dei Tumori Ginecologici Ospedale Vittorio Emanuele, Catania, Italy|Clinica Ostetrica Ginecologica, Ospedale Careggi, Firenze, Italy|Struttura Complessa Oncologia Chirurgica C Istituto Scientifico dei Tumori IST, Genova, Italy|Servizio di Ginecologia Preventiva, Istituti Clinici di Perfezionamento, Milano, Italy|Clinica Ostetrica Ginecologica Azienda Ospedaliera L. Sacco, Milano, Italy|Unità di Ginecologia Preventiva e Oncologica Università di Modena e Reggio Emilia, Modena, Italy|Unità Operativa di Ginecologia Oncologica, Ospedale Oncologico M. Ascoli, Palermo, Italy|Ostetricia e Ginecologia, Ospedale S. Maria delle Grazie, Pozzuoli, Italy|Ambulatorio di Colposcopia e Patologia Cervico-Vaginale, Università Cattolica del Sacro Cuore, Roma, Italy		https://ClinicalTrials.gov/show/NCT00189293
459	NCT01360996	Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism	BEYAZ-PCOS	Completed	Has Results	Polycystic Ovary Syndrome	Drug: 3 mg DRSP/20 μg EE	Biochemical Assessment of Hyperandrogenism|Cardiometabolic Measures|Post Therapy BMI.|Biochemical Indicator of B-vitamin Status|Menstrual Cycle Regularity|Adrenal Androgen DHEAS|Oral Disposition Index	Woman's|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma	Female	16 Years to 35 Years   (Child, Adult)	Phase 4	64	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RP 11-003	August 2011	February 2015	February 2015	May 26, 2011	March 31, 2017	March 31, 2017	Woman's Hospital, Baton Rouge, Louisiana, United States		https://ClinicalTrials.gov/show/NCT01360996
460	NCT01118598	Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome		Completed	No Results Available	Polycystic Ovary Syndrome	Drug: tredaptive (nicotinic acid/ laropiprant)|Drug: placebo	Reduction in postprandial triglyceride|Reduction in high sensitivity C-reactive protein (CRP)|Improvement in peripheral arterial tone (PAT- index)	Hull and East Yorkshire Hospitals NHS Trust|Merck Sharp & Dohme Corp.	Female	18 Years to 50 Years   (Adult)	Phase 4	34	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	R0920 PCOS & Niacin|ISRCTN37787683	June 2010	May 2012	May 2012	May 6, 2010		July 15, 2019	Hull & East Yorkshire Hospitals NHS Trust, Hull, United Kingdom		https://ClinicalTrials.gov/show/NCT01118598
461	NCT00565682	Pain Post Abdominal Laparoscopy Prevention With Arcoxia		Completed	No Results Available	Laparoscopic Surgery for Appendicitis|Laparoscopic Surgery for Cholecystitis|Laparoscopic Surgery for Ovarian Cysts	Drug: etoricoxib 120 mg	To measure the amount of rescue medication (opioid) needed to relief|To determine the overall analgesic effect using the visual analog scale (VAS)	Hospital Vozandez|Merck Sharp & Dohme Corp.	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 4	60	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	DOLAAR	April 2006		December 2006	November 30, 2007		November 30, 2007			https://ClinicalTrials.gov/show/NCT00565682
462	NCT00444379	Anti-Retrovirals for Kaposi's Sarcoma	ARKS	Completed	No Results Available	Kaposi's Sarcoma|HIV Infections	Drug: Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir	Blinded assessment of the change in the burden of KS lesions|CD4+ T cell count and HIV plasma HIV RNA levels|KSHV DNA levels in saliva and blood|Humoral and cellular KSHV immune response markers|Quality-of-life assessment|Incidence of Kaposi's sarcoma-associated Immune Reconstitution Inflammatory Syndrome (KS-IRIS)	University of California, San Francisco|National Institutes of Health (NIH)|Gilead Sciences|Abbott|Merck Sharp & Dohme Corp.	All	18 Years and older   (Adult, Older Adult)	Phase 4	224	Other|NIH|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	NIH/NCI Grant #: R01 CA119903	April 2007	February 2012	July 2012	March 7, 2007		August 20, 2014	Infectious Diseases Institute, Mulago Hospital, Kampala, Uganda		https://ClinicalTrials.gov/show/NCT00444379
463	NCT02162849	Reward Sensitivity and Pharmacotherapy for Smoking Cessation		Active, not recruiting	No Results Available	Tobacco Use Cessation	Drug: Varenicline|Drug: Nicotine Patch|Drug: Placebo Patch|Drug: Placebo Tablet|Behavioral: Questionnaires|Behavioral: Counseling Sessions|Other: Lab Session|Other: Saliva Test	Continuous Nicotine Abstinence|Continuous and Prolonged Nicotine Abstinence	M.D. Anderson Cancer Center|NAL PHARMA|Pfizer	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	204	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	2014-0207|NCI-2014-01485|RP140262	December 14, 2015	December 2019	December 2020	June 13, 2014		May 20, 2019	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02162849
464	NCT00252408	Danish Osteoporosis Prevention Study		Completed	No Results Available	Osteoporosis	Drug: Hormone replacement therapy	Fracture|Bone mineral density|Breast cancer|Menopausal symptoms	University of Aarhus|Karen Elise Jensen Foundation|Novo Nordisk A/S|LEO Pharma|Novartis	Female	45 Years to 58 Years   (Adult)	Phase 4	2000	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	1990/1821|DOPS	October 1990		December 2003	November 11, 2005		September 4, 2009	The Osteoporosis Clinic, Aarhus Sygehus, Aarhus, Denmark		https://ClinicalTrials.gov/show/NCT00252408
465	NCT02716714	Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis		Completed	Has Results	Actinic Keratosis	Drug: ingenol mebutate gel 0.015%|Drug: ingenol mebutate gel 0.05%	CC Rate of AK Lesions in the Selected Treatment Area|Percentage Change of the Number of AK Lesions in the Selected Treatment Area|Sustained CC Rate in CC Group|Recurrence Rate in CC Group|Percentage Change of the Number of AK Lesions in the Selected Treatment Area of CC Group|Change From Baseline in Quality of Life (Skindex-29)|Treatment Satisfaction Questionnaire for Medication (TSQM)|Cosmetic Outcomes Assessment (COA)|Time to Relapse in CC Group	Korea University|LEO Pharma|Chonnam National University Hospital|Severance Hospital|Ajou University School of Medicine|Asan Medical Center|Samsung Medical Center|Seoul National University Bundang Hospital|Dong-A University Hospital|Korea University Anam Hospital|Seoul National University Hospital	All	19 Years and older   (Adult, Older Adult)	Phase 4	77	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	KSSCLK2014-01	April 2015	June 2016	June 2016	March 23, 2016	April 18, 2018	April 18, 2018	Korea University Ansan Hospital, Ansan-si, Gyeonggi-do, Korea, Republic of		https://ClinicalTrials.gov/show/NCT02716714
466	NCT00380770	HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT	KAART	Completed	No Results Available	HIV|AIDS|Kaposi's Sarcoma|Human Herpesvirus 8	Drug: Generic HAART Triomune : d4T, 3TC, NVP|Drug: Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV	Clinical response of KS|Skin: tumour measurements of 5 indicator skin lesions. Assessment of KS as per AMC RKS 02 (www.amc.uab.edu)|photography of indicator lesions with metric tape in frame|Visceral: chest radiograph and endoscopy, where necessary, bronchoscopy|Safety and toxicity by DAIDS Toxicity criteria|Immunological and virological response to HAART as measured by CD4 and HIV-viral load|QOL by EORTC QLQ C30|Adherence	University of KwaZulu|AIDS Care Research in Africa|National Research Foundation, Singapore|AIDS Malignancy Consortium|Cipla Medpro|Dermatological Society of South Africa	All	18 Years and older   (Adult, Older Adult)	Phase 4	112	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	H029/02	January 2003	February 2009	March 2009	September 26, 2006		July 21, 2010	Department of Dermatology, King Edward VIII Hospital, Durban, Kwazulu Natal, South Africa		https://ClinicalTrials.gov/show/NCT00380770
467	NCT00221039	Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A		Completed	No Results Available	Cutaneous T Cell Lymphoma|Mycosis Fungoides	Drug: Methoxsalen+ECP	The primary endpoint will be the overall response based on skin-weighted assessment.|Quality of life assessed by questionnaire	M.D. Anderson Cancer Center|Boston Medical Center|University of Pittsburgh|Case Western Reserve University|Vanderbilt University Medical Center|University of Minnesota - Clinical and Translational Science Institute|Rush University Medical Center|Mallinckrodt	All	18 Years and older   (Adult, Older Adult)	Phase 4	7	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ECTCL1	April 2, 2004	April 5, 2011	April 5, 2011	September 22, 2005		August 17, 2018	Rush-Presbyterian Hospital, Chicago, Illinois, United States|Boston Medical Center, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|University Hospital of Cleveland/Case Western Reserve University, Cleveland, Ohio, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00221039
